Credit Agreement and Guaranty dated as of August 31, 2018 among Icagen, Inc. as the Borrower, Certain Subsidiaries of the Borrower from Time to Time Party hereto, as the Subsidiary Guarantors, The Lenders from Time to Time Party hereto, as the...

Exhibit 10.1

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Execution Version

Credit Agreement and Guaranty

dated as of

August 31, 2018

among

Icagen, Inc.
as the Borrower,

Certain Subsidiaries of the Borrower from Time to Time Party hereto,
as the Subsidiary Guarantors,

The Lenders from Time to Time Party hereto,
as the Lenders,

and

Perceptive Credit Holdings II, LP
as the Administrative Agent

U.S. $7,250,000

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Table of Contents

Section	Heading	Page
Section 1.	Definitions	1
Section 1.01.	Certain Defined Terms	1
Section 1.02.	Accounting Terms and Principles	24
Section 1.03.	Interpretation	24
Section 1.04.	Changes to GAAP	25
Section 2.	The Commitments And The Term Loan	26
Section 2.01.	Term Loan	26
Section 2.02.	Notes	27
Section 2.03.	Use of Proceeds	27
Section 2.04.	Proportionate Shares	27
Section 3	Payments of Principal and Interest	27
Section 3.01.	Repayments and Prepayments Generally; Application	27
Section 3.02.	Interest	27
Section 3.03.	Prepayments; Prepayment Premium	28
Section 3.04.	Closing Fees	30
Section 4.	Payments, Etc.	30
Section 4.01.	Payments	30
Section 4.02.	Computations	30
Section 4.03.	Set-Off	30
Section 5.	Yield Protection, Etc.	31
Section 5.01.	Additional Costs	31
Section 5.02.	Illegality	32
Section 5.03.	Taxes	32
Section 5.04.	Delay in Requests	37
Section 6.	Conditions Precedent	37
Section 6.01.	Conditions to the Closing Date	37
Section 7.	Representations and Warranties	40
Section 7.01.	Power and Authority	41
Section 7.02.	Authorization; Enforceability	41
Section 7.03.	Governmental and Other Approvals; No Conflicts	41

-i-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Section 7.04.	Financial Statements; Material Adverse Change	41
Section 7.05.	Properties	42
Section 7.06.	No Actions or Proceedings	44
Section 7.07.	Compliance with Laws and Agreements	45
Section 7.08.	Taxes	45
Section 7.09.	Full Disclosure	45
Section 7.10.	Investment Company and Margin Stock Regulation	45
Section 7.11.	Solvency	46
Section 7.12	Equity Holders; Subsidiaries; Equity Investments	46
Section 7.13.	Indebtedness and Liens	46
Section 7.14.	Material Agreements	47
Section 7.15.	Restrictive Agreements	47
Section 7.16.	Real Property	47
Section 7.17.	Pension Matters	47
Section 7.18.	Priority of Obligations; Collateral; Security Interest	47
Section 7.19.	Regulatory Approvals	47
Section 7.20.	Transactions with Affiliates	48
Section 7.21.	OFAC	49
Section 7.22.	Anti-Corruption	49
Section 7.23.	Deposit and Disbursement Accounts	49
Section 7.24.	Royalty and Other Payments	49
Section 8.	Affirmative covenants	49
Section 8.01.	Financial Statements and Other Information	50
Section 8.02.	Notices of Material Events	52
Section 8.03.	Existence; Conduct of Business	55
Section 8.04.	Payment of Obligations	55
Section 8.05.	Insurance	55
Section 8.06.	Books and Records; Inspection Rights	56
Section 8.07.	Compliance with Laws and Other Obligations	56
Section 8.08.	Maintenance of Properties, Etc.	56
Section 8.09.	Maintenance of Regulatory Approvals and Material Intellectual Property	57
Section 8.10.	Action Under Environmental Laws	57
Section 8.11.	Use of Proceeds	57
Section 8.12.	Certain Obligations Respecting Subsidiaries; Further Assurances	58
Section 8.13.	Termination of Non-Permitted Liens	58
Section 8.14.	Intellectual Property	59
Section 8.15.	ERISA Compliance	59
Section 8.16.	Cash Management	59
Section 8.17.	Post-Closing Obligations	59
Section 8.18.	Milestone	59
Section 8.19.	Icagen-T Lien	59
Section 8.20.	Board Observer Rights	60

-ii-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Section 9.	Negative Covenants	60
Section 9.01.	Indebtedness	60
Section 9.02.	Liens	62
Section 9.03.	Fundamental Changes and Acquisitions	65
Section 9.04.	Lines of Business	65
Section 9.05.	Investments	65
Section 9.06.	Restricted Payments	67
Section 9.07.	Payments of Indebtedness	68
Section 9.08.	Change in Fiscal Year	68
Section 9.09.	Sales of Assets, Etc	68
Section 9.10.	Transactions with Affiliates	69
Section 9.11.	Restrictive Agreements	69
Section 9.12.	Modifications and Terminations of Material Agreements and Organic Documents	69
Section 9.13.	Licensing of Intellectual Property	70
Section 9.14.	Sales and Leasebacks	70
Section 9.15.	Hazardous Material	70
Section 9.16.	Accounting Changes	70
Section 9.17.	Compliance with ERISA	70
Section 10.	Financial Covenants	70
Section 10.01.	Minimum Liquidity	70
Section 10.02.	Minimum Revenue	71
Section 11.	Events of Default	71
Section 11.01.	Events of Default	71
Section 11.02.	Remedies	74
Section 11.03.	Additional Remedies	74
Section 11.04.	Prepayment Premium and Redemption Price	75
Section 12.	Guarantee	75
Section 12.01.	The Guarantee	75
Section 12.02.	Obligations Unconditional	75
Section 12.03.	Reinstatement	76
Section 12.04.	Subrogation	76
Section 12.05.	Remedies	77
Section 12.06.	Instrument for the Payment of Money	77
Section 12.07.	Continuing Guarantee	77
Section 12.08.	Rights of Contribution	77
Section 12.09.	General Limitation on Guarantee Obligations	78

-iii-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Section 13.	Administrative agent	78
Section 13.01.	Appointment	78
Section 13.02.	Rights as a Lender	78
Section 13.03.	Exculpatory Provisions	79
Section 13.04.	Reliance by Administrative Agent	80
Section 13.05.	Delegation of Duties	80
Section 13.06.	Resignation of Agent.	80
Section 13.07.	Non-Reliance on Administrative Agent and Other Lenders	81
Section 13.08.	Administrative Agent May File Proofs of Claim	82
Section 13.09.	Collateral and Guaranty Matters; Appointment of Collateral Agent	82
Section 14.	Miscellaneous	83
Section 14.01.	No Waiver	83
Section 14.02.	Notices	83
Section 14.03.	Expenses, Indemnification, Etc.	84
Section 14.04.	Amendments, Etc.	85
Section 14.05.	Successors and Assigns	85
Section 14.06.	Survival	88
Section 14.07.	Captions	88
Section 14.08.	Counterparts	88
Section 14.09.	Governing Law	88
Section 14.10.	Jurisdiction, Service of Process and Venue	88
Section 14.11.	Waiver of Jury Trial	89
Section 14.12.	Waiver of Immunity	89
Section 14.13.	Entire Agreement	89
Section 14.14.	Severability	89
Section 14.15.	No Fiduciary Relationship	90
Section 14.16.	Confidentiality	90
Section 14.17.	Right of Setoff	91
Section 14.18.	Judgment Currency	91
Section 14.19.	USA PATRIOT Act	91
Section 14.20.	Release of Collateral and Guarantees; Non-Disturbance Agreements	91
Section 14.21.	Acknowledgement and Consent to Bail-In of EEA Financial Institutions	92

-iv-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Schedules and Exhibits

Schedule 1	—	Commitments and Warrant Shares
Schedule 7.05(b)	—	Obligor Intellectual Property
Schedule 7.05(c)	—	Material Intellectual Property
Schedule 7.06(a)	—	Certain Litigation
Schedule 7.06(c)	—	Labor Matters
Schedule 7.12(a)	—	Equity Holders
Schedule 7.12(b)	—	Information Regarding Subsidiaries
Schedule 7.12(c)	—	Equity Investments
Schedule 7.13(a)	—	Outstanding Indebtedness
Schedule 7.13(b)	—	Pay-Off Indebtedness
Schedule 7.13(c)	—	Liens
Schedule 7.14	—	Material Agreements of Obligors
Schedule 7.15	—	Restrictive Agreements
Schedule 7.16	—	Real Property Owned or Leased by Obligors or any Subsidiary
Schedule 7.17	—	Pension Matters
Schedule 7.19(b)	—	Regulatory Approvals
Schedule 7.19(e)	—	Certain Regulatory Matters
Schedule 7.20	—	Transactions with Affiliates
Schedule 7.21	—	OFAC Matters
Schedule 7.23	—	Deposit and Disbursement Accounts
Schedule 7.24	—	Royalty and Payments
Schedule 8.17	—	Post-Closing Obligations
Schedule 9.05	—	Existing Investments
Schedule 9.10	—	Transactions with Affiliates
Schedule 9.14	—	Permitted Sales and Leasebacks
Schedule 10.02	—	Contemplated Collaboration Agreement

-v-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Exhibit A	—	Form of Note
Exhibit B	—	[Reserved]
Exhibit C	—	Form of Guarantee Assumption Agreement
Exhibit D-1	—	Forms of U.S. Tax Compliance Certificate
Exhibit D-2	—	Forms of U.S. Tax Compliance Certificate
Exhibit D-3	—	Forms of U.S. Tax Compliance Certificate
Exhibit D-4	—	Forms of U.S. Tax Compliance Certificate
Exhibit E	—	Form of Compliance Certificate
Exhibit F	—	Form of Assignment and Assumption
Exhibit G	—	Form of Landlord Consent
Exhibit H	—	Form of Security Agreement
Exhibit I	—	Form of Collateral Questionnaire
Exhibit J	—	Form of Patent Security Agreement
Exhibit K	—	Form of Trademark Security Agreement
Exhibit L	—	Form of Copyright Security Agreement
Exhibit M	—	Form of Closing Date Certificate

-vi-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Credit Agreement and Guaranty

Credit Agreement and Guaranty, dated as of August 31, 2018 (this “Agreement”), among Icagen, Inc., a Delaware corporation (the “Borrower”), certain of the Borrower’s Subsidiaries from time to time parties hereto, the lenders from time to time party hereto (each, a “Lender” and collectively, the “Lenders”), and Perceptive Credit Holdings II, LP, as administrative agent for the Lenders (in such capacity, the “Administrative Agent”).

Witnesseth:

Whereas, the Borrower has requested that the Lenders provide a senior secured term loan facility to the Borrower in an aggregate principal amount of $7,250,000; and

Whereas, the Lenders are willing, on the terms and subject to the conditions set forth herein, to provide such senior secured term loan facility.

Now, Therefore, the parties hereto agree as follows:

Section 1. Definitions.

Section 1.01. Certain Defined Terms. As used herein, the following terms have the following respective meanings:

“Accounting Change Notice” has the meaning set forth in Section 1.04(a).

“Acquisition” means any transaction, or any series of related transactions, by which any Person directly or indirectly, by means of a take-over bid, tender offer, amalgamation, merger, purchase of assets, or similar transaction having the same effect as any of the foregoing, (i) acquires all or substantially all of the assets, business unit or division of any Person, (ii) acquires control of Equity Interests of a Person representing more than fifty percent (50%) of the ordinary voting power for the election of directors to the board of directors or other governing body of such Person, or (iii) acquires control of more than fifty percent (50%) of the Equity Interests in any Person.

“Act” has the meaning set forth in Section 14.19.

“Administrative Agent” has the meaning set forth in the preamble hereto.

“Affiliate” means, with respect to a specified Person, another Person that directly, or indirectly through one or more intermediaries, Controls or is Controlled by or is under common Control with the Person specified; provided that, with respect to any Lender, an Affiliate of such Lender shall include, without limitation, all of such Lender’s Related Funds, but shall exclude any portfolio companies or partners of such Lender or of such Related Funds.

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

“Agreement” has the meaning set forth in the preamble hereto.

“Applicable Margin” means nine and three-quarters percent (9.75%), as such percentage may be increased pursuant to Section 3.02(b).

“Asset Sale” has the meaning set forth in Section 9.09.

“Assignment and Assumption” means an assignment and assumption entered into by a Lender and an assignee of such Lender in substantially the form of Exhibit F.

“Bail-In Action” means the exercise of any Write-Down and Conversion Powers by the applicable EEA Resolution Authority in respect of any liability of an EEA Financial Institution.

“Bail-In Legislation” means, with respect to any EEA Member Country implementing Article 55 of Directive 2014/59/EU of the European Parliament and of the Council of the European Union, the implementing law for such EEA Member Country from time to time which is described in the EU Bail-In Legislation Schedule.

“Bailee Letter” means a bailee letter in form and substance reasonably satisfactory to the Administrative Agent.

“Bankruptcy Code” means Title 11 of the United States Code entitled “Bankruptcy”.

“Board” means, with respect to any Person, the board of directors (or equivalent management body) of such Person or any committee thereof duly authorized to act on behalf of such board or management body.

“Borrower” has the meaning set forth in the preamble hereto.

“Borrowing” means the borrowing of the Term Loan on the Closing Date.

“Bridge Notes” means, collectively, those certain 10% Subordinated Promissory Notes in the aggregate principal amount of $500,000, issued by Borrower pursuant to those certain Securities Purchase Agreements, dated as of August 13, 2018, by and among the Borrower and the investors from time to time party thereto.

“Business Day” means a day (other than a Saturday or Sunday) on which commercial banks are not authorized or required to close in New York City.

“Calculation Date” has the meaning set forth in Section 10.02.

-2-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

“Capital Lease Obligations” means, as to any Person, the obligations of such Person to pay rent or other amounts under a lease of (or other agreement conveying the right to use) real and/or personal property which obligations are required to be classified and accounted for as a capital lease on a balance sheet of such Person under GAAP and, for purposes of this Agreement, the amount of such obligations shall be the capitalized amount thereof, determined in accordance with GAAP.

“Casualty Event” means the damage, destruction or condemnation, as the case may be, of property of any Person or any of its Subsidiaries excluding any such property with a fair market value as of the date thereof of less than $1,000,000 per occurrence.

“Casualty Event Reinvestment Notice” has the meaning set forth in Section 3.03(b).

“Change of Control” means at any time of determination, either (i) the acquisition of ownership, directly or indirectly, beneficially or of record, by any Person (or group of Persons acting jointly or otherwise in concert) (other than the Management Investors) of Equity Interests of the Borrower having more than thirty-five percent (35%) of the aggregate ordinary voting power, determined on a fully diluted basis; (ii) the Borrower shall cease to own, directly or indirectly, beneficially and of record, one hundred percent (100%) of the issued and outstanding Equity Interests of each of its Subsidiaries (except for any such securities in the nature of directors’ qualifying shares required pursuant to applicable Law), in each case free and clear of all Liens except Liens created by the Security Documents; (iii) during any period of twelve (12) consecutive calendar months, the occupation of a majority of the seats (other than vacant seats) on the board of directors of Borrower by Persons who were neither (a) nominated by the board of directors of Borrower, nor (b) appointed by directors on the board of directors on the date hereof or so nominated; (iv) the sale of all or substantially all of the property or business of the Borrower and its Subsidiaries, taken as a whole; or (v) a Key Person Event shall have occurred.

“Claims” includes litigations, claims, demands, complaints, grievances, actions, suits, orders, charges, indictments, prosecutions, information (brought by a public prosecutor without grand jury indictment) or other similar processes, assessments or reassessments.

“Closing Date” means August 31, 2018.

“Closing Fee” has the meaning set forth in Section 3.04.

“Code” means the Internal Revenue Code of 1986, as amended.

“Collateral” means any asset or property of any Person in which a Lien is purported to be granted under any Loan Document (or all such property, as the context may require).

“Collateral Questionnaire” means the collateral questionnaire in substantially the form set forth in Exhibit I which shall be delivered pursuant to Section 6.01(k).

-3-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

“Commitment” means the commitment of a Lender to make or otherwise fund a Term Loan and “Commitments” means such commitments of all Lenders in the aggregate. The amount of each Lender’s Commitment is set forth on Schedule 1. The aggregate Commitments of all Lenders as of the Closing Date is $7,250,000.

“Committee” has the meaning set forth in Section 8.20.

“Commodity Account” means a “Commodity Account” as defined in the NY UCC.

“Compliance Certificate” has the meaning set forth in Section 8.01(d).

“Connection Income Taxes” means Other Connection Taxes that are imposed on or measured by net income (however denominated) or that are franchise Taxes or branch profits Taxes.

“Consolidated Net Revenue” means revenue of the Borrower and its Subsidiaries determined on a consolidated basis in accordance with GAAP; provided, however, that Consolidated Net Revenue shall exclude any upfront fees and one-time milestone payments received by the Borrower or any of its Subsidiaries from a collaboration agreement with a pharmaceutical or biotechnology company other than those upfront fees in an aggregate amount not to exceed $5,000,000 received by the Borrower or any of its Subsidiaries in connection with the collaboration agreements contemplated to be entered into on Schedule 10.02.

“Contracts” means any contract, license, lease, agreement, obligation, promise, undertaking, understanding, arrangement, document, commitment, entitlement or engagement under which a Person has, or will have, any liability or contingent liability (in each case, whether written or oral, express or implied and whether in respect of monetary or payment obligations, performance obligations or otherwise).

“Control” means, in respect of a particular Person, the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of such Person, whether through the ability to exercise voting power, by contract or otherwise. “Controlling” and “Controlled” have meanings correlative thereto.

“Controlled Account” has the meaning set forth in Section 8.16(a).

“Copyright” means all copyrights, copyright registrations and applications for copyright registrations, including all renewals and extensions thereof, all rights to recover for past, present or future infringements thereof and all other rights whatsoever accruing thereunder or pertaining thereto.

“Default” means any Event of Default and any event that has occurred which, upon the giving of notice thereof, or the lapse of time, or both, would constitute an Event of Default.

-4-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

“Default Rate” has the meaning set forth in Section 3.02(b).

“Deposit Account” is defined in the Security Agreement.

“Designated Jurisdiction” means any country or territory to the extent that such country or territory is the subject of any Sanction.

“Disqualified Equity Interests” means, with respect to any Person, any Equity Interest of such Person that, by its terms (or by the terms of any security or other Equity Interest into which it is convertible or for which it is exchangeable), or upon the happening of any event or condition (i) matures or is mandatorily redeemable (other than solely for Qualified Equity Interests), including pursuant to a sinking fund obligation or otherwise, (ii) is redeemable at the option of the holder thereof (other than solely for Qualified Equity Interests), in whole or in part, (iii) provides for the scheduled payments of dividends in cash, or (iv) is or becomes convertible into or exchangeable for Indebtedness or any other Equity Interests that would constitute Disqualified Equity Interests, in each case, prior to the date that is one hundred and eighty (180) days after the Maturity Date; provided that, if such Equity Interests are issued pursuant to any plan for the benefit of directors, officers, employees or consultants of such Person or by any such plan to such directors, officers, employees or consultants, such Equity Interests shall not constitute Disqualified Equity Interests solely because they may be required to be repurchased by such Person upon the death, disability, retirement or termination of employment or service of such director, officer, employee or consultant.

“Dollars” and “$” means lawful money of the United States of America.

“EEA Financial Institution” means (a) any credit institution or investment firm established in any EEA Member Country which is subject to the supervision of an EEA Resolution Authority, (b) any entity established in an EEA Member Country which is a parent of an institution described in clause (a) of this definition, or (c) any financial institution established in an EEA Member Country which is a subsidiary of an institution described in clauses (a) or (b) of this definition and is subject to consolidated supervision with its parent.

“EEA Member Country” means any of the member states of the European Union, Iceland, Liechtenstein, and Norway.

“EEA Resolution Authority” means any public administrative authority or any person entrusted with public administrative authority of any EEA Member Country (including any delegee) having responsibility for the resolution of any EEA Financial Institution.

“Eligible Transferee” means and includes (i) any commercial bank, (ii) any insurance company, (iii) any finance company, (iv) any financial institution, (v) any investment fund that invests in loans, (vi) with respect to any Lender, any of its Affiliates, and (vii) any other “accredited investor” (as defined in Regulation D of the Securities Act) that is principally in the business of managing investments or holding assets for investment purposes; provided that so long as no Event of Default has occurred and is continuing, an Eligible Transferee shall not include any competitor of any Obligor.

-5-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

“Environmental Law” means any federal, state, provincial or local governmental law, rule, regulation, order, writ, judgment, injunction or decree, whether U.S. or non-U.S., relating to pollution or protection of the environment or the treatment, storage, disposal, release, threatened release or handling of hazardous materials, and all local laws and regulations, whether U.S. or non-U.S., related to environmental matters and any specific agreements entered into with any Governmental Authorities which include commitments related to environmental matters.

“Equity Interests” means, with respect to any Person (for purposes of this defined term, an “issuer”), all shares of, interests or participations in, or other equivalents in respect of such issuer’s capital stock, including all membership interests, partnership interests or equivalent, and all debt or other securities directly or indirectly exchangeable, exercisable or otherwise convertible into such issuer’s capital stock, whether outstanding as of the Closing Date or issued after the Closing Date, and in each case however designated and whether voting or non-voting.

“ERISA” means the United States Employee Retirement Income Security Act of 1974, as amended.

“ERISA Affiliate” means, collectively, any Obligor, Subsidiary thereof, and any Person under common control, or treated as a single employer, with any Obligor or Subsidiary thereof, within the meaning of Section 414(b), (c) or, solely with respect to Code Section 412 or ERISA Section 302, (m) or (o) of the Code.

“ERISA Event” means (i) a reportable event as defined in Section 4043 of ERISA with respect to a Title IV Plan, excluding, however, such events as to which the PBGC by regulation has waived the requirement of Section 4043(a) of ERISA that it be notified within thirty (30) days of the occurrence of such event; (ii) a withdrawal by any Obligor or any ERISA Affiliate thereof from a Title IV Plan or the termination of any Title IV Plan resulting in liability under Sections 4063 or 4064 of ERISA; (iii) the withdrawal of any Obligor or any ERISA Affiliate thereof in a complete or partial withdrawal (within the meaning of Section 4203 and 4205 of ERISA) from any Multiemployer Plan if there is any liability therefore, or the receipt by any Obligor or any ERISA Affiliate thereof of notice from any Multiemployer Plan that it is in insolvency pursuant to 4245 of ERISA; (iv) the filing of a notice of intent to terminate, the treatment of a plan amendment as a termination under Section 4041 or 4041A of ERISA, or the commencement of proceedings by the PBGC to terminate a Title IV Plan or Multiemployer Plan; (v) the imposition of liability on any Obligor or any ERISA Affiliate thereof pursuant to Sections 4062(e) or 4069 of ERISA or by reason of the application of Section 4212(c) of ERISA; (vi) the failure by any Obligor or any ERISA Affiliate thereof to make any required contribution to a Title IV Plan, or the failure to meet the minimum funding standard of Section 412 of the Code with respect to any Title IV Plan (whether or not waived in accordance with Section 412(c) of the Code) or the failure to make by its due date a required installment under Section 430 of the Code with respect to any Title IV Plan or the failure to make any required contribution to a Multiemployer Plan; (vii) the determination that any Title IV Plan is considered an at-risk plan or a plan in endangered to critical status within the meaning of Sections 430, 431 and 432 of the Code or Sections 303, 304 and 305 of ERISA; (viii) an event or condition which would reasonably be expected to constitute grounds under Section 4042 of ERISA for the termination of, or the appointment of a trustee to administer, any Title IV Plan or Multiemployer Plan; (ix) the imposition of any liability under Title I or Title IV of ERISA, other than PBGC premiums due but not delinquent under Section 4007 of ERISA, upon any Obligor or any ERISA Affiliate thereof; (x) an application for a funding waiver under Section 412 of the Code or an extension of any amortization period pursuant to Section 433 of the Code with respect to any Title IV Plan; or (xi) the imposition of any lien (or the fulfillment of the conditions for the imposition of any lien) on any of the rights, properties or assets of any Obligor or any ERISA Affiliate thereof, pursuant to Title IV of ERISA, 303(k) of ERISA or Section 430(k) of the Code.

-6-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

“EU Bail-In Legislation Schedule” means the EU Bail-In Legislation Schedule published by the Loan Market Association (or any successor Person), as in effect from time to time.

“Event of Default” has the meaning set forth in Section 11.01.

“Excess Funding Guarantor” has the meaning set forth in Section 12.08.

“Excess Payment” has the meaning set forth in Section 12.08.

“Exchange Act” means the Securities Exchange Act of 1934, as amended.

“Excluded Account” means, collectively, (i) accounts used exclusively for payroll, the withheld employee portion of payroll taxes and other employee wage and benefit payments, and (ii) fiduciary and other trust accounts.

“Excluded Taxes” means any of the following Taxes imposed on or with respect to a Recipient or required to be withheld or deducted from a payment to a Recipient: (i) Taxes imposed on or measured by net income (however denominated), franchise Taxes and branch profits Taxes, in each case, (x) imposed as a result of such Recipient being organized under the laws of, or having its principal office or, in the case of any Lender, its applicable lending office located in, the jurisdiction imposing such Tax (or any political subdivisions thereof) or (y) that are Other Connection Taxes, (ii) in the case of a Lender, U.S. federal withholding Taxes imposed on amounts payable to or for the account of such Lender with respect to an applicable interest in a Term Loan or Commitment pursuant to a law in effect on the date on which (1) such Lender acquires such interest in the Term Loan or Commitment (other than pursuant to an assignment request by the Borrower pursuant to Section 5.03(h)) or (2) such Lender changes its lending office, except in each case to the extent that, pursuant to Section 5.03, amounts with respect to such Taxes were payable either to such Lender’s assignor immediately before such Lender became a party hereto or to such Lender immediately before it changed its lending office, (iii) Taxes attributable to such Recipient’s failure to comply with Section 5.03(f), and (iv) any withholding Taxes imposed under FATCA.

-7-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

“Fair Share” has the meaning set forth in Section 12.08.

“FATCA” means Sections 1471 through 1474 of the Code, as of the date of this Agreement (or any amended or successor version that is substantively comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof, any agreements entered into pursuant to Section 1471(b)(1) of the Code, and any fiscal or regulatory legislation, rules or practices adopted pursuant to any intergovernmental agreement, treaty or convention among Governmental Authorities and implementing such Sections of the Code.

“FD&C Act” means the U.S. Food, Drug and Cosmetic Act of 1938 (or any successor thereto), as amended from time to time, and the rules, regulations, guidelines, guidance, documents and compliance policy guides issued or promulgated thereunder.

“FDA” means the U.S. Food and Drug Administration and any successor entity.

“Foreign Lender” means a Lender (or, if the Lender is a disregarded entity for U.S. federal income tax purposes, the Person treated as the owner of the assets of such Lender for U.S. federal income tax purposes) that is not a U.S. Person.

“Foreign Subsidiary” means a Subsidiary of the Borrower that is not incorporated, formed or organized under the laws of the United States, any State of the United States or the District of Columbia.

“GAAP” means generally accepted accounting principles in the United States of America, as in effect from time to time, set forth in the opinions and pronouncements of the Accounting Principles Board and the American Institute of Certified Public Accountants, in the statements and pronouncements of the Financial Accounting Standards Board and in such other statements by such other entity as may be in general use by significant segments of the accounting profession that are applicable to the circumstances as of the date of determination. The definition of GAAP shall be subject to Sections 1.02 and 1.04.

“Governmental Approval” means any required consent, authorization, approval, order, license, franchise, permit, certification, accreditation, registration, clearance, exemption, filing or notice that is issued or granted by or from (or pursuant to any act of) any applicable Governmental Authority, including any application or submission related to any of the foregoing.

“Governmental Authority” means any nation, government, branch of power (whether executive, legislative or judicial), state, province or municipality or other political subdivision thereof and any entity exercising executive, legislative, judicial, monetary, regulatory or administrative functions of or pertaining to government, including without limitation regulatory authorities, governmental departments, agencies, commissions, bureaus, officials, ministers, courts, bodies, boards, tribunals and dispute settlement panels, and other law-, rule- or regulation-making organizations or entities of any state, territory, county, city or other political subdivision of any country, in each case whether U.S. or non-U.S.

-8-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

“Guarantee” of or by any Person (the “guarantor”) means any obligation, contingent or otherwise, of the guarantor guaranteeing or having the economic effect of guaranteeing any Indebtedness or other monetary obligation of any other Person (the “primary obligor”) in any manner, whether directly or indirectly, and including any obligation of the guarantor, direct or indirect, (i) to purchase or pay (or advance or supply funds for the purchase or payment of) such Indebtedness or other monetary obligation or to purchase (or to advance or supply funds for the purchase of) any security for the payment thereof, (ii) to purchase or lease property, securities or services for the purpose of assuring the owner of such Indebtedness or other monetary obligation of the payment thereof, (iii) to maintain working capital, equity capital or any other financial statement condition or liquidity of the primary obligor so as to enable the primary obligor to pay such Indebtedness or other monetary obligation, or (iv) as an account party in respect of any letter of credit or letter of guaranty issued to support such Indebtedness or monetary obligation; provided that the term Guarantee shall not include endorsements for collection or deposit in the ordinary course of business. The amount of any Guarantee shall be deemed to be an amount equal to the stated or determinable amount of the related primary obligation, or portion thereof, in respect of which such Guarantee is made or, if not stated or determinable, the maximum reasonably anticipated liability in respect thereof as determined by the guaranteeing Person in good faith.

“Guarantee Assumption Agreement” means a Guarantee Assumption Agreement substantially in the form of Exhibit C by an entity that, pursuant to Section 8.12(a), is required to become a “Subsidiary Guarantor.”

“Guaranteed Obligations” has the meaning set forth in Section 12.01.

“Hazardous Material” means any substance, element, chemical, compound, product, solid, gas, liquid, waste, by-product, pollutant, contaminant or material which is hazardous or toxic, and includes, without limitation, (i) asbestos, polychlorinated biphenyls and petroleum (including crude oil or any fraction thereof) and (ii) any material classified or regulated as “hazardous” or “toxic” or words of like import pursuant to an Environmental Law.

“Hedging Agreement” means any interest rate exchange agreement, foreign currency exchange agreement, commodity price protection agreement or other interest or currency exchange rate or commodity price hedging arrangement.

“HIPAA” means the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act of the American Recovery and Reinvestment Act of 2009.

-9-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

“Icagen-T” means Icagen-T, Inc., a Delaware corporation.

“Icagen-T Credit Agreement” means that certain Credit Agreement and Guaranty, dated as of the date hereof, by and among Icagen-T, as borrower, the lenders from time to time party thereto and Perceptive Credit Holdings II, LP, as administrative agent (as amended, restated, supplemented or otherwise modified from time to time).

“Icagen-T Loan Documents” has the meaning ascribed to the term “Loan Documents” in the Icagen-T Credit Agreement.

“Icagen-T MSA” means that certain Master Services Agreement dated as of July 15, 2016, by and among Icagen-T and Sanofi US Services Inc.

“Impermissible Qualification” means any qualification or exception to the opinion or certification of any independent public accountant as to any financial statement of the Borrower or any of its Subsidiaries which is of a “going concern” or similar nature.

“Indebtedness” of any Person means, without duplication, (i) all obligations of such Person for borrowed money, (ii) all obligations of such Person evidenced by bonds, debentures, notes or similar instruments, (iii) all obligations of such Person upon which interest charges are customarily paid, (iv) all obligations of such Person in respect of the deferred purchase price of property or services or under conditional sale or other title retention agreements relating to property acquired by such Person, and including any purchase price adjustments or indemnity requirements incurred in connection with any Permitted Acquisition (excluding current trade accounts payable incurred in the ordinary course of business), (v) all Indebtedness of others secured by (or for which the holder of such Indebtedness has an existing right, contingent or otherwise, to be secured by) any Lien on property owned or acquired by such Person, whether or not the Indebtedness secured thereby has been assumed, (vi) all Guarantees by such Person of Indebtedness of others, (vii) all Capital Lease Obligations of such Person, (viii) all obligations, contingent or otherwise, of such Person as an account party in respect of letters of credit and letters of guaranty, (ix) obligations under any Hedging Agreement, currency swaps, forwards, futures or derivatives transactions, (x) all obligations, contingent or otherwise, of such Person in respect of bankers’ acceptances, (xi) all obligations of such Person under license or other agreements containing a guaranteed minimum payment or purchase by such Person, other than operating leases entered into in the ordinary course of business and any such license or other agreement for the purchase or use of goods, software and other intangibles, services or supplies in the ordinary course of business and (xii) any Disqualified Equity Interests of such Person. The Indebtedness of any Person shall include the Indebtedness of any other entity (including any partnership in which such Person is a general partner) to the extent such Person is liable therefor as a result of such Person’s ownership interest in or other relationship with such entity, except to the extent the terms of such Indebtedness provide that such Person is not liable therefor.

“Indemnified Party” has the meaning set forth in Section 14.03(c).

-10-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

“Indemnified Taxes” means (i) Taxes, other than Excluded Taxes, imposed on or with respect to any payment made by or on account of any Obligation and (ii) to the extent not otherwise described in clause (i), Other Taxes.

“Industrial Designs” has the meaning set forth in the Security Documents.

“Insolvency Proceeding” means (i) any case, action or proceeding before any court or other Governmental Authority relating to bankruptcy, reorganization, insolvency, liquidation, receivership, dissolution, winding-up or relief of debtors, or (ii) any general assignment for the benefit of creditors, composition, marshaling of assets for creditors, or other similar arrangement in respect of any Person’s creditors generally or any substantial portion of such Person’s creditors, in each case undertaken under U.S. Federal, state or foreign Law, including the Bankruptcy Code.

“Intellectual Property” means all Patents, Trademarks, Copyright, Industrial Designs, Technical Information and other intellectual property, whether registered or not and whether existing under, U.S. or non-U.S. Law or jurisdiction, including (without limitation) all of the following: (i) all applications or registrations relating to the foregoing; (ii) all rights and privileges arising under any applicable Law with respect to the foregoing; (iii) rights to xxx for past, present or future infringements of such Intellectual Property; and (iv) all rights of the same or similar effect or nature in any jurisdiction corresponding to such Intellectual Property anywhere in the world.

“Interest Period” means (a) the period commencing on (and including) the Closing Date and ending on (and including) the last day of the calendar month in which the Closing Date occurs, and (b) thereafter, the period beginning on (and including) the first day of each succeeding calendar month and ending on the earlier of (and including) (x) the last day of such calendar month and (y) the Maturity Date.

“Interest Rate” means the sum of (i) the Applicable Margin plus (ii) the greater of (x) the Reference Rate and (y) two and one-quarter percent (2.25%).

“Invention” means any novel, inventive or useful art, apparatus, method, process, machine, manufacture or composition of matter, or any novel, inventive and useful improvement in any art, method, process, machine, manufacture or composition of matter.

“Investment” means, for any Person: (i) any direct or indirect acquisition or investment by such Person, whether by means of (a) the purchase or other acquisition of Equity Interests or debt or other securities of another Person, (ii) a loan, advance or capital contribution to, Guarantee or assumption of debt of, or purchase or other acquisition of any other debt or equity participation or interest in, another Person, including any partnership or joint venture interest in such other Person, or (iii) the purchase or other acquisition (in one transaction or a series of transactions) of all or substantially all of the property and assets or business of another Person or assets constituting a business unit, line of business or division of such Person. The amount of an Investment will be determined at the time the Investment is made without giving effect to any subsequent changes in value.

-11-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

“IRS” means the U.S. Internal Revenue Service or any successor agency.

“Key Person” means Xxxxxxx Xxxxxxxxxx or such other person as may be acceptable by the Lenders as Xxxxxxx Xxxxxxxxxx’x replacement pursuant to the definition of “Key Person Event.”

“Key Person Event” means that (a) the Key Person (i) ceases to hold the office of chief executive officer (or equivalent) of Borrower or fails to be directly and actively involved in the day to day management and direction of Borrower and its Subsidiaries and a successor reasonably acceptable to the Lenders shall not have been appointed within 90 days of such cessation, or (ii) becomes or is an employee, manager or officer of any entity other than Borrower and its Subsidiaries and (b) Xxx Xxxxx is no longer serving as the Chairman of the Board of the Borrower.

“Landlord Consent” means a Landlord Consent substantially in the form of Exhibit G or in a form otherwise reasonably satisfactory to the Administrative Agent.

“Law” means any U.S. or non-U.S. federal, state, provincial, territorial, municipal or local statute, treaty, rule, guideline, regulation, ordinance, code or administrative or judicial precedent or authority, including any interpretation or administration thereof by any Governmental Authority charged with the enforcement, interpretation or administration thereof, and all applicable administrative orders, directed duties, requests, licenses, authorizations and permits of, and agreements with, any Governmental Authority, in each case, whether or not having the force of law.

“Lenders” has the meaning set forth in the preamble hereto.

“Lien” means any mortgage, lien, pledge, charge or other security interest, or any lease, title retention agreement, easement, right-of-way or other encumbrance of any kind or character whatsoever or any preferential arrangement that has the practical effect of creating a security interest.

“Loan Documents” means, collectively, this Agreement, the Notes, the Warrant, the Security Documents, the Series C Preferred Subordination Agreement, the Guarantee Assumption Agreements and any subordination agreement, intercreditor agreement or other present or future document, instrument, agreement or certificate delivered to any Lender in connection with this Agreement or any of the other Loan Documents, in each case, as amended, restated, supplemented or otherwise modified.

“Loss” means any judgment, debt, liability, expense, cost, damage or loss, contingent or otherwise, whether liquidated or unliquidated, matured or unmatured, disputed or undisputed, contractual, legal or equitable, including loss of value, professional fees, including reasonable fees and disbursements of legal counsel, and all costs incurred in investigating or pursuing any Claim or any proceeding relating to any Claim.

-12-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

“Majority Lenders” means, at any time, Lenders having at such time in excess of fifty percent (50%) of the aggregate Commitments (or, if such Commitments are terminated, the outstanding principal amount of the Term Loan) then in effect.

“Management Investors” means any current directors, officers, management and/or employees of the Borrower or any of its Subsidiaries and any of their respective family members, trusts or other estate planning vehicles and any Person owned or controlled by any of the foregoing, in each case, holding, beneficially or of record, Equity Interests in the Borrower.

“Margin Stock” means “margin stock” within the meaning of Regulations T, U and X.

“Material Adverse Change” and “Material Adverse Effect” mean a material adverse change in or effect on (i) the business, condition (financial or otherwise), operations or performance of the Borrower and its Subsidiaries, taken as a whole, (ii) the ability of either (x) the Borrower or (y) the Obligors, taken as a whole, to perform its or their, as the case may be, obligations under the Loan Documents, as and when due or (iii) the legality, validity, binding effect or enforceability of any Loan Document or the rights and remedies of any Secured Party under any of the Loan Documents.

“Material Agreement” means (i) any Contract to which any Obligor or any of its properties is bound or subject to and which is listed on Schedule 7.14, (ii) any other Contract to which any Obligor is a party or a beneficiary from time to time, the absence or termination of which could reasonably be expected to result in a Material Adverse Effect, and (iii) any other Contract to which any Obligor is a party that during any period of 12 consecutive months is reasonably expected to (1) result in payments or receipts (including royalty, licensing or similar payments) made to any Obligor or any of its Subsidiaries in an aggregate amount in excess of $1,000,000 or (2) require payments or expenditures (including royalty, licensing or similar payments) to be made by any Obligor or any of its Subsidiaries in an aggregate amount in excess of $1,000,000.

“Material Indebtedness” means, at any time, any Indebtedness of any Obligor (excluding intercompany Indebtedness among Obligors and/or their Subsidiaries to the extent permitted hereunder), the outstanding principal amount of which, individually or in the aggregate, exceeds $500,000.

“Material Intellectual Property” means (i) all Obligor Intellectual Property listed in Schedule 7.05(c) and (ii) all other Obligor Intellectual Property, whether currently owned or licensed or acquired, developed or otherwise licensed or obtained after the date hereof (a) the loss of which could reasonably be expected to have a Material Adverse Effect or (b) that has a fair market value in excess of $500,000.

-13-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

“Maturity Date” means August 31, 2022.

“Multiemployer Plan” means any multiemployer plan, as defined in Section 4001(a)(3) of ERISA, to which any ERISA Affiliate incurs or otherwise has any obligation or liability, contingent or otherwise.

“Net Cash Proceeds” means, with respect to any Casualty Event, the amount of cash proceeds received (directly or indirectly) from time to time by or on behalf of any Obligor after deducting therefrom only (w) reasonable fees, costs and expenses related thereto incurred by such Obligor in connection therewith, (x) amounts required to be repaid on account of any Permitted Indebtedness or other obligations (other than the Obligations) required to be repaid as a result of such Casualty Event, (y) amounts required to be reserved in accordance with GAAP for indemnities and against liabilities associated with the property damaged, destructed or condemned in such Casualty Event and (z) Taxes (including transfer Taxes or net income Taxes) paid or payable in connection therewith; provided that amounts specified therein in respect of costs, expenses or repayments shall only be deducted from aggregate cash proceeds to the extent such amounts are (1) actually paid to a Person that is not an Affiliate of the Borrower or any of its Subsidiaries and (2) properly attributable to such Casualty Event.

“Note” means a promissory note, in substantially the form of Exhibit A hereto, executed and delivered by the Borrower to any Lender in accordance with Section 2.02.

“NY UCC” means the UCC as in effect from time to time in New York.

“Obligations” means, with respect to any Obligor, all amounts, obligations, liabilities, covenants and duties of every type and description owing by such Obligor to any Secured Party (including all Guaranteed Obligations and the Warrant Obligations), arising out of, under, or in connection with, any Loan Document, whether direct or indirect (regardless of whether acquired by assignment), absolute or contingent, due or to become due, whether liquidated or not, now existing or hereafter arising and however acquired, and whether or not evidenced by any instrument or for the payment of money, including, without duplication, (i) if such Obligor is the Borrower, the Term Loan, (ii) all interest accruing under the Loan Documents, whether or not accruing after the filing of any petition in bankruptcy or after the commencement of any insolvency, reorganization or similar proceeding, and whether or not a claim for post-filing or post-petition interest is allowed in any such proceeding, and (iii) all other fees, expenses (including fees, charges and disbursement of counsel), interest, commissions, charges, costs, disbursements, indemnities and reimbursement of amounts paid and other sums, in each case, chargeable to such Obligor under any Loan Document.

“Obligor Intellectual Property” means, at any time of determination, Intellectual Property owned by any of the Obligors at such time including, without limitation, the Intellectual Property listed on Schedule 7.05(b).

-14-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

“Obligors” means, collectively, the Borrower and the Subsidiary Guarantors and their respective successors and permitted assigns.

“Observer” has the meaning set forth in Section 8.20.

“One-Month LIBOR” means, with respect to any applicable Interest Period hereunder, the one-month London Interbank Offered Rate for deposits in Dollars, as determined by the Administrative Agent from the appropriate Bloomberg or Telerate page selected by the Administrative Agent (or any successor thereto or similar source reasonably determined by the Administrative Agent from time to time), which shall be that one-month London Interbank Offered Rate for deposits in Dollars in effect at approximately 11:00 a.m. (London, England time) two (2) Business Days prior to the first Business Day of such Interest Period rounded up to the nearest 1/100 of one percent (1%). The Administrative Agent’s determination of interest rates shall be determinative in the absence of manifest error.

“Organic Document” means, for any Person, its certificate of incorporation, by-laws, certificate of partnership, partnership agreement, certificate of formation, limited liability agreement, operating agreement and all shareholder agreements, voting trusts and similar arrangements applicable to such Person’s Equity Interests.

“Other Connection Taxes” means, with respect to any Recipient, Taxes imposed as a result of a present or former connection between such Recipient and the jurisdiction imposing such Tax (other than connections arising from such Recipient having executed, delivered, become a party to, performed its obligations under, received payments under, received or perfected a security interest under, engaged in any other transaction pursuant to or enforced any Loan Document, or sold or assigned an interest in the Term Loan or Loan Document).

“Other Taxes” means all present or future stamp, court or documentary, intangible, recording, filing or similar Taxes that arise from any payment made under, from the execution, delivery, performance, enforcement or registration of, from the receipt or perfection of a security interest under, or otherwise with respect to, any Loan Document, except any such Taxes that are Other Connection Taxes imposed with respect to an assignment (other than an assignment made at the request of the Borrower pursuant to Section 5.03(h)).

“Participant” has the meaning set forth in Section 14.05(e).

“Participant Register” has the meaning set forth in Section 14.05(e).

“Patents” means all patents and patent applications, including the inventions and improvements described and claimed therein together with the reissues, divisions, continuations, renewals, extensions and continuations in part thereof, all income, royalties, damages and payments now or hereafter due and/or payable with respect thereto, all damages and payments for past or future infringements thereof and rights to xxx therefor, and all rights corresponding thereto throughout the world.

-15-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

“Payment Date” means (i) the last day of each Interest Period and (ii) the Maturity Date; provided that, in the event any such day is not a Business Day, then the payment due on such day shall be payable on the next occurring Business Day.

“Pay-Off Indebtedness” means the Indebtedness listed on Schedule 7.13(b).

“Pay-Off Letters” means each payoff letter in respect of the Pay-Off Indebtedness, in form and substance reasonably satisfactory to the Administrative Agent.

“PBGC” means the United States Pension Benefit Guaranty Corporation referred to and defined in ERISA and any successor entity performing similar functions.

“Permitted Acquisition” means any Acquisition by the Borrower or any of its Subsidiaries whether by purchase, merger or otherwise, of (i) all or substantially all of the assets of any U.S. Person, (ii) more than fifty percent (50%) of all voting Equity Interests of any U.S. Person (determined on a fully diluted basis), (iii) an entire business line or unit or division of any U.S. Person or (iv) any other asset or assets (other than assets in the nature of inventory acquired in the ordinary course of business) located in the United States; provided that:

(a) immediately prior to, and after giving effect thereto, no Default or Event of Default shall have occurred and be continuing or would reasonably be expected to result therefrom;

(b) all transactions in connection therewith shall be consummated, in all material respects, in accordance with all applicable Laws, and in conformity in all material respects with all applicable Governmental Approvals;

(c) in the case of the Acquisition of any Equity Interests of any Person, all of such Equity Interests shall be majority owned by Borrower or its Subsidiaries, and the Borrower shall have taken or caused to be taken, as of the date such Equity Interests are acquired, all necessary actions to comply with Section 8.12(a), as applicable;

(d) in the case of the Acquisition of assets, all assets acquired shall be owned by Borrower or its Subsidiaries, and the Borrower shall have taken or caused to be taken, as of the date the assets are acquired, all necessary actions to comply with Section 8.12(a), as applicable;

(e) such Person (in the case of an Acquisition of Equity Interests) or assets (in the case of an Acquisition of assets or a division) shall be engaged or used, as the case may be, in substantially the same business or lines of business in which the Borrower and its Subsidiaries are engaged as of the Closing Date or a business reasonably related, incidental or complimentary thereto or a reasonable extension thereof or a business having a similar customer base;

-16-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

(f) on a pro forma basis after giving effect to such Acquisition, the Borrower and its Subsidiaries shall be in compliance with the financial covenants set forth in Section 10;

(g) the aggregate consideration for all such Acquisitions together with all Acquisitions permitted under the Icagen-T Credit Agreement does not exceed $1,000,000 in cash in any fiscal year;

(h) the Borrower shall have provided the Administrative Agent with at least fifteen (15) Business Days’ prior written notice of any such Acquisition, together with summaries, prepared in reasonable detail, of all due diligence conducted by or on behalf of the Borrower or the applicable Subsidiary prior to such Acquisition;

(i) the Administrative Agent shall have received a certificate of a Responsible Officer of the Borrower (prepared in reasonable detail), certifying as to any contingent liabilities and, to the extent applicable, prospective research and development costs associated with the Person or assets being acquired; and

(j) all of the assets or Equity Interests acquired in connection with such Acquisition shall be of a U.S. Person.

“Permitted Cash Equivalent Investments” means (i) marketable direct obligations issued or unconditionally guaranteed by the United States or any agency or any State thereof having maturities of not more than one (1) year from the date of acquisition, (ii) commercial paper maturing no more than one (1) year after its creation and having the highest rating from either Standard & Poor’s Ratings Group or Xxxxx’x Investors Service, Inc., (iii) time deposits with, or insured certificates of deposit or banker’s acceptances of, any commercial bank that (x) is organized under the laws of the United States or is the principal banking subsidiary of a bank holding company organized under the laws of the United States and is a member of the Federal Reserve System and (y) has combined capital and surplus of at least $1,000,000,000, in each case with maturities of not more than one (1) year from the date of acquisition, and (iv) any money market funds at least ninety-five percent (95%) of the assets of which constitute investments of the type described in clauses (i), (ii) or (iii) above.

“Permitted Indebtedness” means any Indebtedness permitted under Section 9.01.

“Permitted Liens” means any Liens permitted under Section 9.02.

-17-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

“Permitted Priority Liens” means Liens permitted under any of the clauses (b), (c), (d), (e), (f) or (i) of Section 9.02.

“Permitted Refinancing” means, with respect to any Permitted Indebtedness, any extension, renewal, replacement or refinancing of such Indebtedness; provided that such extension, renewal, replacement or refinancing (i) shall not increase the outstanding principal amount of such Indebtedness except by accrued and unpaid interest and premiums thereon and fees and expenses associated with such extension, renewal, replacement or refinancing, (ii) contains terms relating to outstanding principal amount, amortization, maturity, collateral (if any) and subordination (if any), and other material terms taken as a whole no less favorable in any material respect to the Borrower and its Subsidiaries or the Secured Parties than the terms of any agreement or instrument governing the Indebtedness being extended, renewed, replaced or refinanced, (iii) shall have an applicable interest rate or equivalent yield which does not exceed the interest rate or equivalent yield of the Indebtedness being extended, renewed, replaced or refinanced, (iv) shall not contain any new requirement to grant any Lien or to give any Guarantee that was not an existing requirement of the Indebtedness being extended, renewed, replaced or refinanced and (v) after giving effect to such extension, renewal, replacement or refinancing, no Default or Event of Default shall have occurred (or would reasonably be expected to occur) as a result thereof.

“Person” means any individual, corporation, company, voluntary association, partnership, limited liability company, joint venture, trust, unincorporated organization or Governmental Authority or other entity of whatever nature.

“Prepayment Date” has the meaning set forth in Section 3.03(a)(i).

“Prepayment Premium” means with respect to any prepayment of principal of the Term Loan referenced in Section 3.03(a) occurring (i) on or prior to the first anniversary of the Closing Date, an amount equal to twelve percent (12%) of the aggregate outstanding principal amount of the Term Loan being prepaid, (ii) at any time after the first anniversary of the Closing Date and on or prior to the second anniversary of the Closing Date, an amount equal to eight percent (8%) of the aggregate outstanding principal amount of the Term Loan being prepaid; and (iii) at any time after the second anniversary of the Closing Date and on or prior to the third anniversary of the Closing Date, an amount equal to three percent (3%) of the aggregate outstanding principal amount of the Term Loan being prepaid on such Prepayment Date.

“Prepayment Price” has the meaning set forth in Section 3.03(a)(i).

“Product” means any future product developed, manufactured, licensed, marketed, sold or otherwise commercialized by any Obligor, including any such product in development or which may be developed, in each case related to Material Intellectual Property.

-18-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

“Product Commercialization and Development Activities” means, with respect to any Product, any combination of research, development, manufacture, importation, use, sale, storage, design, labeling, marketing, promotion, supply, distribution, testing, packaging, purchasing or other commercialization activities, receipt of payment in respect of any of the foregoing, or like activities the purpose of which is to commercially exploit such Product.

“Prohibited Payment” means any bribe, rebate, payoff, influence payment, kickback or other payment or gift of money or anything of value (including meals or entertainment) to any officer, employee or ceremonial office holder of any government or instrumentality thereof, political party or supra-national organization (such as the United Nations), any political candidate, any royal family member or any other person who is connected or associated personally with any of the foregoing that is prohibited under any applicable Law for the purpose of influencing any act or decision of such payee in his official capacity, inducing such payee to do or omit to do any act in violation of his lawful duty, securing any improper advantage or inducing such payee to use his influence with a government or instrumentality thereof to affect or influence any act or decision of such government or instrumentality.

“Proportionate Share” means, with respect to any Lender, the percentage obtained by dividing (i) the sum of the Commitment (or, if the Commitments are terminated, the outstanding principal amount of the Term Loan) of such Lender then in effect by (ii) the sum of the Commitments (or, if the Commitments are terminated, the outstanding principal amount of the Term Loan) of all Lenders then in effect.

“Qualified Equity Interest” means, with respect to any Person, any Equity Interest of such Person that is not a Disqualified Equity Interest.

“Real Property Security Documents” means any Landlord Consents, Bailee Letters, any mortgage or deed of trust or any other real property security document executed or required hereunder to be executed by any Obligor and granting a security interest in real property owned or leased (as tenant) by any Obligor in favor of the Secured Parties.

“Recipient” means any Lender or the Administrative Agent.

“Reference Rate” means One-Month LIBOR; provided that, if One-Month LIBOR can no longer be determined by the Administrative Agent (in its sole discretion) or any Governmental Authority having jurisdiction over the quotation or determination of the London Interbank Offered Rates declares that it will no longer supervise or sanction such rates for purposes of interest rates on loans, then the Reference Rate for purposes hereof and of each other Loan Document shall be a comparable rate as may be selected by the Administrative Agent in its reasonable discretion.

“Register” has the meaning set forth in Section 14.05(d).

“Regulation T” means Regulation T of the Board of Governors of the Federal Reserve System, as amended.

-19-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

“Regulation U” means Regulation U of the Board of Governors of the Federal Reserve System, as amended.

“Regulation X” means Regulation X of the Board of Governors of the Federal Reserve System, as amended.

“Regulatory Approvals” means any registrations, licenses, authorizations, permits or approvals issued by any Governmental Authority and applications or submissions related to any of the foregoing.

“Regulatory Authority” means any Governmental Authority that is concerned with or has regulatory oversight with respect to the use, control, safety, efficacy, reliability, manufacturing, marketing, distribution or sale relating to the business of an Obligor, including the FDA and all equivalent of such agencies in other jurisdictions.

“Related Fund” means, with respect to any Lender, a fund which is managed or advised by the same investment manager or investment adviser as such Lender or, if it is managed by a different investment manager or investment adviser, a fund whose investment manager or investment adviser is an Affiliate of the investment manager or investment adviser of such Lender.

“Related Parties” has the meaning set forth in Section 14.16.

“Resignation Effective Date” has the meaning set forth in Section 13.06(a).

“Responsible Officer” of any Person means each of the president, chief executive officer, chief financial officer and similar officer of such Person.

“Restricted Payment” means any dividend or other distribution (whether in cash, securities or other property) with respect to any Equity Interests of the Borrower or any of its Subsidiaries, or any payment (whether in cash, securities or other property), including any (i) sinking fund or similar deposit, on account of the purchase, redemption, retirement, acquisition, cancellation or termination of any such shares of capital stock of the Borrower or any of its Subsidiaries, (ii) payment of interest, principal or fees in respect of Indebtedness owed by the Borrower to any holder of any capital stock of the Borrower or (iii) option, warrant or other right to acquire any such shares of capital stock of the Borrower or any of its Subsidiaries.

“Restrictive Agreement” means any indenture, agreement, instrument or other arrangement that prohibits, restricts or imposes any condition upon (i) the ability of the Borrower or any other Obligor to create, incur or permit to exist any Lien (other than Permitted Liens) upon any of its property or assets (other than (x) customary provisions in contracts (including without limitation leases and licenses of Intellectual Property) restricting the assignment thereof or, in the case of any lease or license, the sublease or sublicense or other disposition of the applicable leased or licensed property, (y) restrictions or conditions imposed by any agreement governing secured Permitted Indebtedness permitted under Section 9.01(g), to the extent that such restrictions or conditions apply only to the property or assets securing such Indebtedness and (z) restrictions in agreements related to any Asset Sale to the extent such Asset Sale would be a permitted Asset Sale under this Agreement), or (ii) the ability of any Subsidiary to pay dividends or other distributions with respect to any shares of its capital stock or to make or repay loans or advances to the Borrower or any other Obligor or the ability of any Subsidiary to guarantee Indebtedness of the Borrower or any other Obligor to the extent such guarantee is required by Section 8.12.

-20-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

“Sanction” means any international economic sanction administered or enforced by the United States Government (including, without limitation, OFAC), the United Nations Security Council, the European Union or its Member States, Her Majesty’s Treasury or other similar relevant sanctions authority.

“SEC” means the U.S. Securities and Exchange Commission.

“Secured Parties” means the Lenders, the Administrative Agent, each other Indemnified Party, any other holder of any Obligation, and any of their respective permitted transferees or assigns.

“Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

“Security Agreement” means the Security Agreement, dated as of the Closing Date and substantially in the form of Exhibit H hereto, among the grantors party thereto and the Administrative Agent, granting a security interest in the Obligors’ personal property in favor of the Administrative Agent.

“Security Documents” means, collectively, the Security Agreement, each Short-Form IP Security Agreement, each Real Property Security Document and each other security document, control agreement or financing statement required or recommended to perfect Liens in favor of the Secured Parties for purposes of securing the Obligations.

“Securities Account” has the meaning given to it in Section 8-501(a) of the NY UCC.

“Series C Holders” means any holder of the Series C Preferred Stock.

“Series C Preferred Stock” means the Borrower’s Series C Convertible Redeemable Preferred Stock.

“Series C Preferred Subordination Agreement” means that certain Series C Preferred Subordination Agreement, dated as of the Closing Date, among the Series C Holders, the Borrower and the Administrative Agent, pursuant to which the Series C Holders subordinate all rights to cash payments owed such Series C Holders by Borrower due to such Series C Holders’ ownership of Series C Preferred Stock until the Obligations (other than Warrant Obligations) have been paid in full.

-21-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

“Short-Form IP Security Agreements” means short-form patent, trademark or copyright (as the case may be) security agreements, substantially in the forms of Exhibits J, K and L to this Agreement, as applicable, entered into by one (1) or more Obligors in favor of the Administrative Agent for the benefit of each Secured Party.

“Solvent” means, with respect to any Person at any time, that (i) the present fair saleable value of the property of such Person is greater than the total amount of liabilities (including contingent liabilities) of such Person, (ii) the present fair saleable value of the property of such Person is not less than the amount that will be required to pay the probable liability of such Person on its debts as they become absolute and matured and (iii) such Person has not incurred and does not intend to, and does not believe that it will, incur debts or liabilities beyond such Person’s ability to pay such debts and liabilities as they mature.

“Subsidiary” means, with respect to any Person (the “parent”) at any date, any corporation, limited liability company, partnership, association or other entity the accounts of which would be consolidated with those of the parent in the parent’s consolidated financial statements if such financial statements were prepared in accordance with GAAP as of such date, as well as any other corporation, limited liability company, partnership, association or other entity of which securities or other ownership interests representing more than fifty percent (50%) of the equity or more than fifty percent (50%) of the ordinary voting power or, in the case of a partnership, more than fifty percent (50%) of the general partnership interests are, as of such date, directly or indirectly, owned, controlled or held.

“Subsidiary Guarantors” means each Subsidiary of the Borrower identified under the caption “SUBSIDIARY GUARANTORS” on the signature pages hereto and each Subsidiary of the Borrower that becomes, or is required to become, a “Subsidiary Guarantor” after the date hereof pursuant to Section 8.12(a).

“Taxes” means all present or future taxes, levies, imposts, duties, deductions, withholdings (including backup withholding), assessments, fees or other charges imposed by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto.

“Technical Information” means all trade secrets and other proprietary or confidential information, public information, non-proprietary know-how, any information of a scientific, technical, or business nature in any form or medium, standards and specifications, conceptions, ideas, innovations, discoveries, Invention disclosures, all documented research, developmental, demonstration or engineering work and all other information, data, plans, specifications, reports, summaries, experimental data, manuals, models, samples, know-how, technical information, systems, methodologies, computer programs, information technology and any other information.

-22-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

“Term Loan” means each loan advanced by a Lender pursuant to Section 2.01(a). For purposes of clarification, any calculation of the aggregate outstanding principal amount of the Term Loan on any date of determination shall mean the aggregate principal amount of the Term Loan made pursuant to Section 2.01(a) that has not yet been repaid as of such date.

“Title IV Plan” means an employee benefit plan (as defined in Section 3(3) of ERISA) other than a Multiemployer Plan (i) that is or within the last six years was maintained or sponsored by any Obligor or any ERISA Affiliate thereof or to which any Obligor or any ERISA Affiliate thereof within the last six years made, or was obligated to make, contributions, and (ii) that is or was subject to Section 412 of the Code, Section 302 of ERISA or Title IV of ERISA.

“Trademarks” means all trade names, trademarks and service marks, logos, trademark and service xxxx registrations, and applications for trademark and service xxxx registrations, including all renewals of trademark and service xxxx registrations, all rights to recover for all past, present and future infringements thereof and all rights to xxx therefor, and all rights corresponding thereto throughout the world, together, in each case, with the product lines and goodwill of the business connected with the use thereof.

“Transactions” means the negotiation, preparation, execution, delivery and performance by each Obligor of this Agreement and the other Loan Documents to which such Obligor is (or is intended to be) a party, the making of the Term Loan hereunder, and all other transactions contemplated pursuant to this Agreement and the other Loan Documents.

“UCC” means, with respect to any applicable jurisdictions, the Uniform Commercial Code as in effect in such jurisdiction, as may be modified from time to time.

“United States” or “U.S.” means the United States of America, its fifty (50) states and the District of Columbia.

“U.S. Person” means a “United States person” within the meaning of Section 7701(a)(30) of the Code.

“U.S. Tax Compliance Certificate” has the meaning set forth in Section 5.03(f)(ii)(B).

“Warrant” means the warrant to be delivered to the Administrative Agent pursuant to Section 6.01 on the Closing Date, that, among other things, grants the holder thereof the right to purchase the number of shares of common stock of the Borrower as indicated on the Warrant Shares table on Schedule 1, as the Warrant may be amended, replaced or otherwise modified pursuant to the terms thereof.

“Warrant Obligations” means all Obligations of the Borrower arising out of, under or in connection with the Warrant.

-23-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

“Withholding Agent” means the Borrower, any Obligor and the Administrative Agent.

“Write-Down and Conversion Powers” means, with respect to any EEA Resolution Authority, the write-down and conversion powers of such EEA Resolution Authority from time to time under the Bail-In Legislation for the applicable EEA Member Country, which write-down and conversion powers are described in the EU Bail-In Legislation Schedule.

Section 1.02. Accounting Terms and Principles. Unless otherwise specified, all accounting terms used in each Loan Document shall be interpreted, and all accounting determinations and computations thereunder (including under Section 10 and any definitions used in such calculations) shall be made, in accordance with GAAP; provided that, for purposes of determining compliance with any covenant contained in Section 9 or the existence of any Default or Event of Default under Section 11, in determining whether any lease is required to be accounted for as a capital lease or an operating lease, such determination shall be made based on GAAP as in effect on the date of this Agreement. Unless otherwise expressly provided, all financial covenants and defined financial terms shall be computed on a consolidated basis for the Borrower and its Subsidiaries, in each case, without duplication.

Section 1.03. Interpretation. For all purposes of this Agreement, except as otherwise expressly provided herein or unless the context otherwise requires,

(a) the terms defined in this Agreement include the plural as well as the singular and vice versa;

(b) words importing gender include all genders;

(c) any reference to a Section, Annex, Schedule or Exhibit refers to a Section of, or Annex, Schedule or Exhibit to, this Agreement;

(d) any reference to “this Agreement” refers to this Agreement, including all Annexes, Schedules and Exhibits hereto, and the words herein, hereof, hereto and hereunder and words of similar import refer to this Agreement and its Annexes, Schedules and Exhibits as a whole and not to any particular Section, Annex, Schedule, Exhibit or any other subdivision;

(e) references to days, months and years refer to calendar days, months and years, respectively;

(f) all references herein to “include” or “including” shall be deemed to be followed by the words “without limitation”;

(g) the word “from” when used in connection with a period of time means “from and including” and the word “until” means “to but not including”;

-24-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

(h) where any provision in this Agreement or any other Loan Document refers to an action to be taken by any Person, or an action which such Person is prohibited from taking, such provision shall be applicable whether such action is taken directly or indirectly;

(i) references to any Lien granted or created hereunder or pursuant to any other Loan Document securing any Obligations shall be deemed to be a Lien for the benefit of the Secured Parties;

(j) the words “asset” and “property” shall be construed to have the same meaning and effect and to refer broadly to any and all assets and properties, whether tangible or intangible, real or personal, including cash, securities, rights under contractual obligations and permits and any right or interest in any such assets or property except where otherwise noted herein;

(k) accounting terms not specifically defined herein (other than “property” and “asset”) shall be construed in accordance with GAAP;

(l) the word “will” shall be construed to have the same meaning as the word “shall”; and

(m) a Schedule shall refer to those Schedules provided as of the date hereof and as may be further updated in accordance with the terms of this Agreement (which updates, for the avoidance of doubt, shall be acceptable to the Administrative Agent unless such updates reflect an item that is otherwise prohibited under this Agreement on the date thereof).

Unless otherwise expressly provided herein, references to organizational documents, agreements (including the Loan Documents) and other contractual instruments shall be deemed to include all subsequent amendments, restatements, extensions, supplements and other modifications thereto permitted by the Loan Documents.

Section 1.04. Changes to GAAP. Subject to Section 1.02, if, after the date hereof, any change occurs in GAAP or in the application thereof and such change would cause any amount required to be determined for the purposes of the covenants to be maintained or calculated pursuant to Section 8, 9 or 10 to be materially different than the amount that would be determined prior to such change, then:

(a) the Borrower will provide a detailed notice of such change (an “Accounting Change Notice”) to the Administrative Agent within thirty (30) days after a Responsible Officer’s learning that such change would so impact the covenants and calculations hereunder;

-25-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

(b) either the Borrower or the Administrative Agent may indicate within ninety (90) days following the date of the Accounting Change Notice that they wish to revise the method of calculating such covenants or amend any such amount, in which case the parties will in good faith attempt to agree upon a revised method for calculating the financial covenants;

(c) until the Borrower and the Administrative Agent have reached agreement on such revisions, such covenants or amounts as set forth herein shall remain in effect and will be determined without giving effect to such change;

(d) if no party elects to revise the method of calculating the covenants or amounts, then the covenants or amounts will not be revised and will be determined in accordance with GAAP without giving effect to such change; and

(e) any Event of Default arising as a result of such change which is cured by operation of this Section 1.04 shall be deemed to be of no effect ab initio.

Section 2. The Commitments and the Term Loan.

Section 2.01. Term Loan.

(a)  The Term Loan.

(i) Subject to the terms and conditions of this Agreement and relying on the representations and warranties set forth herein, each Lender, severally and not jointly, agrees to provide its share of the Term Loan to Borrower on the Closing Date in Dollars in a principal amount equal to such Lender’s Commitment. No Lender shall have an obligation to make a Term Loan in excess of such Lender’s Commitment.

(ii) Borrower may make one borrowing under the Commitments which shall be on the Closing Date. Subject to Section 3.03, all amounts owed hereunder with respect to the Term Loan shall be paid in full no later than the Maturity Date. Each Lender’s Commitment shall terminate immediately and without further action on the Closing Date after giving effect to the funding of such Lender’s Commitment on such date.

(iii)  Upon satisfaction or waiver of the conditions precedent set forth in this Agreement, the Lenders shall make the proceeds of the Term Loan available to Borrower on the Closing Date.

(b) No amounts paid or prepaid with respect to the Term Loan may be reborrowed. Any term or provision hereof (or of any other Loan Document) to the contrary notwithstanding, the Term Loan made to the Borrower will be denominated solely in Dollars and will be repayable solely in Dollars and no other currency.

-26-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Section 2.02. Notes. If requested by any Lender, the Term Loan of such Lender shall be evidenced by one or more Notes. If so requested, the Borrower shall prepare, execute and deliver to the Administrative Agent such promissory note(s) payable to the Lenders (or, if requested by the Lenders, to the Lenders and their registered permitted assigns) substantially in the form attached hereto as Exhibit A.

Section 2.03. Use of Proceeds. The Borrower shall use the proceeds of the Term Loan solely (a) for general corporate purposes, including, without limitation, business development and licensing purposes, (b) to refinance the Pay-Off Indebtedness and (c) to pay the fees, costs and expenses associated with the Transactions.

Section 2.04. Proportionate Shares. The Term Loan shall be made, and all participations purchased, by the Lenders simultaneously and proportionately to their respective Proportionate Shares, it being understood that no Lender shall be responsible for any default by any other Lender in such other Lender’s obligation to make a Term Loan hereunder or purchase a participation required hereby nor shall the Commitment of any Lender be increased or decreased as a result of a default by any other Lender in such Lender’s obligation to make a Term Loan requested hereunder or purchase a participation required hereby.

Section 3 Payments of Principal and Interest.

Section 3.01. Repayments and Prepayments Generally; Application. (a) There will be no scheduled amortization payments of principal on the Term Loan prior to the second (2nd) anniversary of the Closing Date.

(b) Commencing with the Payment Date occurring immediately after the second (2nd) anniversary of the Closing Date and on each Payment Date occurring thereafter, the Borrower shall make a scheduled amortization payment of principal on the Term Loan in an amount equal to 1.0% of the aggregate principal amount of the Term Loan borrowed on the Closing Date.

(c) Any term or provision hereof to the contrary notwithstanding, on the Maturity Date the Borrower shall repay the entire remaining outstanding balance of the Term Loan in full in cash.

(d) The Borrower agrees that the Term Loan, and any fees or interest accrued or accruing thereon, shall be repaid and prepaid solely in Dollars pursuant to the terms of this Section 3. Except as otherwise provided in this Agreement, each payment (including each repayment and prepayment) by the Borrower will be deemed to be made ratably in accordance with the Lenders’ Proportionate Share.

Section 3.02. Interest.

(a) Interest Generally. The outstanding principal amount of the Term Loan, as well as the amount of all other outstanding Obligations, shall accrue interest at the Interest Rate.

-27-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

(b) Default Interest. Notwithstanding the foregoing, upon the occurrence and during the continuance of any Event of Default, the Applicable Margin shall increase automatically by four percent (4%) per annum (the Interest Rate, as increased pursuant to this Section 3.02(b), being the “Default Rate”). If any Obligation is not paid when due under any applicable Loan Document (after giving effect to any applicable grace period), the amount thereof shall accrue interest at the Default Rate.

(c) Interest Payment Dates. Accrued interest on the Term Loan shall be payable in cash and in arrears on each Payment Date with respect to the most recently completed Interest Period, and upon the payment or prepayment of the Term Loan (on the principal amount being so paid or prepaid); provided that interest payable at the Default Rate shall also be payable from time to time on demand by the Administrative Agent.

(d) Maximum Rate. Notwithstanding any other provision of this Agreement, in no event will any interest or rates referred to herein exceed the maximum interest rate permitted by applicable law. If such maximum interest rate would be exceeded by the terms hereof, the rates of interest payable hereunder will be reduced to the extent necessary so that such rates (together with any fees or other amounts which are construed by a court of competent jurisdiction to be interest or in the nature of interest) equal the maximum interest rate permitted by applicable law, and any overpayment of interest received by the Lenders before such rates are so construed will be applied, forthwith after determination of such overpayment, to pay all then outstanding interest, and thereafter to pay outstanding principal.

Section 3.03. Prepayments; Prepayment Premium.

(a) Optional Prepayments. (i) Subject to prior written notice pursuant to clause (ii) below, the Borrower shall have the right to optionally prepay, in whole or in part, the outstanding principal amount of the Term Loan on any Business Day (a “Prepayment Date”) for an aggregate amount equal to the sum of (x) the aggregate principal amount of the Term Loan being prepaid, (y) the applicable Prepayment Premium on the principal amount of the Term Loan being prepaid and (z) any accrued but unpaid interest on the principal amount of the Term Loan being prepaid (such aggregate amount, the “Prepayment Price”).

(ii) A notice of optional prepayment shall be effective only if received by the Administrative Agent not later than 2:00 p.m. (Eastern time) on a date not less than one (1) Business Day prior to the proposed Prepayment Date. Each notice of optional prepayment shall specify the Prepayment Price and the principal amount to be prepaid, as well as the Prepayment Date.

-28-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

(b) Mandatory Prepayments. Subject to the proviso below, upon the occurrence of any Casualty Event, the Borrower shall make a mandatory prepayment of the Term Loan in an aggregate amount equal to the sum of (x) one hundred percent (100%) of the Net Cash Proceeds received by the Borrower or any other Obligor as a result of such Casualty Event, and (y) any accrued but unpaid interest on such principal amount of the Term Loan being prepaid; provided that so long as no Default or Event of Default has occurred and is continuing at the time the Borrower or any Obligor shall have received such Net Cash Proceeds, if, within five (5) Business Days following the occurrence of any such Casualty Event, a Responsible Officer of the Borrower may deliver to the Administrative Agent a notice (each, a “Casualty Event Reinvestment Notice”) to the effect that the Borrower or applicable Obligor intends to apply the Net Cash Proceeds from such Casualty Event to acquire, replace or rebuild the property subject to such Casualty Event or to the cost of purchase or construction of other assets useful in the business of the Borrower or its Subsidiaries, then such Net Cash Proceeds of such Casualty Event may be applied for such purpose in lieu of such mandatory prepayment, provided further that, in the event that Net Cash Proceeds have not been so applied within one hundred eighty (180) days following the occurrence of such Casualty Event, the Borrower shall make a mandatory prepayment of the Term Loan in an aggregate amount equal to the sum of (A) one hundred percent (100%) of the unused balance of such Net Cash Proceeds received by the Borrower or any other Obligor as a result of such Casualty Event, and (B) any accrued but unpaid interest on such principal amount of the Term Loan being prepaid, provided, further, that to the extent that the property subject to the Casualty Event is Collateral, then any such acquired, replaced, repaired, purchased or constructed property shall be Collateral in which the Administrative Agent, for the benefit of the Lenders, has been granted a security interest under the Security Documents.

(c) Prepayment Premium. Without limiting the foregoing, whenever the Prepayment Premium is in effect and payable pursuant to the terms hereof, such premium shall be payable on all payments and prepayments of the Term Loan, whether as a result of clause (a) above in this Section 3.03, acceleration or otherwise (but excluding any prepayment pursuant to clause (b) above).

(d) Application. Proceeds of any prepayment made pursuant to clauses (a) or (b) above shall be applied in the following order of priority, with proceeds being applied to a succeeding level of priority only if amounts owing pursuant to the immediately preceding level of priority have been paid in full in cash:

(i) first, to the payment of any unpaid costs or expenses referred to in Section 14.03 then due and owing;

(ii) second, to the payment of any accrued and unpaid interest and any fees then due and owing;

(iii) third, to the payment of unpaid principal of the Term Loan;

(iv) fourth, to the payment of any Prepayment Premium then due and payable; and

-29-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

(v) fifth, to the Borrower or such other Persons as may lawfully be entitled to or directed by the Borrower to receive the remainder.

Section 3.04. Closing Fee. On the Closing Date, the Borrower shall pay to the Administrative Agent out of the proceeds of the Term Loan a non-refundable fee in the amount equal to two percent (2%) of the principal amount of the Term Loan advanced by the Lenders on such date (the “Closing Fee”). Payment of the Closing Fee shall be in addition to such fees, costs and expenses due and payable pursuant to Section 14.03. Upon receipt of payment from the Borrower, the Administrative Agent will promptly thereafter distribute like funds relating to any such payment to the Lenders pro rata on the basis of each Lender’s Proportionate Share.

Section 4. Payments, Etc.

Section 4.01. Payments.

(a) Payments Generally. Each payment of principal, interest and other amounts to be made by the Obligors under this Agreement or any other Loan Document shall be made (i) in Dollars, in immediately available funds, without deduction, set off or counterclaim, to the deposit account of the Administrative Agent (for the benefit of the Lenders) designated by the Administrative Agent by notice to the Borrower and (ii) not later than 2:00 p.m. (Eastern time) on the date on which such payment is due (each such payment made after such time on such due date shall be deemed to have been made on the next succeeding Business Day).

(b) Application of Payments. All such payments referenced in clause (a) above shall be applied as set forth in Section 3.03(d) above.

(c) Non-Business Days. If the due date of any payment under this Agreement (whether in respect of principal, interest, fees, costs or otherwise) would otherwise fall on a day that is not a Business Day, such date shall be extended to the next succeeding Business Day, and, in the case of any payment accruing interest, interest thereon shall be payable for the period of such extension.

Section 4.02. Computations. All computations of interest and fees hereunder shall be computed on the basis of a year of three hundred and sixty (360) days and actual days elapsed during the period for which payable.

Section 4.03. Set-Off.

(a) Set-Off Generally. Upon the occurrence and during the continuance of any Event of Default, the Administrative Agent, each of the Lenders and each of their Affiliates is hereby authorized at any time and from time to time, to the fullest extent permitted by law, to set off and apply any and all deposits (general or special, time or demand, provisional or final) at any time held and other indebtedness at any time owing by any Lender and any of their Affiliates to or for the credit or the account of any Obligor against any and all of the Obligations, whether or not such Person shall have made any demand and although such obligations may be unmatured. Any Person exercising rights of set off hereunder agrees promptly to notify the Borrower after any such set-off and application, provided that the failure to give such notice shall not affect the validity of such set-off and application. The rights of the Lenders and each of their Affiliates under this Section 4.03 are in addition to other rights and remedies (including other rights of set-off) that such Persons may have.

-30-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

(b) Exercise of Rights Not Required. Nothing contained in Section 4.03(a) shall require the Administrative Agent, any Lender or any of their Affiliates to exercise any such right or shall affect the right of such Persons to exercise, and retain the benefits of exercising, any such right with respect to any other indebtedness or obligation of any Obligor.

Section 5. Yield Protection, Etc.

Section 5.01. Additional Costs.

(a) Change in Law Generally. If, on or after the date hereof, the adoption of any Law, or any change in any Law, or any change in the interpretation or administration thereof by any court or other Governmental Authority charged with the interpretation or administration thereof, or compliance by any Lender (or its lending office) with any request or directive (whether or not having the force of law) of any such Governmental Authority, shall impose, modify or deem applicable any reserve (including any such requirement imposed by the Board of Governors of the Federal Reserve System), special deposit, contribution, insurance assessment or similar requirement, in each case that becomes effective after the date hereof, against assets of, deposits with or for the account of, or credit extended by, a Lender (or its lending office) or shall impose on a Lender (or its lending office) any other condition affecting the Term Loan or the Commitment, and the result of any of the foregoing is to increase the cost to such Lender of making or maintaining the Term Loan, or to reduce the amount of any sum received or receivable by such Lender under this Agreement or any other Loan Document, or subject any Lender to any Taxes on its Term Loan, Commitment or other obligations, or its deposits, reserves, other liabilities or capital (if any) attributable thereto by an amount reasonably deemed by such Lender in good faith to be material (other than (i) Indemnified Taxes, (ii) Taxes described in clauses (ii) through (iv) of the definition of “Excluded Taxes” and (iii) Connection Income Taxes), then the Borrower shall pay to such Lender on demand such additional amount or amounts as will compensate such Lender for such increased cost or reduction.

(b) Change in Capital Requirements. If a Lender shall have determined that, on or after the date hereof, the adoption of any applicable Law regarding capital adequacy, or any change therein, or any change in the interpretation or administration thereof by any Governmental Authority charged with the interpretation or administration thereof, or any request or directive regarding capital adequacy (whether or not having the force of law) of any such Governmental Authority, in each case that becomes effective after the date hereof, has or would have the effect of reducing the rate of return on capital of a Lender (or its parent) as a consequence of a Lender’s obligations hereunder or the Term Loan to a level below that which a Lender (or its parent) could have achieved but for such adoption, change, request or directive by an amount reasonably deemed by it to be material, then the Borrower shall pay to such Lender on demand such additional amount or amounts as will compensate such Lender (or its parent) for such reduction.

-31-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

(c) Notification by Lender. Each Lender will promptly notify the Borrower of any event of which it has knowledge, occurring after the date hereof, which will entitle such Lender to compensation pursuant to this Section 5.01. Before giving any such notice pursuant to this Section 5.01(c) such Lender shall designate a different lending office if such designation (x) will, in the reasonable judgment of such Lender, avoid the need for, or reduce the amount of, such compensation and (y) will not, in the reasonable judgment of such Lender, be materially disadvantageous to such Lender. A certificate of such Lender claiming compensation under this Section 5.01, setting forth in reasonable detail the additional amount or amounts to be paid to it hereunder, shall be conclusive and binding on the Borrower in the absence of manifest error.

(d) Notwithstanding anything herein to the contrary, (x) the Xxxx-Xxxxx Xxxx Street Reform and Consumer Protection Act and all requests, rules, guidelines or directives thereunder or issued in connection therewith and (y) all requests, rules, guidelines or directives promulgated by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the United States or foreign regulatory authorities, in each case pursuant to Basel III, shall in each case be deemed to constitute a change in Law for all purposes of this Section 5.01, regardless of the date enacted, adopted or issued.

Section 5.02. Illegality. Notwithstanding any other provision of this Agreement, in the event that on or after the date hereof the adoption of or any change in any applicable Law or in the interpretation or application thereof by any competent Governmental Authority shall make it unlawful for a Lender or its lending office to make or maintain the Term Loan by such Lender (and, in the opinion of such Lender, the designation of a different lending office would either not avoid such unlawfulness or would be disadvantageous to such Lender), then such Lender shall promptly notify the Borrower thereof, following which (i) such Lender’s Commitment shall be suspended until such time as such Lender may again make and maintain the Term Loan hereunder and (ii) if such Law shall so mandate, the Term Loan shall be prepaid by the Borrower on or before such date as shall be mandated by such Law in an amount equal to the aggregate principal amount of the Term Loan outstanding on the date of such prepayment plus any accrued but unpaid interest thereon.

Section 5.03. Taxes. For purposes of this Section 5.03, the term “applicable Law” includes FATCA.

(a) Payments Free of Taxes. Any and all payments by or on account of any Obligation shall be made without deduction or withholding for any Taxes, except as required by any applicable Law. If any applicable Law (as determined in the good faith discretion of an applicable Withholding Agent) requires the deduction or withholding of any Tax from any such payment by a Withholding Agent, then the applicable Withholding Agent shall be entitled to make such deduction or withholding and shall timely pay the full amount deducted or withheld to the relevant Governmental Authority in accordance with applicable Law and, if such Tax is an Indemnified Tax, then the sum payable by such Obligor shall be increased as necessary so that after such deduction or withholding has been made (including such deductions and withholdings applicable to additional sums payable under this Section 5.03) the applicable Recipient receives an amount equal to the sum it would have received had no such deduction or withholding been made.

-32-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

(b) Payment of Other Taxes by the Borrower. The Borrower shall timely pay to the relevant Governmental Authority in accordance with applicable Law, or at the option of the Administrative Agent, timely reimburse it for the payment of, Other Taxes.

(c) Evidence of Payments. As soon as reasonably practicable after any payment of Taxes by the Borrower to a Governmental Authority pursuant to this Section 5.03, the Borrower shall deliver to the Administrative Agent the original or a certified copy of a receipt issued by such Governmental Authority evidencing such payment, a copy of the return reporting such payment or other evidence of such payment reasonably satisfactory to the Administrative Agent.

(d) Indemnification by the Borrower. The Borrower shall reimburse and indemnify each Recipient, within ten (10) days after demand therefor, for the full amount of any Indemnified Taxes (including Indemnified Taxes imposed or asserted on or attributable to amounts payable under this Section 5.03) payable or paid by such Recipient or required to be withheld or deducted from a payment to such Recipient and any reasonable expenses arising therefrom or with respect thereto, whether or not such Indemnified Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. A certificate as to the amount of such payment or liability delivered to the Borrower by a Lender (with a copy to the Administrative Agent), or by the Administrative Agent on its own behalf or on behalf of a Lender, shall be conclusive absent manifest error.

(e) Indemnification by the Lender. Each Lender shall severally indemnify the Administrative Agent, within 10 days after demand therefor, for (i) any Indemnified Taxes attributable to such Lender (but only to the extent that the Borrower has not already indemnified the Administrative Agent for such Indemnified Taxes and without limiting the obligation of the Borrower to do so), and (ii) any Taxes attributable to such Lender, in each case, that are payable or paid by the Administrative Agent in connection with any Loan Document, and any reasonable expenses arising therefrom or with respect thereto, whether or not such Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. A certificate as to the amount of such payment or liability delivered to any Lender by the Administrative Agent shall be conclusive absent manifest error. Each Lender hereby authorizes the Administrative Agent to set off and apply any and all amounts at any time owing to such Lender under any Loan Document or otherwise payable by the Administrative Agent to such Lender from any other source against any amount due to the Administrative Agent under this paragraph (e).

-33-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

(f) Status of Lenders. (i) Any Lender that is entitled to an exemption from or reduction of withholding Tax with respect to payments made under any Loan Document shall deliver to the Borrower and the Administrative Agent, at the time or times prescribed by applicable Law or reasonably requested by the Borrower or the Administrative Agent, such properly completed and executed documentation reasonably requested by the Borrower or the Administrative Agent as will permit such payments to be made without withholding or at a reduced rate of withholding. In addition, any Lender shall deliver such other documentation prescribed by Law or reasonably requested by the Borrower or the Administrative Agent as will enable the Borrower or the Administrative Agent to determine whether or not such Lender is subject to backup withholding or information reporting requirements. Notwithstanding anything to the contrary in the preceding two sentences, the completion, execution and submission of such documentation (other than such documentation set forth in Section 5.03(f)(ii)(A), (ii)(B), and (ii)(D)) shall not be required if in such Lender’s reasonable judgment such completion, execution or submission would subject such Lender to any material unreimbursed cost or expense or would materially prejudice the legal or commercial position of such Lender.

(ii) Without limiting the generality of the foregoing:

(A) any Lender (or, if the Lender is a disregarded entity for U.S. federal income tax purposes, the Person treated as the owner of the assets of such Lender for U.S. federal income Tax purposes) that is a U.S. Person shall deliver to the Borrower and the Administrative Agent on or prior to the date on which such Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Administrative Agent), executed copies of IRS Form W-9 (or successor form) certifying that such Lender is exempt from U.S. federal backup withholding Tax;

(B) any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Borrower and the Administrative Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower and the Administrative Agent), whichever of the following is applicable:

(1) in the case of a Foreign Lender claiming the benefits of an income tax treaty to which the United States is a party (x) with respect to payments of interest under any Loan Document, executed copies of IRS Form W-8BEN or IRS Form W-8BEN-E as applicable (or successor forms) establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the “interest” article of such tax treaty and (y) with respect to any other applicable payments under any Loan Document, IRS Form W-8BEN or IRS Form W-8BEN-E as applicable (or successor forms) establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the “business profits” or “other income” article of such tax treaty;

-34-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

(2) executed copies of IRS Form W-8ECI (or successor form);

(3) in the case of a Foreign Lender claiming the benefits of the exemption for portfolio interest under Section 881(c) of the Code, (x) a certificate substantially in the form of Exhibit D-1 to the effect that such Foreign Lender is not a “bank” within the meaning of Section 881(c)(3)(A) of the Code, a “10 percent shareholder” of the applicable the Borrower within the meaning of Section 881(c)(3)(B) of the Code, or a “controlled foreign corporation” described in Section 881(c)(3)(C) of the Code (a “U.S. Tax Compliance Certificate”) and (y) executed copies of IRS Form W-8BEN or IRS Form W-8BEN-E as applicable (or successor forms); or

(4) to the extent a Foreign Lender is not the beneficial owner, executed copies of IRS Form W-8IMY (or successor form), accompanied by IRS Form W-8ECI (or successor form), IRS Form W-8BEN (or successor form), IRS Form W-8BEN-E, a U.S. Tax Compliance Certificate, substantially in the form of Exhibit D-2 or D-3, IRS Form W-9 (or successor form), and/or other certification documents from each beneficial owner, as applicable; provided that if the Foreign Lender is a partnership and one (1) or more direct or indirect partners of such Foreign Lender are claiming the portfolio interest exemption, such Foreign Lender may provide a U.S. Tax Compliance Certificate substantially in the form of Exhibit D-4 on behalf of each such direct and indirect partner.

(C) any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Borrower and the Administrative Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter at the time or times prescribed by applicable Law or upon the reasonable request of the Borrower or the Administrative Agent), executed copies of any other form prescribed by applicable Law as a basis for claiming exemption from or a reduction in U.S. federal withholding Tax, duly completed, together with such supplementary documentation as may be prescribed by applicable Law to permit the Borrower or the Administrative Agent to determine the withholding or deduction required to be made; and

(D) if a payment made to a Lender under any Loan Document would be subject to U.S. federal withholding Tax imposed by FATCA if such Lender were to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section 1471(b) or 1472(b) of the Code, as applicable), such Lender shall deliver to the Borrower and the Administrative Agent at the time or times prescribed by Law and at such time or times as reasonably requested by the Borrower or the Administrative Agent such documentation prescribed by applicable Law (including as prescribed by Section 1471(b)(3)(C)(i) of the Code) and such additional documentation reasonably requested by the Borrower or the Administrative Agent as may be necessary for the Borrower and the Administrative Agent to comply with their obligations under FATCA and to determine that such Lender has complied with such Lender’s obligations under FATCA or to determine the amount to deduct and withhold from such payment. Solely for purposes of this clause (D), “FATCA” shall include any amendments made to FATCA after the date of this Agreement.

-35-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Each Lender agrees that if any form or certification it previously delivered expires or becomes obsolete or inaccurate in any respect, it shall update such form or certification or promptly notify the Borrower and the Administrative Agent in writing of its legal inability to do so.

(g) Treatment of Certain Tax Benefits. If any party to this Agreement determines, in its sole discretion exercised in good faith, that it has received a refund of any Taxes as to which it has been indemnified pursuant to this Section 5.03 (including by the payment of additional amounts pursuant to this Section 5.03), it shall pay to the indemnifying party an amount equal to such refund (but only to the extent of indemnity payments made under this Section 5.03 with respect to the Taxes giving rise to such refund), net of all out-of-pocket expenses (including Taxes) of such indemnified party and without interest (other than any interest paid by the relevant Governmental Authority with respect to such refund). Such indemnifying party, upon the request of such indemnified party, shall repay to such indemnified party the amount paid over pursuant to this paragraph (plus any penalties, interest or other charges imposed by the relevant Governmental Authority) in the event that such indemnified party is required to repay such refund to such Governmental Authority. Notwithstanding anything to the contrary in this Section 5.03(g), in no event will the indemnified party be required to pay any amount to an indemnifying party pursuant to this Section 5.03(g) the payment of which would place the indemnified party in a less favorable net after-Tax position than the indemnified party would have been in if the Tax subject to indemnification and giving rise to such refund had not been deducted, withheld or otherwise imposed and the indemnification payments or additional amounts with respect to such Tax had never been paid. This Section 5.03(g) shall not be construed to require any indemnified party to make available its Tax returns (or any other information relating to its Taxes that it deems confidential) to the indemnifying party or any other Person.

(h) Designation of a Different Lending Office. If the Borrower is required to pay any Indemnified Taxes or additional amounts to any Lender or to any Governmental Authority for the account of any Lender pursuant to Section 5.01 or this Section 5.03, then such Lender shall (at the request of the Borrower) use commercially reasonable efforts to designate a different lending office for funding or booking its Term Loan hereunder or to assign and delegate its rights and obligations hereunder to another of its offices, branches or Affiliates if, in the sole reasonable judgment of such Lender, such designation or assignment and delegation would (i) eliminate or reduce amounts payable pursuant to Section 5.01 or this Section 5.03, as the case may be, in the future, (ii) not subject such Lender to any unreimbursed cost or expense and (iii) not otherwise be disadvantageous to such Lender. The Borrower hereby agrees to pay all reasonable costs and expenses incurred by any Lender in connection with any such designation or assignment and delegation.

-36-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

(i) Survival. Each party’s obligations under this Section 5 shall survive the resignation or replacement of the Administrative Agent or any assignment of rights by, or the replacement of, a Lender, the termination of the Commitments and the repayment, satisfaction or discharge of all Obligations under any Loan Document.

Section 5.04. Delay in Requests. Failure or delay on the part of any Lender to demand compensation pursuant to this Section 5 shall not constitute a waiver of such Lender’s right to demand such compensation; provided that the Borrower shall not be required to compensate a Lender pursuant to this Section for any increased costs incurred or reductions suffered more than six-months prior to the date that such Lender notifies the Borrower of the change in Law giving rise to such increased costs or reductions, and of such Lender’s intention to claim compensation therefor (except that, if the change in Law giving rise to such increased costs or reductions is retroactive, then the sixth-month period referred to above shall be extended to include the period of retroactive effect thereof).

Section 6. Conditions Precedent.

Section 6.01. Conditions to the Closing Date. The obligation of each Lender to make the Term Loan shall be subject to the execution and delivery of this Agreement by the parties hereto and the prior or concurrent satisfaction (or waiver thereof by the Administrative Agent) of each of the conditions precedent set forth below in this Section 6.01.

(a) Secretary’s Certificate, Etc. The Administrative Agent shall have received from each Obligor (i) a copy of a good standing certificate, dated a date reasonably close to the Closing Date, for each such Person and (ii) a certificate, dated as of the Closing Date, duly executed and delivered by such Person’s Secretary or Assistant Secretary, managing member, general partner or equivalent, as to:

(i) resolutions of each such Person’s Board then in full force and effect authorizing the execution, delivery and performance of each Loan Document to be executed by such Person and the Transactions;

(ii) the incumbency and signatures of those of its officers, managing member, general partner or equivalent authorized to act with respect to each Loan Document to be executed by such Person; and

(iii) the full force and validity of each Organic Document of such Person and copies thereof.

-37-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

(b) Closing Date Certificate. The Administrative Agent shall have received a certificate, dated as of the Closing Date and duly executed and delivered by a Responsible Officer of the Borrower, which certificate shall be in the form attached hereto as Exhibit M, stating that (i) both immediately before and after giving effect to the Borrowing of the Term Loan, (x) the representations and warranties set forth in each Loan Document shall, in each case, be true and correct in all material respects (or, in the case of any such representation or warranty already qualified by materiality, in all respects) and (y) no Default shall have then occurred and be continuing, or would result from the making of the Term Loan being advanced on the Closing Date and (ii) all of the conditions set forth in Section 6.01 have been satisfied or waived by the Administrative Agent.

(c) Solvency, Etc. The Administrative Agent shall have received a solvency certificate duly executed and delivered by the chief financial or accounting Responsible Officer of the Borrower, dated as of the Closing Date, in form and substance reasonably satisfactory to the Administrative Agent.

(d) Financial Information, Etc. The Administrative Agent shall have received:

(i) audited consolidated financial statements of the Borrower and its Subsidiaries for the fiscal year ended December 31, 2017; provided that the Borrower’s filing of an Annual Report on Form 10-K with the SEC with respect thereto shall be deemed to satisfy the requirements of this Section; and

(ii) unaudited consolidated balance sheets of the Borrower and its Subsidiaries for each fiscal quarter ended after December 31, 2017, together with the related consolidated statement of operations for such fiscal quarter; provided that the Borrower’s filing of a Quarterly Report on Form 10-Q with the SEC with respect to each such quarter shall be deemed to satisfy the requirements of this Section.

(e) Compliance Certificate. The Administrative Agent shall have received an initial Compliance Certificate, prepared on a pro forma basis as of the Closing Date demonstrating compliance with the covenants set forth in Section 10, duly executed (and with all schedules thereto duly completed) and delivered by a Responsible Officer of the Borrower.

(f) Opinions of Counsel. The Administrative Agent shall have received one (1) or more opinions, dated the Closing Date and addressed to the Administrative Agent and the Lenders, from Gracin & Xxxxxx, LLP, independent legal counsel to the Borrower and the other Obligors, and Xxxxxxx Xxxxx & Xxxxxxx, Nevada legal counsel to the Borrower and the other Obligors, each in form and substance reasonably acceptable to the Administrative Agent.

(g) Delivery of Notes. Each Lender that has requested a Note shall have received a Note for its Term Loan, duly executed and delivered by a Responsible Officer of the Borrower.

-38-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

(h) Security Documents. The Administrative Agent shall have received executed counterparts of each Security Document, dated as of Closing Date, duly executed and delivered by each Obligor, together with:

(i) subject to Section 8.17, delivery of all certificates (in the case of Equity Interests that are securities (as defined in the NY UCC)) evidencing the issued and outstanding capital securities owned by each Obligor that are required to be pledged under the Security Agreement, which certificates in each case shall be accompanied by undated instruments of transfer duly executed in blank or, in the case of Equity Interests that are uncertificated securities (as defined in the NY UCC), confirmation and evidence reasonably satisfactory to the Administrative Agent that the security interest required to be pledged therein under the Security Agreement has been transferred to and perfected by the Administrative Agent in accordance with Articles 8 and 9 of the NY UCC and all laws otherwise applicable to the perfection of the pledge of such Equity Interests;

(ii) financing statements naming each Obligor as a debtor and the Administrative Agent as the secured party (for the benefit of all Secured Parties) or other similar instruments or documents, in each case suitable for filing, to be filed under the Uniform Commercial Code (or equivalent law) of all jurisdictions as may be necessary to perfect the Liens of the Administrative Agent, for the benefit of the Lenders, pursuant to the Security Agreement;

(iii) UCC-1 (or equivalent) Lien searches reasonably satisfactory in scope and substance to the Administrative Agent covering each Obligor and its properties;

(iv) UCC-3 termination statements, or equivalent, as may be necessary to release all Liens and other rights of any Person in any collateral described in the Security Agreement previously granted by any Person; and

(v) all Short-Form IP Security Agreements required to be provided under the Security Agreement, each dated as of the Closing Date, duly executed and delivered by each Obligor that is required to do so under the Security Agreement.

(i) Material Adverse Change. No Material Adverse Change shall have occurred since December 31, 2017.

(j) Fees and Expenses, Etc. Each of the Administrative Agent and each Lender shall have received, for its own account, the fees, costs and expenses due and payable to it on the Closing Date pursuant to Sections 3.04 and 14.03, including all reasonable closing costs and fees and all unpaid reasonable expenses of the Administrative Agent and the Lenders incurred in connection with the Transactions (including the Administrative Agent’s and the Lenders’ reasonable and documented legal fees and expenses).

-39-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

(k) Collateral Questionnaire. The Administrative Agent shall have received a fully completed Collateral Questionnaire, dated as of the Closing Date, duly executed and delivered by a Responsible Officer of the Borrower.

(l) Warrant. The Administrative Agent shall have received the executed Warrant, dated as of the Closing Date.

(m) Insurance. The Administrative Agent shall have received certificates and endorsements of insurance evidencing the existence of all insurance required to be maintained by the Obligors and their respective Subsidiaries pursuant to Section 8.05 and the designation of the Administrative Agent as the Borrower’s loss payee or additional insured, as applicable.

(n) Pay-Off Letters. The Administrative Agent shall have received executed Pay-Off Letters terminating and cancelling the Pay-Off Indebtedness in full, in form and substance reasonably acceptable to it.

(o) Due Diligence. The Administrative Agent and the Lenders shall have received and be satisfied with all due diligence (including without limitation historical financial statements, projections, technical, operational, legal, intellectual property, commercial market forecasts, clinical and regulatory assessments, supply chain, securities, labor, Tax, litigation, environmental, reimbursement and regulatory authority matters) in their sole discretion.

(p) Icagen-T Loan Documents. The Administrative Agent shall have received executed copies of all Icagen-T Loan Documents.

(q) Bridge Notes. The Administrative Agent shall have received executed amendments to each Bridge Note existing on the Closing Date, in form and substance satisfactory to the Administrative Agent in order to subordinate all obligations thereunder to the Obligations, subject to permitted payments under Section 9.07.

(r) Series C Preferred Subordination Agreement. The Administrative Agent shall have received an executed copy of the Series C Preferred Subordination Agreement.

-40-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Section 7. Representations and Warranties.

The Borrower and each other Obligor hereby jointly and severally represents and warrants to the Administrative Agent and each Lender that:

Section 7.01. Power and Authority. Each Obligor (i) is duly organized and validly existing under the laws of its jurisdiction of organization, (ii) has all requisite corporate or other organizational power, and has all Governmental Approvals necessary to own its assets and carry on its business as now being, or as proposed to be conducted, except to the extent that failure to have the same would not reasonably be expected to have a Material Adverse Effect, (iii) is qualified to do business and is in good standing in all jurisdictions in which the nature of the business conducted by it makes such qualification necessary and where failure so to qualify (either individually or in the aggregate) would reasonably be expected to have a Material Adverse Effect, and (iv) has full power, authority and legal right to enter into and perform its obligations under each of the Loan Documents to which it is a party and, in the case of the Borrower, to borrow the Term Loan hereunder.

Section 7.02. Authorization; Enforceability. The Transactions are within each Obligor’s corporate or other organizational powers and have been duly authorized by all necessary corporate or other organizational action and, if required, by all necessary equity holder action on the part of such Obligor. This Agreement has been duly executed and delivered by each Obligor and constitutes, and each of the other Loan Documents to which it is a party when executed and delivered by such Obligor will constitute, a legal, valid and binding obligation of such Obligor, enforceable against such Obligor in accordance with its terms, except as such enforceability may be limited by (i) bankruptcy, insolvency, reorganization, moratorium or similar laws of general applicability affecting the enforcement of creditors’ rights and (ii) the application of general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law).

Section 7.03. Governmental and Other Approvals; No Conflicts. None of the Transactions (i) requires any Governmental Approval of, registration or filing with, or any other action by, any Governmental Authority or any other Person, except for (x) such as have been obtained or made and are in full force and effect and (y) filings and recordings in respect of perfecting or recording the Liens created pursuant to the Security Documents, (ii) will violate any applicable Law or any Organic Document of any Obligor or any of its Subsidiaries or any order of any Governmental Authority, other than any such violations that, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect, (iii) will result in a default under (x) any Material Agreement or (y) any Contract creating or evidencing any Material Indebtedness or (iv) will result in the creation or imposition of any Lien (other than Permitted Liens) on any asset of any Obligor.

Section 7.04. Financial Statements; Material Adverse Change.

(a) Financial Statements. The Borrower has heretofore furnished to the Administrative Agent and the Lenders certain consolidated financial statements as provided for in Section 6.01(d). Such financial statements, and all other financial statements delivered by the Borrower pursuant hereto (whether prior to the Closing Date or otherwise), present fairly, in all material respects, the consolidated financial position and results of operations and cash flows of the Borrower and its Subsidiaries as of such dates and for such periods in accordance with GAAP, subject to year-end audit adjustments and the absence of footnotes in the case of the statements of the type described in Section 8.01(a) and (b). Neither the Borrower nor any of its Subsidiaries has any material contingent liabilities or unusual forward or long-term commitments not disclosed in the aforementioned financial statements.

-41-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

(b) No Material Adverse Change. Since December 31, 2017, there has been no Material Adverse Change.

Section 7.05. Properties.

(a) Property Generally. Each Obligor has good title to, or valid leasehold interests in, all its real and tangible personal property material to its business subject only to Permitted Liens and except as would not reasonably be expected to materially interfere with its ability to conduct its business as currently conducted or to utilize such properties for their intended purposes.

(b) Intellectual Property.

(i) Schedule 7.05(b) lists all United States and foreign registrations of and applications for Patents, Trademarks, Copyrights, Industrial Designs and Technical Information that are Obligor Intellectual Property, including the applicable jurisdiction, registration or application number and date, as applicable thereto, and a designation as to whether it is licensed or owned by Obligor.

(ii) Obligors own or possess all legal and beneficial rights, title and interest in and to Obligor Intellectual Property designated on Schedule 7.05(b) as being owned by that Obligor and has the right to use the Obligor Intellectual Property licensed to that Obligor, in each case with good and marketable title, free and clear of any Liens or Claims of any kind whatsoever other than Permitted Liens.

(iii) To Obligors’ knowledge, Obligors’ current use of its Material Intellectual Property does not violate any license or infringe any valid and enforceable Intellectual Property right of another.

(iv) Other than with respect to the Material Agreements, or as permitted by Section 9.09, the Obligors have not transferred ownership of Material Intellectual Property, in whole or in part, to any Person who is not an Obligor.

(v) Other than as set forth on Schedule 7.05(b) and to Obligors’ knowledge, Obligors have not received any written communications, nor is there any pending or threatened action in writing, suit, proceeding or claim in writing by another, alleging that any of the Obligors has violated, infringed, diluted or misappropriated or, by conducting its business as currently conducted or as proposed to be conducted does or would violate, infringe, dilute or misappropriate any Intellectual Property of another, and to Obligors’ knowledge, there is no basis for such an allegation.

-42-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

(vi) To the Obligors’ knowledge, there is no pending or threatened action in writing, suit, proceeding or claim in writing by another (a) challenging Obligors’ rights in or to any Intellectual Property owned by, or licensed to, Obligors, and Obligors have no knowledge of any facts which could form a reasonable basis for any such action, suit, proceeding or claim; or (b) challenging the validity, enforceability or scope of any Intellectual Property owned by, or licensed to, Obligors, and Obligors have no knowledge of any facts which could form a reasonable basis for any such action, suit, proceeding or claim.

(vii) Obligors have taken reasonable precautions to protect the secrecy, confidentiality and value of the Obligor Intellectual Property, including without limitation, by requiring that all relevant current and former employees, contractors and consultants of Obligors execute written confidentiality agreements.

(viii) Obligors have complied with the material terms of each Material Agreement pursuant to which Intellectual Property has been licensed to Obligors (which material terms shall include, but not be limited to, pricing and duration of the agreement), and all such Material Agreements are in full force and effect, and Obligors have no knowledge of any facts which could form a reasonable basis for any claims of breach or default under such Material Agreements.

(ix) Other than those permitted by Section 9.09, or as set forth on Schedule 7.05(b), (a) there are no outstanding options, licenses, agreements, claims, encumbrances or shared ownership interests of any kind relating to the Intellectual Property owned by, or licensed to, Obligors and (b) nor are Obligors bound by, or a party to, any options, licenses or agreements of any kind with respect to any Intellectual Property of another other than standard rights of customers and contract research organizations.

(x) Obligors have no knowledge of any prior art that would reasonably be expected to render any claim of any United States Patent within the Material Intellectual Property invalid that has not been disclosed to the United States Patent and Trademark Office.

(xi) All maintenance fees, annuities, and the like due or payable on the Patents have been timely paid or the failure to so pay was the result of an intentional decision by the applicable Obligor, which would not reasonably be expected to result in a Material Adverse Change.

-43-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

(xii) To Obligors’ knowledge, there are no material defects in any of the Patents that constitute the Material Intellectual Property and no such Patents have ever been finally adjudicated to be invalid, unpatentable or unenforceable for any reason in any administrative, arbitration, judicial or other proceeding.

(xiii) Obligors have not received any notice asserting that the Patents constituting Material Intellectual Property are invalid, unpatentable or unenforceable and, to Obligors’ knowledge, neither they nor any current or prior owner of such Patents or their respective agents or representatives, have engaged in any conduct, or omitted to perform any necessary act, the result of which would invalidate or render unpatentable or unenforceable any such Patent.

(xiv) To Obligors’ knowledge, other than as set forth in Schedule 7.05(b), Obligors are not obligated to make any payment by way of royalties, fees or otherwise to any owner or licensee of, or other claimant to, any Obligor Intellectual Property, with respect to the use thereof or in connection with the conduct of its business or otherwise.

(xv) To Obligors’ knowledge, no employee of Obligors is or has been in violation of any term of any employment contract, patent disclosure agreement, invention assignment agreement, non-competition agreement, non-solicitation agreement, nondisclosure agreement or any restrictive covenant to or with a former employer where the basis of such violation relates to such employee’s employment with Obligors.

(xvi) Each employee and each consultant retained to generate intellectual property for any Obligor has waived all moral rights and assigned to Obligors all intellectual property rights he or she owns that are related to Obligors’ business as now conducted and as presently proposed to be conducted.

Section 7.06. No Actions or Proceedings.

(a) Litigation. There is no litigation, investigation or proceeding pending or, to the Borrower’s knowledge, threatened in writing with respect to any Obligor or any of its Subsidiaries by or before any Governmental Authority or arbitrator that (i) either individually or in the aggregate would reasonably be expected to have a Material Adverse Effect, except as specified in Schedule 7.06(a), or (ii) involves this Agreement, any other Loan Document or the Transactions.

(b) Environmental Matters. The operations and property of such Obligor and each of its Subsidiaries comply with all applicable Environmental Laws, except to the extent the failure to so comply (either individually or in the aggregate) would not reasonably be expected to have a Material Adverse Effect. There have been no conditions, occurrences or release of Hazardous Materials which would reasonably be expected to form the basis of any environmental liability claim under applicable Environmental Laws with respect to Borrower’s and its Subsidiaries’ businesses, operations or properties.

-44-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

(c) Labor Matters. There are no labor disputes against the Borrower or any Subsidiary or, to the Borrower’s knowledge, threatened in writing against the Borrower or any Subsidiary, and no unfair labor practice complaint is pending against the Borrower or any Subsidiary or, to the knowledge of the Borrower, threatened in writing against any of them before any Governmental Authority, in each case which would reasonably be expected to result in a Material Adverse Effect. There is no material strike or work stoppage in existence or threatened in writing against the Borrower or any Subsidiary. Except as set forth on Schedule 7.06(c), the Borrower is not party to any collective bargaining agreements or contracts, no union representation exists at any facilities of the Borrower or any of its Subsidiaries and, to the knowledge of the Borrower, no union organizing activities with respect to its business are taking place.

Section 7.07. Compliance with Laws and Agreements. Each of the Obligors is in compliance with all Laws, regulations and orders of any Governmental Authority applicable to it or its property and all indentures, agreements and other instruments binding upon it or its property, except where the failure to do so, individually or in the aggregate, would not reasonably be expected to result in a Material Adverse Effect. To the extent applicable, Obligors and their Subsidiaries are in compliance with 21 CFR §§ 210-211 and 21 CFR §§ 600-610.

Section 7.08. Taxes. Each of the Obligors has timely filed or caused to be filed all income and other material tax returns and reports required to have been filed and has paid or caused to be paid all material Taxes, fees, assessments and governmental charges or levies required to have been paid by it, except Taxes, fees, assessments and governmental charges or levies that are being contested in good faith by appropriate proceedings and for which such Obligor has set aside on its books adequate reserves with respect thereto in accordance with GAAP.

Section 7.09. Full Disclosure. None of the reports, financial statements, certificates or other information furnished by or on behalf of the Obligors to any Lender in connection with the negotiation of this Agreement and the other Loan Documents or delivered hereunder or thereunder (as modified or supplemented by other information so furnished) contains any misstatement of material fact or omits to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided that, with respect to projected financial information, the Borrower represents only that such information was prepared in good faith based upon assumptions believed to be reasonable at the time (it being understood by the Administrative Agent and the Lenders that such projected financial information is not to be viewed as fact, and that no assurances can be given that any particular projections will be realized and that actual results during the period or periods covered by any such projections may differ from the projected results and such differences may be material).

Section 7.10. Investment Company and Margin Stock Regulation.

(a) Investment Company Act. Neither the Borrower nor any of its Subsidiaries is an “investment company” as defined in, or subject to regulation under, the Investment Company Act of 1940.

-45-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

(b) Margin Stock. Neither the Borrower nor any of its Subsidiaries is engaged principally, or as one of its important activities, in the business of extending credit for the purpose, whether immediate, incidental or ultimate, of buying or carrying Margin Stock, and no part of the proceeds of the Term Loan will be used to buy or carry any Margin Stock in violation of Regulation T, U or X.

Section 7.11. Solvency. The Borrower and its Subsidiaries, on a consolidated basis, are and, immediately after giving effect to the Borrowing and the use of proceeds thereof, will be Solvent.

Section 7.12 Equity Holders; Subsidiaries; Equity Investments. (a)  Set forth on Schedule 7.12(a) is a complete and correct list of all holders of the Equity Interests of Borrower, setting forth the name of each such holder, the series or class of Equity Interest of Borrower held by such holder and the fully diluted percentage ownership of Borrower held beneficially by such holder. Borrower is not in material breach of any Material Agreement between the Borrower and any of the holders of Equity Interests of the Borrower, and the Borrower has fulfilled all of its material obligations under any such Material Agreements. The Borrower has received all consents of the holders of the Equity Interests of the Borrower necessary for the Transactions, including any such consent pursuant to any right of first refusal, right of first offer, tag-along right, co-sale right or similar rights, and, as of the date hereof, all of the holders of Equity Interests of the Borrower with any such rights have declined to exercise such rights in connection with the Transactions.

(b) Set forth on Schedule 7.12(b) is a complete and correct list of all Subsidiaries of the Borrower. Each such Subsidiary is duly organized and validly existing under the jurisdiction of its organization shown in said Schedule 7.12(b), and the percentage ownership by the Borrower or other entity of each such Subsidiary is as shown in said Schedule 7.12(b).

(c) Set forth on Schedule 7.12(c) is a complete and correct list of all other Equity Interests held by each Obligor in any Person that is not a direct or indirect Subsidiary of the Borrower. Such Schedule 7.12(c) also sets forth in reasonable detail, the type of Equity Interest held by each such Obligor in such Person and the fully-diluted percentage ownership held beneficially by such Obligor in such Person.

Section 7.13. Indebtedness and Liens. Set forth on Schedule 7.13(a) is a complete and correct list of all Indebtedness of the Borrower and each other Obligor outstanding as of the date hereof that will remain outstanding immediately after the making of the Term Loan and the application of the proceeds therefrom on the Closing Date. Set forth on Schedule 7.13(b) is a complete and correct list of all Indebtedness outstanding on the date hereof that will be repaid and satisfied in full on the Closing Date with proceeds of the Term Loan made on such date. Schedule 7.13(c) is a complete and correct list of all Liens granted by the Borrower and other Obligors with respect to their respective property which are outstanding as of the Closing Date after giving effect to the Transactions (other than the Liens granted pursuant to the Loan Documents).

-46-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Section 7.14. Material Agreements. Set forth on Schedule 7.14 is a complete and correct list of the Material Agreements that will remain outstanding as of the Closing Date after giving effect to the Transactions. No Obligor is in material default under any Material Agreement and the Borrower has no knowledge of any material default by any counterparty to any such Material Agreement or Contract. Except as otherwise disclosed on Schedule 7.14, all Material Agreements that include a grant of rights under any Material Intellectual Property to an Obligor are in full force and effect without material modification from the form in which the same were disclosed to the Administrative Agent.

Section 7.15. Restrictive Agreements. Except as set forth in Schedule 7.15, no Obligor is subject to any Restrictive Agreement as of the Closing Date after giving effect to the Transactions, except those permitted under Section 9.11.

Section 7.16. Real Property. Except as set forth in Schedule 7.16, no Obligor owns or leases (as tenant thereof) any real property.

Section 7.17. Pension Matters. Schedule 7.17 sets forth a complete and correct list of, and that separately identifies, (i) all Title IV Plans and (ii) all Multiemployer Plans. Except for those that would not reasonably be expected to, in the aggregate, have a Material Adverse Effect or result under ERISA or Code Section 430(k) in a Lien under on the assets or property of any Obligor or any of its Subsidiaries, no ERISA Event has occurred in connection with which obligations and liabilities (contingent or otherwise) remain outstanding or is reasonably expected to occur.

Section 7.18. Collateral; Security Interest. Each Security Document is effective to create in favor of the Administrative Agent (for the benefit of the Secured Parties) a legal, valid and enforceable security interest, as security for the Obligations, in the Collateral subject to such Security Document and each such security interest is perfected on a first-priority basis (subject only to Permitted Priority Liens).

Section 7.19. Regulatory Approvals. (a) Each Obligor and each of its Subsidiaries holds either directly or through licensees and agents, all Regulatory Approvals, licenses, permits and similar governmental authorizations of a Governmental Authority necessary or required for each Obligor and its Subsidiaries to conduct their operations and business substantially in the manner currently conducted.

(b) Set forth on Schedule 7.19(b) is a complete and accurate list as of the date hereof of all Regulatory Approvals relating to the Obligors and the conduct of their business. All such Regulatory Approvals are (i) legally and beneficially owned exclusively by the Obligors, free and clear of all Liens other than Permitted Liens, (ii) validly registered and on file with the applicable Governmental Authority, in material compliance with all registration, filing and maintenance requirements (including any fee requirements) thereof, and (iii) in good standing, valid and enforceable with the applicable Governmental Authority in all material respects.

-47-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

(c) (i) All material regulatory filings required by any Regulatory Authority have been made, and all such filings are complete and correct in all material respects and have complied in all material respects with all applicable laws and regulations and (ii) each Obligor has disclosed to the Administrative Agent all such material regulatory filings and all material communications between representatives of each Obligor and any Regulatory Authority.

(d) Each Obligor and each of its agents are in compliance in all material respects with all applicable Laws (including all Regulatory Approvals) of all applicable Governmental Authorities, including the FDA and all other Regulatory Authorities. Each Obligor has and maintains in full force and effect all the necessary and requisite Regulatory Approvals. Each Obligor is in compliance in all material respects with all applicable registration and listing requirements set forth in the FD&C Act or equivalent regulation of each other Governmental Authority having jurisdiction over such Person. Each Obligor adheres in all material respects to all applicable regulations of all Regulatory Authorities.

(e) Except as set forth on Schedule 7.19(e), no Obligor has received from any Regulatory Authority any notice of adverse findings, including any FDA Form 483 inspectional observations, notices of violations, Warning Letters, criminal proceeding notices under Section 305 of the FD&C Act, or any other similar communication from any Regulatory Authority.

(f) Neither any Obligor nor any officer, employee or agent thereof, has made an untrue statement of a material fact or fraudulent statements to the FDA or any other Regulatory Authority, failed to disclose a material fact required to be disclosed to the FDA or any other Regulatory Authority, or committed an act, made a statement, or failed to make a statement that, at the time such disclosure was made (or was not made), would reasonably be expected to provide a basis for the FDA or any other Regulatory Authority to invoke its policy respecting Fraud, Untrue Statements of Material Facts, Bribery and Illegal Gratuities, set forth in 56 Fed. Reg. 46191 (September 10, 1991) or any similar policy.

(g) The clinical, preclinical, safety and other studies and tests conducted by or on behalf of or sponsored by each Obligor (if any) were (and if still pending, are) being conducted materially in accordance with standard medical and scientific research procedures. Each Obligor has operated within, and currently is in compliance in all material respects with, all applicable laws, and Regulatory Approvals, as well as the rules and regulations of the FDA and each other Regulatory Authority.

(h) No Obligor is in the business of Product Commercialization and Development Activities, as well as any clinical or preclinical trials with respect thereto.

Section 7.20. Transactions with Affiliates. Except as set forth on Schedule 7.20, no Obligor nor any of its Subsidiaries has entered into, renewed, extended or been a party to, any transaction (including the purchase, sale, lease, transfer or exchange of property or assets of any kind or the rendering of services of any kind) with any Affiliate during the three-year period prior to the Closing Date.

-48-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Section 7.21. OFAC. Except as set forth on Schedule 7.21, no Obligor nor any of its Subsidiaries, nor, to the knowledge of the Borrower, any of their respective directors, officers, or employees nor, to the knowledge of the Borrower, any agents or other Persons acting on behalf of any of the foregoing (i) is currently the target of any Sanctions, (ii) is located, organized or residing in any Designated Jurisdiction, (iii) is or has been engaged in any transaction with, or for the benefit of, any Person who is now or was then the target of Sanctions or who is located, organized or residing in any Designated Jurisdiction or (iv) is or has ever been in violation in any material respect of or subject to an investigation relating to Sanctions. No Term Loan, nor the proceeds from the Term Loan, has been or will be used, directly or indirectly, to lend, contribute or provide to, or has been or will be otherwise made available to fund, any activity or business in any Designated Jurisdiction or to fund any activity or business of any Person, to the Borrower’s knowledge, located, organized or residing in any Designated Jurisdiction or who is the subject of any Sanctions, or in any other manner that will result in any violation in any material respect by the Borrower or any of its Subsidiaries of Sanctions.

Section 7.22. Anti-Corruption. No Obligor nor any of its Subsidiaries, nor, to the knowledge of the Borrower, any of their respective directors, officers or employees nor, to the knowledge of the Borrower, any agents or other Persons acting on behalf of any of the foregoing, directly or indirectly, has (i) violated or is in violation, in any material respect, of any applicable anti-corruption Law, or (ii) made, offered to make, promised to make or authorized the payment or giving of, directly or indirectly, any Prohibited Payment. To the Borrower’s knowledge, no Obligor has been subject to any investigation by any Governmental Authority with regard to any actual or alleged Prohibited Payment.

Section 7.23. Deposit and Disbursement Accounts. Schedule 7.23 contains a list of all banks and other financial institutions at which any Obligor or any of its Subsidiaries maintains Deposit Accounts, Securities Accounts and Commodity Accounts, and Schedule 7.23 sets forth the name, address and telephone number of each such bank or financial institution, the name in which such account is held, the type of such account and the complete account number therefor.

Section 7.24. Royalty and Other Payments. Except as set forth on Schedule 7.24, no Obligor, nor any of its Subsidiaries, is obligated to pay any royalty, milestone payment, deferred payment or any other contingent payment.

-49-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Section 8. Affirmative Covenants.

Each Obligor covenants and agrees with the Lenders that, until the Commitments have expired or been terminated and all Obligations (other than Warrant Obligations and contingent obligations as to which no claims have been asserted) have been indefeasibly paid in full in cash:

Section 8.01. Financial Statements and Other Information. The Borrower will furnish to the Administrative Agent:

(a) as soon as available and in any event within 30 days after the end of each month (including the last month of each fiscal quarter), a consolidated balance sheet for the Borrower and its Subsidiaries as of the end of such month, and the related consolidated statements of income and cash flows for such month and the portion of the fiscal year through the end of such month, all in reasonable detail and setting forth in comparative form the figures for the corresponding period in the preceding fiscal year, together with a certificate of a Responsible Officer of the Borrower stating that such financial statements fairly present in all material respects the financial condition of the Borrower and its Subsidiaries as at such date and the results of operations of the Borrower and its Subsidiaries for the period ended on such date and have been prepared in accordance with GAAP, subject to changes resulting from normal, year-end audit adjustments and except for the absence of notes;

(b) as soon as available and in any event within five (5) Business Days following the date on which the Borrower files or is required to file a Quarterly Report on Form 10-Q with the SEC, a consolidated balance sheet for the Borrower and its Subsidiaries as of the end of such quarter, and the related consolidated statements of income and cash flows for such quarter and the portion of the fiscal year through the end of such quarter, all in reasonable detail and setting forth in comparative form the figures for the corresponding period in the preceding fiscal year, together with a certificate of a Responsible Officer of the Borrower stating that such financial statements fairly present in all material respects the financial condition of the Borrower and its Subsidiaries as at such date and the results of operations of the Borrower and its Subsidiaries for the period ended on such date and have been prepared in accordance with GAAP, subject to changes resulting from normal, year-end audit adjustments and except for the absence of notes; provided that, so long as the Borrower is subject to the public reporting requirements of the Exchange Act, the Borrower’s filing of a Quarterly Report on Form 10-Q with the SEC shall be deemed to satisfy the requirements of this Section 8.01(b) on the date on which such report is first available via the SEC’s XXXXX system or a successor system related thereto;

(c) as soon as available and in any event within five (5) Business Days following the date on which the Borrower files or is required to file its Annual Report on Form 10-K with the SEC, a consolidated balance sheet for the Borrower and its Subsidiaries as of the end of such fiscal year, and the related consolidated statements of income, shareholders’ equity and cash flows for such fiscal year, all in reasonable detail and setting forth in comparative form the figures for the previous fiscal year, accompanied by a report and opinion thereon of RBSM LLP or another firm of independent certified public accountants of recognized national standing reasonably acceptable to the Administrative Agent, which report and opinion shall be prepared in accordance with GAAP and which shall not be subject to any Impermissible Qualification; provided that, the financial statements for the fiscal years ending 2018 and 2019 may be subject to an Impermissible Qualification; provided further that, so long as the Borrower is subject to the public reporting requirements of the Exchange Act, the Borrower’s filing of an Annual Report on Form 10-K with the SEC shall be deemed to satisfy the requirements of this Section 8.01(c) on the date on which such report is first available via the SEC’s XXXXX system or a successor system related thereto;

-50-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

(d) together with the financial statements required pursuant to Sections 8.01(a) (b) and (c), a compliance certificate signed by a Responsible Officer of the Borrower as of the end of the applicable accounting period substantially in the form of Exhibit E (a “Compliance Certificate”), including details of any issues raised by the Borrower’s auditors that would be reasonably likely to result in a Material Adverse Effect and the creation or other acquisition of any Intellectual Property by any Obligor or any of its Subsidiaries after the date hereof and during such prior fiscal quarter for which such Compliance Certificate is delivered, which is registered or becomes registered or the subject of an application for registration with the U.S. Copyright Office or the U.S. Patent and Trademark Office, as applicable, or with any other equivalent foreign Governmental Authority;

(e) within three (3) Business Days after the end of each fiscal month, a certificate signed by a Responsible Officer of the Borrower as of the end of such fiscal month demonstrating compliance with Section 10.01 hereof;

(f) as soon as available and in any event no later than forty-five (45) days following the end of any fiscal year of the Borrower, copies of an annual budget (or equivalent) for the Borrower and its Subsidiaries, approved by the Borrower’s Board for the next succeeding fiscal year, in form reasonably satisfactory to the Administrative Agent, accompanied by a certificate of the chief financial officer of the Borrower certifying that (i) such budget was prepared by the Borrower in good faith, (ii) the Borrower had at the time of preparation of the budget, and at all times thereafter (including on and as of the date of delivery to the Administrative Agent of such budget) has continued to have, a reasonable basis for all of the assumptions contained in such budget and (iii) such budget was prepared in accordance with, and based upon, such assumptions;

(g) promptly, and in any event within five (5) Business Days after receipt thereof by any Obligor, copies of each notice or other correspondence received from the SEC (or comparable agency in any applicable non-U.S. jurisdiction) concerning any investigation or possible investigation or other inquiry by such agency regarding financial or other operational results of such Obligor (but in any case excluding any routine comments and letters from the SEC relating to such Obligor’s filings with the SEC or information that would violate confidentiality obligations to a Governmental Authority);

(h) information regarding insurance maintained by the Borrower and its Subsidiaries as required under Section 8.05;

-51-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

(i) within five (5) days after delivery thereof, copies of all statements, reports and notices made available to Borrower’s Board or holders of Borrower’s Equity Interests; provided that any such material may be redacted by the Borrower to (i) exclude information relating to the Lenders (including the Borrower’s strategy regarding the Term Loan), (ii) prevent the disclosure of trade secrets and (iii) protect and preserve attorney-client privilege;

(j) as soon as possible and in any event within five (5) Business Days after the Borrower obtains knowledge of any Claim related to any Obligor that that involves more than $500,000, written notice thereof from a Responsible Officer of the Borrower which notice shall include any statement setting forth details of such Claim; and

(k) such other information respecting the operations, properties, business or condition (financial or otherwise) of the Obligors (including with respect to the Collateral) as the Administrative Agent may from time to time reasonably request;

provided, notwithstanding the foregoing, Borrower covenants and agrees that neither Borrower, nor any other Person acting on its behalf, will provide, or be obligated to provide, any Lender or its representatives with any information that Borrower believes constitutes material non-public information, unless prior thereto such Lender shall have confirmed to Borrower in writing that it consents to receive such information. Borrower understands and confirms that each Lender shall be relying on the foregoing covenant in effecting transactions in securities of Borrower.

Section 8.02. Notices of Material Events. Borrower will furnish to the Administrative Agent written (or, in the case of Section 8.02(n), written or telephonic) notice of the following promptly (but in any event, except as otherwise set forth in 8.02(o), within five (5) Business Days) after a Responsible Officer obtains knowledge of the existence thereof (or as otherwise provided below); provided that the Borrower’s disclosure of such event in a press release and/or through a filing with the SEC in a Quarterly Report on Form 10-Q, an Annual Report on Form 10-K or a Current Report on Form 8-K shall be deemed to satisfy the requirements of this Section 8.02:

(a) the occurrence of any Default or Event of Default;

(b) the occurrence of any event with respect to any Obligor’s property or assets resulting in a Loss aggregating in excess of $250,000;

(c) (i) any proposed Acquisition by any Obligor that would reasonably be expected to result in environmental liability under Environmental Laws in excess of $250,000, (ii) any spillage, leakage, discharge, disposal, leaching, migration or release of any Hazardous Material required to be reported to any Governmental Authority under applicable Environmental Laws that would reasonably be expected to result in a liability in excess of $250,000 and (iii) all Claims, notices of violation, hearings, investigations or proceedings pending or, to the Borrower’s knowledge, threatened in writing against or directly affecting any Obligor or any of its Subsidiaries or with respect to the ownership, use, maintenance and operation of their respective businesses, operations or properties, relating to Environmental Laws or Hazardous Material, in each case that would reasonably be expected to result in a liability in excess of $250,000;

-52-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

(d) the assertion in writing by any Person against, or with respect to the activities of, any Obligor of any alleged violation of or non-compliance with any Environmental Laws or any permits, licenses or authorizations required pursuant to any Environmental Law which would reasonably be expected to result in liability to such Obligor in excess of $250,000;

(e) the filing or commencement of any action, suit or proceeding by or before any arbitrator or Governmental Authority against or directly affecting any Obligor or any of its Subsidiaries that, if adversely determined, would reasonably be expected to result in a Material Adverse Effect;

(f) (i) on or prior to any filing by any ERISA Affiliate of any notice of intent to terminate any Title IV Plan, a copy of such notice and (ii) promptly, and in any event within ten (10) days, after any Responsible Officer of any ERISA Affiliate knows or has reason to know that an ERISA Event has occurred, a notice (which may be made by telephone if promptly confirmed in writing) describing such ERISA Event and any action that any ERISA Affiliate proposes to take with respect thereto, together with (if applicable) a copy of any notice filed with the PBGC or the IRS pertaining thereto;

(g) (i) the termination of any Material Agreement other than on its scheduled termination date; (ii) the receipt by any Obligor of any notice under any Material Agreement (and a copy thereof); (iii) the entering into of any new Material Agreement by an Obligor (and a copy thereof); or (iv) any material amendment to a Material Agreement (and a copy thereof);

(h) the reports and notices as required by the Security Documents;

(i) any material change in accounting policies or financial reporting practices by the Obligors;

(j) any labor controversy resulting in or threatening to result in any strike, work stoppage, boycott, shutdown or other material labor disruption against or involving an Obligor or any of its Subsidiaries;

-53-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

(k) any licensing agreement or similar arrangement entered into by any Obligor or any of its Subsidiaries in connection with any material infringement or alleged material infringement of the Intellectual Property of another Person;

(l) any change to any Obligor’s or any of its Subsidiaries’ ownership or maintenance of Deposit Accounts, Securities Accounts and Commodity Accounts (other than Excluded Accounts), by delivering to the Administrative Agent a supplement to the Schedules to this Agreement and the Security Agreement, as applicable, setting forth a complete and correct list of all such accounts as of the date of such change;

(m) (i) any safety alerts, marketing suspensions, removals or similar actions conducted, to be undertaken, or issued by, any Obligor or any of its Subsidiaries or (ii) any material safety alerts, marketing suspensions, removals or similar actions conducted, to be undertaken, or issued by, any Obligor’s and any of its Subsidiaries’ agents, suppliers, licensors or licensees, as the case may be, in each case of (i) and (ii) above, whether voluntary or at the request, demand or order of any Regulatory Authority or otherwise;

(n) any Claim by any Person that any Obligor or any of its Subsidiaries has infringed upon any Intellectual Property of such Person, in each case to the extent such Claim would reasonably be expected to cause a Material Adverse Effect;

(o) with respect to any “Grantor” under the Security Agreement, if such Grantor intends to (i) change its location (as defined in Section 9-307 of the UCC), or (ii) change its name from the name shown as its current legal name on Schedule 1 to the Security Agreement, the Borrower shall provide five (5) days’ prior written notice to the Administrative Agent (or such shorter period as may be acceptable to Administrative Agent in its reasonable discretion);

(p) the occurrence or existence of any event, circumstance, act or omission that would cause any representation or warranty contained in Sections 7.07, 7.18 or 7.19 to be incorrect in any material respect if such representation or warranty was to be made at the time the Borrower learned of such event, circumstance, act or omission; provided that in the event notice is required hereunder with respect to Section 7.19(h), Borrower hereby agrees that it will take all such actions that the Administrative Agent may reasonably request to amend the Loan Document to reflect such change; and

(q) any other development that results in, or would reasonably be expected to result in, a Material Adverse Effect.

Each notice delivered under this Section 8.02 shall be accompanied by a statement of a Responsible Officer of the Borrower setting forth in reasonable detail the event or development requiring such notice and any action taken or proposed to be taken with respect thereto. Nothing in this Section 8.02 is intended to waive, consent to, or otherwise permit any action or omission that is otherwise prohibited by this Agreement or any other Loan Document.

-54-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Section 8.03. Existence; Conduct of Business. Such Obligor will, and will cause each of its Subsidiaries to, do or cause to be done all things necessary to preserve, renew and keep in full force and effect its legal existence and all Governmental Approvals material to the conduct of its business; provided that the foregoing shall not prohibit any transaction permitted under Section 9.03.

Section 8.04. Payment of Obligations. Such Obligor will, and will cause each of its Subsidiaries to, pay and discharge its obligations, including (i) all material Taxes, fees, assessments and governmental charges or levies imposed upon it or upon its properties or assets prior to the date on which penalties attach thereto, and all material lawful Claims for labor, materials and supplies which, if unpaid, would become a Lien (other than a Permitted Lien) upon any properties or assets of such Obligor any of its Subsidiaries, except to the extent such Taxes, fees, assessments or governmental charges or levies are Permitted Liens and (ii) all other lawful Claims which, if unpaid, would by Law become a Lien (other than a Permitted Lien) upon any material properties or assets of such Obligor or any of its Subsidiaries, except to the extent any of the foregoing are being contested in good faith by appropriate proceedings and are adequately reserved against in accordance with GAAP.

Section 8.05. Insurance. At its own cost and expense, each Obligor will, and will cause each of its Subsidiaries, to obtain and maintain insurance of the kinds, and in the amounts, set forth below, it being understood and agreed that the insurance held by the Obligors on the Closing Date is deemed to fulfill this requirement on the date hereof:

(a) All Risks of Physical Loss Insurance. Insurance against loss, destruction or damage to its properties and assets (including the Collateral) as determined in its good faith business judgment to be customary for companies similar to the Borrower.

(b) Commercial General Liability Insurance. Commercial general liability insurance covering bodily injury, death, property damage, products liability in such amounts as are generally required by institutional lenders for businesses and assets comparable to the business and assets of the Borrower.

(c) Workers Compensation Insurance. Workers’ compensation insurance with respect to any work performed on or about the property or assets of the Borrower.

-55-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

(d) General Requirements. All of the insurance policies of the Obligors required pursuant to this Section 8.05 will (i) be issued by financially sound and reputable insurers, and (ii) from and after the Closing Date (or such later date as agreed to by the Administrative Agent in its reasonable discretion), (x) name the Administrative Agent as a “loss payee,” “additional insured” or “mortgagee,” as applicable, and (y) provide for thirty (30) days’ prior written notice (ten (10) days’ prior written notice from the Borrower for nonpayment of premium) to the Administrative Agent before such policy is canceled or terminated. In the event the Obligors fail to maintain the insurance required pursuant to this Section 8.05, then the Administrative Agent may obtain insurance necessary to comply with this Section 8.05 with respect to such Obligors, in each case at the expense of the Borrower (payable on demand). The amount of any such expenses shall accrue interest at the Default Rate if not paid on demand, and shall constitute “Obligations.” All of the insurance policies required hereby will be evidenced by one or more certificates of insurance, together with appropriate loss payee or additional insured clauses or endorsements in favor of the Administrative Agent as required by this Section, delivered to the Administrative Agent at such times as the Administrative Agent may reasonably request from time to time. Unless an Event of Default has occurred and is continuing, the Administrative Agent agrees to turn over to the Borrower any proceeds from insurance received by the Administrative Agent within fifteen (15) Business Days following its receipt of a notice by the Borrower of the Borrower’s intention to reinvest such proceeds as set forth in Section 3.03(b).

Section 8.06. Books and Records; Inspection Rights. Such Obligor will, and will cause each of its Subsidiaries to, keep proper books of record and account in which full, true and correct entries are made of all dealings and transactions. Such Obligor will, and will cause each of its Subsidiaries to, permit any representatives designated by the Administrative Agent, upon at least three (3) Business Days’ prior written notice and during normal business hours, to visit and inspect its properties, to examine and make extracts from its books and records (excluding records subject to attorney-client privilege, subject to confidentiality agreements with third parties that preclude disclosure to the Administrative Agent (acting in such capacity) or subject to confidentiality restrictions pursuant to Law (including HIPAA)), and to discuss its affairs, finances and condition with its officers and independent accountants, all at such reasonable times (but not more often than twice per year unless an Event of Default has occurred and is continuing) as the Administrative Agent may request. The Borrower shall pay all reasonable and documented costs and expenses of all such inspections.

Section 8.07. Compliance with Laws and Other Obligations. Such Obligor will, and will cause each of its Subsidiaries to, (i) comply in all material respects with all applicable Laws (including Environmental Laws) and (ii) comply in all material respects with all terms of outstanding Indebtedness and all Material Agreements, except where the failure to do so, individually or in the aggregate, would not reasonably be expected to result in a Material Adverse Effect.

Section 8.08. Maintenance of Properties, Etc. Such Obligor shall, and shall cause each of its Subsidiaries to, maintain and preserve all of its real and tangible personal property necessary in the conduct of its business in good working order and condition in accordance with the general practice of other Persons of similar character and size, ordinary wear and tear and damage from casualty or condemnation excepted.

-56-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Section 8.09. Maintenance of Regulatory Approvals and Material Intellectual Property. (a) Such Obligor shall, and shall cause each of its Subsidiaries to, maintain, in full force and effect in all material respects, each Regulatory Approval required to conduct their respective businesses as presently conducted; provided that such Obligor or such Subsidiary shall not be required to preserve any such Regulatory Approval if such Obligor or such Subsidiary shall determine in its reasonable good faith judgment that the preservation thereof is no longer necessary in the conduct of its business.

(b) Such Obligor shall, and shall cause each of its Subsidiaries to, use commercially reasonable efforts to (i) protect and preserve all Material Intellectual Property necessary in the conduct of its business and (ii) enforce or defend the Material Intellectual Property against infringement, misappropriation, violation or interference by any other Persons; provided that nothing in this Section 8.09(b) shall prohibit or prevent such Obligor or any Subsidiary from discontinuing the protection, preservation or maintenance of, or failing to enforce and defend, any of its Intellectual Property if, in the reasonable good faith judgment of such Obligor or such Subsidiary, such Intellectual Property is no longer necessary and material to the conduct of its business.

Section 8.10. Action Under Environmental Laws. Such Obligor shall, and shall cause each of its Subsidiaries to, upon the Borrower obtaining knowledge of the release of any Hazardous Materials or the existence of any environmental liability under applicable Environmental Laws with respect to their respective businesses, operations or properties, take all actions, at their cost and expense, as shall be necessary or advisable to investigate and clean up the condition of their respective businesses, operations or properties, including all required removal, containment and remedial actions, and restore their respective businesses, operations or properties to a condition in each case in compliance with applicable Environmental Laws, except to the extent the failure to take such action would not reasonably be likely to result in a Material Adverse Effect.

Section 8.11. Use of Proceeds. The proceeds of the Term Loan will be used only as provided in Section 2.03. Without limiting the foregoing, no part of the proceeds of the Term Loan will be used, whether directly or indirectly, for any purpose that entails a violation of any of the Regulations of the Board of Governors of the Federal Reserve System, including Regulations T, U and X.

-57-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Section 8.12. Certain Obligations Respecting Subsidiaries; Further Assurances.

(a) Subsidiary Guarantors. Such Obligor will take such action, and will cause each of its Subsidiaries to take such action, from time to time as shall be necessary to ensure that all Subsidiaries are “Subsidiary Guarantors” hereunder, provided, that neither Icagen-T nor any of its Subsidiaries shall be required to become a “Subsidiary Guarantor” hereunder until such time as it no longer prohibited from doing so under the Icagen-T MSA. Without limiting the generality of the foregoing, in the event that Borrower or any of its Subsidiaries (other than any Subsidiary owned by Icagen-T, until such time as it is no longer prohibited from doing so under the Icagen-T MSA) shall form or acquire any new Subsidiary, it and its Subsidiaries shall concurrently:

(i) cause such new Subsidiary to become a “Subsidiary Guarantor” hereunder, and a “Grantor” under the Security Agreement, pursuant to a Guarantee Assumption Agreement;

(ii) take such action or cause such Subsidiary to take such action (including joining the Security Agreement, delivering such shares of stock together with undated transfer powers executed in blank and entering into the applicable Short-Form IP Security Agreements) as shall be necessary to create and perfect valid and enforceable first priority Liens (subject to Permitted Liens) on substantially all of the personal property of such new Subsidiary (other than Excluded Accounts) as collateral security for the obligations of such new Subsidiary hereunder;

(iii) cause the parent of such Subsidiary to execute and deliver a pledge agreement in favor of the Administrative Agent for the benefit of the Secured Parties in respect of all outstanding issued shares of such Subsidiary; and

(iv) deliver such proof of corporate or other organizational action, incumbency of officers, opinions of counsel and other documents as is consistent with those delivered by each Obligor pursuant to Section 6.01, or as the Administrative Agent shall have reasonably requested.

(b) Further Assurances. Subject to the limitations set forth herein and in the other Loan Documents, such Obligor will, and will cause each of its Subsidiaries (other than Icagen-T and its Subsidiaries, until such actions are no longer prohibited by the Icagen-T MSA) to, take such action from time to time as shall reasonably be requested by the Administrative Agent to effectuate the purposes and objectives of this Agreement.

Without limiting the generality of the foregoing, each Obligor will, and will cause each Person that is required to be a Subsidiary Guarantor to, take such action from time to time (including executing and delivering such assignments, security agreements, control agreements and other instruments) as shall be reasonably requested by the Administrative Agent to create, in favor of the Lenders, perfected security interests and Liens in substantially all of the personal property of such Obligor as collateral security for the Obligations; provided that any such security interest or Lien shall be subject to the relevant requirements of the Security Documents.

Section 8.13. Termination of Non-Permitted Liens. In the event that the Borrower obtains knowledge of or receives notification from the Administrative Agent of the existence of any outstanding Lien against any property of such Obligor or any of its Subsidiaries, which Lien is not a Permitted Lien, such Obligor shall promptly terminate or cause the termination of such Lien.

-58-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Section 8.14. Intellectual Property. In the event that any Obligor acquires Obligor Intellectual Property during the term of this Agreement, then the provisions of this Agreement shall automatically apply thereto and any such Obligor Intellectual Property shall automatically constitute part of the Collateral under the Security Documents, without further action by any party, in each case from and after the date of such acquisition (except that any representations or warranties of any Obligor shall apply to any such Obligor Intellectual Property only from and after the date, if any, subsequent to such acquisition that such representations and warranties are brought down).

Section 8.15. ERISA Compliance. Such Obligor shall comply, and to the extent applicable, shall cause each of its Subsidiaries to comply, in all material respects with the provisions of ERISA with respect to any Title IV Plans and Multiemployer Plans to which such Obligor or any such Subsidiary is a party as employer.

Section 8.16. Cash Management.

(a) Subject to Section 8.17, on and after the Closing Date (or such later date as agreed to by the Administrative Agent in its reasonable discretion), each Obligor shall maintain all Deposit Accounts, Securities Accounts, Commodity Accounts and lockboxes (other than Excluded Accounts) with a bank or financial institution that has executed and delivered to the Administrative Agent an account control agreement, in form and substance reasonably acceptable to the Administrative Agent (each such Deposit Account, Securities Account, Commodity Account and lockbox, a “Controlled Account”); and

(b) the Obligors shall deposit promptly, and in any event no later than five (5) Business Days after the date of receipt thereof, all cash, checks, drafts or other similar items of payment relating to or constituting payments made in respect of any and all accounts and other rights and interests into a Deposit Account of an Obligor (which Deposit Account shall, on and after the Closing Date (or such later date as agreed to by the Administrative Agent in its reasonable discretion), be a Controlled Account).

Section 8.17. Post-Closing Obligations. Within the time periods specified on Schedule 8.17 (as each may be extended by the Administrative Agent in its reasonable discretion), complete such undertakings as are set forth on Schedule 8.17.

Section 8.18. Milestone. On or before March 31, 2019, enter into a collaboration agreement with a pharmaceutical or biotechnology company that results in aggregate upfront fees in excess of $5,000,000.

Section 8.19. Icagen-T Lien. Within thirty (30) days after the earlier of (i) the date the Icagen-T MSA no longer prohibits Icagen-T and its Subsidiaries from being a Subsidiary Guarantor and (ii) the date the Icagen-T MSA is terminated, Borrower shall (x) deliver all certificates representing 100% of Icagen-T’s Equity Interests to the Administrative Agent, accompanied by undated instruments of transfer duly executed in blank, and (y) take all such actions required (including, without limitation, all such actions described in Section 8.12) to cause Icagen-T and its Subsidiaries to become Subsidiary Guarantors and to pledge a first priority Lien on all of their respective assets to the Administrative Agent for the benefit of the Lenders (subject to Permitted Priority Liens).

-59-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Section 8.20. Board Observer Rights. Until the Obligations (other than the Warrant Obligations and contingent indemnification obligations for which no claim has been made) have been paid in full in cash, Borrower shall permit the Administrative Agent on behalf of all of the Lenders (the “Observer”) to attend and observe (but not vote) at all meetings of Borrower’s (or any Subsidiary’s, as applicable) Board or any committee thereof (each a “Committee”), whether in person, by telephone or otherwise as requested by the Observer. Borrower and such Subsidiaries shall notify the Observer in writing at the same time as furnished to members of the applicable Board or Committee of (i) the date and time for each general or special meeting of any such Board or Committee and (ii) the adoption of any resolutions or actions by any such Board or any such Committee by written consent (describing, in reasonable detail, the nature and substance of such action). Borrower and each of its Subsidiaries shall concurrently deliver to the Observer all notices and any materials delivered to the official members of such Board or Committee in connection with a meeting or action to be taken by written consent, including a draft of any material resolutions or actions proposed to be adopted by written consent. The Observer shall be free prior to such meeting or adoption by written consent to contact members of any applicable Board or Committee and discuss the pending actions to be taken. Notwithstanding the foregoing, the Observer shall not be entitled to receive materials relating to, or be in attendance for, any discussions relating to topics which (x) are subject to attorney client privilege, or (y) present a conflict of interest for the Observer. All such discussions and materials shall be subject to the confidentiality provisions set forth in Section 14.16.

Section 9. Negative Covenants.

Each Obligor covenants and agrees with the Lenders that, until the Commitments have expired or been terminated and all Obligations (other than Warrant Obligations and contingent obligations as to which no claims have been asserted) have been paid in full indefeasibly in cash:

Section 9.01. Indebtedness. Such Obligor will not, and will not permit any of its Subsidiaries to, create, incur, assume or permit to exist any Indebtedness, whether directly or indirectly, except:

(a) the Obligations;

(b) Indebtedness existing on the on the Closing Date and set forth on Schedule 7.13(a) and Permitted Refinancings thereof;

-60-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

(c) accounts payable to trade creditors for goods and services and current operating liabilities (not the result of the borrowing of money) incurred in the ordinary course of such Obligor’s or such Subsidiary’s business in accordance with customary terms and paid within ninety (90) days of becoming due, unless contested in good faith by appropriate proceedings and reserved for in accordance with GAAP;

(d) Indebtedness consisting of guarantees resulting from the endorsement of negotiable instruments for collection in the ordinary course of business;

(e) Indebtedness of an Obligor and its Subsidiaries to the extent the same is permitted as an Investment pursuant to Section 9.05;

(f) Guarantees by any Obligor of Indebtedness of any other Obligor;

(g) Purchase money and capital lease financing; provided that (i) if secured, the collateral therefor consists solely of the assets being financed, the products and proceeds thereof and books and records related thereto, and (ii) the aggregate outstanding principal amount of such Indebtedness does not exceed $1,000,000 at any time;

(h) Indebtedness under Hedging Agreements permitted by Section 9.05(f);

(i) Indebtedness consisting of the financing of insurance premiums in respect of insurance policies insuring assets or businesses of an Obligor and/or its Subsidiaries written or arranged in the ordinary course of business, in each case in an amount not to exceed the amount of the applicable insurance premium in respect of any such policy plus interest and financing charges applicable thereto;

(j) Indebtedness in respect of any agreement providing for treasury, depositary or cash management services, including in connection with any credit cards, automated clearing house transfers of funds transaction, securities settlements, foreign exchange contracts or any similar transfers, netting services, overdraft protections and other cash management and similar arrangements, in each case in the ordinary course of business;

(k) advances or deposits from customers or vendors received in the ordinary course of business;

(l) workers’ compensation claims, payment obligations in connection with health, disability or other types of social security benefits, unemployment or other insurance obligations and reclamation and statutory obligations, in each case incurred in the ordinary course of business;

-61-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

(m) Indebtedness consisting of letters of credit, letters of guaranty and bankers’ acceptances to the extent incurred in the ordinary course of business in an aggregate amount not to exceed $1,000,000;

(n) Indebtedness which may be deemed to exist pursuant to any guaranties, indemnities, performance, surety, statutory, appeal or similar obligations incurred in the ordinary course of business and Indebtedness constituting guaranties in the ordinary course of business of the obligations of suppliers, customers, franchisees and licensees of the Borrower and its Subsidiaries;

(o) Indebtedness of the Obligors and their Subsidiaries incurred pursuant to the Icagen-T Loan Documents;

(p) Indebtedness of one Obligor to another Obligor, provided that such Indebtedness shall be (A) evidenced by promissory notes and all such notes shall be subject to a first priority Lien pursuant to the Security Agreement, (B) unsecured, and (C) subordinated in right of payment to the payment in full of the Obligations (other than the Warrant Obligations) pursuant to the terms of the applicable promissory notes or an intercompany subordination agreement, in each case in form and substance satisfactory to the Administrative Agent in its sole discretion;

(q) Indebtedness owed to Pfizer, Inc. pursuant to the terms of that certain Asset Purchase and Collaboration Agreement, dated as of June 26, 2015, by and among Pfizer Research (NC), Inc. and Borrower, as amended by that certain Amendment to Asset Purchase and Collaboration Agreement, dated as of July 15, 2016; and

(r) (A) the Bridge Notes, provided that on or prior to the Closing Date, the Bridge Notes have been amended in form and substance satisfactory to the Administrative Agent to subordinate right of payment to the payment in full of the Obligations (other than the Warrant Obligations), subject to permitted payments under Section 9.07, and (B) any Permitted Refinancings thereof, provided that Borrower may elect to increase the interest rate on such Bridge Notes to 12% per annum, payable in accordance with Section 9.07 hereof.

Section 9.02. Liens. Such Obligor will not, and will not permit any of its Subsidiaries to, create, incur, assume or permit to exist any Lien on any property now owned or hereafter acquired by it or such Subsidiary, except:

(a) Liens securing the Obligations;

(b) any Lien on any property or asset of such Obligor or any of its Subsidiaries existing on the Closing Date and set forth on Schedule 7.13(c); provided that (i) no such Lien shall extend to any other property or asset of such Obligor or any of its Subsidiaries other than that which it secures on the date hereof and any cross-collateralization of other assets financed with the same holder of such Lien, and (ii) any such Lien shall secure only those obligations which it secures on the Closing Date and extensions, renewals and replacements thereof that do not increase the outstanding principal amount thereof, plus fees and expenses incurred in connection therewith;

-62-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

(c) Liens securing Indebtedness permitted by Section 9.01(g); provided that (i) such Liens are limited solely to the assets, products, proceeds and books and records permitted to be secured pursuant to Section 9.01(g), and (ii) the Indebtedness secured thereby does not exceed the lower of the cost or fair market value of the assets being financed or acquired and Liens incurred in connection with extension, renewal or refinancing of such Indebtedness;

(d) Liens imposed by any applicable Law arising in the ordinary course of business, including (but not limited to) carriers’, warehousemen’s, landlord’s and mechanics’ liens and other similar Liens arising in the ordinary course of business and which (x) do not in the aggregate materially detract from the value of the property subject thereto or materially impair the use thereof in the operations of the business of such Person or (y) are being contested in good faith by appropriate proceedings, which proceedings have the effect of preventing the forfeiture or sale of the property subject to such Liens and for which adequate reserves have been made if required in accordance with GAAP;

(e) Liens, pledges or deposits made in the ordinary course of business in connection with leases, or bids, contracts, appeal bonds, workers’ compensation, unemployment insurance or other similar social security legislation, and not in connection with money borrowed;

(f) Liens securing Taxes, assessments and other governmental charges, the payment of which (i) is not yet delinquent or (ii) is being contested in good faith by appropriate proceedings promptly initiated and diligently conducted and for which adequate reserves have been made if required in accordance with GAAP;

(g) servitudes, easements, rights of way, restrictions and other similar encumbrances on real property imposed by any applicable Law and Liens consisting of zoning or building restrictions, easements, licenses, restrictions on the use of property or minor imperfections in title thereto which, in the aggregate, are not material, and which do not in any case materially detract from the value of the property subject thereto or interfere with the ordinary conduct of the business of any of the Obligors or any of their Subsidiaries;

(h) with respect to any real property, (i) such defects or encroachments as might be revealed by an up-to-date survey of such real property; (ii) the reservations, limitations, provisos and conditions expressed in the original grant, deed or patent of such property by the original owner of such real property pursuant to Laws; (iii) rights of expropriation, access or user or any similar right conferred or reserved by or in any Law, which, in the aggregate for clauses (i), (ii) and (iii), are not material, and which do not in any case materially detract from the value of the property subject thereto or interfere with the ordinary conduct of the business of any of the Obligors or their Subsidiaries; and (iv) leases or subleases in the ordinary course of business;

-63-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

(i) bankers’ liens, rights of setoff, netting and similar Liens incurred on deposits made in the ordinary course of business or otherwise in connection with the services permitted by Section 9.01(j);

(j) Liens in connection with any ordinary course interest or title of a licensor, sublicensor, lessor or sublessor not otherwise prohibited by Section 9.13;

(k) deposits made in connection with a contemplated Permitted Acquisition in an aggregate amount not to exceed ten percent (10%) of the consideration of such Acquisition;

(l) Liens incurred in connection with the Indebtedness permitted by Sections 9.01(m), and 9.01(n);

(m) Liens on insurance policies and the proceeds thereof (excluding any benefits or any rights to receive payment under any insurance policies) incurred in connection with the financing in the ordinary course of business of insurance premiums, provided, that such Liens shall be limited only to the unused portion of the premiums payable under such insurance policies and the proceeds of such insurance premiums;

(n) (i) Restrictive Agreements permitted pursuant to Section 9.11, (ii) any customary provisions in contracts (including without limitation leases and licenses of Intellectual Property) restricting the assignment thereof or, in the case of any lease or license, the sublease or sublicense or other disposition of the applicable leased or licensed property, (iii) restrictions or conditions imposed by any agreement governing secured Permitted Indebtedness permitted under Section 9.01(g), to the extent that such restrictions or conditions apply only to the property or assets securing such Indebtedness and (iv) restrictions in agreements related to any Asset Sale to the extent such Asset Sale would be a permitted Asset Sale under this Agreement;

(o) Liens of the Obligors and their Subsidiaries granted pursuant to the Icagen-T Loan Documents; and

(p) Liens in favor of customs and revenue authorities arising as a matter of law to secure payments of custom duties in connection with the importation of goods;

provided that no Lien otherwise permitted under any of the foregoing clauses shall apply to any Material Intellectual Property except for Liens described in clauses (a), (j) and (n).

-64-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Section 9.03. Fundamental Changes and Acquisitions. Such Obligor will not, and will not permit any of its Subsidiaries to, (i) enter into any transaction of merger, amalgamation or consolidation, (ii) liquidate, wind up or dissolve itself (or suffer any liquidation or dissolution), (iii) make or consummate any Acquisition of any Person, (iv) acquire or create any Foreign Subsidiary, or (v) acquire any other assets or properties (other than assets or properties in the nature of inventory, software, equipment, supplies and other assets acquired for use in the ordinary course of business, including in connection with the expansion or replacement of equipment used in the Borrower’s and its Subsidiaries’ facilities), except:

(a) transactions permitted by Section 9.01 and 9.05;

(b) the merger, amalgamation, consolidation, liquidation, winding up or dissolution of any Subsidiary Guarantor with or into any Obligor; provided that with respect to any such transaction involving the Borrower, the Borrower must be the surviving or successor entity of such transaction;

(c) the sale, lease, transfer or other disposition by any Subsidiary of any or all of its property (upon voluntary liquidation or otherwise) to any Obligor;

(d) the sale, transfer or other disposition of the Equity Interests of any Subsidiary Guarantor to the Borrower;

(e) the creation of any Subsidiary subject to compliance with Section 8.12; and

(f) Permitted Acquisitions.

Section 9.04. Lines of Business. Such Obligor will not, and will not permit any of its Subsidiaries to, engage in any business other than the business engaged in on the date hereof by such Obligor or such Subsidiary or a business reasonably related, incidental or complimentary thereto or a reasonable extension thereof or a business having a similar customer base.

Section 9.05. Investments. Such Obligor will not, and will not permit any of its Subsidiaries to, make, directly or indirectly, or permit to remain outstanding any Investments except:

(a) Investments outstanding on the date hereof and identified in Schedule 9.05 and any modification, replacement, renewal or extension thereof to the extent not involving new or additional Investments;

-65-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

(b) operating deposit accounts with banks and securities accounts with banks and other financial institutions that either qualify as an Excluded Account or comply with Section 8.16;

(c) extensions of credit in the nature of deposits, accounts receivable, trade debt granted or notes receivable arising from the purchase or sale of goods or services in the ordinary course of business and prepaid royalties and other credit extensions and advances arising in the ordinary course of business;

(d) Permitted Cash Equivalent Investments to the extent held in a Controlled Account;

(e) Investments by (i) any Obligor in any other Obligor, (ii) any Subsidiary that is not an Obligor in any other Subsidiary that is not an Obligor, and (iii) by Borrower in Icagen-T;

(f) Hedging Agreements entered into in by any Obligor or its Subsidiary in the ordinary course of business for the purpose of hedging currency risks or interest rate risks (and not for speculative purposes) not to exceed $250,000 in the aggregate outstanding at any time;

(g) Investments consisting of prepaid expenses, negotiable instruments held for collection or deposit, security deposits with utilities, landlords and other like Persons and deposits in connection with workers’ compensation and similar deposits, in each case made in the ordinary course of business;

(h) loans, advances and guarantees to or in favor of employees, officers, directors and consultants in the ordinary course of business which in the aggregate shall not exceed $250,000 outstanding at any time;

(i) Investments (i) in connection with a Permitted Acquisition and (ii) in connection with Casualty Events permitted by Section 3.03(b);

(j) Investments received in connection with any Insolvency Proceedings in respect of any customers, suppliers or clients or in settlement of delinquent obligations of, and other disputes with, customers, suppliers or clients;

(k) Investments permitted by Sections 9.01, 9.02, 9.03, 9.06 and 9.09;

(l) Investments in newly created Subsidiaries to the extent such Subsidiary complies with Section 8.12 to the extent applicable; and

-66-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

(m) so long as no Default or Event of Default has occurred and is continuing at the time such Investments are made, other Investments in an aggregate principal amount not to exceed $500,000 at any time outstanding.

Section 9.06. Restricted Payments. Such Obligor will not, and will not permit any of its Subsidiaries to, declare or make, or agree to pay or make, directly or indirectly, any Restricted Payment; provided that the following Restricted Payments shall be permitted so long as no Event of Default has occurred and is continuing or could reasonably be expected to occur or result from such Restricted Payment:

(a) distributions with respect to the Borrower’s Equity Interests payable solely in shares of its Qualified Equity Interests (or the equivalent thereof);

(b) the Borrower’s purchase, redemption, retirement, or other acquisition of shares of its Equity Interests with the proceeds received from a substantially concurrent issue of new shares of its Qualified Equity Interests;

(c) upon the death, incapacity or termination of any stockholder or the exercise of a right of first refusal or similar right in respect of any stockholder, the Borrower may repurchase the stock of such stockholder or such stockholder’s family, trusts, estates and heirs pursuant to stock plans or stock repurchase agreements in an amount not to exceed $250,000 per fiscal year;

(d) cash in lieu of the issuance of fractional shares upon the conversion of convertible securities (or in connection with the exercise of warrants or similar securities) not to exceed $100,000 in the aggregate;

(e) any non-cash (other than cash in lieu of fractional shares) conversion or exercise requests in respect of any convertible securities, options or warrants of the Borrower into Equity Interests of the Borrower pursuant to the terms of such convertible securities, options or warrants or otherwise in exchange therefor;

(f) distributions paid by any Subsidiary directly or indirectly to any Obligor;

(g) cash payments made to redeem, purchase, repurchase or retire the Warrant Obligations in accordance with the terms of the Warrant;

(h) payments of Indebtedness permitted pursuant to Section 9.07;

(i) the non-cash accrual of dividends pursuant to the terms of the Series C Preferred Stock; and

solely to the extent considered a Restricted Payment, Investments permitted pursuant to Section 9.05 and transactions permitted pursuant to Section 9.03.

-67-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Section 9.07. Payments of Indebtedness. Such Obligor will not, and will not permit any of its Subsidiaries to, make any payments in respect of any Indebtedness for borrowed money other than (i) payments of the Obligations, (ii) payments of the “Obligations” (as defined in the Icagen-T Credit Agreement), pursuant to the terms of the Icagen-T Credit Agreement, (iii) scheduled payments of any other Permitted Indebtedness (other than the Bridge Notes), (iv) non-cash payments of interest under the Bridge Notes, (v) Permitted Refinancings of Permitted Indebtedness, and (vi) cash payments of principal and interest on the Bridge Notes (including any accrued interest thereon) so long as at the time of such payment and after giving effect thereto, no Default or Event of Default shall have occurred and is continuing.

Section 9.08. Change in Fiscal Year. Such Obligor will not, and will not permit any of its Subsidiaries to, change the last day of its fiscal year from that in effect on the date hereof, except to change the fiscal year of a Subsidiary acquired in connection with a Permitted Acquisition to conform its fiscal year to that of the Borrower.

Section 9.09. Sales of Assets, Etc. Such Obligor will not, and will not permit any of its Subsidiaries to, sell, lease, transfer, or otherwise dispose of any of its assets or property (including accounts receivable and capital stock of Subsidiaries), or forgive, release or compromise any amount owed to such Obligor or Subsidiary, in each case, in any single transaction or series of transactions (any thereof, an “Asset Sale”), except (so long as such proposed Asset Sale does not result in, or could not reasonably be expected to result in, an Event of Default):

(a) sales or leases of inventory in the ordinary course of its business on ordinary business terms;

(b) the forgiveness, release, discounts or compromise of any amount owed to any Obligor or Subsidiary in the ordinary course of business;

(c) Asset Sales that constitute licenses of Intellectual Property in the ordinary course of business that are not otherwise prohibited by Section 9.13;

(d) transfers of assets or property (other than any Material Intellectual Property) by any Subsidiary Guarantor to any Obligor;

(e) dispositions of any assets or property (other than any Material Intellectual Property) that is obsolete or worn out or no longer used or useful in the business;

(f) dispositions resulting from Casualty Events;

-68-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

(g) in connection with any transaction permitted by Sections 9.02, 9.03, 9.05 and 9.06;

(h) disposition of cash or Permitted Cash Equivalent Investments; and

(i) so long as no Default or Event of Default has occurred and is continuing at the time of such sale, other Asset Sales not to exceed $250,000 in the aggregate per fiscal year.

Section 9.10. Transactions with Affiliates. Such Obligor will not, and will not permit any of its Subsidiaries to, sell, lease, license or otherwise transfer any assets to, or purchase, lease, license or otherwise acquire any assets from, or otherwise engage in any other transactions with, any of its Affiliates, except:

(a) transactions between or among Borrower or any Subsidiary of Borrower and any other Subsidiary of Borrower;

(b) any transaction permitted by Section 9.01, 9.03, 9.05, 9.06 or 9.09;

(c) customary compensation and indemnification of, and other employment arrangements with, directors, officers and employees of such Obligor or any of its Subsidiaries in the ordinary course of business;

(d) other transactions having terms that are no less favorable (including the amount of cash or other consideration received or paid by any Obligor) to any Obligor or any of its Subsidiaries, as the case may be, than those that would be obtained in a comparable arm’s-length transaction with a Person not an Affiliate of such Person; and

(e) the transactions set forth on Schedule 9.10.

Section 9.11. Restrictive Agreements. Such Obligor will not, and will not permit any of its Subsidiaries to, directly or indirectly, enter into, incur or be a party to any Restrictive Agreement; provided that the foregoing shall not apply to (i) restrictions and conditions imposed by Law or the Loan Documents and (ii) any Restrictive Agreement to which any Obligor or any of its Subsidiaries is party on the date hereof and that is listed on Schedule 7.15.

Section 9.12. Modifications and Terminations of Material Agreements and Organic Documents. Such Obligor will not, and will not permit any of its Subsidiaries to:

(a) amend, modify or terminate any Organic Document that adversely affects the Lenders (solely in their capacity as Lenders and not as shareholders) in any material respect without the prior written consent of the Administrative Agent which shall not be unreasonably withheld, conditioned or delayed; or

-69-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

(b) take or omit to take any action that results in the termination of, or permits any other Person to terminate, any Material Agreement or Material Intellectual Property that adversely affects the Lenders in any material respect, without the prior written consent of the Administrative Agent which shall not be unreasonably withheld, conditioned or delayed.

Section 9.13. Licensing of Intellectual Property. No Obligor shall enter into an exclusive license of its Material Intellectual Property without the prior written consent of the Administrative Agent.

Section 9.14. Sales and Leasebacks. Except as disclosed on Schedule 9.14, such Obligor will not, and will not permit any of its Subsidiaries to, become liable, directly or indirectly, with respect to any lease, whether an operating lease or a Capital Lease Obligation, of any property (whether real, personal, or mixed), whether now owned or hereafter acquired, (i) which such Person has sold or transferred or is to sell or transfer to any other Person and (ii) which such Obligor or Subsidiary intends to use for substantially the same purposes as property which has been or is to be sold or transferred.

Section 9.15. Hazardous Material. Such Obligor will not, and will not permit any of its Subsidiaries to, use, generate, manufacture, install, treat, release, store or dispose of any Hazardous Material, except in compliance with all applicable Environmental Laws or where the failure to comply would not reasonably be expected to result in a Material Adverse Effect.

Section 9.16. Accounting Changes. Such Obligor will not, and will not permit any of its Subsidiaries to, make any significant change in accounting treatment or reporting practices, except as required or permitted by GAAP.

Section 9.17. Compliance with ERISA. No ERISA Affiliate shall cause or suffer to exist (i) any ERISA Event that would reasonably be expected to result in the imposition of a Lien under ERISA or Code Section 430(k) on the assets or property of any Obligor or any of its Subsidiaries or (ii) any other ERISA Event that would reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.

Section 10. Financial Covenants.

Section 10.01. Minimum Liquidity. Borrower and its Subsidiaries shall maintain a minimum aggregate balance of (x) from the Closing Date until March 31, 2019, $1,000,000, and (y) at all times thereafter, $1,500,000, in each case in cash in one or more accounts (which accounts shall, on and after the Closing Date (or such later date as agreed to by the Administrative Agent in its reasonable discretion), be Controlled Accounts), free and clear of all Liens, other than Liens granted hereunder in favor of the Administrative Agent and other Permitted Liens.

-70-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Section 10.02. Minimum Revenue. On each date set forth below (a “Calculation Date”) under the heading “Calculation Date,” the Consolidated Net Revenue for the trailing twelve-month period ended on such Calculation Date shall not be less than the amount set forth opposite such Calculation Date:

Calculation Date		Net Revenue
December 31, 2018		$	11,337,000
March 31, 2019		$	11,430,000
June 30, 2019		$	10,822,000
September 30, 2019		$	10,777,000
December 31, 2019		$	10,836,000
March 31, 2020		$	11,256,000
June 30, 2020		$	12,112,000
September 30, 2020		$	12,604,000
December 31, 2020		$	14,117,000
March 31, 2021		$	14,258,000
June 30, 2021		$	14,435,000
September 30, 2021		$	14,590,000
December 31, 2021		$	14,823,000
March 31, 2022		$	14,971,000
June 30, 2022		$	15,157,000

Section 11. Events of Default.

Section 11.01. Events of Default. Each of the following events shall constitute an “Event of Default”:

(a) Principal or Interest Payment Default. The Borrower shall fail to pay any principal of or interest on the Term Loan, when and as the same shall become due and payable, whether at the due date thereof, at a date fixed for prepayment thereof or otherwise.

(b) Other Payment Defaults. Any Obligor shall fail to pay any Obligation (other than an amount referred to in Section 11.01(a)) when and as the same shall become due and payable, and such failure shall continue unremedied for a period of three (3) Business Days.

(c) Representations and Warranties. Any representation or warranty made or deemed made by or on behalf of any Obligor in this Agreement or any other Loan Document or any amendment or modification hereof or thereof, or in any report, certificate, financial statement or other document furnished pursuant to or in connection with this Agreement or any other Loan Document or any amendment or modification hereof or thereof, shall: (i) prove to have been incorrect when made or deemed made to the extent that such representation or warranty contains any materiality or Material Adverse Effect qualifier; or (ii) prove to have been incorrect in any material respect when made or deemed made to the extent that such representation or warranty does not otherwise contain any materiality or Material Adverse Effect qualifier.

-71-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

(d) Certain Covenants. Any Obligor shall fail to observe or perform any covenant, condition or agreement contained in Sections 8.03 (with respect to such Obligor’s existence), 8.11, 8.12, 8.14, 8.16, Section 9 or Section 10.

(e) Other Covenants. Any Obligor shall fail to observe or perform any covenant or agreement contained in this Agreement (other than those specified in Section 11.01(a), (b) or (d)) or any other Loan Document, and, in the case of any failure that is capable of cure, such failure shall continue unremedied for a period of thirty (30) or more days.

(f) Payment Default on Other Indebtedness. Any Obligor or any of its Subsidiaries shall fail to make any payment (whether of principal or interest and regardless of amount) in respect of (i) any Material Indebtedness, or (ii) Indebtedness under the Icagen-T Credit Agreement, in each case, when and as same shall become due and payable after giving effect to any applicable grace or cure period as originally provided by the terms of such Indebtedness.

(g) Other Defaults on Other Indebtedness. (i) Any material breach of, or “event of default” or similar event under, the Contract governing any Material Indebtedness shall occur, or (ii) any event or condition occurs (x) that results in any Material Indebtedness becoming due prior to its scheduled maturity or (y) that enables or permits (with or without the giving of notice, the lapse of time or both) the holder or holders of such Material Indebtedness or any trustee or agent on its or their behalf to cause such Material Indebtedness to become due, or to require the prepayment, repurchase, redemption or defeasance thereof, prior to its scheduled maturity; provided that this Section 11.01(g) shall not apply to secured Indebtedness that becomes due as a result of the voluntary sale or transfer of the property or assets securing such Material Indebtedness; provided further that if the holder or holders of such Material Indebtedness or any trustee or agent on its or their behalf waives any such event or condition within the time period set forth therein, then such event or condition shall not be an Event of Default hereunder.

(h) Other Defaults under the Icagen-T Credit Agreement. Any “Event of Default” under the Icagen-T Credit Agreement shall occur that is not cured or waived within the grace period set forth therein.

-72-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

(i) Insolvency, Bankruptcy, Etc. (i) Any Obligor or any of its Subsidiaries generally does not pay its debts as the same become due or admits in writing its inability to pay its debts generally; (ii) any Obligor or any of its Subsidiaries institutes any Insolvency Proceeding; (iii) any Obligor or any of its Subsidiaries takes any corporate action to approve, effect, consent to or authorize any of the actions described in Section 11.01(i)(ii); or (iv) any Insolvency Proceeding is filed against any Obligor or any of its Subsidiaries and, such Insolvency Proceeding continues undismissed, or unstayed and in effect, for a period of sixty (60) days after the institution thereof.

(j) Judgments. One (1) or more judgments for the payment of money in an aggregate amount in excess of $1,000,000 (to the extent not covered by independent third party insurance as to which the insurer has been notified of the potential claim and does not dispute coverage) shall be rendered against any Obligor or any of its Subsidiaries or any combination thereof and the same shall remain undismissed, unsatisfied or undischarged for a period of sixty (60) consecutive calendar days during which execution shall not be effectively stayed, or any action shall be legally taken by a judgment creditor to attach or levy upon any assets of any Obligor to enforce any such judgment.

(k) ERISA and Pension Plans. An ERISA Event shall have occurred that, in the reasonable determination of the Administrative Agent, when taken together with all other ERISA Events that have occurred, would reasonably be expected to result in the imposition of a Lien (other than a Permitted Lien) under ERISA or Code Section 430(k) on a material portion of the assets or property of any Obligor or any of its Subsidiaries or have a Material Adverse Effect.

(l) Change of Control, Etc. A Change of Control shall have occurred.

(m) Material Adverse Change. A Material Adverse Change shall have occurred.

(n) Impairment of Security, Etc. If any of the following events occurs: (i) Any Lien created by any of the Security Documents, shall at any time not constitute a valid and perfected Lien on the applicable Collateral in favor of the Secured Parties, free and clear of all other Liens (other than Permitted Liens or other Liens on Collateral not exceeding $100,000 in the aggregate) to the extent required by the Loan Documents, except due to the action or inaction of the Administrative Agent, (ii) except for expiration in accordance with its terms, any of the Security Documents or any Guarantee of any of the Obligations (including that contained in Section 12) shall for whatever reason cease to be in full force and effect, or (iii) any Obligor shall, directly or indirectly, contest in any manner such effectiveness, validity, binding nature or enforceability of any such Lien or any Loan Document.

-73-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

(o) Regulatory Matters, Etc. (i) The FDA or any other Regulatory Authority initiates enforcement action against, or issues a warning letter with respect to, any Obligor or any of its Subsidiaries, or the manufacturing facilities therefore, that causes such Person the loss of more than ten percent (10%) of the Borrower’s revenue for the twelve (12) month period following such enforcement action as compared to the same period ending on the same date in the prior period, or (ii) any Obligor enters into a settlement agreement with the FDA or any other Regulatory Authority that results in aggregate liability as to any single or related series of transactions, incidents or conditions, in excess of $500,000 to the extent not covered by insurance.

Section 11.02. Remedies. Upon the occurrence of any Event of Default (other than an Event of Default described in Section 11.01(i)), then, and in every such event, and at any time thereafter during the continuance of such event, the Administrative Agent may, by notice to the Borrower, declare the Term Loan then outstanding to be due and payable in whole (or in part, in which case any principal not so declared to be due and payable may thereafter be declared to be due and payable), and thereupon the principal of the Term Loan so declared to be due and payable, together with accrued interest thereon and all fees and other Obligations, shall become due and payable immediately (in the case of the Term Loan, at the Prepayment Price therefor), without presentment, demand, protest or other notice of any kind, all of which are hereby waived by each Obligor; and in case of an Event of Default described in Section 11.01(i), the principal of the Term Loan then outstanding, together with accrued interest thereon and all fees and other Obligations, shall automatically become due and payable immediately (in the case of the Term Loan, at the Prepayment Price therefor), without presentment, demand, protest or other notice of any kind, all of which are hereby waived by each Obligor.

Section 11.03. Additional Remedies. Upon the occurrence and during the continuance of any Event of Default, (a) if any Obligor or any of its Subsidiaries shall be in default under a Material Agreement, the Lenders shall have the right (but not the obligation) to cause the default or defaults under such Material Agreement to be remedied (including without limitation by paying any unpaid amount thereunder) and otherwise exercise any and all rights of such Obligor or Subsidiary, as the case may be, thereunder, as may be necessary to prevent or cure any default and (b) without limiting the foregoing, upon any such default, each Obligor shall promptly execute, acknowledge and deliver to the Lenders such instruments as may reasonably be required of such Obligor to permit the Lenders to cure any default under the applicable Material Agreement or permit the Lenders to take such other action required to enable the Lenders to cure or remedy the matter in default and preserve the interests of the Lenders. Any amounts paid by the Lenders pursuant to and in accordance with this Section 11.03 shall be payable on demand by the Obligors, shall accrue interest at the Default Rate if not paid on demand and shall constitute “Obligations”.

-74-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Section 11.04. Prepayment Premium and Prepayment Price. For the avoidance of doubt, the applicable Prepayment Premium (as a component of the Prepayment Price) shall be due and payable at any time the Term Loan becomes due and payable in full prior to the Maturity Date in accordance with the terms hereof, whether due to acceleration pursuant to the terms of this Agreement (in which case it shall be due immediately, upon the giving of notice to the Borrower or automatically by operation of law or otherwise in accordance with Section 11.02) (including, without limitation, on account of any bankruptcy filing). In view of the impracticability and extreme difficulty of ascertaining the actual amount of damages to the Lenders or profits lost by the Lenders as a result of such acceleration, and by mutual agreement of the parties as to a reasonable estimation and calculation of the lost profits or damages of the Lenders, the Prepayment Premium shall be due and payable upon such date. Each Obligor hereby waives any defense to payment, whether such defense may be based in public policy, ambiguity, or otherwise. The Obligors and the Lenders acknowledge and agree that any Prepayment Premium due and payable in accordance with this Agreement shall not constitute unmatured interest, whether under Section 5.02(b)(3) of the Bankruptcy Code or otherwise. Each Obligor further acknowledges and agrees, and waives any argument to the contrary, that payment of such amount does not constitute a penalty or an otherwise unenforceable or invalid obligation.

Section 12. Guarantee.

Section 12.01. The Guarantee. The Subsidiary Guarantors hereby jointly and severally guarantee to the Administrative Agent and the Lenders, and their successors and assigns, the prompt payment in full when due (whether at stated maturity, by acceleration or otherwise) of the principal of and interest on the Term Loan, all fees and other amounts and Obligations from time to time owing to the Administrative Agent and the Lenders by the Borrower and each other Obligor under this Agreement or under any other Loan Document, in each case strictly in accordance with the terms hereof and thereof (such obligations being herein collectively called the “Guaranteed Obligations”). The Subsidiary Guarantors hereby further jointly and severally agree that if the Borrower or any other Obligor shall fail to pay in full when due (whether at stated maturity, by acceleration or otherwise) any of the Guaranteed Obligations, the Subsidiary Guarantors will promptly pay the same, without any demand or notice whatsoever, and that in the case of any extension of time of payment or renewal of any of the Guaranteed Obligations, the same will be promptly paid in full when due (whether at extended maturity, by acceleration or otherwise) in accordance with the terms of such extension or renewal.

Section 12.02. Obligations Unconditional. The obligations of the Subsidiary Guarantors under Section 12.01 are absolute and unconditional, joint and several, irrespective of the value, genuineness, validity, regularity or enforceability of the obligations of the Borrower under this Agreement or any other agreement or instrument referred to herein, or any substitution, release or exchange of any other guarantee of or security for any of the Guaranteed Obligations, and, to the fullest extent permitted by Law, irrespective of any other circumstance whatsoever that might otherwise constitute a legal or equitable discharge or defense of a surety or guarantor, it being the intent of this Section 12.02 that the obligations of the Subsidiary Guarantors hereunder shall be absolute and unconditional, joint and several, under any and all circumstances. Without limiting the generality of the foregoing, it is agreed that the occurrence of any one or more of the following shall not alter or impair the liability of the Subsidiary Guarantors hereunder, which shall remain absolute and unconditional as described above:

(a) at any time or from time to time, without notice to the Subsidiary Guarantors, the time for any performance of or compliance with any of the Guaranteed Obligations shall be extended, or such performance or compliance shall be waived;

-75-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

(b) any of the acts mentioned in any of the provisions of this Agreement or any other agreement or instrument referred to herein shall be done or omitted;

(c) the maturity of any of the Guaranteed Obligations shall be accelerated, or any of the Guaranteed Obligations shall be modified, supplemented or amended in any respect, or any right under this Agreement or any other agreement or instrument referred to herein shall be waived or any other guarantee of any of the Guaranteed Obligations or any security therefor shall be released or exchanged in whole or in part or otherwise dealt with; or

(d) any lien or security interest granted to, or in favor of, the Secured Parties as security for any of the Guaranteed Obligations shall fail to be perfected.

The Subsidiary Guarantors hereby expressly waive diligence, presentment, demand of payment, protest and all notices whatsoever, and any requirement that the Administrative Agent or any Lender exhaust any right, power or remedy or proceed against the Borrower under this Agreement or any other agreement or instrument referred to herein, or against any other Person under any other guarantee of, or security for, any of the Guaranteed Obligations.

Section 12.03. Reinstatement. The obligations of the Subsidiary Guarantors under this Section 12 shall be automatically reinstated if and to the extent that for any reason any payment by or on behalf of the Borrower in respect of the Guaranteed Obligations is rescinded or must be otherwise restored by any holder of any of the Guaranteed Obligations, whether as a result of any proceedings in bankruptcy or reorganization or otherwise, and the Subsidiary Guarantors jointly and severally agree that they will indemnify the Administrative Agent and the Lenders on demand for all reasonable costs and expenses (including fees of counsel) incurred by such Persons in connection with such rescission or restoration, including any such costs and expenses incurred in defending against any claim alleging that such payment constituted a preference, fraudulent transfer or similar payment under any bankruptcy, insolvency or similar Law.

Section 12.04. Subrogation. The Subsidiary Guarantors hereby jointly and severally agree that, until the payment and satisfaction in full of all Guaranteed Obligations and the expiration and termination of the Commitments, they shall not exercise any right or remedy arising by reason of any performance by them of their guarantee in Section 12.01, whether by subrogation or otherwise, against the Borrower or any other guarantor of any of the Guaranteed Obligations or any security for any of the Guaranteed Obligations.

-76-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Section 12.05. Remedies. The Subsidiary Guarantors jointly and severally agree that, as between the Subsidiary Guarantors, on one hand, and the Administrative Agent and the Lenders, on the other hand, the obligations of the Borrower under this Agreement and under the other Loan Documents may be declared to be forthwith due and payable as provided in Section 11 (and shall be deemed to have become automatically due and payable in the circumstances provided in Section 11) for purposes of Section 12.01 notwithstanding any stay, injunction or other prohibition preventing such declaration (or such obligations from becoming automatically due and payable) as against the Borrower and that, in the event of such declaration (or such obligations being deemed to have become automatically due and payable), such obligations (whether or not due and payable by the Borrower) shall forthwith become due and payable by the Subsidiary Guarantors for purposes of Section 12.01.

Section 12.06. Instrument for the Payment of Money. Each Subsidiary Guarantor hereby acknowledges that the guarantee in this Section 12 constitutes an instrument for the payment of money, and consents and agrees that the Administrative Agent and the Lenders, at their sole option, in the event of a dispute by such Subsidiary Guarantor in the payment of any moneys due hereunder, shall have the right to proceed by motion for summary judgment in lieu of complaint pursuant to N.Y. Civ. Prac. L&R § 3213.

Section 12.07. Continuing Guarantee. The guarantee in this Section 12 is a continuing guarantee, and shall apply to all Guaranteed Obligations whenever arising.

Section 12.08. Rights of Contribution. The Subsidiary Guarantors hereby agree, as between themselves, that if any Subsidiary Guarantor shall become an Excess Funding Guarantor (as defined below) by reason of the payment by such Subsidiary Guarantor of any Guaranteed Obligations, each other Subsidiary Guarantor shall, on demand of such Excess Funding Guarantor (but subject to the next sentence), pay to such Excess Funding Guarantor an amount equal to such Subsidiary Guarantor’s Fair Share (as defined below and determined, for this purpose, without reference to the properties, debts and liabilities of such Excess Funding Guarantor) of the Excess Payment (as defined below) in respect of such Guaranteed Obligations. The payment obligation of a Subsidiary Guarantor to any Excess Funding Guarantor under this Section 12.08 shall be subordinate and subject in right of payment to the prior payment in full of the obligations of such Subsidiary Guarantor under the other provisions of this Section 12 and such Excess Funding Guarantor shall not exercise any right or remedy with respect to such excess until payment and satisfaction in full of all of such obligations.

For purposes of this Section 12.08, (i) “Excess Funding Guarantor” means, in respect of any Guaranteed Obligations, a Subsidiary Guarantor that has paid an amount in excess of its Fair Share of such Guaranteed Obligations, (ii) “Excess Payment” means, in respect of any Guaranteed Obligations, the amount paid by an Excess Funding Guarantor in excess of its Fair Share of such Guaranteed Obligations and (iii) “Fair Share” means, for any Subsidiary Guarantor, the ratio (expressed as a percentage) of (x) the amount by which the aggregate present fair saleable value of all properties of such Subsidiary Guarantor (excluding any shares of stock of any other Subsidiary Guarantor) exceeds the amount of all the debts and liabilities of such Subsidiary Guarantor (including contingent, subordinated, unmatured and unliquidated liabilities, but excluding the obligations of such Subsidiary Guarantor hereunder and any obligations of any other Subsidiary Guarantor that have been guaranteed by such Subsidiary Guarantor) to (y) the amount by which the aggregate fair saleable value of all properties of all of the Subsidiary Guarantors exceeds the amount of all the debts and liabilities (including contingent, subordinated, unmatured and unliquidated liabilities, but excluding the obligations of the Borrower and the Subsidiary Guarantors hereunder and under the other Loan Documents) of all of the Subsidiary Guarantors, determined (A) with respect to any Subsidiary Guarantor that is a party hereto on the Closing Date, as of the Closing Date, and (B) with respect to any other Subsidiary Guarantor, as of the date such Subsidiary Guarantor becomes a Subsidiary Guarantor hereunder.

-77-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Section 12.09. General Limitation on Guarantee Obligations. In any action or proceeding involving any provincial, territorial or state corporate law, or any state or federal bankruptcy, insolvency, reorganization or other law affecting the rights of creditors generally, if the obligations of any Subsidiary Guarantor under Section 12.01 would otherwise, taking into account the provisions of Section 12.08, be held or determined to be void, invalid or unenforceable, or subordinated to the claims of any other creditors, on account of the amount of its liability under Section 12.01, then, notwithstanding any other provision hereof to the contrary, the amount of such liability shall, without any further action by such Subsidiary Guarantor, the Administrative Agent, any Lender or any other Person, be automatically limited and reduced to the highest amount that is valid and enforceable and not subordinated to the claims of other creditors as determined in such action or proceeding.

Section 13. Administrative Agent.

Section 13.01. Appointment. Each of the Lenders hereby irrevocably appoints Perceptive Credit Holdings II, LP, a Delaware limited partnership, to act on its behalf as the Administrative Agent hereunder and under the other Loan Documents and authorizes the Administrative Agent to take such actions on its behalf and to exercise such powers as are delegated to the Administrative Agent by the terms hereof or thereof, together with such actions and powers as are reasonably incidental thereto. The provisions of this Section 13 are solely for the benefit of the Administrative Agent and the Lenders, and neither the Borrower nor any other Obligor will have rights as a third-party beneficiary of any of such provisions. It is understood and agreed that the use of the term “agent” herein or in any other Loan Documents (or any other similar term) with reference to the Administrative Agent is not intended to connote any fiduciary or other implied (or express) obligations arising under agency doctrine of any applicable Law. Instead, such term is used as a matter of market custom, and is intended to create or reflect only an administrative relationship between contracting parties.

Section 13.02. Rights as a Lender. The Person serving as the Administrative Agent hereunder will have the same rights and powers in its capacity as a Lender as any other Lender and may exercise the same as though it were not the Administrative Agent, and the term “Lender” or “Lenders” will, unless otherwise expressly indicated or unless the context otherwise requires, include the Person serving as the Administrative Agent hereunder in its individual capacity to the extent such Person is a Lender. Such Person and its Affiliates may accept deposits from, lend money to, own securities of, act as the financial advisor or in any other advisory capacity for, and generally engage in any kind of business with, the Borrower, the other Obligors or any other Subsidiaries or Affiliates of the Obligors as if such Person were not the Administrative Agent hereunder and without any duty to account therefor to the Lenders.

-78-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Section 13.03. Exculpatory Provisions. (a) The Administrative Agent will not have any duties or obligations except those expressly set forth herein and in the other Loan Documents, and its duties hereunder are administrative in nature. Without limiting the generality of the foregoing, the Administrative Agent:

(i) will not be subject to any fiduciary or other implied duties, regardless of whether a Default has occurred and is continuing;

(ii) will not have any duty to take any discretionary action or exercise any discretionary powers, except discretionary rights and powers expressly contemplated hereby or by the other Loan Documents that the Administrative Agent is required to exercise as directed in writing by the Majority Lenders (or such other number or percentage of the Lenders as will be expressly provided for herein or in the other Loan Documents); provided that the Administrative Agent will not be required to take any action that, in its opinion or the opinion of its counsel, may expose the Administrative Agent to liability or that is contrary to any Loan Document or applicable Law, including any action that may be in violation of the automatic stay under any Insolvency Proceeding; and

(iii) will not, except as expressly set forth herein and in the other Loan Documents, have any duty to disclose, and will not be liable for the failure to disclose, any information relating to the Obligors or any of its Subsidiaries or Affiliates that is communicated to or obtained by the Person serving as the Administrative Agent or any of its Affiliates in any capacity.

(b) The Administrative Agent will not be liable for any action taken or not taken by it (i) with the consent or at the request of the Majority Lenders (or such other number or percentage of the Lenders as will be necessary, or as the Administrative Agent believes in good faith will be necessary, under the circumstances), or (ii) in the absence of its own gross negligence or willful misconduct as determined by a court of competent jurisdiction by final and nonappealable judgment. The Administrative Agent will be deemed not to have knowledge of any Default unless and until notice describing such Default is given to the Administrative Agent in writing by the Borrower or a Lender.

-79-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

(c) The Administrative Agent will not be responsible for or have any duty to ascertain or inquire into (i) any statement, warranty or representation made in or in connection with this Agreement or any other Loan Document, (ii) the contents of any certificate, report or other document delivered hereunder or thereunder or in connection herewith or therewith, (iii) the performance or observance of any of the covenants, agreements or other terms or conditions set forth herein or therein or the occurrence of any Default, (iv) the validity, enforceability, effectiveness or genuineness of this Agreement, any other Loan Document or any other agreement, instrument or document or (v) the satisfaction of any condition set forth in Section 6 or elsewhere herein, other than to confirm receipt of items expressly required to be delivered to the Administrative Agent.

Section 13.04. Reliance by Administrative Agent. The Administrative Agent will be entitled to rely upon, and will not incur any liability for relying upon, any notice, request, certificate, consent, statement, instrument, document or other writing (including any electronic message, Internet or intranet website posting or other distribution) believed by it to be genuine and to have been signed, sent or otherwise authenticated by the proper Person. The Administrative Agent also may rely upon any statement made to it orally or by telephone and believed by it to have been made by the proper Person, and will not incur any liability for relying thereon. In determining compliance with any condition hereunder to the making of the Term Loan that by its terms must be fulfilled to the satisfaction of a Lender, the Administrative Agent may presume that such condition is satisfactory to such Lender unless the Administrative Agent has received notice to the contrary from such Lender prior to the making of such Term Loan. The Administrative Agent may consult with legal counsel (who may be counsel for the Borrower), independent accountants and other experts selected by it, and will not be liable for any action taken or not taken by it in accordance with the advice of any such counsel, accountants or experts.

Section 13.05. Delegation of Duties. The Administrative Agent may perform any and all of its duties and exercise its rights and powers hereunder or under any other Loan Document by or through any one or more sub-agents appointed by the Administrative Agent. The Administrative Agent and any such sub-agent may perform any and all of its duties and exercise its rights and powers by or through their respective Affiliates. The exculpatory provisions of this Section will apply to any such sub-agent and to the Affiliates of the Administrative Agent and any such sub-agent, and will apply to their respective activities in connection with the syndication of the facility as well as activities as Administrative Agent. The Administrative Agent will not be responsible for the negligence or misconduct of any sub-agents except to the extent that a court of competent jurisdiction determines in a final and nonappealable judgment that the Administrative Agent acted with gross negligence or willful misconduct in the selection of such sub-agents.

Section 13.06. Resignation of Agent. (a) The Administrative Agent may at any time give notice of its resignation to the Lenders and the Borrower, which notice shall set forth the effective date of such resignation (the “Resignation Effective Date”), such date not to be earlier than the thirtieth (30th) day following the date of such notice. The Majority Lenders and the Borrower shall mutually agree upon a successor to the Administrative Agent. If the Majority Lenders and the Borrower are unable to so mutually agree and no successor shall have been appointed within twenty-five (25) days after the retiring Administrative Agent gives notice of its resignation, then the retiring Administrative Agent may (but will not be obligated to), on behalf of the Lenders, appoint a successor Administrative Agent it shall designate (in its reasonable discretion after consultation with the Borrower and the Majority Lenders). Whether or not a successor has been appointed, such resignation will become effective in accordance with such notice on the Resignation Effective Date.

-80-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

(b) With effect from the Resignation Effective Date (i) the retiring Administrative Agent will be discharged from its duties and obligations hereunder and under the other Loan Documents (except that in the case of any Collateral held by the Administrative Agent on behalf of the Lenders under any of the Loan Documents, the retiring Administrative Agent will continue to hold such Collateral until such time as a successor Administrative Agent is appointed) and (ii) except for any indemnity payments owed to the retiring Administrative Agent, all payments, communications and determinations provided to be made by, to or through the Administrative Agent will instead be made by or to each Lender directly, until such time, if any, as the Majority Lenders appoint a successor Administrative Agent as provided for above. Upon the acceptance of a successor’s appointment as Administrative Agent hereunder, such successor will succeed to and become vested with all of the rights, powers, privileges and duties of the retiring Administrative Agent (other than any rights to indemnity payments owed to the retiring Administrative Agent), and the retiring Administrative Agent will be discharged from all of its duties and obligations hereunder or under the other Loan Documents. The fees payable by the Borrower to a successor Administrative Agent will be the same as those payable to its predecessor unless otherwise agreed between the Borrower and such successor. After the retiring Administrative Agent’s resignation hereunder and under the other Loan Documents, the provisions of this Section 13 and Sections 14.03 and 14.04 will continue in effect for the benefit of such retiring Administrative Agent, its sub-agents and their respective Affiliates in respect of any actions taken or omitted to be taken by any of them while the retiring Administrative Agent was acting as Administrative Agent.

Section 13.07. Non-Reliance on Administrative Agent and Other Lenders. Each Lender acknowledges that it has, independently and without reliance upon the Administrative Agent or any other Lender or any of their Affiliates and based on such documents and information as it has deemed appropriate, made its own credit analysis and decision to enter into this Agreement. Each Lender also acknowledges that it will, independently and without reliance upon the Administrative Agent or any other Lender or any of their Affiliates and based on such documents and information as it will from time to time deem appropriate, continue to make its own decisions in taking or not taking action under or based upon this Agreement, any other Loan Document or any related agreement or any document furnished hereunder or thereunder.

-81-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Section 13.08. Administrative Agent May File Proofs of Claim. In case of the pendency of any Insolvency Proceeding or any other judicial proceeding relative to the Borrower, the Administrative Agent (irrespective of whether the principal of the Term Loan will then be due and payable as herein expressed or by declaration or otherwise and irrespective of whether the Administrative Agent has made any demand on the Borrower) will be entitled and empowered (but not obligated), by intervention in such proceeding or otherwise:

(a) to file and prove a claim for the whole amount of the principal and interest owing and unpaid in respect of the Term Loan and all other Obligations that are owing and unpaid hereunder or under any other Loan Document and to file such other documents as may be necessary or advisable in order to have the claims of the Lenders and the Administrative Agent (including any claim for the reasonable compensation, expenses, disbursements and advances of the Lenders and the Administrative Agent and their respective agents and counsel and all other amounts due the Lenders and the Administrative Agent under this Agreement or any other Loan Document) allowed in such judicial proceeding; and

(b) to collect and receive any monies or other property payable or deliverable on any such claims and to distribute the same.

Any custodian, receiver, assignee, trustee, liquidator, sequestrator or other similar official in any such judicial proceeding is hereby authorized by each Lender to make any payments of the type described above in this Section 13.08 to the Administrative Agent and, in the event that the Administrative Agent consents to the making of such payments directly to the Lenders, to pay to the Administrative Agent any amount due for the reasonable compensation, expenses, disbursements and advances of the Administrative Agent and its agents and counsel, and any other amounts due the Administrative Agent under this Agreement or any other Loan Document.

Section 13.09. Collateral and Guaranty Matters; Appointment of Collateral Agent. (a) Without limiting the provisions of Section 13.08, the Lenders irrevocably agree as follows:

(i) the Administrative Agent is authorized, at its option and in its discretion, to release any Lien on any property granted to or held by the Administrative Agent under any Loan Document (A) on the date when all Obligations have been satisfied in full in cash (other than Warrant Obligations and contingent obligations as to which no claims have been asserted), (B) that is sold or otherwise disposed of or to be sold or otherwise disposed of as part of or in connection with any sale or other disposition permitted under the Loan Documents, or (C) subject to Sections 14.01 and 14.04, if approved, authorized or ratified in writing by the Majority Lenders; and

(ii) the Administrative Agent is authorized, at its option and discretion, to release any Subsidiary Guarantor from its obligations hereunder if such Person ceases to be a Subsidiary as a result of a transaction permitted under the Loan Documents.

Upon request by the Administrative Agent at any time, each Lender will confirm in writing the Administrative Agent’s authority to release or subordinate its interest in particular types or items of Collateral, or to release any Subsidiary Guarantor from its obligations under its guaranty pursuant to this Section 13.09.

-82-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

(b) The Administrative Agent will not be responsible for or have a duty to ascertain or inquire into any representation or warranty regarding the existence, value or collectability of the Collateral, the existence, priority or perfection of the Administrative Agent’s Lien thereon, or any certificate prepared by any Obligor in connection therewith, nor will the Administrative Agent be responsible or liable to the Lenders for any failure to monitor or maintain any portion of the Collateral.

(c) Each Lender hereby appoints the Administrative Agent as its collateral agent under each of the Security Documents and agrees that, in so acting, the Administrative Agent will have all of the rights, protections, exculpations, indemnities and other benefits provided to the Administrative Agent under this Agreement, and hereby authorizes and directs the Administrative Agent, on behalf of such Lender and all Lenders, without the necessity of any notice to or further consent from any of the Lenders, from time to time to (i) take any action with respect to any Collateral or any Security Document which may be necessary to perfect and maintain perfected the Liens on the Collateral granted pursuant to any such Security Document or protect and preserve the Administrative Agent’s ability to enforce the Liens or realize upon the Collateral, (ii) act as collateral agent for each Secured Party for purposes of acquiring, holding, enforcing and perfecting all Liens created by the Loan Documents and all other purposes stated therein, (iii) enter into intercreditor or subordination agreements, as the case may be, in connection with Indebtedness permitted pursuant to Section 9.01(n), (iv) enter into non-disturbance or similar agreements in connection with licensing agreements and arrangements permitted by this Agreement and the other Loan Documents and (v) otherwise to take or refrain from taking any and all action that the Administrative Agent shall deem necessary or advisable in fulfilling its role as collateral agent under any of the Security Documents.

Section 14. Miscellaneous.

Section 14.01. No Waiver. No failure on the part of the Administrative Agent or the Lenders to exercise and no delay in exercising, and no course of dealing with respect to, any right, power or privilege under any Loan Document shall operate as a waiver thereof, nor shall any single or partial exercise of any right, power or privilege under any Loan Document preclude any other or further exercise thereof or the exercise of any other right, power or privilege. The remedies provided herein are cumulative and not exclusive of any remedies provided by law.

Section 14.02. Notices. All notices, requests, instructions, directions and other communications provided for herein (including any modifications of, or waivers, requests or consents under, this Agreement) shall be given or made in writing (including by telecopy or email) delivered, if to the Borrower, another Obligor, the Administrative Agent or any Lender, to its address specified on the signature pages hereto or its Guarantee Assumption Agreement, as the case may be, or at such other address as shall be designated by such party in a written notice to the other parties. Except as otherwise provided in this Agreement, all such communications shall be deemed to have been duly given upon receipt of a legible copy thereof, in each case given or addressed as aforesaid. All such communications provided for herein by telecopy shall be confirmed in writing promptly after the delivery of such communication (it being understood that non-receipt of written confirmation of such communication shall not invalidate such communication).

-83-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Section 14.03. Expenses, Indemnification, Etc.

(a) Closing Expenses. The Borrower agrees to pay or reimburse the Administrative Agent and the Lenders for all of their reasonable and documented out of pocket costs and expenses (including the reasonable and documented fees and expenses of Xxxxxxx and Xxxxxx LLP, special counsel to the Administrative Agent) in connection with the negotiation, preparation, execution and delivery of this Agreement and the other Loan Documents and the making of the Term Loan.

(b) Other Expenses. The Borrower agrees to pay or reimburse (i) the Administrative Agent and the Lenders for all of their reasonable and documented out of pocket post-closing costs and expenses in connection the negotiation or preparation of any modification, supplement or waiver of any of the terms of this Agreement or any of the other Loan Documents (whether or not consummated) and (ii) the Administrative Agent and the Lenders for all of their out of pocket costs and expenses (including the fees and expenses of legal counsel) in connection with any enforcement or collection proceedings resulting from the occurrence of an Event of Default.

(c) Indemnification. The Borrower hereby indemnifies the Administrative Agent, the Lenders and their respective Affiliates, directors, officers, employees, attorneys, agents, advisors and controlling parties (each, an “Indemnified Party”) from and against, and agrees to hold them harmless against, any and all Claims and Losses of any kind (including reasonable and documented fees and disbursements of counsel), joint or several, that may be incurred by or asserted or awarded against any Indemnified Party, in each case arising out of or in connection with or relating to any investigation, litigation or proceeding or the preparation of any defense with respect thereto arising out of or in connection with or relating to this Agreement or any of the other Loan Documents or the Transactions or any use made or proposed to be made with the proceeds of the Term Loan, whether or not such investigation, litigation or proceeding is brought by the Borrower, any of its shareholders or creditors, an Indemnified Party or any other Person, or an Indemnified Party is otherwise a party thereto, and whether or not any of the conditions precedent set forth in Section 6 are satisfied or the other transactions contemplated by this Agreement are consummated, except to the extent such Claim or Loss is found in a final, non-appealable judgment by a court of competent jurisdiction to have resulted from such Indemnified Party’s gross negligence or willful misconduct. No Obligor shall assert any claim against any Indemnified Party, on any theory of liability, for consequential, indirect, special or punitive damages arising out of or otherwise relating to this Agreement or any of the other Loan Documents or any of the Transactions or the actual or proposed use of the proceeds of the Term Loan. No Lender shall assert any claim against the Borrower or any of its Subsidiaries or any of their respective directors, officers, employees, attorneys, agents, advisors or controlling parties on any theory of liability, for consequential, indirect, special or punitive damages arising out of or otherwise relating to this Agreement or any of the other Loan Documents or any of the transactions contemplated hereby or thereby or the actual or proposed use of the proceeds of the Term Loan. This Section 14.03(c) shall not apply with respect to Taxes other than any Taxes that represent Claims and Losses arising from any non-Tax claim.

-84-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Section 14.04. Amendments, Etc. Except as otherwise expressly provided in this Agreement, any provision of this Agreement and any other Loan Document may be modified or supplemented only by an instrument in writing signed by the Borrower, the Administrative Agent and the Majority Lenders; provided that:

(a) any such modification or supplement that is disproportionately adverse to any Lender as compared to other Lenders or subjects any Lender to any additional obligation shall not be effective without the consent of such affected Lender;

(b) the consent of all of the Lenders shall be required to:

(i) amend, modify, discharge, terminate or waive any of the terms of this Agreement or any other Loan Document if such amendment, modification, discharge, termination or waiver would increase the amount of the Term Loan, reduce the fees payable hereunder, reduce interest rates or other amounts payable with respect to the Term Loan, extend any date fixed for payment of principal, interest or other amounts payable relating to the Term Loan or extend the repayment dates of the Term Loan;

(ii) amend, modify, discharge, terminate or waive any Security Document if the effect is to release a material part of the Collateral subject thereto other than pursuant to the terms hereof or thereof; or

(iii) amend this Section 14.04.

Section 14.05. Successors and Assigns.

(a) General. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and assigns permitted hereby; provided that the neither the Borrower nor any other Obligor may assign or transfer its rights or obligations hereunder without the prior written consent of the Administrative Agent. No Lender may assign or otherwise transfer any of its rights or obligations hereunder or under any of the other Loan Documents except (i) to an assignee in accordance with the provisions of Section 14.05(b), or (ii) by way of participation in accordance with the provisions of Section 14.05(e) (and any other attempted assignment or transfer by any party hereto shall be null and void). Nothing in this Agreement, expressed or implied, shall be construed to confer upon any Person (other than the parties hereto, their respective successors and assigns permitted hereby, Participants to the extent provided in Section 14.05(e) and, to the extent expressly contemplated hereby, the Indemnified Parties) any legal or equitable right, remedy or claim under or by reason of this Agreement.

-85-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

(b) Assignments by Lender. Any of the Lenders may at any time assign to one or more Eligible Transferees (or, if an Event of Default has occurred and is continuing, to any Person) all or a portion of its rights and obligations under this Agreement (including all or a portion of the Commitment and the Term Loan at the time owing to it) and the other Loan Documents; provided that no such assignment shall be made to the Borrower, any Affiliate of the Borrower or any employees or directors of any Obligor at any time. Subject to the recording thereof by the Administrative Agent pursuant to Section 14.05(d), from and after the effective date specified in each Assignment and Assumption, the assignee thereunder shall be a party to this Agreement and, to the extent of the interest assigned by such Assignment and Assumption, have the rights and obligations of such Lender under this Agreement and the other Loan Documents, and correspondingly the assigning Lender shall, to the extent of the interest assigned by such Assignment and Assumption, be released from its obligations under this Agreement (and, in the case of an Assignment and Assumption covering all of the Lender’s rights and obligations under this Agreement, such Lender shall cease to be a party hereto) and the other Loan Documents but shall continue to be entitled to the benefits of Section 5 and Section 14.03. Any assignment or transfer by a Lender of rights or obligations under this Agreement that does not comply with this Section 14.05(b) shall be treated for purposes of this Agreement as a sale by such Lender of a participation in such rights and obligations in accordance with Section 14.05(e).

(c) Amendments to Loan Documents. Each of the Lenders and the Obligors agrees to enter into such amendments to the Loan Documents, and such additional Security Documents and other instruments and agreements, in each case in form and substance reasonably acceptable to the Lenders and the Obligors, as shall reasonably be necessary to implement and give effect to any assignment made under this Section 14.05.

(d) Register. The Administrative Agent shall maintain a copy of each Assignment and Assumption delivered to it pursuant to clause (b) above and a register for the recordation of the names and addresses of the Lenders, and the Commitments of, and principal amounts (and stated interest) of the Term Loan owing to, each Lender pursuant to the terms hereof from time to time (the “Register”). The entries in the Register shall be conclusive absent manifest error, and the Borrower, the Administrative Agent and the Lenders shall treat each Person whose name is recorded in the Register pursuant to the terms hereof as a Lender hereunder for all purposes of this Agreement. The Register shall be available for inspection by the Borrower and any Lender, at any reasonable time and from time to time upon reasonable prior notice. The Obligations under the Loan Documents (other than the Warrant Obligations) are intended to be maintained in, and this Section shall be construed so that the Commitments and Term Loan are at all times maintained in, “registered form” within the meaning of Section 163(f), 871(h)(2) and 881(c)(2) of the Code and any related regulations (and any other relevant or successor provisions of the Code or such regulations).

-86-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

(e) Participations. Any of the Lenders may at any time, without the consent of, or notice to, the Borrower, sell participations to any Person which would constitute an Eligible Transferee (other than a natural person or a holding company, investment vehicle or trust for, or owned and operated for the primary benefit of, a natural person or the Borrower or any of the Borrower’s Affiliates or Subsidiaries) (each, a “Participant”) in all or a portion of such Lender’s rights and/or obligations under this Agreement (including all or a portion of the Commitment and/or the Term Loan owing to it); provided that (i) such Lender’s obligations under this Agreement shall remain unchanged, (ii) such Lender shall remain solely responsible to the other parties hereto for the performance of such obligations and (iii) the Borrower shall continue to deal solely and directly with such Lender in connection therewith. Any agreement or instrument pursuant to which a Lender sells such a participation shall provide that such Lender shall retain the sole right to enforce this Agreement and to approve any amendment, modification or waiver of any provision of this Agreement; provided that such agreement or instrument may provide that such Lender will not, without the consent of the Participant, agree to any amendment, modification or waiver that would (i) increase or extend the term of such Lender’s Commitment, (ii) extend the date fixed for the payment of principal of or interest on the Term Loan or any portion of any fee hereunder payable to the Participant, (iii) reduce the amount of any such payment of principal, or (iv) reduce the rate at which interest is payable thereon to a level below the rate at which the Participant is entitled to receive such interest (other than with respect to default interest). The Borrower agrees that each Participant shall be entitled to the benefits of Section 5 (subject to the requirements and limitations therein, including the requirements of Section 5.03(f) (it being understood that the documentation required under Section 5.03(f) shall be delivered to the participating Lender)) to the same extent as if such Participant had acquired its interest by assignment pursuant to Section 14.05(b); provided that such Participant shall not be entitled to receive any greater payment under Section 5 with respect to any participation, than its participating Lender would have been entitled to receive. To the extent permitted by Law, each Participant also shall be entitled to the benefits of Section 4.03(a) as though it were a Lender. Each Lender that sells a participation shall, acting solely for this purpose as a non-fiduciary agent of the Borrower, maintain a register on which it enters the name and address of each Participant and the principal amounts (and stated interest) of each Participant’s interest in the Term Loan or other obligations under the Loan Documents (the “Participant Register”); provided that no Lender shall have any obligation to disclose all or any portion of the Participant Register (including the identity of any Participant or any information relating to a Participant’s interest in any commitments, loans, letters of credit or its other obligations under any Loan Document) to any Person except to the extent that such disclosure is necessary to establish that such commitment, loan, letter of credit or other obligation is in registered form under Section 5f.103-1(c) of the United States Treasury Regulations. The entries in the Participant Register shall be conclusive absent manifest error, and the parties hereto shall treat each Person whose name is recorded in the Participant Register as the owner of such participation for all purposes of this Agreement notwithstanding any notice to the contrary.

(f) Security Interest. Notwithstanding anything to the contrary contained in this Section 14.05, a Lender may collaterally assign any of its rights or obligations hereunder or under any of the other Loan Documents by way of pledge or collateral assignment of all or a portion of such Lender’s rights under the Loan Documents to a Federal Reserve Bank provided that no such pledge or assignment shall release such Lender from its obligations hereunder.

-87-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Section 14.06. Survival. The obligations of the Borrower under Sections 5.01, 5.02, 5.03, 14.03 and the obligations of the Subsidiary Guarantors under Section 12 (solely to the extent guaranteeing any of the obligations under the foregoing Sections) shall survive the repayment of the Obligations and the termination of the Commitment and, in the case of the Lenders’ assignment of any interest in the Commitment or the Term Loan hereunder, shall survive, in the case of any event or circumstance that occurred prior to the effective date of such assignment, the making of such assignment, notwithstanding that the Lenders may cease to be “Lenders” hereunder. In addition, each representation and warranty made herein or pursuant hereto shall survive the making of such representation and warranty.

Section 14.07. Captions. The table of contents and captions and section headings appearing herein are included solely for convenience of reference and are not intended to affect the interpretation of any provision of this Agreement.

Section 14.08. Counterparts. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument and any of the parties hereto may execute this Agreement by signing any such counterpart. Delivery of an executed signature page of this Agreement by facsimile transmission or electronic transmission (in PDF format) shall be effective as delivery of a manually executed counterpart hereof.

Section 14.09. Governing Law. This Agreement and the rights and obligations of the parties hereunder shall be governed by, and construed in accordance with, the law of the State of New York, without regard to principles of conflicts of laws that would result in the application of the laws of any other jurisdiction; provided that Section 5-1401 of the New York General Obligations Law shall apply.

Section 14.10. Jurisdiction, Service of Process and Venue.

(a) Submission to Jurisdiction. Each Obligor agrees that any suit, action or proceeding with respect to this Agreement or any other Loan Document to which it is a party or any judgment entered by any court in respect thereof may be brought initially in the federal or state courts in New York, New York or in the courts of its own corporate domicile and irrevocably submits to the exclusive jurisdiction of each such court for the purpose of any such suit, action, proceeding or judgment. This Section 14.10(a) is for the benefit of the Administrative Agent and the Lenders only and, as a result, neither the Administrative Agent nor any Lender shall be prevented from taking proceedings in any other courts located in the United States with jurisdiction, or to extent assets of an Obligor are or may be located in a foreign jurisdiction, in such foreign jurisdiction. To the extent allowed by any Law, the Administrative Agent and the Lenders may take concurrent proceedings in any number of jurisdictions located in the United States and any foreign jurisdictions where the assets of any Obligor are or may be located.

-88-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

(b) Alternative Process. Nothing herein shall in any way be deemed to limit the ability of the Lenders to serve any process or summons in any manner permitted by Law.

(c) Waiver of Venue, Etc. Each Obligor irrevocably waives to the fullest extent permitted by law any objection that it may now or hereafter have to the laying of the venue of any suit, action or proceeding arising out of or relating to this Agreement or any other Loan Document and hereby further irrevocably waives to the fullest extent permitted by law any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum. A final judgment (in respect of which time for all appeals has elapsed) in any such suit, action or proceeding shall be conclusive and may be enforced in any court to the jurisdiction of which such Obligor is or may be subject, by suit upon judgment.

Section 14.11. Waiver of Jury Trial. Each Obligor, the Administrative Agent and each Lender hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any suit, action or proceeding arising out of or relating to this Agreement, the other Loan Documents or the transactions contemplated hereby or thereby.

Section 14.12. Waiver of Immunity. To the extent that any Obligor may be or become entitled to claim for itself or its property or revenues any immunity on the ground of sovereignty or the like from suit, court jurisdiction, attachment prior to judgment, attachment in aid of execution of a judgment or execution of a judgment, and to the extent that in any such jurisdiction there may be attributed such an immunity (whether or not claimed), such Obligor hereby irrevocably agrees not to so claim and hereby irrevocably waives such immunity with respect to its obligations under this Agreement and the other Loan Documents.

Section 14.13. Entire Agreement. This Agreement and the other Loan Documents constitute the entire agreement among the parties with respect to the subject matter hereof and thereof and supersede any and all previous agreements and understandings, oral or written, relating to the subject matter hereof, including any confidentiality (or similar) agreements. Each Obligor acknowledges, represents and warrants that in deciding to enter into this Agreement and the other Loan Documents or in taking or not taking any action hereunder or thereunder, it has not relied, and will not rely, on any statement, representation, warranty, covenant, agreement or understanding, whether written or oral, of or with the Lenders other than those expressly set forth in this Agreement and the other Loan Documents.

Section 14.14. Severability. If any provision hereof is found by a court to be invalid or unenforceable, to the fullest extent permitted by any applicable Law the parties agree that such invalidity or unenforceability shall not impair the validity or enforceability of any other provision hereof.

-89-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Section 14.15. No Fiduciary Relationship. The Borrower acknowledges that the Administrative Agent and the Lenders have no fiduciary relationship with, or fiduciary duty to, the Borrower arising out of or in connection with this Agreement or the other Loan Documents, and the relationship between the Lenders and the Borrower is solely that of creditor and debtor. This Agreement and the other Loan Documents do not create a joint venture among the parties.

Section 14.16. Confidentiality. Each Lender agrees to keep confidential all non-public information provided to it by any Obligor pursuant to this Agreement; provided that nothing herein shall prevent any Lender from disclosing any such information (i) to any other Lender or, subject to a written agreement to comply with the provisions of this Section 14.16, any Affiliate of a another Lender or any prospective assignee or participant of the Term Loan permitted by and pursuant to Section 14.05(b) or (d) that, in each case, is also subject to confidentiality provisions at least as stringent as the provisions of this Section 14.16, (ii) subject to an agreement to comply with the provisions of this Section, to any actual or prospective direct or indirect counterparty to any Hedging Agreement (or any professional advisor to such counterparty), (iii) to its Affiliates employees, officers, directors, agents, attorneys, accountants, trustees and other professional advisors (collectively, its “Related Parties”); provided that the applicable Lender shall remain liable hereunder for any breach of this Section 14.16 by any of its Related Parties, (iv) upon the request or demand of any Governmental Authority or any Regulatory Authority having jurisdiction over such Person or its Related Parties (including any self-regulatory authority, such as the National Association of Insurance Commissioners), (v) in response to any order of any court or other Governmental Authority or as may otherwise be required pursuant to any applicable Law, (vi) if required to do so in connection with any litigation or similar proceeding, (vii) that has been publicly disclosed (other than as a result of a disclosure in violation of this Section 14.16), (viii) on a confidential basis to the National Association of Insurance Commissioners or any similar organization or any nationally recognized rating agency that requires access to information about a Lender’s investment portfolio in connection with ratings issued with respect to such Lender, (ix) in connection with the exercise of any remedy permitted hereunder or under any other Loan Document, (x) on a confidential basis to (A) any rating agency in connection with rating the Borrower or its Subsidiaries or the Term Loan or (B) the CUSIP Service Bureau or any similar agency in connection with the issuance and monitoring of CUSIP numbers of other market identifiers with respect to the Term Loan or (xi) to any other party that is, and is permitted pursuant to the terms hereof to be, a party hereto; provided further that, unless specifically prohibited by applicable law or court order, each Lender shall notify the Borrower of any request by any Governmental Authority or Regulatory Authority or representative thereof (other than any such request in connection with any examination of the financial condition or other routine examination of such Lender by such Governmental Authority or Regulatory Authority) for disclosure of any such non-public information prior to disclosure of such information to enable the Borrower to seek a protection order or otherwise prevent or restrict such disclosure.

-90-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Section 14.17. Right of Setoff. If an Event of Default shall have occurred and be continuing, each Lender and each of its Affiliates is hereby authorized at any time and from time to time, to the fullest extent permitted by applicable Law, to set off and apply any and all deposits (general or special, time or demand, provisional or final, in whatever currency) at any time held and other obligations (in whatever currency) at any time owing by such Lender or any such Affiliate to or for the credit or the account of the Borrower or any other Obligor against any and all of the Obligations now or hereafter existing under this Agreement or any other Loan Document to such Lender or its Affiliates, irrespective of whether or not such Lender or Affiliate shall have made any demand under this Agreement or any other Loan Document and although such Obligations of the Borrower or such Obligor may be contingent or unmatured or are owed to an Affiliate of such Lender. The rights of each Lender and its Affiliates under this Section are in addition to other rights and remedies (including other rights of setoff) that such Lender and Affiliates may have. Each Lender agrees to notify the Borrower promptly after any such setoff and application; provided that the failure to give such notice shall not affect the validity of such setoff and application.

Section 14.18. Judgment Currency. (a) If, for the purposes of obtaining judgment in any court, it is necessary to convert a sum due hereunder in Dollars into another currency, the parties hereto agree, to the fullest extent permitted by Law, that the rate of exchange used shall be that at which, in accordance with normal banking procedures, the Administrative Agent could purchase Dollars with such other currency at the buying spot rate of exchange in the New York foreign exchange market on the Business Day immediately preceding that on which any such judgment, or any relevant part thereof, is given.

(b) The obligations of the Obligors in respect of any sum due to the Administrative Agent hereunder and under the other Loan Documents shall, notwithstanding any judgment in a currency other than Dollars, be discharged only to the extent that on the Business Day following receipt by the Administrative Agent of any sum adjudged to be so due in such other currency the Administrative Agent may, in accordance with normal banking procedures, purchase Dollars with such other currency. If the amount of Dollars so purchased is less than the sum originally due to the Administrative Agent in Dollars, the Borrower agrees, to the fullest extent that it may effectively do so, as a separate obligation and notwithstanding any such judgment, to indemnify the Administrative Agent against such loss. If the amount of Dollars so purchased exceeds the sum originally due to the Administrative Agent in Dollars, the Administrative Agent shall remit such excess to the Borrower.

Section 14.19. USA PATRIOT Act. The Administrative Agent and the Lenders hereby notify the Obligors that pursuant to the requirements of the USA PATRIOT Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)) (the “Act”), they are required to obtain, verify and record information that identifies the Obligors, which information includes the name and address of each Obligor and other information that will allow such Person to identify such Obligor in accordance with the Act.

Section 14.20. Release of Collateral and Guarantees; Non-Disturbance Agreements. (a) The Administrative Agent hereby agrees, at the sole expense of the Borrower, to execute any documents, releases, terminations and agreements reasonably requested by the Borrower (i) to release any Lien on any Collateral (A) on the date when all Obligations (other than Warrant Obligations and contingent obligations as to which no claims have been asserted) have been satisfied in full in cash, (B) that is sold or otherwise disposed of or to be sold or otherwise disposed of as part of or in connection with an Asset Sale permitted pursuant to Section 9.09 or (C) subject to Sections 14.01 and 14.04, if approved, authorized or ratified in writing by the Administrative Agent and (ii) to release any Subsidiary Guarantor from its obligations as a guarantor hereunder if such Person ceases to be a Subsidiary as a result a transaction permitted under the Loan Documents.

-91-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

(b) The Administrative Agent hereby agrees to, and each Lender hereby agrees that Administrative Agent may, enter into non-disturbance or similar agreements in connection with licensing agreements permitted by this Agreement or any other Loan Document, in each case in form and substance reasonably satisfactory to the Administrative Agent and the counterparty or counterparties to the licensing agreements.

Section 14.21. Acknowledgement and Consent to Bail-In of EEA Financial Institutions. Notwithstanding anything to the contrary in any Loan Document or in any other agreement, arrangement or understanding among any such parties, each party hereto acknowledges that any liability of any EEA Financial Institution arising under any Loan Document, to the extent such liability is unsecured, may be subject to the write-down and conversion powers of an EEA Resolution Authority and agrees and consents to, and acknowledges and agrees to be bound by:

(a) the application of any Write-Down and Conversion Powers by an EEA Resolution Authority to any such liabilities arising hereunder which may be payable to it by any party hereto that is an EEA Financial Institution; and

(b) the effects of any Bail-In Action on any such liability, including, if applicable:

(i) a reduction in full or in part or cancellation of any such liability;

(ii) a conversion of all, or a portion of, such liability into shares or other instruments of ownership in such EEA Financial Institution, its parent undertaking, or a bridge institution that may be issued to it or otherwise conferred on it, and that such shares or other instruments of ownership will be accepted by it in lieu of any rights with respect to any such liability under this Agreement or any other Loan Document; or

(iii) the variation of the terms of such liability in connection with the exercise of the write-down and conversion powers of any EEA Resolution Authority.

[Signature Pages Follow]

-92-

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

In Witness Whereof, the parties hereto have caused this Agreement to be duly executed and delivered as of the day and year first above written.

	Borrower:
	Icagen, Inc.
	By:	/s/ Xxxxxxx Xxxxxxxxxx
		Name: Xxxxxxx Xxxxxxxxxx
		Title: Chief Executive Officer
	Address for Notices:
	0000 Xxxxxxx Xxxx.
	Xxxxxx, XX 00000
	Attn: Xxxxxx Xxxxxxxxxx
	Email: xxxxxxxxxxx@xxxxxx.xxx

[Signature Page to Credit Agreement and Guaranty]

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

	Subsidiary Guarantors:
	Icagen Corp., a Nevada corporation
	By:	/s/ Xxxxxxx Xxxxxxxxxx
		Name: Xxxxxxx Xxxxxxxxxx
		Title: Chief Executive Officer
	Caldera Discovery, Inc., a Delaware corporation
	By:	/s/ Xxxxxxx Xxxxxxxxxx
		Name: Xxxxxxx Xxxxxxxxxx
		Title: Chief Executive Officer
	XRPro Sciences, Inc., a Delaware corporation
	By:	/s/ Xxxxxxx Xxxxxxxxxx
		Name: Xxxxxxx Xxxxxxxxxx
		Title: Chief Executive Officer

[Signature Page to Credit Agreement and Guaranty]

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

	Administrative Agent:
	Perceptive Credit Holdings II, LP
	By:	Perceptive Credit Opportunities GP, LLC, its general partner
	By:	/s/ Xxxxxxx Xxxxx
		Name: Xxxxxxx Xxxxx
		Title: Chief Credit Officer
	By:	/s/ Xxx Xxxxxx
		Name: Xxx Xxxxxx
		Title: Portfolio Manager

Address for Notices:

Perceptive Credit Holdings II, LP

c/o Perceptive Advisors LLC

00 Xxxxx Xxxxx, 00xx Xxxxx

Xxx Xxxx, XX  00000

Attn: Xxxxxxx Xxxxx

Email: Xxxxxxx@xxxxxxxxxxxxxx.xxx

[Signature Page to Credit Agreement and Guaranty]

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

	Lenders:
	Perceptive Credit Holdings II, LP
	By:	Perceptive Credit Opportunities GP, LLC, its general partner
	By:	/s/ Xxxxxxx Xxxxx
		Name: Xxxxxxx Xxxxx
		Title: Chief Credit Officer
	By:	/s/ Xxx Xxxxxx
		Name: Xxx Xxxxxx
		Title: Portfolio Manager

Address for Notices:

Perceptive Credit Holdings II, LP

c/o Perceptive Advisors LLC

00 Xxxxx Xxxxx, 00xx Xxxxx

Xxx Xxxx, XX  00000

Attn: Xxxxxxx Xxxxx

Email: Xxxxxxx@xxxxxxxxxxxxxx.xxx

[Signature Page to Credit Agreement and Guaranty]

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Schedule 1

Commitments and Warrant Shares

Commitments

Name of Lender		Commitment Amount
Perceptive Credit Holdings II, LP		$ 7,250,000

Warrant Shares

Name of Lender		Warrant Shares
Perceptive Credit Holdings II, LP		723,550-aggregate number of shares to be issued by Icagen, Inc. under the Credit Agreements for the loans to Icagen, Inc. and Icagen-T, Inc.

***

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Schedule 7.05(b)

Obligor Intellectual Property

List of Patents and Trademarks

Patents

Owner

Title

Country

Application No.

Pub. No.

Patent No.

Status

Icagen, Inc.

METHOD FOR DETECTING BINDING EVENTS USING MICRO-X-RAY FLUORESCENCE SPECTROMETRY

United States

09/859,701

2003-0027129

7,858,385

Patented

Icagen, Inc.

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

Europe

3748920

1525458

1525458

Patented

Icagen, Inc.

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

Belgium

3748920

1525458

1525458

Patented

Icagen, Inc.

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

Switzerland/ Liechtenstein

3748920

1525458

1525458

Patented

Icagen, Inc.

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

Germany

3748920

1525458

1525458

Patented

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Owner

Title

Country

Application No.

Pub. No.

Patent No.

Status

Icagen, Inc.

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

Denmark

3748920

1525458

1525458

Patented

Icagen, Inc.

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

Spain

3748920

1525458

1525458

Patented

Icagen, Inc.

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

Finland

3748920

1525458

1525458

Patented

Icagen, Inc.

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

France

3748920

1525458

1525458

Patented

Icagen, Inc.

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

United Kingdom

3748920

1525458

1525458

Patented

Icagen, Inc.

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

Italy

3748920

1525458

1525458

Patented

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Owner

Title

Country

Application No.

Pub. No.

Patent No.

Status

Icagen, Inc.

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

Sweden

3748920

1525458

1525458

Patented

Icagen, Inc.

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

Netherlands

3748920

1525458

1525458

Patented

Icagen, Inc.

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

Japan

2004-524531

2006-503268

4560403

Patented

Icagen, Inc.

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

Singapore

200500360-3

109345

109345

Patented

Icagen, Inc.

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

United States

11/444,660

2007-0003008

7,519,145

Patented

Icagen, Inc.

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

United States

12/396,592

2009-0175410

7,929,662

Patented

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Owner

Title

Country

Application No.

Pub. No.

Patent No.

Status

Icagen, Inc.

METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING

Europe

4755687.3

1644095

1644095

Patented

Icagen, Inc.

METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING

Switzerland/ Liechtenstein

4755687.3

1644095

1644095

Patented

Icagen, Inc.

METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING

Germany

4755687.3

1644095

1644095

Patented

Icagen, Inc.

METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING

France

4755687.3

1644095

1644095

Patented

Icagen, Inc.

METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING

United Kingdom

4755687.3

1644095

1644095

Patented

Icagen, Inc.

METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING

Ireland

4755687.3

1644095

1644095

Patented

Icagen, Inc.

METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING

Netherlands

4755687.3

1644095

1644095

Patented

Icagen, Inc.

METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING

Japan

2006-520181

2007527524

4782676

Patented

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Owner

Title

Country

Application No.

Pub. No.

Patent No.

Status

Icagen, Inc.

METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING

Singapore

2005085584

118682

Patented

Icagen, Inc.

METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING

United States

10/621,825

2005-0011818

6,858,148

Patented

Icagen, Inc.

METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING

United States

10/986,519

2005-0095636

7,241,381

Patented

Icagen, Inc.

DRUG DEVELOPMENT AND MANUFACTURING

United States

10/880,388

2004-0235059

9,157,875

Patented

Icagen, Inc.

X-RAY FLUORESCENCE ANALYSIS METHOD

Europe

7874491.9

2084519

2084519

Patented

Icagen, Inc.

X-RAY FLUORESCENCE ANALYSIS METHOD

Switzerland/ Liechtenstein

07 874 491.9

2084519

2084519

Patented

Icagen, Inc.

X-RAY FLUORESCENCE ANALYSIS METHOD

Germany

60 2007 024 468.4

2084519

608007024468.4

Patented

Icagen, Inc.

X-RAY FLUORESCENCE ANALYSIS METHOD

Denmark

07 874 491.9

2084519

2084519

Patented

Icagen, Inc.

X-RAY FLUORESCENCE ANALYSIS METHOD

France

07 874 491.9

2084519

2084519

Patented

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Owner

Title

Country

Application No.

Pub. No.

Patent No.

Status

Icagen, Inc.

X-RAY FLUORESCENCE ANALYSIS METHOD

United Kingdom

7874491.9

2084519

2084519

Patented

Icagen, Inc.

ADVANCED DRUG DEVELOPMENT AND MANUFACTURING

Hong Kong (via EP -005EPDV)

13104259.3

1177280

1177280

Patented

Icagen, Inc.

X-RAY FLUORESCENCE ANALYSIS METHOD

Ireland

7874491.9

1177280

2084519

Patented

Icagen, Inc.

X-RAY FLUORESCENCE ANALYSIS METHOD

Italy

7874491.9

1177280

2084519

Patented

Icagen, Inc.

X-RAY FLUORESCENCE ANALYSIS METHOD

Netherlands

7874491.9

1177280

2084519

Patented

Icagen, Inc.

X-RAY FLUORESCENCE ANALYSIS METHOD

Sweden

7874491.9

1177280

2084519

Patented

Icagen, Inc.

X-RAY MICROSCOPE

Europe

12164870.3

2511844

2511844

Patented

Icagen, Inc.

X-RAY MICROSCOPE

Switzerland and Lichtenstein

12164870.3

2511844

2511844

Patented

Icagen, Inc.

X-RAY MICROSCOPE

Germany

12164870.3

2511844

602007042616.2

Patented

Icagen, Inc.

X-RAY MICROSCOPE

France

12164870.3

2511844

2511844

Patented

Icagen, Inc.

X-RAY MICROSCOPE

United Kingdom

12164870.3

2511844

2511844

Patented

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Owner

Title

Country

Application No.

Pub. No.

Patent No.

Status

Icagen, Inc.

ADVANCED DRUG DEVELOPMENT AND MANUFACTURING

Hong Kong (via EP -005EPDV)

2013104259.3

1177280

1177280

Patented

Icagen, Inc.

X-RAY MICROSCOPE

Ireland

12164870.3

2511844

2511844

Patented

Icagen, Inc.

ADVANCED DRUG DEVELOPMENT AND MANUFACTURING

Japan

2009-532446

2010509566

5143841

Patented

Icagen, Inc.

ADVANCED DRUG DEVELOPMENT AND MANUFACTURING

Japan

2014-123249

2014-123249

5913441

Patented

Icagen, Inc.

ADVANCED DRUG DEVELOPMENT AND MANUFACTURING

United States

14/693,094

2015-0309021

N/A

Pending

Icagen, Inc.

ADVANCED DRUG DEVELOPMENT AND MANUFACTURING

United States

15/876,931

N/A

N/A

Pending

Icagen, Inc.

WELL PLATE

Europe

8798006.6

2183644

2183644

Patented

Icagen, Inc.

WELL PLATE

Belgium

8798007.6

2183644

2183644

Patented

Icagen, Inc.

WELL PLATE

Switzerland/ Liechtenstein

8798008.6

2183644

2183644

Patented

Icagen, Inc.

WELL PLATE

Germany

8798009.6

2183644

602008044640.9

Patented

Icagen, Inc.

WELL PLATE

Denmark

8798010.6

2183644

2183644

Patented

Icagen, Inc.

WELL PLATE

Spain

8798011.6

2183644

2183644

Patented

Icagen, Inc.

WELL PLATE

Finland

8798012.6

2183644

2183644

Patented

Icagen, Inc.

WELL PLATE

France

8798013.6

2183644

2183644

Patented

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Owner

Title

Country

Application No.

Pub. No.

Patent No.

Status

Icagen, Inc.

WELL PLATE

United Kingdom

8798014.6

2183644

2183644

Patented

Icagen, Inc.

WELL PLATE

Ireland

8798015.6

2183644

2183644

Patented

Icagen, Inc.

WELL PLATE

Italy

8798016.6

2183644

2183644

Patented

Icagen, Inc.

WELL PLATE

Netherlands

8798017.6

2183644

2183644

Patented

Icagen, Inc.

WELL PLATE

Norway

8798018.6

2183644

2183644

Patented

Icagen, Inc.

WELL PLATE

Sweden

8798019.6

2183644

2183644

Patented

Icagen, Inc.

WELL PLATE

Japan

2010-521206

2010537171

5628035

Patented

Icagen, Inc.

WELL PLATE

Japan

2013-117600

0000000000

5755682

Patented

Icagen, Inc.

WELL PLATE

Japan

2014-202871

0000000000

6076308

Patented

Icagen, Inc.

WELL PLATE

United States

12/192,762

2009-0046832

8,238,515

Patented

Icagen, Inc.

WELL PLATE

United States

13/567,613

2013-0034205

8,873,707

Patented

Icagen, Inc.

WELL PLATE

United States

14/508,322

2015-0023467

9,476,846

Patented

Icagen, Inc.

WELL PLATE

United States

15/273,767

2017-0010228

N/A

Pending

Icagen, Inc.

METHOD AND APPARATUS FOR MEASURING PROTEIN POST-TRANSLATIONAL MODIFICATION

Japan

2010-5272

2010539944

5743135

Patented

Icagen, Inc.

METHOD AND APPARATUS FOR MEASURING PROTEIN POST-TRANSLATIONAL MODIFICATION

Japan

2014-221166

0000000000

N/A

Pending

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Owner

Title

Country

Application No.

Pub. No.

Patent No.

Status

Icagen, Inc.

METHOD AND APPARATUS FOR MEASURING PROTEIN POST-TRANSLATIONAL MODIFICATION

United States

15/052,914

2016-0201111

9976172

Patented

Icagen, Inc.

METHOD AND APPARATUS FOR MEASURING PROTEIN POST-TRANSLATIONAL MODIFICATION

United States

15/961,480

N/A

N/A

Pending

Icagen, Inc.

METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS

China

200980125952.3

102083365

ZL 200980125952.3

Patented

Icagen, Inc.

METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS

China

201310298029.8

103411988

2077368

Patented

Icagen, Inc.

METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS

China

201510083796.6

N/A

N/A

Pending

Icagen, Inc.

METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS

Europe

09774467.6

2306897

2306897

Patented

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Owner

Title

Country

Application No.

Pub. No.

Patent No.

Status

Icagen, Inc.

METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS

Switzerland/ Liechtenstein

09774467.6

2306897

2306897

Patented

Icagen, Inc.

METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS

Germany

09774467.6

2306897

2306897

Patented

Icagen, Inc.

METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS

France

09774467.6

2306897

2306897

Patented

Icagen, Inc.

METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS

United Kingdom

09774467.6

2306897

2306897

Patented

Icagen, Inc.

METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS

Hong Kong

11112984.0

1158478

1158478

Patented

Icagen, Inc.

METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE

United States

12/496,532

2010-0003697

8,431,357

Patented

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Owner

Title

Country

Application No.

Pub. No.

Patent No.

Status

Icagen, Inc.

METHOD FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE USING X-RAY FLUORESCENCE

United States

13/871,697

2013-0236887

9,063,154

Patented

Icagen, Inc.

METHOD FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE

United States

14/669,923

2015-0198615

9,506,931

Patented

Icagen, Inc.

METHOD FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE

United States

15/334,854

2017-0045530

N/A

Pending

Icagen, Inc.

METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE

United States

13/317,341

2012-0093286

9,063,066

Patented

Icagen, Inc.

METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE

United States

14/715,206

2015-0276631

9,435,756

Patented

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Owner

Title

Country

Application No.

Pub. No.

Patent No.

Status

Icagen, Inc.

METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE

United States

14/715,218

2015-0276632

9,442,085

Patented

Icagen, Inc.

METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE

United States

14/715,233

2015-0260664

9,335,284

Patented

Icagen, Inc.

METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE

United States

15/227,292

2016-0341678

N/A

Pending

Icagen, Inc.

METHODS AND APPARATUS FOR MEASURING METALS AND METALLOIDS

International

PCT/US17/28064

N/A

N/A

Pending

Icagen, Inc.

METHODS OF DETECTION USING X-RAY FLUORESCENCE

United States

62/558,528

N/A

N/A

Pending

Trademarks

Owner

Xxxx

Country

Application No.

Registration No.

Status

Icagen, Inc.

ICAGEN

USA

87008899

5243971

Live

Icagen, Inc.

MXRF

USA

85291101

4390286

Live

Icagen, Inc.

XRPRO

USA

77377389

3507712

Live

***

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Schedule 7.05(b)(ix) and (xiv)

Research Development and Commercialization Agreement made May 1, 2018 by and between Icagen, Inc. and Cystic Fibrosis Foundation and amendment No. 1 thereto

Research Collaboration and License Agreement made May 1, 2018 between Sanofi and Icagen, Inc.

Asset Purchase Agreement and Collaboration Agreement dated as of June 26, 2015 between XRpro Sciences, Inc. (now known as Icagen, Inc.) and Icagen, Inc. (a subsidiary of Pfizer, Inc.)

Master Service Agreement dated as of June 26, 2015 between XRPro Sciences, Inc. (now known as Icagen, Inc.) and Icagen, Inc. (a subsidiary of Pfizer, Inc.)

First and Second Amendment to Asset Purchase and Collaboration Agreement between Icagen, Inc. (f/k/a XRpro Sciences, Inc. and Pfizer Research (NC, Inc. (f/k/a Icagen, Inc.) dated July 15, 2016 and May 31, 2017, respectively

***

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

SCHEDULE 7.05(c)

Material IP

None

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Schedule 7.06(a)

Certain Litigation

None.

***

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Schedule 7.06(c)

Labor Matters

None

***

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Schedule 7.08

Taxes

None

***

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Schedule 7.12(a)

Equity Holders

Attached is a list of each holder of shares of common stock, preferred stock, warrants and options and the numbers of securities held by each holder.

ICAGEN INC
COMMON SHAREHOLDERS
NAME		NUMBER OF SHARES
XXXXXXXX XXXXXX			1443250
INTER-MARKETING GROUP USA INC			8750
XXXXXXX XXXXXX			3312
XXXXX XXXXXXXXXX & TOBI			21432
XXXXXX XXXXX - REVOCABLE TRUST			56145
XXXX XXXXXX TRUST			37430
XXXXXXX XXXXXXX			21429
XXXXXX & XXXXXXXXXX XXXXXXXX			8445
XXXXXX X XXXXXXX			21429
2030 INVESTORS LLC/401 K PLAN			00000
XXXXXXXX XXXXXX XXX XXXXX XXXXX			00000
C XXXXX XXXXXX			80673
XXXX XXX BIU			56480
CIRRUS ADVISORS INC			13125
XXXXXXX XXXXXX			19561
EIGHT FAMILY TRUST			29727
XXXX XXXXX			19821
XXXXXX W & XXXXXXXX X XXXXXX			316372
XXXXXXX XXXXXX			56442
XXXXXXX BHARTI			000
XXXXXX X XXXXXX			00000
S/L TRILLING TRUST			37939
XXXXX XXXXXX			31442
XXXXXXXX AND XXXXX XXXX			74967
SIN XX XXXX AND XXX XXXX			18972
XXXXX XXXXXX			13125
THE BIBICOFF FAMILY TRUST DTD 5/16/00			30000
XXXXXXX X XXXXX			6700
XXXXXX X XXXXXXX TRUST UAD 2-5-90			4000
XXXXXXX X XXXXX & XXXX X XXXXX JT TEN			19998
XXXXXXX XXXXXX			00000
XXXXXX X XXXXX			21428

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

PENSION INC TRUSTEE FBO THUEMLING			4000
SHADOW CAPITAL LLC			56826
STERLING FAMILY INVESTMENT LLC			19142
THE SDM IRREVOCABLE TRUST FBO XXXXXX			14356
THE SDM IRREVOCABLE TRUST FBO LAUREN			14356
XXXX X XXXXXXX TRUST DTD 12/4/2004			37808
XXXX XXXX			28412
XXXX XXXXXXX POA TAG/KENT PARTNERSHIP			14286
XXXXXXX X XXXXXXXX			00000
XXXXXXX X XXXXXX			00000
X0XX LLC			15000
XXXXXX XXXXXXXXX			7598
AIC HOLDINGS LLC			43783
XXXXXXX X XXXXXXX AND XXXXX B			1500
XXXXXX XXXXX XXXXXXXX SEPARATE			250
XXXXX XXXXX			4375
DON AND XXXXX XXXXXXX			500
XXXXXX XXXXXX			1000
XX XXXXXX XXXXXX			3500
XXXXXX XXXXXXXXX			000
XXXXXX XXXXXXXX XXXXXXX XX XXX XXXXXX			00000
XXXXXXXXX XXXXXXX			500
XXXXXX XXXXXXX			915
XXXX XXXXXXX			000
XXXXX XXXXX XXXXXX MANAGEMENT			50000
XXXXX (JEREMIEL) XXXXXXXXX			52000
XXXXXX XXXXXX			578
XXXXX XXXXXXXXXXX			1230
XXXXX XXX			1000
XXXX XXXXXX			5000
XXXXX XXXXXXXX			1000
XXXX X XXXXXX			500
XXXX XXXXXXXX			1500
XXXXXX X XXXXX			500
XXXX XXXXXX			500
XXXX XXXXXX			500
XXXX X XXXXXXX			750
XXXXX XXXXXX XXXXXX			500
XXXXXXX XXXXXXXXX			1000
XXXX XXXXX			500
XXXXXX & XXXXXX INC SALARY DEFERRAL			107
XXXX XXXXX			1500
XXXXXXX X XXXX PROFIT SHARING PLAN			12858
XXXXXX XXXXXX			1209
XXXXXXX XXXX			750

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

PIONEER VENTURE PARTNERS LLC			1250
XXXXXX PARTNERS			5000
XXXXXXX X XXXXXXXXXX			500
XXXXXXX XXXXX XXXX			36786
XXXXXX X XXXXX AND XXXXX X XXXXX			1500
XXXXXX X XXXXXX TRUST UDT 3/13/85			1500
XXXXXX WULSOHN			1000
SADDINGTON FAMILY TRUST			000
XXXXXXX X XXXXXXXX			500
STRATEGIC XX			000
XXXXX XXXXXX XXX			00000
THRG LLC			4375
XXX XXXXXX			500
W FOUR LLC XX XXXXXX XXXXXXXX			1250
XXXXX A AND L XXXX XXXXXXXXX 1992			500
XXXXXXX XXXXXXX			15000
XXXXXXXX XXXXXXXXXX			3500
XXXXXX X XXXXXXXXX XX TRUST UA DTD			30000
PATIENCE PARTNERS LLC			8000
XXXXXXXX X XXXXX PROTOTYP			6000
T MINA SUPPLY INC			23070
XXXXX XXXXXXX			0000
XXXXXX X XXXXX XXXXXXX XXXXX XXX			00000
XXXX HOLDING INC			5714
THE XXXXXX W MAIN TRUST DTD 9/7/05			2858
C XXXX XXXXX			2286
XXXXXX XXXXX			7142
XXXXX XXXXXXXXXXX			1640
XXXXXX X XXXXXX			2858
XXXXX XXXXXXX & XXXXXXXXX XXXXXXX			3000
XXXXXX XXXXXXXX			10000
XX XXXXXXX X XXXXX & XXXXXX X XXXXX			10000
XXXX X XXXXXX & XXXXXX XXXXXX JT TEN			2860
XXXXXXX X XXXXXXXX			4000
XXXXXXX X XXXXXXX & XXXXX X XXXXXXX			10000
XXXXXXX X XXXXXX & XXXXXXX X XXXXXX			1000
XXXXXXX X XXXXXXXX & XXXXX X XXXXXXXX			8000
XXXXX X XXXXXXX			4000
XXXXXX XXXXXXXXX			8000
XXXXXXX XXXXXXXX			8000
THE XXXXXXX XXXXXXXX REVOCABLE TRUST			8000
BIBICOFF XXXXXXXX INC			3142
XXXXXX XXXXXXXX			30000
XXXX XXXXXX & XXXXXXX XXXXXX			71428
XXXXXX X XXXXXX			2000
XXXXXXXX XXXXXXXX			2856

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

XXXXX A RANDOM			15712
XXXXX W & XXXXX X XXXXXXX LIVING TR			15712
XXXXXXX X XXXX & XXXX XXX XXXX JTWROS			9300
THE XXXXXXX X XXXXXX LIVING TRUST			9286
XXXXX X XXXX & XXXXXXXX X XXXX 1999			9286
XXXXXXX XXXX XXXXX			9286
XXXXXX X XXXXXX TRUST UAD 12/31/94			8570
NORPER INVESTMENTS			7658
XXXXX XXXXXX			7658
XXXX X XXXXXXXXXX			5998
XXXX XXXXXXX & XXXXXX XXXXXXX JTWROS			4000
XXXXXXX XXXXXXX			4000
XXXXX X XXXXXX & XXXXX X XXXXXX JTWROS			4000
XXXXXX X XXXXXX			3000
XXXXXXX XXXXXXXXXX			2858
XXXX XXXXXXX			2858
XXXXXXX X XXXXXXX			2856
XX XXXXXX XXXXXXX & XXXXXX XXXXXXX			8570
ROSE XXXX XXXXXXX XXXXXX XXXXXXX POA			8570
XXXXX XXXXXXXXXX			8570
XXXX XXXX			3000
XXXXX XXXXX			2000
XXXXXXX X XXXX			13062
XXXXXXX X XXXXXXX & XXXXXX X XXXXXXX			7140
XXXX XXXXXXX & XXXXXX XXXXXXX JT TEN			5200
XXXXXXX X XXXXXXX			10002
XXXX X XXXX			10002
XXXX X XXXXXX & XXXX XXXXXX JTWROS			1430
XXXXXX XXXXXXXXX			2000
XXXX XXXXXXXXXX XXXXXXXX FAMILY TRUST			3000
XXXXXX XXXXXXXXXXX &			2000
XXXXX X XXXXX			4998
THE XXXXXX FAMILY LEGACY TRUST NO 2			3000
XXXXXX XXXXX REVOCABLE TRUST			5742
RAVICH REVOCABLE TRUST			4690
XXXXX XXXXXX			3000
XXXXX XXXXXXXXXX			5742
XXXXXX XXXXXXX			2858
XXXXXXXX XXXX			14286
XXXXXX XXXXXX			4200
XXXXX XXXXXXX WARDEN			4756
XXX XXXXXX			28570
XXXXXXXXX FAMILY LTD PARTNERS			6700
XXXXX X XXXXX			15312
XXXXXXX XXXX			9380

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

XXXX XXXXX & XXXX XXXXX JTWROS			4000
XXXXXX XXXXXXX			9570
XXXXX XXXXX & XXXXXXXX XXXXX JTWROS			9570
XXXXX XXXXXX			9570
XXXXXX X XXXXX & XXXXX X XXXXX JT TEN			10000
XXXXXXX X XXXXXX			10000
XXXXXXXXX X XXXXXXXXXXX			5742
XXXX X XXXXXXX REVOCABLE LIVING TRUST			4784
XXXXXX X XXXX			2860
XXXXXX XXXXXXX			5360
XXXXXX & XXXXX XXXXXX FAMILY TRUST			3684
XXXXX THORSTENN & MAGNUS THORSTENN			19140
BARKTONES LLC			00000
XXXXXX X XXXXX XX			00000
XXXX XXXXXX			20100
XXXXX XXXXXX			3000
XXXXXX X XXXX			15312
REVOC LIVING TRST OF XXXXXXX XXXXXX			19142
DAZIA CAPITAL SPAIN S L			7144
XXXX X XXXXXXX			14356
JUNGE REVOCABLE TRUST UAD 12/09/91			38284
XXXXXX X & XXXXXX XXXXXXX XXXXXXXX			00000
BFJK INVESTMENT PARTNERSHIP			10000
XXXXX & XXXXXXXX XXXXXX REVOCABLE UAD			23928
XXXXXX X XXXXXXXXX TRUST UAD 3/16/77			3000
IVANKA XXXXX XXXXX			2858
XXXXX X XXXXXXXXX			0000
XXX XXX XXXXXX X XXXXXXX			1428
XXX FBO XXXXXX X XXXXXXXX			10000
XXX FBO XXXXXXX X XXXXXXXXXXX			5714
XXX FBO XXXXXXX XXXXXXXXXX			22800
XXXXXXX X XXXXXXX XXXXX-ACCOUNT			285714
XXXXXXX XXXXXXX CUST FOR			5714
XXXXXXX XXXXXXX CUST FBO			5714
XXXXXXX XXXXXXX CUST FBO			5714
XXX FBO P XXXXXXX XXXX			2860
XXXXXXXX XXXXXXX & XXXXXXX XXXXXXX			0000
XXXXXX XX XXXXXXX XXXXXX XXXXXXX			00000
XXX FBO XXXXXX X XXXXXXX			285714
XXXXXX X XXXXXXX & XXXXXX X XXXXXXX			2846
XXXXXXX XXXXXXX			12000
TYSON REVOCABLE TRUST			142856
XXXXXXXX X XXXXXXXX &			14854
XXXXX XXXXXX			3000
XXXXXXX XX			7140
XXXXXX X XXXXXXX			2900

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

XXXXX XXXXXXX			2600
XXXXX XXXXXXXX			3000
XXXXX XXXXXX			5720
XXXXXXX X XXXXX			5714
XXXX XXXXXX			5714
THE XXXX FAMILY TRUST UAD 02/01/07			6000
XXXXXXX XXXXXX			2800
XXXXXX XXXXXXX			28570
XXXXXX X XXXX			9572
XXXXXXX XXXXXXXX			1428
XXXX XXXXXXXXX			42856
XXXXXX XXXXXXX			19000
XXXX XXXXX & XXXXXXXXX XXXXX JTWROS			1430
XXXXX X XXXXXX			400
XXXXXXX XXXXXXXXX TRUSTEE			7980
NINA XXXX XXXXXXX			2870
XXXX XXXXX XXXXXXXX			2534
XXXXXXX XXXXXX TABLONE			2533
PERSHING LLC			879600
THE HOPE A TAGLICH FIRST PARTY			5714
XXXXXXXX XXXXXXXX			9570
XXXXXX X XXXXXXXX TUW FBO			9570
THE XXXXX XXXXXX REVOCABLE TRUST UAD			28510
XXXXXXX XXXXXXXXXX			21428
XXX XXXXX			21428
XXXXXX X XXXXXXXXX 2017 TRUST			15312
PERSHING LLC			99818
PERSHING LLC			87088
XXXX X XXXXXXXXXXX MARITAL TRUST -			6700
XXXX XXXXX WORTHINGTON			3350
XXXXXXX XXXXXXXXXXX XXXX			3350
XXXXXXX BRAND & XXXXX XXX BRAND JT TEN			19140
GST EXEMPT MARITAL TRUST			102
XXXXXX X XXXXX TRUST			34146
XXXXX X XXXXX RESIDUARY TRUST			5670
XXXXXX X XXXXX III RESIDUARY TRUST			5670
XXXXXX X XXXXX RESIDUARY TRUST			5670
XXXXXX X XXXXX RESIDUARY TRUST			5670
XXXX X XXXXXXXXXX &			8445
TOTAL			6,393,107

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

ICAGEN INC
SERIES C PREFERRED SHAREHOLDERS
NAME		NUMBER OF SHARES
TYSON REVOCABLE TRUST			685,704
XXXXX XXXXXXXXX			28,571
			714,275

ICAGEN

OPTIONS OUTSTANDING

Option Holder

Grant Date

Expiry Date/ Expiry on emp termination

Term (in years)

Active options

2005 PLAN OPTIONS

2010

Xxxxxx Xxxxxx

1/11/2010

1/10/2020

10

8,791

Xxxxx Xxxxxxx

7/29/2010

7/28/2020

10

5,000

2011

Xxxxxxx Xxxx

5/1/2011

4/30/2021

10

6,000

2012

Xxxxxx Xxxxxxx

5/1/2012

4/30/2022

10

15,000

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

2013
Xxxxx Xxxxx		3/5/2013		3/4/2023			10				5,000
Xxxxxxxx Xxxxxx		3/15/2013		3/14/2023			10				92,500
Xxxxxx Xxxxxxxx		3/15/2013		3/14/2023			10				92,500
FSAM - Clive and Xxxx		3/15/2013		3/14/2023			10				75,000
Xxx Xxxxxx		3/15/2013		3/14/2023			10				52,500
Xxxx Xxxxxx		7/1/2013		6/30/2020			7				12,500
Xxxxxxx X Xxxxx		10/1/2013		9/30/2020			7				10,000
2014
Xxxxxx Xxxxxxx		4/1/2014		3/31/2021			7				10,000
Xxxxxxx Xxxxxxxx		4/1/2014		3/31/2021			7				10,000
Xxxxxxxx Xxxxxxx		4/1/2014		3/31/2021			7				10,000
Xxxxxxx Xxxxx		4/1/2014		3/31/2021			7				66,000
Kanalis Consulting		4/10/2014		4/9/2019			5				10,000
2015
Xxxxxx Xxxxxxxxxx		1/7/2015		1/6/2025			10				250,000
											730,791
2015 PLANS OPTIONS
2016
Xxxxxxx Xxxxxx		5/19/2016		5/18/2026			10				100,000
Xxxxxx Xxxxxxx		5/19/2016		5/18/2026			10				12,500
Xxxxxxx Xxxxxxxx		5/19/2016		5/18/2026			10				12,500
Xxxxxxxx Xxxxxxx		5/19/2016		5/18/2026			10				12,500
Xxxxxxx Xxxxx		5/19/2016		5/18/2026			10				12,500
Xxxxx Xxxxxxxxx		5/19/2016		5/18/2026			10				12,500
Xxxx Xxxxxx		5/19/2016		1/31/2019			10				12,986

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Xxxx Xxxxxx		5/19/2016		5/18/2026			10				-
Xxxx Xxxxxx		5/19/2016		5/18/2026			10				30,000
Xxxxxxxxxxx Xxxxxx		5/19/2016		5/18/2026			10				13,500
Xxxx Xxxxxxx		5/19/2016		5/18/2026			10				12,000
Xxxxx Xxxxxxx		5/19/2016		5/18/2026			10				10,200
Xxxxx Xxxxxxx		5/19/2016		5/18/2026			10				9,800
Xxxxx Xxxxxxx		5/19/2016		5/18/2026			10				5,100
Xxxxx Xxxxxx		5/19/2016		5/18/2026			10				5,100
Xxxxxxx Xxxxxxx		5/19/2016		5/18/2026			10				4,300
Xxxxxxx Xxxxxxx		7/15/2016		7/14/2026			10				80,000
Xxxx August		7/15/2016		7/14/2026			10				50,000
Xxxx Xxxx		7/15/2016		7/14/2026			10				50,000
Xxxxxx Xxxxx		7/15/2016		7/14/2026			10				50,000
Xxxx Xxxxxx		7/15/2016		7/14/2026			10				20,000
Xxxxx Xxxxxx		8/22/2016		12/31/2018			10				16,668
2017
Xxxxxx Xxxxxxx		3/15/2017		3/14/2027			10				10,000
Xxxxxxx Xxxxxxxx		3/15/2017		3/14/2027			10				10,000
Xxxxxxxx Xxxxxxx		3/15/2017		3/14/2027			10				10,000
Xxxxxxx Xxxxx		3/15/2017		3/14/2027			10				10,000
Xxxxx Xxxxxxxxx		3/15/2017		3/14/2027			10				10,000
Xxxxxxx Xxxxxxxxx		3/15/2017		3/14/2027			10				20,000
To be allocated		3/15/2017		3/14/2027			10				50,000
											652,154
Total											1,382,945

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

ICAGEN, INC

WARRANTS OUTSTANDING

$3.50 Warrants

$3.85 Warrants

Name

TOTAL

Issue Date

Expiry Date

Warrants

Issue Date

Expiry Date

Warrants

Bridge Note conversion Warrants

Xxxxxxx X. Xxxxxx

10,047

4/19/2013

4/19/2020

10,047

Xxx Xxxxxxxxx

5,032

4/19/2013

4/19/2020

5,032

Xxxxxxx X. Xxxxxxx

20,677

4/19/2013

4/19/2020

20,677

R2MJ LLC

5,032

4/19/2013

4/19/2020

5,032

Xxxxxx X. Xxxxxxx

20,677

4/19/2013

4/19/2020

20,677

Xxxxxxx X. Xxxxxxxx

10,339

4/19/2013

4/19/2020

10,339

Xxxxxxx X. Xxxxxxxx

5,030

4/19/2013

4/19/2020

5,030

Series B Warrants

Xxxxxx X. Xxxxxxx

10,000

4/23/2013

4/23/2020

10,000

Xxxxxx K Light

20,000

4/23/2013

4/23/2020

20,000

Xxx X Xxxxxxxxx

6,000

4/23/2013

4/23/2020

6,000

Xxxxxxx Holdings Inc

6,000

4/23/2013

4/23/2020

6,000

Xxxxx X. Xxxxx And Xxxxxx X. Xxxxx Jtwros

4,000

4/23/2013

4/23/2020

4,000

Xxxxx And Xxxxxxxxx Xxxxxxxx Trust Uad 09/09/05 Xxxxx Xxxxxxxx & Xxxxxxxxx Xxxxxxxx Ttees

2,000

4/23/2013

4/23/2020

2,000

Xxxxxx Xxxxxxxx And Xxxxxxxxxx Xxxxxxxx Trustees Of The Bibicoff Family Trust Dtd 5/16/00

5,000

4/23/2013

4/23/2020

5,000

Xxxxxxx X Xxxxx & Xxxxxxx X Xxxxx Jtwros

5,000

4/23/2013

4/23/2020

5,000

Xxxx X Xxxxxx Xx Ttee Xxxx X Xxxxxx Xx Xxx Trust

4,000

4/23/2013

4/23/2020

4,000

Xxxxxx Xxxxxx

2,000

4/23/2013

4/23/2020

2,000

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Xxxxxx Family Trust 2002 Xxxxxx X. Xxxxxx Ttee			2,000			4/23/2013		4/23/2020			2,000
Xxxxxxx X Xxxxxxx Xxxxxxx Xxxxxxx Jtwros			10,000			4/23/2013		4/23/2020			10,000
Xxxx Xxxxxxx Poa Tag/Kent Partnership F/B/X Xxxxxxxxxxxx/M Taglich B Taglich			30,000			4/23/2013		4/23/2020			30,000
Pension Inc Trustee Fbo Xxxxxxxxx Industrial Products Inc Profit Sharing Plan			20,000			4/23/2013		4/23/2020			20,000
Xxxxxxx X Xxxxx & Xxxx X Xxxxx Jt Ten			10,000			4/23/2013		4/23/2020			10,000
Shadow Capital Llc			25,000			4/23/2013		4/23/2020			25,000
Xxxxxxx X Xxxxxxxxx			5,000			4/23/2013		4/23/2020			5,000
Xxxxxx X Xxxxxxx Trust Uad 10/5/94 Xxxxxx X Xxxxxxx & Xxxxxx X Xxxxxxx Ttee			27,000			4/23/2013		4/23/2020			27,000
Xxxxxx X Xxxxxxx Trust Uad 10/5/94 Xxxxxx X Xxxxxxx & Xxxxxx X Xxxxxxx Ttee			27,000			4/23/2013		4/23/2020			27,000
Xxxxxxxx Xxxx			5,000			4/23/2013		4/23/2020			5,000
Xxxxxxx Xxxx			10,000			4/23/2013		4/23/2020			10,000
Xxxxx X Xxxxxxxx Rev Trust U A Dtd 1/31/85 Xxxxx X Xxxxxxxx Ttee			4,000			5/3/2013		5/3/2020			4,000
Xxxx X. Xxxxxx Trust Uad 12/30/94 Xxxx X Xxxxxx Ttee			3,000			5/3/2013		5/3/2020			3,000
Xxxxxx Xxxxxx			25,000			5/3/2013		5/3/2020			25,000
Xxxxxx X Xxxxx & Xxxxx X Xxxxx Jt Ten Wros			5,000			5/3/2013		5/3/2020			5,000
Xxxxxx X Xxxxx			10,000			5/3/2013		5/3/2020			10,000
Xxxx X Xxxxxxx Trust Dtd 12/4/2004 Xxxx X Xxxxxxx Trustee			30,000			5/3/2013		5/3/2020			30,000
Xxxxxx X Xxxxxxxx			3,000			5/3/2013		5/3/2020			3,000
Xxxxxxx Xxxxxxxxxx Tr Xxxxxxx Xxxxxxxxxx Ttee Dtd 7/30/84			5,000			5/3/2013		5/3/2020			5,000
Xxxxxxx X Xxxxxxxxx			3,000			5/3/2013		5/3/2020			3,000
Xxxxxxx X Xxxxxxxxx			5,000			5/3/2013		5/3/2020			5,000

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Xxxxxx Family Living Trust Dtd 08/01/2007 Xxxxxx X Xxxxxx And Xxxx X Xxxxxx Co-Trustees			2,000			5/3/2013		5/3/2020			2,000
Xxxxxxxx X Xxxxxxxxxx			5,000			5/3/2013		5/3/2020			5,000
Xxxx Xxxxx			2,000			5/3/2013		5/3/2020			2,000
Xxxxx X Xxxxxxxx Xx			3,000			5/3/2013		5/3/2020			3,000
Xxxxxxx Xxxxxx			30,000			5/3/2013		5/3/2020			30,000
Xxxxxxx X Xxxxx			3,000			5/3/2013		5/3/2020			3,000
Xxxxx X Xxxxxxx			10,000			5/3/2013		5/3/2020			10,000
Xxxx X Xxxxxx			20,000			5/3/2013		5/3/2020			20,000
Xxxx Xxxx			35,000			5/3/2013		5/3/2020			35,000
Xxxxxx Xxxxxxxx & Xxxxxxxxxx Xxxxxxxx Jt Ten			5,000			5/3/2013		5/3/2020			5,000
Xxxxxx Family Limited Partners			3,000			5/3/2013		5/3/2020			3,000
Xxxxxxx X Xxxxxxx Trust U A/D 12-23-96 Xxxxxxx X Xxxxxxx Ttee			5,000			5/3/2013		5/3/2020			5,000
Xxxxxx X Xxxxxxx			5,000			5/3/2013		5/3/2020			5,000
Xxxxxx Xxxxxx			5,000			5/3/2013		5/3/2020			5,000
Xxxxxx X Xxxxxxx Trust Uad 2-5-90 Xxxxxx X Xxxxxxx Ttee			2,000			5/3/2013		5/3/2020			2,000
Sterling Family Investment LLC			30,000			5/3/2013		5/3/2020			30,000
Xxx Xxxxxx			6,000			5/3/2013		5/3/2020			6,000
The Xxxxxxxxx Family Revocable Living Trust Uad 04/11/11 Xxxx X Xxxxxxxxx & Xxxxx X Xxxxxxxxx Ttees			10,000			5/3/2013		5/3/2020			10,000
The SDM Irrevocable Trust FBO Xxxxxx Xxxx Uad 11/05/04 Xxxx Xxxx Ttee			7,500			5/3/2013		5/3/2020			7,500
The SDM Irrevocable Trust FBO Xxxxxx Xxxx Uad 11/05/04 Xxxx Xxxx Ttee			7,500			5/3/2013		5/3/2020			7,500
Wafgal Limited			3,000			5/3/2013		5/3/2020			3,000
Xxxxxxx X Xxxx			5,000			5/3/2013		5/3/2020			5,000

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Xxxxxx Ventures LP

20,000

5/10/2013

5/10/2020

20,000

Xxxxxx Xxxxxxxxx

2,000

7/18/2013

7/18/2020

2,000

Xxxxx XxXxxxxxx

3,000

7/18/2013

7/18/2020

3,000

Xxxxxxx Xxxxxx

2,000

7/18/2013

7/18/2020

2,000

2013 Fund Raise Placement Agent Warrants

Xxxxxxx X. Xxxxxx

16,411

6/30/2013

6/30/2020

16,411

Xxxxxxx X. Xxxxxxx

33,929

6/30/2013

6/30/2020

33,929

Xxxxxx X. Xxxxxxx

33,928

6/30/2013

6/30/2020

33,928

Xxxxxxx X. Xxxxxxxx

31,894

6/30/2013

6/30/2020

31,894

Xxxxxx Xxxxxxxxx

7,135

6/30/2013

6/30/2020

7,135

Xxxx Xxxxxx

1,427

6/30/2013

6/30/2020

1,427

Xxxxxxx Xxxxx

1,427

6/30/2013

6/30/2020

1,427

Xxxxxxx Xx

8,000

6/30/2013

6/30/2020

8,000

Xxxxxxx Xxxxxxxxxx

1,000

6/30/2013

6/30/2020

1,000

Xxxxxxx Xxxxxxx

2,500

6/30/2013

6/30/2020

2,500

Xxxxxxx Xxxxxxx

1,000

6/30/2013

6/30/2020

1,000

Xxxxx Xxxxxxx

500

6/30/2013

6/30/2020

500

Xxxxxx X Xxxxxxx XX

1,250

6/30/2013

6/30/2020

1,250

Xxxxx Xxxxxxxx

500

6/30/2013

6/30/2020

500

Xxxxx XxXxxx

1,000

6/30/2013

6/30/2020

1,000

Xxxxxx Xxxxxxx

500

6/30/2013

6/30/2020

500

Xxxx Xxxxxx XXX Dtd 3/21/06

500

6/30/2013

6/30/2020

500

Xxxx X Xxxxx

500

6/30/2013

6/30/2020

500

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Common Stock Warrants - Private Placement 2014/2015 Raise

Xxxxxx X Xxxxxxxx And Xxxxxx Xxxxxxx Xxxxxxxx Xx Ten

5,982

12/31/2014

12/30/2019

5,982

Xxxxxx Xxxxxxxx & Xxxxxxxx Xxxxxxxx Jtwros

4,785

12/31/2014

12/30/2019

4,785

Xxxx Xxxxx And Xxxx Xxxxx Jtwros

1,000

12/31/2014

12/30/2019

1,000

Xxxxxxx Xxxxxxxx

2,000

12/31/2014

12/30/2019

2,000

Xxxxx Xxxxx Xxxxxxxx Xxxxx Jt Wros

2,393

12/31/2014

12/30/2019

2,393

Xxxxxxxxx Family Ltd Partners Xxxxxx Xxxxxxxxx General Ptnr

1,675

12/31/2014

12/30/2019

1,675

Barktones Llc

4,785

12/31/2014

12/30/2019

4,785

Bfjk Investment Partnership

2,500

12/31/2014

12/30/2019

2,500

Bibicoff Xxxxxxxx Inc

786

12/31/2014

12/30/2019

786

C Xxxx Xxxxx

572

12/31/2014

12/30/2019

572

Xxxxxxx Brand

4,785

12/31/2014

12/30/2019

4,785

Xxxxx A Random

3,928

12/31/2014

12/30/2019

3,928

Xxxxx Xxxxxxxxxx

2,143

12/31/2014

12/30/2019

2,143

Xxxxx Xxxxx Xxxx & Xxxxxxxx Xx Xxxx 1999 Trust Dtd 6/22/99

2,322

12/31/2014

12/30/2019

2,322

Xxxxx X Xxxxx

3,828

12/31/2014

12/30/2019

3,828

Dazia Capital Spain S.L.

1,786

12/31/2014

12/30/2019

1,786

Xxxxx Xxxxxx

7,128

12/31/2014

12/30/2019

7,128

Xxxxxx X Xxxxxx

715

12/31/2014

12/30/2019

715

Xxxxxxx Xxxxxxxxx & Xxxxxxx Xxxxxxxxx Jt/Wros

1,995

12/31/2014

12/30/2019

1,995

Xx Xxxxxxx X Xxxxx & Angela F Olsen

2,500

12/31/2014

12/30/2019

2,500

Dr Thomas Heirigs & Sheryl Heirigs Jt/Wros

2,143

12/31/2014

12/30/2019

2,143

Elaine Dines Revocable Trust

1,436

12/31/2014

12/30/2019

1,436

Elizabeth M Chamberlain

1,436

12/31/2014

12/30/2019

1,436

Eric Seid

750

12/31/2014

12/30/2019

750

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Frank Gimenez & Philomena Gimenez Jtwros			750			12/31/2014		12/30/2019			750
Frank R Jazzo			1,250			12/31/2014		12/30/2019			1,250
Gary A. Hafner And Leeann Hafner Jt Ten			715			12/31/2014		12/30/2019			715
Harrison H Augur Prototyp			1,500			12/31/2014		12/30/2019			1,500
Harvey Bibicoff And Jacqueline Bibicoff Trustees Of The Bibicoff Family Trust Dtd 5/16/00			7,500			12/31/2014		12/30/2019			7,500
Henry Jackson Warden			1,189			12/31/2014		12/30/2019			1,189
Howard A Kalka			5,357			12/31/2014		12/30/2019			5,357
Ilyne Sandas			750			12/31/2014		12/30/2019			750
Jack Dimaio Kathryn Dimaio			17,857			12/31/2014		12/30/2019			17,857
James E Puerner			1,000			12/31/2014		12/30/2019			1,000
James Tadych And Patricia Tadych Revocable Trust Uad 09/23/93 James L Tadych & Patricia A Tadych Ttees			5,982			12/31/2014		12/30/2019			5,982
Jeffrey G Hipp & Mary Ann Hipp Jt/Wros			2,325			12/31/2014		12/30/2019			2,325
Jeffrey L Sadar			1,675			12/31/2014		12/30/2019			1,675
John R Bertsch Trust Dtd 12/4/2004 John R Bertsch Trustee			9,452			12/31/2014		12/30/2019			9,452
John R Wiencek			3,589			12/31/2014		12/30/2019			3,589
John R Worthington Tr John R Worthington Trust U A Dated 3-28-00			3,350			12/31/2014		12/30/2019			3,350
John T Glancy & Lisa Glancy Jtwros			358			12/31/2014		12/30/2019			358
John W Crow			2,501			12/31/2014		12/30/2019			2,501
Jonathan Rothschild			875			12/31/2014		12/30/2019			875
Joseph Debellis			7,500			12/31/2014		12/30/2019			7,500
Joseph Vosilla			1,340			12/31/2014		12/30/2019			1,340
Judith Greenberg			500			12/31/2014		12/30/2019			500

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Junge Revocable Trust Uad 12/09/91 John P Junge Ttee Amd 09/26/06			9,571			12/31/2014		12/30/2019			9,571
Keith Becker			2,393			12/31/2014		12/30/2019			2,393
Kenneth J Feroldi Nancy J Feroldi Jtwros			2,500			12/31/2014		12/30/2019			2,500
Kettle Hill Patners Ii, Lp			7,857			12/31/2014		12/30/2019			7,857
Kettle Hill Patners Lp			18,929			12/31/2014		12/30/2019			18,929
Kevin Conroy			375			12/31/2014		12/30/2019			375
Kyle G Buchakjian			1,500			12/31/2014		12/30/2019			1,500
Larry S Kaplan Marla B Kaplan Jt/Wros			1,000			12/31/2014		12/30/2019			1,000
Lawrence Kane			3,572			12/31/2014		12/30/2019			3,572
Lucille Solomon			1,000			12/31/2014		12/30/2019			1,000
Mark Bourque			715			12/31/2014		12/30/2019			715
Mark Ravich			5,025			12/31/2014		12/30/2019			5,025
Mark Vaughan Andrea Vaughan Jt Ten			1,300			12/31/2014		12/30/2019			1,300
Mary Marguerite Schnurer Family Trust Uad 12/08/05 Mary Marguerite Schnurer Ttee			750			12/31/2014		12/30/2019			750
Matthew G Kiernan Cheryl A Kiernan Jt Ten			1,785			12/31/2014		12/30/2019			1,785
Michael A Rutledge Tanya S Rutledge Jtwros			2,000			12/31/2014		12/30/2019			2,000
Michael Dunham			3,589			12/31/2014		12/30/2019			3,589
Michael P Hagerty			2,501			12/31/2014		12/30/2019			2,501
Mitchell Spearman			714			12/31/2014		12/30/2019			714
Monica Bertsch			715			12/31/2014		12/30/2019			715
Nina B Sando			718			12/31/2014		12/30/2019			718
Norman And Sally Ravich Family Trust Uad 12/24/92 Mark H Ravich Ttee			921			12/31/2014		12/30/2019			921
Norper Investments			1,915			12/31/2014		12/30/2019			1,915
Nutie Dowdle			1,915			12/31/2014		12/30/2019			1,915

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Pamela M Walsh Brian P Walsh Jt Ten			2,500			12/31/2014		12/30/2019			2,500
Patience Partners Llc			2,000			12/31/2014		12/30/2019			2,000
Pension Inc Trustee Fbo Thuemling Industrial Products Inc Profit Sharing Plan			1,000			12/31/2014		12/30/2019			1,000
Peter Fitzpatrick			410			12/31/2014		12/30/2019			410
Peter Mangiameli			1,436			12/31/2014		12/30/2019			1,436
Peter White			500			12/31/2014		12/30/2019			500
Rachel T Baroni Trust Uad 12/31/94 P J Baroni & R T Baroni Ttees Amd 08/11/09			2,143			12/31/2014		12/30/2019			2,143
Randall S Knox			3,266			12/31/2014		12/30/2019			3,266
Ravich Revocable Trust			1,173			12/31/2014		12/30/2019			1,173
Raymond M Beebe & Joan P Beebe Jt Ten			5,000			12/31/2014		12/30/2019			5,000
Revocable Living Trust Of Frances Deluca Uad 10/09/01 Guerino Deluca Amd 08/08/07			4,786			12/31/2014		12/30/2019			4,786
Richard Buchakjian			715			12/31/2014		12/30/2019			715
Richard Duke			2,345			12/31/2014		12/30/2019			2,345
Robert D Vanroijen Jr Trust U A Dtd 12-14-82 Robert D Vanroijen Ttee			7,500			12/31/2014		12/30/2019			7,500
Robert Edmondson			3,828			12/31/2014		12/30/2019			3,828
Robert Koski			1,786			12/31/2014		12/30/2019			1,786
Robert L Banzer			500			12/31/2014		12/30/2019			500
Robert Moussa			1,050			12/31/2014		12/30/2019			1,050
Robert P Giesen			750			12/31/2014		12/30/2019			750
Robert W Allen Jr			4,785			12/31/2014		12/30/2019			4,785
Robert W Corby Kenneth Wieck Poa			3,572			12/31/2014		12/30/2019			3,572
Robert W Main Ttee Under The Robert W Main Trust Dtd 9/7/05			715			12/31/2014		12/30/2019			715

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Roger W. Lunstra And Joyce M. Lunstra Living Trust Dtd 6/15/07 Roger W. Lunstra And Joyce M Lunstra Co-Ttees			3,928			12/31/2014		12/30/2019			3,928
Ronald A Bero			3,828			12/31/2014		12/30/2019			3,828
Ronald Johnson			2,393			12/31/2014		12/30/2019			2,393
Rose Mary Heirigs Thomas Heirigs Poa			2,143			12/31/2014		12/30/2019			2,143
Sally Ravich			750			12/31/2014		12/30/2019			750
Samuel E Leonard Trust Uad 2-5-90 Samuel E Leonard Ttee			1,000			12/31/2014		12/30/2019			1,000
Sandra P Nitz			715			12/31/2014		12/30/2019			715
Scot Holding Inc			1,429			12/31/2014		12/30/2019			1,429
Shadow Capital Llc			14,207			12/31/2014		12/30/2019			14,207
Stephen M Koppekin			1,000			12/31/2014		12/30/2019			1,000
Sterling Family Investment Llc			4,786			12/31/2014		12/30/2019			4,786
Steven Botwinick			2,000			12/31/2014		12/30/2019			2,000
Steven Mucciolo			2,500			12/31/2014		12/30/2019			2,500
Susan M Allen Trust Uad 04/29/08 Susan Allen Ttee			14,232			12/31/2014		12/30/2019			14,232
Susan Thorstenn & Magnus Thorstenn Ten Comm			4,785			12/31/2014		12/30/2019			4,785
T. Mina Supply Inc			5,768			12/31/2014		12/30/2019			5,768
The Carolyn L. Foutch Living Trust Uad 05/17/13 Carolyn L Foutch Ttee			2,322			12/31/2014		12/30/2019			2,322
The Hillary Bibicoff Revocable Trust Dtd 4/19/07 Hillary Bibicoff Trustee			2,000			12/31/2014		12/30/2019			2,000
The Sdm Irrevocable Trust Fbo Andrew Seid Uad 11/05/04 Paul Seid Ttee			3,589			12/31/2014		12/30/2019			3,589
The Sdm Irrevocable Trust Fbo Lauren Seid Uad 11/05/04 Paul Seid Ttee			3,589			12/31/2014		12/30/2019			3,589
The Temkin Family Legacy Trust No. 2 Uad 12/01/10 Mark J Temkin Ttee			750			12/31/2014		12/30/2019			750
Thomas Fitzpatrick Barbara Fitzpatrick Jt Ten			500			12/31/2014		12/30/2019			500

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Tom Mcfall			7,143			12/31/2014		12/30/2019			7,143
Vincent R Milazzo			714			12/31/2014		12/30/2019			714
Vito S Portera Revocable Living Trust Uad 10/19/12 Vito S Portera Ttee			1,196			12/31/2014		12/30/2019			1,196
William Kyle Neely			2,322			12/31/2014		12/30/2019			2,322
William M Stokes Rebecca A Stokes Jt Ten			250			12/31/2014		12/30/2019			250
William P Kaiser			2,500			12/31/2014		12/30/2019			2,500
Wulf Paulick & Renate Paulick Jt/Wros			1,000			12/31/2014		12/30/2019			1,000
			-								-
Paul Seid			7,103			1/7/2015		1/6/2020			7,103
Donald B. Mcculloch Trust U/A/Dtd 3/16/77			750			1/7/2015		1/6/2020			750
Ivanka Marie Kokot			715			1/7/2015		1/6/2020			715
Keith R Schroeder			2,143			1/7/2015		1/6/2020			2,143
Ira Fbo Gordon C Johnson Pershing Llc As Custodian Rollover Account			357			1/7/2015		1/6/2020			357
Ira Fbo Donald C Holliday Pershing Llc As Custodian Rollover Account			2,500			1/7/2015		1/6/2020			2,500
Ira Fbo Timothy M Fitzpatrick Pershing Llc As Custodian Rollover Account			1,429			1/7/2015		1/6/2020			1,429
Ira Fbo Francis Bissaillon Pershing Llc As Custodian			5,700			1/7/2015		1/6/2020			5,700
Michael N. Taglich Keogh-Account			71,429			1/7/2015		1/6/2020			71,429
Mike Taglich Poa Tag/Kent Partnership F/B/O Garlinghouse/M Taglich B Taglich			3,572			1/7/2015		1/6/2020			3,572
Michael Taglich C/F Hope Taglich Ugma			1,429			1/7/2015		1/6/2020			1,429
Michael Taglich Cust For Lucy Taglich Utma Ny			1,429			1/7/2015		1/6/2020			1,429
Michael Taglich Custodian Fbo Amanda Taglich Utma Ny Until Age 21			1,429			1/7/2015		1/6/2020			1,429
Michael Taglich Custodian Fbo Stella Taglich Utma Ny Until Age 21			1,429			1/7/2015		1/6/2020			1,429

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Ira Fbo P. Kenneth Nitz Pershing Llc As Custodian			715			1/7/2015		1/6/2020			715
Nicholas Taglich & Juliana Taglich Jt/Wros			2,143			1/7/2015		1/6/2020			2,143
Estate Of Richard Curtis Clayton Deborah Ann Clayton Executor			4,643			1/7/2015		1/6/2020			4,643
Ira Fbo Robert F Taglich Pershing Llc As Custodian Rollover Account			71,429			1/7/2015		1/6/2020			71,429
Robert M Lorenzo & Sandra J Lorenzo Jt Wros			712			1/7/2015		1/6/2020			712
Michael Brunone			358			1/7/2015		1/6/2020			358
Russell Bernier			3,000			1/7/2015		1/6/2020			3,000
Tyson Revocable Trust			35,714			1/7/2015		1/6/2020			35,714
Maryanne R Palmieri Joseph V Palmieri Jt/Wros			3,714			1/7/2015		1/6/2020			3,714
David Kurnov			750			1/7/2015		1/6/2020			750
Vincent M Palmieri			5,565			1/7/2015		1/6/2020			5,565
Richard Oh			1,785			1/7/2015		1/6/2020			1,785
Howard A Halpern			725			1/7/2015		1/6/2020			725
Linda Taglich			650			1/7/2015		1/6/2020			650
Gilda Gaertner Tod Dated 05/10/2013			750			1/7/2015		1/6/2020			750
Denis Mcevoy Tod Dtd 03/19/2013			1,430			1/7/2015		1/6/2020			1,430
William M Cooke			1,429			1/7/2015		1/6/2020			1,429
Gary Kurnov			1,429			1/7/2015		1/6/2020			1,429
Douglas E Hailey			7,500			1/7/2015		1/6/2020			7,500
R2Mj Llc			3,750			1/7/2015		1/6/2020			3,750
The Baum Family Trust Uad 02/01/07 Patricia Donoghue Ttee			1,500			1/7/2015		1/6/2020			1,500
Robert Schroeder			1,072			1/7/2015		1/6/2020			1,072
Michael Kurnov			700			1/7/2015		1/6/2020			700
Lenore Mahoney			7,143			1/7/2015		1/6/2020			7,143
Robert G Paul			2,393			1/7/2015		1/6/2020			2,393
Michael Ferrigno			357			1/7/2015		1/6/2020			357
Mark Degennaro			10,714			1/7/2015		1/6/2020			10,714

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Placement Agent Warrants 2014/2015 Fund Raise

Douglas E Hailey

37,650

1/7/2015

1/6/2020

37,650

Robert Schroeder

27,650

1/7/2015

1/6/2020

27,650

Vincent M Palmieri

67,305

1/7/2015

1/6/2020

67,305

Gary Kurnov

2,530

1/7/2015

1/6/2020

2,530

William M Cooke

2,530

1/7/2015

1/6/2020

2,530

Denis Mcevoy

8,800

1/7/2015

1/6/2020

8,800

Michael N. Taglich

84,444

1/7/2015

1/6/2020

84,444

Robert F. Taglich

70,091

1/7/2015

1/6/2020

70,091

Richard Oh

11,000

1/7/2015

1/6/2020

11,000

Leonard Schleicher

4,500

1/7/2015

1/6/2020

4,500

Michael Brunone

8,500

1/7/2015

1/6/2020

8,500

Russell Bernier

8,500

1/7/2015

1/6/2020

8,500

Linda Taglich

2,500

1/7/2015

1/6/2020

2,500

Robert M Lorenzo Ii

4,000

1/7/2015

1/6/2020

4,000

Gilda Gaertner Tod Dated 05/10/2013

2,500

1/7/2015

1/6/2020

2,500

Howard A Halpern

3,500

1/7/2015

1/6/2020

3,500

John Nobile Tod Dtd 3/21/06

3,500

1/7/2015

1/6/2020

3,500

Juan V Noble

3,500

1/7/2015

1/6/2020

3,500

IR Agent Warrants

Dan Boutcher

32,500

1/7/2015

1/6/2020

32,500

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Bridge Note warrants - 6/30/16

Michael Taglich

37,500

6/30/2016

6/29/2021

37,500

Vincent Palmieri

7,500

6/30/2016

6/29/2021

7,500

Robert F. Taglich

30,000

6/30/2016

6/29/2021

30,000

Robert W. Allen Trust

18,750

6/30/2016

6/29/2021

18,750

Shadow Capital LLC

15,000

6/30/2016

6/29/2021

15,000

Joseph W. and Patricia G. Abrams Family Trust

15,000

6/30/2016

6/29/2021

15,000

William E. Alt Trust UAD

15,000

6/30/2016

6/29/2021

15,000

Edward Roffman

3,750

6/30/2016

6/29/2021

3,750

James P. Amaden IV and Sarah S. Amaden

3,750

6/30/2016

6/29/2021

3,750

P. Kenneth Nitz

3,000

6/30/2016

6/29/2021

3,000

Clive Kabatznik

7,500

6/30/2016

6/29/2021

7,500

Timothy Tyson

15,000

7/7/2016

6/29/2021

15,000

Placement Agent - Bridge Notes 6/30/16

Douglas E Hailey

2,500

7/7/2016

6/29/2021

2,500

Robert Schroeder

3,000

7/7/2016

6/29/2021

3,000

Vincent M Palmieri

6,000

7/7/2016

6/29/2021

6,000

Michael N. Taglich

7,820

7/7/2016

6/29/2021

7,820

Robert F. Taglich

6,405

7/7/2016

6/29/2021

6,405

Richard Oh

1,500

7/7/2016

6/29/2021

1,500

Leonard Schleicher

200

7/7/2016

6/29/2021

200

Michael Brunone

300

7/7/2016

6/29/2021

300

Russell Bernier

300

7/7/2016

6/29/2021

300

Linda Taglich

200

7/7/2016

6/29/2021

200

Robert M Lorenzo II

200

7/7/2016

6/29/2021

200

Gilda Gaertner TOD Sated 5/10/2013

200

7/7/2016

6/29/2021

200

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Bridge Note Warrant - 4/12/17

Michael N. Taglich

75,000

4/12/2017

4/11/2022

75,000

Robert F. Taglich

75,000

4/12/2017

4/11/2022

75,000

Timothy Tyson

75,000

4/12/2017

4/11/2022

75,000

Placement Agent - Bridge Notes 4/12/17

Douglas E Hailey

1,500

4/12/2017

4/11/2022

1,500

Robert Schroeder

2,500

4/12/2017

4/11/2022

2,500

Vincent M Palmieri

6,000

4/12/2017

4/11/2022

6,000

Michael N. Taglich

7,500

4/12/2017

4/11/2022

7,500

Robert F. Taglich

7,500

4/12/2017

4/11/2022

7,500

GBP Debt Funding

Warrants

857,143

5/15/2017

5/15/2022

857,143

Series C Warrants

Tim Tyson

571,420

4/2/2018

4/2/2025

571,420

Clive Kabatznik

28,571

5/30/2018

5/30/2025

28,571

Tim Tyson

114,284

7/13/2018

7/13/2025

114,284

Michael Taglich

42,857

8/27/2018

8/27/2025

42,857

Robert Taglich

42,857

8/27/2018

8/27/2025

42,857

Bridge Notes - August 2018

Tim Tyson

45,000

8/13/2018

8/13/2023

45,000

Clive Kabatznik

22,500

8/13/2018

8/13/2023

22,500

Michael Taglich

3,750

8/13/2018

8/13/2023

3,750

Robert Taglich

3,750

8/13/2018

8/13/2023

3,750

3,979,773

3,836,372

143,401

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

set forth below is the beneficial ownership of each officer, director and 5% shareholder of icagen, inc.

ICAGEN INC

DIRECTORS SHAREHOLDING

Date		Description		Common Stock				Series C Preferred				Warrants				Total Before Options				Options vested				Options vesting next 60 days				Total Including options
12/31/2014		Balance outstanding			6,393,107				799,989				3,979,773				11,172,869				1,382,945								12,555,814
					6,393,107				799,989				3,979,773				11,172,869				1,382,945								12,555,814
																																	Common				Series C				Warrants				Options				Total				Percentage
		Officers
		Richard Cunningham			21,428								5,357				26,785				196,944				9,444				233,173				6,393,107				-				5,357				206,388				6,604,852				3.5	%
		Douglas Krafte															-				79,167				4,167				83,333				6,393,107				-				-				83,333				6,476,440				1.3	%
		Mark Korb			25,000												25,000				37,500								62,500				6,393,107				-				-				37,500				6,430,607				1.0	%
					46,428				-				5,357				51,785				313,610				13,611				379,007				6,393,107				-				5,357				327,222				6,725,686				5.6	%
		Directors
		Timothy Tyson			164,284				685,704				861,775				1,711,763				90,213				1,250				1,803,226				6,393,107				685,704				861,775				91,463				8,032,049				22.5	%
		Clive Kabatznik			25,000				28,571				58,571				112,142				51,713				1,250				165,105				6,393,107				28,571				58,571				52,963				6,533,212				2.5	%
		Vincent Palmieri			74,736								144,990				219,726				24,213				1,250				245,189				6,393,107				-				144,990				25,463				6,563,560				3.7	%
		Edward Roffman			29,000								3,750				32,750				39,213				1,250				73,213				6,393,107				-				3,750				40,463				6,437,320				1.1	%
		Michael Taglich			453,314				42,857				439,552				935,723				24,213				1,250				961,186				6,393,107				42,857				439,552				25,463				6,900,979				13.9	%
					746,334				757,132				1,508,638				3,012,104				229,565				6,250				3,247,919				6,393,107				757,132				1,508,638				235,815				8,894,692				36.5	%
		Directors and Officers			792,762				757,132				1,513,995				3,063,889				543,176				19,861				3,626,926				6,393,107				757,132				1,513,995				563,037				9,227,271				39.3	%
		5% Shareholders
		Benjamin Warner			1,497,385								-				1,497,385				92,500								1,589,885				6,393,107				-				-				92,500				6,485,607				24.5	%
		Robert Taglich			373,839				42,857				376,994				793,690				-								793,690				6,393,107				42,857				376,994				-				6,812,958				11.6	%
		Joseph Abrams			316,372								15,000				331,372				52,500								383,872				6,393,107				-				15,000				52,500				6,460,607				5.9	%
		GPB											857,143				857,143												857,143				6,393,107				-				857,143				-				7,250,250				11.8	%
					2,980,358				799,989				2,763,132				6,543,479				688,176				19,861				7,251,516				6,393,107				799,989				2,763,132				708,037				10,664,265				68.0	%

***

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Schedule 7.12(b)

Information Regarding Subsidiaries

Subsidiaries of Icagen, Inc.

Name of Subsidiary		Type of organization (e.g. corporation, limited liability company, limited partnership)		Jurisdiction of Incorporation				Percentage Owned by Borrower
Icagen-T, Inc.		C Corporation			Delaware				100	%
Icagen Corp.		C Corporation			Nevada				100	%
Caldera Discovery, Inc.		C Corporation			Delaware				100	%
XRpro Sciences, Inc.		C Corporation			Delaware				100	%

***

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Schedule 7.12(c)

Equity Investments

None

***

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Schedule 7.13(a)

Outstanding Indebtedness

Indebtedness outstanding as of the Closing Date that will remain after the making of the Term Loan:

	●	Icagen, Inc. has outstanding subordinated promissory notes in the principal amount of $500,000 that were issued in August 2018
	●	U.S Bank Equipment Finance, A Division of U.S. Bank National Association
	●	BlueCat Bio purchase money lien over BluCatBiowasher located in Durham, North Carolina- $35,812.01 plus accrued interest thereon from August 11, 2018 at an effective rate of10.3%, total outstanding installments of $41,125.05
	●	Waters Technologies purchase money lien over software located in Oro Valley, Arizona-$65,018.16 plus accrued interest from August 31, 2018 at an effective interest rate of 6.15% total outstanding installments amount to $71,500
	●	Icagen Corp. owes deferred purchase consideration due to Pfizer of $9,750,000 in the form of an annual royalty payment payable quarterly commencing on May 31, 2017
	●	Property Lease-4222 Emperor Blvd, Suite 350&385, Durham, NC-commitment of $163,601

***

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Schedule 7.13(b)

Pay-Off Indebtedness

The total amount of Pay-Off Indebtedness is $10,000,000 principal plus accrued interest and early settlement penalty thereon.

The Pay-Off Indebtedness was initially incurred as described below and is equal to the principal amount outstanding, accrued and unpaid interest and other amounts payable in connection with the repayment of such Indebtedness.

On May 15, 2017, the Borrower, and its wholly owned subsidiary, Icagen-T, Inc. (“Icagen-T”), entered into a Securities Purchase Agreement (“Securities Purchase Agreement”) with GPB Debt Holdings II, LLC (“GPB”), pursuant to which (i) the Borrower issued to GPB a three year Senior Secured Convertible Note maturing on May 15, 2020, bearing interest at the rate of 13% per annum in the aggregate principal amount of $2,000,000; and (ii) Icagen-T issued to GPB a three year Senior Secured Convertible Note maturing on May 15, 2020, bearing interest at the rate of 13% per annum, in the aggregate principal amount of $8,000,000.

***

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Schedule 7.13(c)

Liens

● UCC-1 Financing Statement-Icagen, Inc.-U.S. Bank Equipment Financing

● BlueCat Bio purchase money lien over BluCatBiowasher located in Durham, North Carolina

***

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Schedule 7.14

Material Agreements of Obligors

Stock Option Plan (Filed as an exhibit to the Registration Statement on Form S-1 filed February 14, 2012)

Assignment of Exclusive License Agreement by The Regents of the University of California to Los Alamos National Security, LLC (Filed as an exhibit to the Registration Statement on Form S-1/A filed April 20, 2012)

OEM Agreement, dated July 5, 2011, by and between the Borrower and our equipment supplier (Filed as an exhibit to the Registration Statement on Form S-1/A filed June 8, 2012)

Exclusive Patent License Agreement, dated September 8, 2005, by and between the Borrower and The Regents of the University of California (Filed as an exhibit to the Registration Statement on Form S-1/A filed June 14, 2012)

Employment Agreement with Richard Cunningham dated as of November 24, 2014 (Filed as an exhibit to the Current Report on Form 8-K filed on November 17, 2014)

Form of Investor Warrant (Filed as an exhibit to Current Report on Form 8-K filed January 7, 2015)

- See Schedule 7.12(a) – Warrants and Notes Outstanding for Individual Issuances

Form of Placement Agent Warrant (Filed as an exhibit to Current Report on Form 8-K filed January 7, 2015)

- See Schedule 7.12(a) – Warrants and Notes Outstanding for Individual Issuances

Form of Bridge Exchange Warrant (Filed as an exhibit to the Current Report on Form 8-K filed on February 3, 2015)

- See Schedule 7.12(a) – Warrants and Notes Outstanding for Individual Issuances

Form of Series B Exchange Warrant (Filed as an exhibit to the Current Report on Form 8-K filed on February 3, 2015)

- See Schedule 7.12(a) – Warrants and Notes Outstanding for Individual Issuances

Form of Placement Agent Exchange Warrant (Filed as an exhibit to the Current Report on Form 8-K filed on February 3, 2015)

- See Schedule 7.12(a) – Warrants and Notes Outstanding for Individual Issuances

Asset Purchase Agreement and Collaboration Agreement dated as of June 26, 2015 between XRpro Sciences, Inc. (now known as Icagen, Inc.) and Icagen, Inc. (a subsidiary of Pfizer, Inc.) (Filed as an exhibit to the Current Report on Form 8-K filed on July 2, 2015)

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Master Service Agreement dated as of June 26, 2015 between XRPro Sciences, Inc. (now known as Icagen, Inc.) and Icagen, Inc. (a subsidiary of Pfizer, Inc.) (Filed as an exhibit to the Current Report on Form 8-K filed on July 2, 2015)

Icagen, Inc. Stock Incentive Plan (Filed as an exhibit to Exhibit B to the Preliminary Information Statement on Schedule 14C filed with the Securities and Exchange Commission on December 24, 2015 and to the Current Report on Form 8-K filed on December 29, 2015)

Icagen, Inc. Stock Option Agreement under the 2015 Stock Incentive Plan, as amended (Filed as an exhibit to the Current Report on Form 8-K filed on December 29, 2015)

- See Schedule 7.12(a) – Options Outstanding for Individual Issuances

Asset Purchase Agreement between Icagen-T, Inc. and Sanofi dated June 27, 2016 (Filed as an exhibit to the Current Report on Form 8-K filed on June 30, 2016)

Form of Warrant issued to investors (Filed as an exhibit to the Current Report on Form 8-K filed on July 7, 2016)

- See Schedule 7.12(a) – Warrants and Notes Outstanding for Individual Issuances

Amendment to Asset Purchase and Collaboration Agreement between Icagen, Inc. (f/k/a XRpro Sciences, Inc.) and Pfizer Research (NC), Inc. (f/k/a Icagen, Inc.) (Filed as an exhibit to the Current Report on Form 8-K filed July 19, 2016)

Master Services Agreement between Icagen-T, Inc. and Sanofi US Services Inc. (Filed as an exhibit to the Current Report on Form 8-K filed July 19, 2016)

Form of Warrant issued to investors (Filed as an exhibit to the Current Report on Form 8-K filed on April 14, 2017)

- See Schedule 7.12(a) – Warrants and Notes Outstanding for Individual Issuances

Warrant, dated May 15, 2017, issued by Icagen, Inc. to GPB Debt Holdings II, LLC (Filed as an exhibit to the Current Report on Form 8-K filed on May 17, 2017)

- See Schedule 7.12(a) – Warrants and Notes Outstanding for Individual Issuances

Employment Agreement, dated June 19, 2017 by and between Douglas Krafte, Ph.D. (Filed as an exhibit to the Current Report on Form 8-K filed on June 21, 2017)

Second Amendment to Asset Purchase and Collaboration Agreement by and between Pfizer Research (NC), Inc. (f/k/a Icagen, Inc.) and Icagen, Inc. (f/k/a XRpro Sciences, Inc.) (Filed as an exhibit to the Quarterly Report on Form 10-Q filed on August 16, 2017)

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Form of Stock Option Agreement 2005 Incentive Stock Plan Warrant (Filed as an exhibit to the Registration Statement on Form S-8 filed on August 17, 2017)

- See Schedule 7.12(a) – Options Outstanding for Individual Issuances

Certificate of Designation for Series C Convertible Preferred Stock (Filed as an exhibit to Current Report on Form 8-K filed April 9, 2018)

Form of Series C Warrant (Filed as an exhibit to Current Report on Form 8-K filed April 9, 2018)

- See Schedule 7.12(a) – Warrants and Notes Outstanding for Individual Issuances

Securities Purchase Agreement by and among Icagen, Inc. and the investors named therein regarding the Series C Convertible Preferred Stock (Filed as an exhibit to the Current Report on Form 8-K filed April 9, 2018)

- Securities Purchase Agreement between Icagen, Inc. and Timothy Tyson Revocable Trust dated April 2, 2018

- Securities Purchase Agreement between Icagen, Inc. and Clive Kabatznik dated May 30, 2018

- Securities Purchase Agreement between Icagen, Inc. and Michael Taglich dated August 27, 2018

- Securities Purchase Agreement between Icagen, Inc. and Robert Taglich dated August 27, 2018

Amended and Restated Warrant to purchase 857,143 shares of common stock dated as of May 15, 2017 issued by Icagen, Inc. to GPB Debt Holdings II, LLC (Filed as an exhibit to the Annual Report on Form 10-K filed on April 17, 2018)

- See Schedule 7.12(a) – Warrants and Notes Outstanding for Individual Issuances

Research Development and Commercialization Agreement made May 1, 2018 by and between Icagen, Inc. and Cystic Fibrosis Foundation and amendment No. 1 thereto

Research Collaboration and License Agreement made May 1, 2018 between Sanofi and Icagen, Inc.

Securities Purchase Agreement by and among Icagen, Inc. and the investors named therein regarding the 10% Subordinated Promissory Notes (Filed as an exhibit to the Current Report on Form 8-K filed August 15, 2018)

- Securities Purchase Agreement between Icagen, Inc. and Timothy Tyson Revocable Trust dated August 13, 2018

- Securities Purchase Agreement between Icagen, Inc. and Clive Kabatznik dated August 13, 2018

- Securities Purchase Agreement between Icagen, Inc. and Michael Taglich dated August 13, 2018

- Securities Purchase Agreement between Icagen, Inc. and Robert Taglich dated August 13, 2018

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Form of 10% Subordinated Promissory Note (Filed as an exhibit to the Current Report on Form 8-K filed August 15, 2018)

- See Schedule 7.12(a) – Warrants and Notes Outstanding for Individual Issuances

Form of Warrant issued with the 10% Subordinated Promissory Notes (Filed as an exhibit to the Current Report on Form 8-K filed August 15, 2018)

- See Schedule 7.12(a) – Warrants and Notes Outstanding for Individual Issuances

***

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Schedule 7.15

Restrictive Agreements

Asset Purchase Agreement and Collaboration Agreement dated as of June 26, 2015 between XRpro Sciences, Inc. (now known as Icagen, Inc.) and Icagen, Inc. (a subsidiary of Pfizer, Inc.) (Filed as an exhibit to the Current Report on Form 8-K filed on July 2, 2015)

Master Service Agreement dated as of June 26, 2015 between XRPro Sciences, Inc. (now known as Icagen, Inc.) and Icagen, Inc. (a subsidiary of Pfizer, Inc.) (Filed as an exhibit to the Current Report on Form 8-K filed on July 2, 2015)

Warrant, dated May 15, 2017, issued by Icagen, Inc. (Filed as an exhibit to the Current Report on Form 8-K filed on May 17, 2017)

Securities Purchase Agreement by and among Icagen, Inc. and the investors named therein regarding the 10% Subordinated Promissory Notes (Filed as an exhibit to the Current Report on Form 8-K filed August 15, 2018)

Form of Warrant issued with the 10% Subordinated Promissory Notes (Filed as an exhibit to the Current Report on Form 8-K filed August 15, 2018)

- See Schedule 7.12(a) – Warrants and Notes Outstanding for Individual Issuances

Research Development and Commercialization Agreement made May 1, 2018 by and between Icagen, Inc. and Cystic Fibrosis Foundation and amendment No. 1 thereto

Research Collaboration and License Agreement made May 1, 2018 between Sanofi and Icagen, Inc.

Amendment to Asset Purchase and Collaboration Agreement between Icagen, Inc. (f/k/a XRpro Sciences, Inc.) and Pfizer Research (NC), Inc. (f/k/a Icagen, Inc.) (Filed as an exhibit to the Current Report on Form 8-K filed July 19, 2016)

Certificate of Designations for Series C Convertible Preferred Stock

***

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Schedule 7.16

Real Property Owned or Leased by Obligors

Set forth below are all the locations where any Obligor owns or leases any real property:

Obligor		Address/City/ State/Zip Code		County		Owned or Leased		Lessor
Icagen, Inc.		4222 Emperor Blvd Suite 350 Research Triangle Park Durham, NC 27703		Durham		Sublease		Pfizer Research (NC), Inc.
Icagen Corp.		4222 Emperor Blvd Suite 350 Research Triangle Park Durham, NC 27703		Durham		Sublease		Pfizer Research (NC), Inc.
Caldera Discovery, Inc.		4222 Emperor Blvd Suite 350 Research Triangle Park Durham, NC 27703		Durham		Sublease		Pfizer Research (NC), Inc.

***

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Schedule 7.17

Pension Matters

Pension, Retirement, Savings, Deferred Compensation and Profit Sharing Plans

The Icagen 401(k) Plan

Blue Cross Blue Shield of North Carolina – Medical Coverage

Principal Financial Group

· Long Term Disability Policy

· Short Term Disability Policy

· Life Policy

· AD&D Policy

· Dental Policy

· Voluntary Life Policy

Superior Vision – Vision Coverage

Lincoln Benefit life

· Disability coverage – legacy employees

· Life cover – legacy employees

The Hartford

· Workers Compensation Policy

· ERISA Bond coverage

***

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Schedule 7.19(b)

Regulatory Approvals

None

***

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Schedule 7.19(e)

Certain Regulatory Matters

None

***

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Schedule 7.20

Transactions with Affiliates

Timothy Tyson

On April 1, 2014, On May 19, 2016, Icagen, Inc., issued ten-year options exercisable for 66,000 shares of common stock at $3.50 per share to Mr. Tyson.

Mr. Tyson participated in the Borrower’s private placement that was consummated on January 7, 2015 as follows: 142,856 shares of Common Stock and 35,714 of Offering Warrants to purchase shares of our Common Stock at an exercise price of $3.50 per share were purchased by Mr. Tyson’s Revocable Trust.

On May 19, 2016, Icagen, Inc., issued ten-year options exercisable for 12,500 shares of common stock at $3.50 per share to Mr. Tyson.

On July 6, 2016, Icagen, Inc., entered into a Securities Purchase Agreement and issued a secured 8% Bridge Note for $100,000 to Mr. Tyson in consideration of $100,000.

On July 6, 2016, Icagen, Inc. issued Mr. Tyson five year Warrants to acquire 15,000 shares of common stock exercisable at $3.50 per share.

On March 15, 2017, Icagen, Inc. issued Mr. Tyson ten-year options exercisable for 10,000 shares of common stock at $3.50 per share.

On April 13, 2017, Icagen, Inc., entered into a Securities Purchase Agreement and issued a secured 8% Bridge Note for $500,000 to Mr. Tyson in consideration of $500,000.

On April 13, 2017, Icagen, Inc. issued Mr. Tyson five year Warrants to acquire 75,000 shares of common stock exercisable at $3.50 per share. These warrants are also exchangeable, at the option of the holder, for a like number of warrants issued to any lender in the next debt financing.

On December 29, 2017, Mr. Tyson purchased 21,428 shares of common stock and a warrant to purchase 5,357 shares of common stock in a private transaction with an existing shareholder of the Company.

On April 4, 2018, Mr. Tyson purchased 571,420 shares of Series C Convertible Preferred Stock with a $3.50 conversion price and a warrant to purchase 571,420 shares of common stock exercisable at $3.50 per share.

On July 13, 2018, Mr. Tyson purchased 114,284 shares of Series C Convertible Preferred Stock with a $3.50 conversion price and a warrant to purchase 114,284 shares of common stock exercisable at $3.50 per share.

On August 13, 2018, Icagen, Inc. entered into a Securities Purchase Agreement and issued a secured 10% Bridge Note for $300,000 to Mr. Tyson in consideration of $300,000.

On August 13, 2018, Icagen, Inc. issued Mr. Tyson five year Warrants to acquire 45,000 shares of common stock exercisable at $3.50 per share.

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Michael Taglich

On April 1, 2014, Icagen, Inc., issued ten-year options exercisable for 12,500 shares of common stock at $3.50 per share to Mr. Taglich.

Mr. Taglich participated in the Borrower’s private placement that was consummated on January 7, 2015 as follows: (a) 285,714 shares of Common Stock and 71,429 Offering Warrants to purchase 71,429 shares of Common Stock were acquired by Mr. Taglich’s Keogh account; (b) an aggregate of 22,856 shares of Common Stock and an aggregate of 5,714 Offering Warrants to purchase 5,714 shares of Common Stock were acquired by four (4) separate custodial accounts for the benefit of Mr. Taglich’s children; and (c) 14,286 shares of Common Stock and 3,572 Offering Warrants to purchase 3,572 shares of Common Stock were acquired by the Tag/Kent Partnership. In addition, Mr. Taglich received 84,444 placement agent warrants in connection with the private placement that was consummated on January 7, 2015.

On January 31, 2015: (a) Mr. Taglich exchanged 41,354 shares of Series B Preferred Stock together with all accrued and unpaid dividends thereon for 35,048 shares of Common Stock; (b) 20,000 shares of Series B Preferred Stock together with all accrued and unpaid dividends thereon were exchanged by Michael and Claudia Taglich as joint tenants with right of survivorship for 16,933 shares of Common Stock; and (c) 60,000 shares of Series B Preferred Stock together with all accrued and unpaid dividends thereon were exchanged by the Partnership for 50,798 shares of Common Stock. On January 31, 2015, the following exchanges occurred: (a) Mr. Taglich exchanged 30,000 Existing Bridge Warrants exercisable at $6.00 per share for 30,000 Bride Exchange Warrants exercisable at $4.20 per share; (b) (i) 20,677 Existing Series B Warrants exercisable at $5.00 per share were exchanged by Mr. Taglich for 20,677 Series B Exchange Warrants exercisable at $3.50 per share, (ii) 10,000 Existing Series B Warrants exercisable at $5.00 per share were exchanged by Michael and Claudia Taglich as joint tenants with right of survivorship for 10,000 Series B Exchange Warrants exercisable at $3.50 per share, and (iii) 30,000 Existing Series B Warrants exercisable at $5.00 per share were exchanged by the Partnership for 30,000 Series B Exchange Warrants exercisable at $3.50 per share; and (c) Mr. Taglich exchanged 33,929 Existing Placement Agent Warrants exercisable at $5.50 per share for 33,929 Placement Agent Exchange Warrants exercisable at $3.85 per share.

On May 19, 2016, Icagen, Inc., issued ten-year options exercisable for 12,500 shares of common stock at $3.50 per share to Mr. Taglich.

On June 30, 2016, Icagen, Inc., entered into a Securities Purchase Agreement and issued a secured 8% Bridge Note for $250,000 to Mr. Taglich in consideration of $250,000.

On June 30, 2016, Icagen, Inc. issued five year Warrants to acquire 37,500 shares of common stock exercisable at $3.50 per share.

Icagen, Inc., retained Taglich Brothers, Inc. as the exclusive placement agent for the 2016 Bridge Note Offering. Icagen, Inc., agreed to pay the placement agent a six percent (6%) commission from the gross proceeds of the Offering ($1,145,000) and agreed to reimburse approximately $15,000 in respect of out of pocket expenses incurred by the placement agent in connection with the Offering. Icagen, Inc., also issued the placement agent the same warrant that the investors received exercisable for an aggregate amount of 28,625 shares of Common Stock at an exercise price of $3.50 per share (the “Placement Agent Warrants”).

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

As an employee and Principal of Taglich Brothers Inc., Mr. Taglich was issued 2016 Placement Agent Warrants to purchase 7,820 shares of Common stock at an exercise price of $3.50 per share.

On March 15, 2017, Icagen, Inc. issued Mr. Taglich ten-year options exercisable for 10,000 shares of common stock at $3.50 per share.

On April 12, 2017, Icagen, Inc., entered into a Securities Purchase Agreement and issued a secured 8% Bridge Note for $500,000 to Mr. Taglich in consideration of $500,000.

On April 12, 2017, Icagen, Inc., issued five year Warrants to acquire 75,000 shares of common stock exercisable at $3.50 per share. These warrants are also exchangeable, at the option of the holder, for a like number of warrants issued to any lender in the next debt financing.

Icagen, Inc., retained Taglich Brothers, Inc. as the exclusive placement agent for the 2017 Bridge Note Offering. Icagen, Inc., agreed to pay the placement agent a six percent (6%) commission from the gross proceeds of the Offering (excluding $500,000 invested by the Chairman of the Board of Directors, Timothy Tyson) for a total commission of $60,000. Icagen, Inc., also issued the Placement Agent the same warrant that the investors received exercisable for an aggregate amount of 25,000 shares of Common Stock at an exercise price of $3.50 per share (the “2017 Placement Agent Warrants”). The Placement Agent has the right to exchange the Placement Agent Warrants for a like number of warrants to be issued to the lender in the next debt financing.

As an employee and Principal of Taglich Brothers Inc., Mr. Taglich was issued 2017 Placement Agent Warrants to purchase 7,500 shares of Common stock.

On December 29, 2017, Mr. Taglich purchased 21,429 shares of common stock and a warrant to purchase 5,358 shares of common stock in a private transaction with an existing shareholder of the Company.

On August 13, 2018, Icagen, Inc. entered into a Securities Purchase Agreement and issued a secured 10% Bridge Note for $50,000 to Mr. Taglich in consideration of $50,000.

On August 13, 2018, Icagen, Inc. issued Mr. Taglich five year Warrants to acquire 7,500 shares of common stock exercisable at $3.50 per share.

On August 27, 2018, Mr. Taglich purchased 42,857 shares of Series C Convertible Preferred Stock with a $3.50 conversion price and a warrant to purchase 42,857 shares of common stock exercisable at $3.50 per share.

Vincent Palmieri

On April 1, 2014, Icagen, Inc. issued ten-year options exercisable for 10,000 shares of common stock at $3.50 per share to Mr. Palmieri.

Mr. Palmieri participated in the Borrower’s private placement that was consummated on January 7, 2015 as follows: 22,258 shares of Common Stock and 5,565 Offering Warrants to purchase 5,565 shares of Common Stock were acquired by Mr. Palmieri. Mr. Palmieri also received 67,305 warrants in connection with his services as placement agent.

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

On January 31, 2015, Mr. Palmieri exchanged 30,737 shares of Series B Preferred Stock together with all accrued dividends thereon for 26,050 shares of our Common Stock. In addition, Mr. Palmieri also exchanged: (i) 22,500 existing Bridge Warrants exercisable for $6.00 per share for 22,500 Bridge Exchange Warrants exercisable for $4.20 per share; (ii) 15,369 Existing Series B Warrants exercisable for $5.00 per share were exchanged for 15,369 Series B Exchange Warrants exercisable at $3.50 per share; and (iii) 31,894 Existing Placement Agent Warrants exercisable at $5.50 per share for 31,894 Placement Agent Exchange Warrants exercisable for $3.85 per share.

On May 19, 2016, Icagen, Inc. issued ten-year options exercisable for 12,500 shares of common stock at $3.50 per share to Mr. Palmieri.

On June 30, 2016, Icagen, Inc. issued entered into a Securities Purchase Agreement and issued a secured 8% Bridge Note for $50,000 to Mr. Palmieri in consideration of $50,000.

On June 30, 2016, Icagen, Inc. issued Mr. Palmieri five year Warrants to acquire 7,500 shares of common stock exercisable at $3.50 per share.

As an employee of Taglich Brothers Inc., Mr. Palmieri was issued 2016 Placement Agent warrants to purchase 6,000 shares of Common stock at an exercise price of $3.50 per share.

On March 15, 2017, Icagen, Inc. issued Mr. Palmieri ten-year options exercisable for 10,000 shares of common stock at $3.50 per share.

As an employee of Taglich Brothers Inc., Mr. Palmieri was issued 2017 Placement Agent Warrants to purchase 6,000 shares of Common stock at an exercise price of $3.50 per share.

On December 29, 2017, Mr. Palmieri purchased 21,428 shares of common stock and a warrant to purchase 5,357 shares of common stock in a private transaction with an existing shareholder of the Company.

Clive Kabatznik

On January 31, 2015, Mr. Kabatznik exchanged 15,000 existing bridge warrants exercisable at $6.00 per share for 15,000 bride exchange warrants exercisable at $4.20 per share.

On May 19, 2016, Icagen, Inc., issued ten-year options exercisable for 12,500 shares of common stock at $3.50 per share to Mr. Kabatznik.

On June 30, 2016, Icagen, Inc., entered into a Securities Purchase Agreement and issued a secured 8% Bridge Note for $50,000 to Mr. Kabatznik in consideration of $50,000 in cash.

On June 30, 2016, Icagen, Inc. issued Mr. Kabatznik five year Warrants to acquire 7,500 shares of common stock exercisable at $3.50 per share.

On March 15, 2017, Icagen, Inc. issued Mr. Kabatznik ten-year options exercisable for 10,000 shares of common stock at $3.50 per share.

On April 4, 2018, Mr. Kabatznik purchased 28,571 shares of Series C Convertible Preferred Stock with a $3.50 conversion price and a warrant to purchase 28,571 shares of common stock exercisable at $3.50 per share.

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

On August 13, 2018, Icagen, Inc. entered into a Securities Purchase Agreement and issued a secured 10% Bridge Note for $150,000 to Mr. Kabatznik in consideration of $150,000.

On August 13, 2018, Icagen, Inc. issued Mr. Kabatznik five year Warrants to acquire 22,500 shares of common stock exercisable at $3.50 per share.

Edward Roffman

On May 1, 2012, Icagen, Inc., issued ten-year options exercisable for 15,000 shares of common stock at $0.40 per share to Mr. Roffman.

On April 1, 2014, Icagen, Inc., issued ten-year options exercisable for 10,000 shares of common stock at $3.50 per share to Mr. Roffman.

On May 19, 2016, Icagen, Inc., issued ten-year options exercisable for 12,500 shares of common stock at $3.50 per share to Mr. Roffman.

On June 30, 2016, Icagen, Inc., entered into a Securities Purchase Agreement and issued a secured 8% Bridge Note for $25,000 to Mr. Roffman in consideration of $25,000.

On June 30, 2016, Icagen, Inc. issued Mr. Roffman five year Warrants to acquire 3,750 shares of common stock exercisable at $3.50 per share.

On March 15, 2017, Icagen, Inc. issued Mr. Roffman ten-year options exercisable for 10,000 shares of common stock at $3.50 per share.

Douglas Krafte

On February 25, 2016, upon the resignation of Dr. Benjamin Warner, as the Borrower’s Chief Scientific Officer, Douglas Krafte, age 56, the Chief Scientific Officer of the Borrower’s subsidiary Icagen Corp., was appointed to the position of Chief Scientific Officer for Icagen, Inc. and its subsidiaries.

On May 19, 2016, Icagen, Inc., issued ten-year options exercisable for 100,000 shares of common stock at $3.50 per common shares to Mr. Krafte.

Richard Cunningham

Pursuant to the terms of an employment agreement entered into with Richard Cunningham, the Borrower’s Chief Executive Officer, stock options to purchase 250,000 shares of Common Stock were awarded to Mr. Cunningham on January 7, 2015, which options vest as follows: (i) Fifty Thousand (50,000) shares shall vest on November 24, 2015; (ii) One Hundred and Fifty Thousand (150,000) shares shall vest monthly on a pro rata basis commencing on December 31, 2015 for a period of thirty six months; and (iii) Fifty Thousand (50,000) shares shall vest on the November 24, 2018. The exercise price for the options is $3.50 per share. Upon a change of control, as defined in the Borrower’s existing stock option plan, all unvested options issued to Mr. Cunningham shall become fully vested immediately upon the change of control.

On March 15, 2017, Icagen, Inc. issued Mr. Cunningham ten-year options exercisable for 20,000 shares of common stock at $3.50 per share.

On December 29, 2017, Mr. Cunningham purchased 21,428 shares of common stock and a warrant to purchase 5,357 shares of common stock in a private transaction with an existing shareholder of the Company.

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Ben Warner

The Company entered into a Settlement and Release Agreement, dated July 7, 2017 with Benjamin Warner (filed as an exhibit to the Current Report on Form 8-K filed on July 11, 2017)

The Company entered into a Settlement and Age Discrimination in Employment Act Release Agreement, dated July 7, 2017, with Dr. Benjamin Warner (filed as an exhibit to the Current Report on Form 8-K filed on July 11, 2017)

Robert Taglich

On June 30, 2016, the Company entered into a Securities Purchase Agreement and issued a secured 8% Bridge Note for $200,000 to Mr. Taglich in consideration of $200,000. The Note matures on June 30, 2017. The Note, together with interest thereon was repaid on August 8, 2016.

In connection with the Note above, on June 30, 2016, Mr. Taglich was issued five year Warrants to acquire 30,000 shares of common stock exercisable at $3.50 per share.

The Company retained Taglich Brothers, Inc. as the exclusive placement agent for the Offering. In connection therewith, the Company agreed to pay the placement agent a six percent (6%) commission from the gross proceeds of the Offering ($1,145,000) and agreed to reimburse approximately $15,000 in respect of out of pocket expenses incurred by the placement agent in connection with the Offering. The Company also issued the placement agent the same warrant that the investors received exercisable for an aggregate amount of 28,625 shares of common stock at an exercise price of $3.50 per share (2,500 shares of common stock for each $100,000 in principal amount of Notes sold) (the “Placement Agent Warrants”). Mr. Taglich was issued 2017 Placement Agent Warrants to purchase 6,405 shares of common stock.

On April 12, 2017, the Company entered into a Securities Purchase Agreement and issued a secured 8% Bridge Note for $500,000 to Mr. Taglich in consideration of $500,000. The Note matures 30 days from the date of issuance. In connection with the Note, Mr. Taglich was issued five year Warrants to acquire 75,000 shares of common stock exercisable at $3.50 per share. These warrants are also exchangeable, at the option of the holder, for a like number of warrants issued to any lender in the Company’s next debt financing.

The Company retained Taglich Brothers, Inc. as the exclusive placement agent for the Offering. In connection therewith, the Company agreed to pay the placement agent a six percent (6%) commission from the gross proceeds of the Offering (excluding $500,000 invested by our Chairman of the Board of Directors, Timothy Tyson) for a total commission of $60,000. The Company also issued the Placement Agent the same warrant that the investors received exercisable for an aggregate amount of 25,000 shares of common stock at an exercise price of $3.50 per share (2,500 shares of common stock for each $100,000 in principal amount of Notes sold, excluding Notes sold to the Chairman) (the “2017 Placement Agent Warrants”). The Placement Agent has the right to exchange the Placement Agent Warrants for a like number of warrants to be issued to the lender in the Company’s next debt financing. As an employee and Principal of Taglich Brothers Inc. Mr. Taglich was issued 2017 Placement Agent Warrants to purchase 7,500 shares of common stock. 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

On August 13, 2018, Icagen, Inc. entered into a Securities Purchase Agreement and issued a secured 10% Bridge Note for $50,000 to Mr. Taglich in consideration of $50,000.

On August 13, 2018, Icagen, Inc. issued Mr. Taglich five year Warrants to acquire 7,500 shares of common stock exercisable at $3.50 per share.

On August 27, 2018, Mr. Taglich purchased 42,857 shares of Series C Convertible Preferred Stock with a $3.50 conversion price and a warrant to purchase 42,857 shares of common stock exercisable at $3.50 per share.

First South Africa Management

The Borrower incurred an expense of $222,000 for services provided by First South Africa Management for provision of CFO services by Mr. Korb and for bookkeeping services for the year ended December 31, 2015.

The Borrower incurred an expense of $180,000 for services provided by First South Africa Management for provision of CFO services by Mr. Korb and $42,000 for bookkeeping services for the year ended December 31, 2016.

The Borrower incurred an expense of $180,000 for services provided by First South Africa Management for provision of CFO services by Mr. Korb for the year ended December 31, 2017 and $89,600 for bookkeeping services for the year ended December 31, 2017. As of December 31, 2017, the Borrower owed First South Africa Management $23,500.

***

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Schedule 7.21

OFAC Matters

None

***

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Schedule 7.23

Deposit and Disbursement Accounts

Set forth below is a list of all bank accounts of any Obligor (checking, savings, money market or the like) in which any Obligor customarily maintains in excess of $10,000.

Obligor		Type of Account		Name & Address of Financial Institutions		Account Number
Icagen, Inc.		Commercial Checking		JP Morgan Chase Bank PO Box 659754 San Antonio, Texas 78265-9754 5950 Glades Road, Boca Raton, FL 33431		672002107
Icagen Corp		Commercial Checking		JP Morgan Chase Bank PO Box 659754 San Antonio, Texas 78265-9754 5950 Glades Road, Boca Raton, FL 33431		793379772
Icagen, Inc.		Business Advantage Checking		Bank of America, N.A. PO Box 15284 Wilmington, DE 197850		229048442728
Icagen-T, Inc.		Commercial Checking		JP Morgan Chase Bank PO Box 659754 San Antonio, Texas 78265-9754 5950 Glades Road, Boca Raton, FL 33431		855068917

***

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Schedule 7.24

Royalty and Payments

Asset Purchase Agreement and Collaboration Agreement dated as of June 26, 2015 between XRpro Sciences, Inc. (now known as Icagen, Inc.) and Icagen, Inc. (a subsidiary of Pfizer) (Filed as an exhibit to the Current Report on Form 8-K filed on July 2, 2015)

Master Service Agreement dated as of June 26, 2015 between XRPro Sciences (now known as Icagen, Inc.) and Icagen, Inc. (a subsidiary of Pfizer) (2) (Filed as an exhibit to the Current Report on Form 8-K filed on July 2, 2015)

Amendment to Asset Purchase and Collaboration Agreement between Icagen, Inc. and Pfizer Research Inc. (Filed as an exhibit to the Current Report on Form 8-K filed July 19, 2016)

Research Development and Commercialization Agreement made May 1, 2018 by and between Icagen, Inc. and Cystic Fibrosis Foundation and amendment No. 1 thereto

Research Collaboration and License Agreement made May 1, 2018 between Sanofi and Icagen, Inc.

***

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Schedule 8.17

Post-Closing Obligations

1. Within five (5) Business Days after the Closing Date, Borrower shall have delivered to the Administrative Agent the original, duly executed stock certificates of (A) Caldera Discovery, Inc., evidenced by Certificate No. C-02, (B) XRPro Sciences, Inc., evidenced by Certificate No. C-01, and (C) Icagen Corp., evidenced by Certificate No. C-02.

2. Within sixty (60) days after the Closing Date, Borrower shall have delivered to the Administrative Agent fully executed control agreements, in form and substance reasonably satisfactory to the Administrative Agent, for the Borrower’s account at J.P. Morgan Chase ending xx2107, and Icagen Corp.’s account at J.P. Morgan Chase ending xx9772.

3. Within ninety (90) days after the Closing Date, the Borrower shall have closed it deposit account ending xx2728 at Bank of America, N.A.

4. Within five (5) Business Days after the Closing Date, the Borrower shall have delivered to the Administrative Agent a signed Estoppel Certificate between the Borrower and Pfizer Research (NC), Inc.

5. Within sixty (60) days after the Closing Date, the Borrower shall use its commercially reasonable efforts to obtain landlord consents from the ultimate owner of the Durham, NC leased property.

6. Within ten (10) Business Days after the Closing Date, the Borrower shall have delivered to the Administrative Agent the endorsements to insurance policies required to be maintained pursuant to Section 8.05 of the Credit Agreement.

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Schedule 9.05

Existing Investments

None

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Schedule 9.10

Transactions with Affiliates

None

***

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Schedule 9.14

Permitted Sales and Leasebacks

None

***

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Schedule 10.02

Contemplated Collaboration Agreement

[*****]

Exhibit A

to Credit Agreement

FORM OF NOTE

U.S. $[___________] [DATE]

FOR VALUE RECEIVED, the undersigned, Icagen, Inc., a Delaware corporation (“Borrower”), hereby promises to pay to [INSERT NAME OF LENDER] or its assigns (the “Lender”) at Lender’s principal office in [_________], in immediately available funds, the aggregate principal sum set forth above, or, if less, the aggregate unpaid principal amount of the Term Loan made by Lender pursuant to Section 2.01 of the Credit Agreement and Guaranty, dated as of August 31, 2018 (as from time to time amended, restated, supplemented or otherwise modified, the “Credit Agreement”), among Borrower, the Subsidiary Guarantors from time to time party thereto, the Lenders from time to time party thereto and Perceptive Credit Holdings II, LP, as administrative agent for the Lenders (in such capacity, the “Administrative Agent”), on the date or dates specified in the Credit Agreement, together with interest on the principal amount of the Term Loan from time to time outstanding thereunder at the rates, and payable in the manner and on the dates, specified in the Credit Agreement.

This Note is a Note issued pursuant to the terms of Section 2.02 of the Credit Agreement, and this Note and the holder hereof are entitled to all the benefits and security provided for thereby or referred to therein, to which Credit Agreement reference is hereby made for a statement thereof. All defined terms used in this Note, except terms otherwise defined herein, shall have the same meaning as in the Credit Agreement.

THIS NOTE AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK, WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAWS THAT WOULD RESULT IN THE APPLICATION OF THE LAWS OF ANY OTHER JURISDICTION; PROVIDED THAT SECTION 5-1401 OF THE NEW YORK GENERAL OBLIGATIONS LAW SHALL APPLY.

Borrower hereby waives demand, presentment, protest or notice of any kind hereunder, other than notices provided for in the Loan Documents. The non-exercise by the holder hereof of any of its rights hereunder in any particular instance shall not constitute a waiver thereof in such particular or any subsequent instance.

[signature to follow]

Exhibit A-1

THIS NOTE MAY NOT BE TRANSFERRED EXCEPT IN COMPLIANCE WITH THE TERMS OF THE CREDIT AGREEMENT.

Icagen, Inc.

By:

Name:  

Title:  

Exhibit A-2

Exhibit B

to Credit Agreement

[Reserved]

Exhibit B-1

Exhibit C

to Credit Agreement

FORM OF GUARANTEE ASSUMPTION AGREEMENT

Guarantee Assumption Agreement dated as of [Date] (this “Agreement”) by [Name of Additional Guarantor], a ___________ [corporation] (the “Additional Guarantor”), under that certain Credit Agreement and Guaranty, dated as of August 31, 2018 (as from time to time amended, restated, supplemented or otherwise modified, the “Credit Agreement”), among Icagen, Inc., a Delaware corporation (“Borrower”), the Subsidiary Guarantors from time to time party thereto, the Lenders from time to time party thereto, and Perceptive Credit Holdings II, LP, as administrative agent for the Lenders (in such capacity, the “Administrative Agent”). The terms defined in the Credit Agreement are herein used as therein defined.

Pursuant to Section 8.12(a) of the Credit Agreement, the Additional Guarantor hereby agrees to become a “Subsidiary Guarantor” for all purposes of the Credit Agreement, and a “Grantor” for all purposes of the Security Agreement. Without limiting the foregoing, the Additional Guarantor hereby, jointly and severally with the other Subsidiary Guarantors, guarantees to the Administrative Agent, each Lender and each of their respective successors and assigns the prompt payment in full when due (whether at stated maturity, by acceleration or otherwise) of all Guaranteed Obligations (as defined in Section 12.01 of the Credit Agreement) in the same manner and to the same extent as is provided in Section 12 of the Credit Agreement. In addition, subject to the Schedules attached hereto, as of the date hereof, the Additional Guarantor hereby makes the representations and warranties set forth in Section 7 of the Credit Agreement, and in Section 2 of the Security Agreement, with respect to itself and its obligations under this Agreement and the other Loan Documents, as if each reference in such Sections to the Loan Documents included reference to this Agreement, such representations and warranties to be made as of the date hereof.

The Additional Guarantor hereby instructs its counsel to deliver the opinions referred to in Section 8.12(a) of the Credit Agreement to the Administrative Agent.

THIS GUARANTEE AND ASSUMPTION AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAW OF THE STATE OF NEW YORK, WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAWS THAT WOULD RESULT IN THE APPLICATION OF THE LAWS OF ANY OTHER JURISDICTION; PROVIDED, THAT SECTION 5-1401 OF THE NEW YORK GENERAL OBLIGATIONS LAW SHALL APPLY.

[signature to follow]

Exhibit C-1

IN WITNESS WHEREOF, the Additional Guarantor has caused this Guarantee Assumption Agreement to be duly executed and delivered as of the day and year first above written.

[ADDITIONAL GUARANTOR]

By:

Name:

Title:

Exhibit C-2

Exhibit D-1

to Credit Agreement

FORM OF U.S. TAX COMPLIANCE CERTIFICATE

(For Foreign Lenders That Are Not Partnerships

For U.S. Federal Income Tax Purposes)

Reference is made to the Credit Agreement and Guaranty, dated as of August 31, 2018 (as from time to time amended, restated, supplemented or otherwise modified, the “Credit Agreement”), among Icagen, Inc., a Delaware corporation (“Borrower”), the Subsidiary Guarantors from time to time party thereto, the Lenders from time to time party thereto, and Perceptive Credit Holdings II, LP, as administrative agent for the Lenders (in such capacity, the “Administrative Agent”). The terms defined in the Credit Agreement are herein used as therein defined.

[________________________] (the “Foreign Lender”) is providing this certificate pursuant to Section 5.03(f)(ii)(B)(3) of the Credit Agreement. The Foreign Lender hereby represents and warrants that:

1. The Foreign Lender is the sole record owner of the Term Loan as well as any obligations evidenced by any Note(s) in respect of which it is providing this certificate;

2. The Foreign Lender is the sole beneficial owner of the Term Loan as well as any obligations evidenced by any Note(s) in respect of which it is providing this certificate;

3. The Foreign Lender is not a “bank” within the meaning of Section 881(c)(3)(A) of the Code;

4. The Foreign Lender is not a “ten-percent shareholder” of Borrower within the meaning of Section 871(h)(3)(B) of the Code; and

5. The Foreign Lender is not a “controlled foreign corporation” related to the Borrower as described in Section 881(c)(3)(C) of the Code.

The undersigned has furnished the Administrative Agent and the Borrower with a certificate of its non-U.S. Person status on IRS Form W-8BEN or IRS Form W-8BEN-E. By executing this certificate, the undersigned agrees that (1) if the information provided on this certificate changes, the undersigned shall promptly so inform the Borrower and the Administrative Agent, and (2) the undersigned shall have at all times furnished the Borrower and the Administrative Agent with a properly completed and currently effective certificate in either the calendar year in which each payment is to be made to the undersigned, or in either of the two calendar years preceding such payments.

[Signature follows]

Exhibit D-1-1

IN WITNESS WHEREOF, the undersigned has caused this certificate to be duly executed and delivered as of the date indicated below.

[NAME OF FOREIGN LENDER]

By:

Name:

Title:

Date: 

Exhibit D-1-2

Exhibit D-2

to Credit Agreement

FORM OF U.S. TAX COMPLIANCE CERTIFICATE

(For Foreign Participants That Are Not Partnerships

For U.S. Federal Income Tax Purposes)

Reference is made to the Credit Agreement and Guaranty, dated as of August 31, 2018 (as from time to time amended, restated, supplemented or otherwise modified, the “Credit Agreement”), among Icagen, Inc., a Delaware corporation (“Borrower”), the Subsidiary Guarantors from time to time party thereto, the Lenders from time to time party thereto, and Perceptive Credit Holdings II, LP, as administrative agent for the Lenders (in such capacity, the “Administrative Agent”). The terms defined in the Credit Agreement are herein used as therein defined.

[________________________] (the “Participant”) is providing this certificate pursuant to Section 5.03(e)(ii)(B)(4) of the Credit Agreement. The Participant hereby represents and warrants that:

1. The Participant is the sole record owner of the participation in respect of which it is providing this certificate;

2. The Participant is the sole beneficial owner of the participation in respect of which it is providing this certificate;

3. The Participant is not a “bank” within the meaning of Section 881(c)(3)(A) of the Code;

4. The Participant is not a “ten-percent shareholder” of Borrower within the meaning of Section 871(h)(3)(B) of the Code; and

5. The Participant is not a “controlled foreign corporation” related to the Borrower as described in Section 881(c)(3)(C) of the Code.

The undersigned has furnished its participating Lender with a certificate of its non-U.S. Person status on IRS Form W-8BEN or IRS Form W-8BEN-E. By executing this certificate, the undersigned agrees that (1) if the information provided on this certificate changes, the undersigned shall promptly so inform such Lender in writing, and (2) the undersigned shall have at all times furnished such Lender with a properly completed and currently effective certificate in either the calendar year in which each payment is to be made to the undersigned, or in either of the two calendar years preceding such payments.

[Signature follows]

Exhibit D-2-1

IN WITNESS WHEREOF, the undersigned has caused this certificate to be duly executed and delivered as of the date indicated below.

[NAME OF PARTICIPANT]

By:

Name:

Title:

Date: 

Exhibit D-2-2

Exhibit D-3

to Credit Agreement

FORM OF U.S. TAX COMPLIANCE CERTIFICATE

(For Foreign Participants That Are Partnerships

For U.S. Federal Income Tax Purposes)

Reference is made to the Credit Agreement and Guaranty, dated as of August 31, 2018 (as from time to time amended, restated, supplemented or otherwise modified, the “Credit Agreement”), among Icagen, Inc., a Delaware corporation (“Borrower”), the Subsidiary Guarantors from time to time party thereto, the Lenders from time to time party thereto, and Perceptive Credit Holdings II, LP, as administrative agent for the Lenders (in such capacity, the “Administrative Agent”). The terms defined in the Credit Agreement are herein used as therein defined.

[________________________] (the “Participant”) is providing this certificate pursuant to Section 5.03(e)(ii)(B)(4) of the Credit Agreement. The Participant hereby represents and warrants that:

1. The Participant is the sole record owner of the participation in respect of which it is providing this certificate;

2. The Participant’s direct or indirect partners/members are the sole beneficial owners of the participation in respect of which it is providing this certificate;

3. With respect to such participation, neither the Participant nor any of its direct or indirect partners/members is a “bank” extending credit pursuant to a loan agreement entered into in the ordinary course of its trade or business within the meaning of Section 881(c)(3)(A) of the Code;

4. None of the Participant’s direct or indirect partners/members is a “ten-percent shareholder” of Borrower within the meaning of Section 871(h)(3)(B) of the Code; and

5. None of the Participant’s direct or indirect partners/members is a “controlled foreign corporation” related to the Borrower as described in Section 881(c)(3)(C) of the Code.

The undersigned has furnished its participating Lender with IRS Form W-8IMY accompanied by one of the following forms from each of its partners/members that is claiming the portfolio interest exemption: (i) an IRS Form W-8BEN or IRS Form W-8BEN-E or (ii) an IRS Form W-8IMY accompanied by an IRS Form W-8BEN or IRS Form W-8BEN-E from each of such partner’s/member’s beneficial owners that is claiming the portfolio interest exemption.. By executing this certificate, the undersigned agrees that (1) if the information provided on this certificate changes, the undersigned shall promptly so inform such Lender, and (2) the undersigned shall have at all times furnished such Lender with a properly completed and currently effective certificate in either the calendar year in which each payment is to be made to the undersigned, or in either of the two calendar years preceding such payments.

[Signature follows]

Exhibit D-3-1

IN WITNESS WHEREOF, the undersigned has caused this certificate to be duly executed and delivered as of the date indicated below.

[NAME OF PARTICIPANT]

By:

Name:

Title:

Date: 

Exhibit D-3-2

Exhibit D-4

to Credit Agreement

FORM OF U.S. TAX COMPLIANCE CERTIFICATE

(For Foreign Lenders That Are Partnerships

For U.S. Federal Income Tax Purposes)

Reference is made to the Credit Agreement and Guaranty, dated as of August 31, 2018 (as from time to time amended, restated, supplemented or otherwise modified, the “Credit Agreement”), among Icagen, Inc., a Delaware corporation (“Borrower”), the Subsidiary Guarantors from time to time party thereto, the Lenders from time to time party thereto, and Perceptive Credit Holdings II, LP, as administrative agent for the Lenders (in such capacity, the “Administrative Agent”). The terms defined in the Credit Agreement are herein used as therein defined.

[________________________] (the “Foreign Lender”) is providing this certificate pursuant to Section 5.03(e)(ii)(B)(4) of the Credit Agreement. The Foreign Lender hereby represents and warrants that:

1. The Foreign Lender is the sole record owner of the Term Loan as well as any obligations evidenced by any Note(s) in respect of which it is providing this certificate;

2. The Foreign Lender’s direct or indirect partners/members are the sole beneficial owners of the Term Loan as well as any obligations evidenced by any Note(s) in respect of which it is providing this certificate;

3. With respect to the extension of credit pursuant to this Credit Agreement or any other Loan Document, neither the Foreign Lender nor any of its direct or indirect partners/members is a “bank” extending credit pursuant to a loan agreement entered into in the ordinary course of its trade or business within the meaning of Section 881(c)(3)(A) of the Code;

4. None of the Foreign Lender’s direct or indirect partners/members is a “ten-percent shareholder” of Borrower within the meaning of Section 871(h)(3)(B) of the Code; and

5. None of the Foreign Lender’s direct or indirect partners/members is a “controlled foreign corporation” related to the Borrower as described in Section 881(c)(3)(C) of the Code.

The undersigned has furnished the Administrative Agent and the Borrower with IRS Form W-8IMY accompanied by one of the following forms from each of its partners/members that is claiming the portfolio interest exemption: (i) an IRS Form W-8BEN or IRS Form W-8BEN-E or (ii) an IRS Form W-8IMY accompanied by an IRS Form W-8BEN or IRS Form W-8BEN-E from each of such partner’s/member’s beneficial owners that is claiming the portfolio interest exemption.. By executing this certificate, the undersigned agrees that (1) if the information provided on this certificate changes, the undersigned shall promptly so inform the Borrower and the Administrative Agent, and (2) the undersigned shall have at all times furnished the Borrower and the Administrative Agent with a properly completed and currently effective certificate in either the calendar year in which each payment is to be made to the undersigned, or in either of the two calendar years preceding such payments.

[Signature follows]

Exhibit D-4-1

IN WITNESS WHEREOF, the undersigned has caused this certificate to be duly executed and delivered as of the date indicated below.

[NAME OF FOREIGN LENDER]

By:

Name:

Title:

Date: 

Exhibit D-4-2

Exhibit E

to Credit Agreement

FORM OF COMPLIANCE CERTIFICATE

[DATE]

This certificate is delivered pursuant to Section 8.01(d) of, and in connection with the consummation of the transactions contemplated in, the Credit Agreement and Guaranty, dated as of August 31, 2018 (as from time to time amended, restated, supplemented or otherwise modified, the “Credit Agreement”), among Icagen, Inc., a Delaware corporation (“Borrower”), the Subsidiary Guarantors from time to time party thereto, the Lenders from time to time party thereto, and Perceptive Credit Holdings II, LP, as administrative agent for the Lenders (in such capacity, the “Administrative Agent”). Capitalized terms used herein and not otherwise defined herein are used herein as defined in the Credit Agreement.

The undersigned, a duly authorized Responsible Officer of Borrower having the name and title set forth below under his signature, hereby certifies solely in his capacity as an officer of Borrower and not in any individual capacity, on behalf of Borrower for the benefit of the Administrative Agent and the Lenders and pursuant to Section 8.01(d) of the Credit Agreement that such Responsible Officer of Borrower is familiar with the Credit Agreement and that, in accordance with each of the following sections of the Credit Agreement, each of the following is true on the date hereof, both before and after giving effect to the Term Loan, if any, to be made on or before the date hereof:

In accordance with Section 8.01[(a)/(b)/(c)] of the Credit Agreement, attached hereto as Annex A are the financial statements for the [month/fiscal quarter/fiscal year] ended [_________] required to be delivered pursuant to Section 8.01[(a)/(b)/(c)] of the Credit Agreement. Such financial statements fairly present in all material respects the consolidated financial position, results of operations and cash flow of Borrower and its Subsidiaries as at the dates indicated therein and for the periods indicated therein substantially in accordance with GAAP [(subject to the absence of footnote disclosure and normal quarterly or year-end audit adjustments)].1

Attached hereto as Annex B are the calculations used to determine compliance with each financial covenant contained in Section 10 of the Credit Agreement.

No Default is continuing as of the date hereof [, except as provided for on Annex C attached hereto, with respect to each of which Borrower proposes to take the actions set forth on Annex C].

No Intellectual Property has been created or otherwise acquired during the prior fiscal quarter for which this Compliance Certificate is being delivered, which is registered or became registered or the subject of an application for registration with the U.S. Copyright Office or the U.S. Patent and Trademark Office, as applicable, or with any other equivalent foreign Governmental Authority [except as provided for on Annex D attached hereto].

[Signature follows]

¹ Insert language in brackets only for certificates delivered under Section 8.01(a) and (b)

Exhibit E-1

IN WITNESS WHEREOF, the undersigned has executed this certificate on the date first written above.

Icagen, Inc.

By:

Name:  

Title:  

Exhibit E-2

Annex A

to Compliance Certificate

FINANCIAL STATEMENTS

[see attached]

Exhibit E-3

Annex B

to Compliance Certificate

CALCULATIONS OF FINANCIAL COVENANT COMPLIANCE

I.		Section 10.01:  Minimum Liquidity
A.		Minimum aggregate balance of cash at any time in one or more accounts (which accounts shall, on and after the Closing Date (or such later date as agreed to by the Administrative Agent in its reasonable discretion), be Controlled Accounts), free and clear of all Liens, other than Liens granted under the Loan Documents in favor of the Administrative Agent and other Permitted Liens, during the fiscal period for which the financial statements attached hereto as Annex A are being delivered:		$___________
B.		Is Line IA greater than (x) from the Closing Date until March 31, 2019, $1,000,000, or (y) thereafter, $1,500,000?:		Yes: In compliance; No: Not in compliance

II.		10.02:  Minimum Revenue2
A.		Consolidated Net Revenue (the revenue of the Borrower and its Subsidiaries determined on a consolidated basis in accordance with GAAP; provided, however, that Consolidated Net Revenue shall exclude any upfront fees and one-time milestone payments received by the Borrower or any of its Subsidiaries from a collaboration agreement with a pharmaceutical or biotechnology company other than those upfront fees in an aggregate amount not to exceed $5,000,000 received by the Borrower or any of its Subsidiaries in connection with the collaboration agreement contemplated to be entered into on Schedule 10.02 of the Credit Agreement) for trailing twelve month period ended on the Calculation Date corresponding with end of the[fiscal quarter/fiscal year] for which this Compliance Certificate is being delivered:		$___________
B.		Net Revenue set forth in the column opposite such Calculation Date as listed in Section 10.02 of the Credit Agreement:		$___________
C.		Is Line 2A greater than or equal to Line 2B?		Yes: In compliance; No: Not in compliance

² To be included only for Compliance Certificates delivered together with the financial statements required pursuant to Sections 8.01(b) and (c).

Exhibit E-4

Exhibit F

to Credit Agreement

FORM OF ASSIGNMENT AND ASSUMPTION

Reference is made to the Credit Agreement and Guaranty, dated as of August 31, 2018 (as from time to time amended, restated, supplemented or otherwise modified, the “Credit Agreement”), among Icagen, Inc., a Delaware corporation (“Borrower”), the Subsidiary Guarantors from time to time party thereto, the Lenders from time to time party thereto, and Perceptive Credit Holdings II, LP, as administrative agent for the Lenders (in such capacity, the “Administrative Agent”). All capitalized terms used and not defined herein have the meanings ascribed thereto in the Credit Agreement.

The “Assignor” referred to on Schedule 1 hereto (the “Assignor”) and the “Assignee” referred to on Schedule 1 hereto (the “Assignee”)3 agrees severally with respect to all information relating to it and its assignment hereunder and on Schedule 1 hereto as follows:

1. The Assignor hereby sells and assigns, without recourse except as to the representations and warranties made by it herein, to the Assignee, and the Assignee hereby purchases and assumes from the Assignor, an interest in and to the Assignor’s rights and obligations under the Credit Agreement as of the Effective Date (as defined herein) equal to the percentage interest specified on Schedule 1 hereto of all outstanding rights and obligations under the Credit Agreement. After giving effect to such sale and assignment, the amount of the Term Loan owing to the Assignee will be as set forth on Schedule 1 hereto.

2. The Assignor (i) represents and warrants that its name set forth on Schedule 1 hereto is its legal name, that it is the legal and beneficial owner of the interest or interests being assigned by it hereunder and that such interest or interests are free and clear of any lien, encumbrance or other adverse claim; (ii) makes no representation or warranty and assumes no responsibility with respect to any statements, warranties or representations made in or in connection with any Loan Document or the execution, legality, validity, enforceability, genuineness, sufficiency or value of, or the perfection or priority of any lien or security interest created or purported to be created under or in connection with, any Loan Document or any other instrument or document furnished pursuant thereto; (iii) makes no representation or warranty and assumes no responsibility with respect to the financial condition of any Obligor or the performance or observance by any Obligor of any of its obligations under any Loan Document or any other instrument or document furnished pursuant thereto; and (iv) attaches the Note or Notes (if any) held by the Assignor and requests that the Administrative Agent exchange such Note or Notes for a new Note or Notes payable to the Assignee (or its registered assigns) in an amount equal to the Term Loan assumed by the Assignee pursuant hereto or new Notes payable to the Assignor in an amount equal to the Term Loan retained by the Assignor under the Credit Agreement, respectively, as specified on Schedule 1 hereto.

³ The form is to be adjusted in connection with any multiple party assignments.

Exhibit F-1

3. The Assignee (i) confirms that, to the extent it has so requested, it has received a copy of the Credit Agreement, together with copies of such other documents and information as it has deemed appropriate to make its own credit analysis and decision to enter into this Assignment and Assumption; (ii) agrees that it will, independently and without reliance upon the Administrative Agent, any Assignor or any other Lender and based on such documents and information as it shall deem appropriate at the time, continue to make its own credit decisions in taking or not taking action under the Credit Agreement; (iii) represents and warrants that its name set forth on Schedule 1 hereto is its legal name; (iv) represents and warrants that it is an Eligible Transferee and is not (x) a natural person, or (y) an Obligor or any of their respective Subsidiaries or Affiliates; (v) appoints and authorizes the Administrative Agent to take such action as agent on its behalf and to exercise such powers and discretion under the Loan Documents as are delegated to the Administrative Agent by the terms thereof, together with such powers and discretion as are reasonably incidental thereto; (vi) agrees that it will perform in accordance with their terms all of the obligations that by the terms of the Credit Agreement are required to be performed by it as a Lender; and (vii) attaches any other forms required under Section 5.03 of the Credit Agreement (and undertakes to deliver to the Administrative Agent and Borrower originals of any such U.S. Internal Revenue Service form required to be provided pursuant to Section 5.03).

4. Following the execution of this Assignment and Assumption, it will be delivered to the Administrative Agent for acceptance and recording by the Administrative Agent. The effective date for this Assignment and Assumption (the “Effective Date”) shall be the date that such assignment is recorded in the Register pursuant to Section 14.05 of the Credit Agreement.

5. Upon such acceptance and recording by the Administrative Agent, as of the Effective Date, (i) the Assignee shall be a party to the Credit Agreement and, to the extent provided in this Assignment and Assumption, have the rights and obligations of a Lender thereunder and (ii) the Assignor shall, to the extent provided in this Assignment and Assumption, relinquish its rights and be released from its obligations under the Credit Agreement in its capacity as a Lender (other than its rights and obligations under the Loan Documents that are specified under the terms of such Loan Documents to survive the payment in full of the Obligations of the Obligors under the Loan Documents to the extent any claim thereunder relates to an event arising prior to the Effective Date of this Assignment and Assumption) and, if this Assignment and Assumption covers all of the remaining portion of the rights and obligations of the Assignor in its capacity as a Lender under the Credit Agreement, the Assignor shall cease to be a party thereto in its capacity as a Lender.

6. Upon such acceptance and recording by the Administrative Agent, from and after the Effective Date, the Administrative Agent shall make all payments under the Credit Agreement and the other Loan Documents in respect of the interest assigned hereby (including, without limitation, all payments of principal and interest with respect thereto) to the Assignee for amounts which have accrued from and after the Effective Date and to the Assignor for amounts which have accrued to but excluding the Effective Date.

7. THIS ASSIGNMENT AND ASSUMPTION SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.

8. This Assignment and Assumption may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Delivery of an executed counterpart of this Assignment and Assumption by telecopier shall be effective as delivery of an original executed counterpart of this Assignment and Assumption.

[signature page follows]

Exhibit F-2

IN WITNESS WHEREOF, the Assignor and the Assignee have caused this Assignment and Assumption to be executed by their officers thereunto duly authorized as of the date specified thereon.

____________________________, as Assignor

[Type or print legal name of Assignor]

By:

Title:

Dated: __________________, 20__

____________________________, as Assignee

[Type or print legal name of Assignee]

By:

Title:

Dated: __________________, 20__

Lending Office:

Exhibit F-3

Acknowledged this ____day

of ___________________, 20__

PERCEPTIVE CREDIT HOLDINGS II, LP,

as Administrative Agent

By

Title:

Exhibit F-4

SCHEDULE 1

TO

ASSIGNMENT AND ASSUMPTION

Assignee: ____________________________________

ASSIGNOR:

Total

Percentage interest assigned

%

%

%

%

%

Outstanding principal amount of Term Loan assigned

$

$

$

$

$

Principal amount of Note payable to Assignor

$

$

$

$

$

Exhibit F-5

Exhibit G

to Credit Agreement

FORM OF LANDLORD’S WAIVER AND CONSENT

[see attached]

Exhibit G-1

Landlord’s Waiver and Consent

This Landlord’s Waiver and Consent (“Waiver and Consent”) is made and entered into as of [_________], 2018, between [_________], a [____________] (“Landlord”), and Perceptive Credit Holdings II, LP, as administrative agent (in such capacity, the “Administrative Agent”) for the lenders (collectively, “Lenders”) from time to time party to the Credit Agreement described below.

Whereas, Icagen, Inc., a Delaware corporation (“Company”), Icagen Corp., a Nevada corporation (“Ica-Corp”), Caldera Discovery, Inc., a Delaware corporation (“Caldera”) and XRPro Sciences, Inc., a Delaware corporation (“XRPro”, and together with Company, Ica-Corp and Caldera, the “Loan Parties”), the Lenders and the Administrative Agent are party to that certain Credit Agreement, dated as of [_______], 2018 (the “Credit Agreement”) providing for loans or extensions of credit to or for the benefit of Loan Parties;

Whereas, to secure the payment and performance of the Loan Parties’ obligations and liabilities to the Administrative Agent and Lenders under the Credit Agreement and the other documents entered in connection therewith (collectively, “Obligations”), each Loan Party has granted to the Administrative Agent, for the benefit of itself and Lenders, a security interest in all of such Loan Party’s property (collectively, the “Collateral”);

Whereas, all or some of the Collateral is now and/or from time to time hereafter may be located at 4222 Emperor Blvd., Suite 350 Research Triangle Park, Durham, NC 27703 (the “Premises”) [owned]¹ and leased by Landlord to [Company]² pursuant to the lease (the “Lease”) attached hereto as Exhibit A³; and

Whereas, Administrative Agent and Lenders have required that Landlord execute and deliver this Waiver and Consent as one of the conditions to entering into the Credit Agreement and making loans and extensions of credit under the Credit Agreement;

Now, Therefore, in consideration of any financial accommodations extended by Lenders to Company at any time, and other good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:

1. No action by the Administrative Agent or any Lender pursuant to this Waiver and Consent shall be deemed to be an assumption by the Administrative Agent or Lenders of any obligation under the Lease, and, except as otherwise provided in this Waiver and Consent, the Administrative Agent shall not have any obligation to Landlord.

¹ Adjust as appropriate if Landlord also leases from a third party.

² Please confirm.

³ Please provide a copy of the lease.

Exhibit G-2

2. Until such time as the Obligations are indefeasibly paid in full, Landlord waives any interest in the Collateral and agrees not to distrain or levy upon any Collateral or to assert any landlord lien, right of distraint or other claim against the Collateral for any reason.

3. Landlord agrees that the Collateral consisting of the Company’s trade fixtures shall not be deemed a fixture or part of the real estate but shall at all times be considered personal property.

4. Upon a termination of the Lease or receipt by Landlord of a written notice from the Administrative Agent that Company is in default under the Credit Agreement, Landlord will permit the Administrative Agent and its representatives and invitees to access the Premises upon two (2) business days’ prior notice to Landlord; provided, that (a) such period of access (the “Disposition Period”) shall not exceed thirty (30) days following receipt of such written notice or termination or, if the Lease has expired by its own terms (absent a default thereunder), up to fifteen (15) days following the natural expiration of the Lease to the extent Landlord has not entered into a lease with a third-party for the Premises which term is scheduled to commence during the Disposition Period, (b) during the Disposition Period, the Administrative Agent will pay to Landlord rent on a pro rata daily basis equal to the amount of rent (base rent and additional rent) due under the Lease for the month immediately preceding such termination or expiration of the Lease, and provide and retain liability and property insurance coverage and utilities to the extent required by the Lease, and (c) such amounts paid by the Administrative Agent to Landlord shall exclude any rent adjustments, indemnity payments or similar amounts for which the Company remains liable under the Lease for default, holdover status or other similar charges.

5. During any Disposition Period, (a) the Administrative Agent and its representatives and invitees may inspect, repossess, remove and otherwise deal with the Collateral (but shall not conduct any public auction on the Premises), and (b) the Administrative Agent shall make the Premises available for inspection by Landlord and prospective tenants and shall cooperate in Landlord’s reasonable efforts to re lease the Premises.

6. The Administrative Agent shall promptly repair, at the Administrative Agent’s expense, or (if requested by Landlord) reimburse Landlord for any physical damage to the Premises caused by any removal of Collateral by or through the Administrative Agent. Neither the Administrative Agent nor any Lender shall be liable for any diminution in value of the Premises caused by the absence of Collateral removed, and neither the Administrative Agent nor any Lender shall have any duty or obligation to remove or dispose of any Collateral or any other property left on the Premises by Company. If the Administrative Agent shall fail to remove the Collateral during the periods described in paragraph 4 above, then at the Landlord’s election, the Administrative Agent shall be deemed to have surrendered the Collateral on the Premises to the Landlord and released its security interest therein.

7. All notices hereunder shall be in writing, sent by certified mail, return receipt requested or by overnight courier, to the respective parties and the addresses set forth on the signature page or at such other address as the receiving party shall designate in writing.

8. This Waiver and Consent may be executed in any number of several counterparts, shall be governed and controlled by, and interpreted under, the laws of the State of New York, and shall inure to the benefit of the Administrative Agent and its successors and assigns and shall be binding upon Landlord and its successors and assigns (including any transferees of the Premises).

[SIGNATURE PAGE FOLLOWS]

Exhibit G-3

IN WITNESS WHEREOF, this Landlord’s Waiver and Consent is entered into as of the date first set forth above.

[________________] [________________] [________________] attention: [________________] Email: [________________]		“LANDLORD” [__________________] By:__________________________________ Name: _______________________________ Title:________________________________
Perceptive Credit Holdings II, LP c/o Perceptive Advisors LLC 51 Astor Place, 10th Floor New York, NY 10003 Attention: Sandeep Dixit Email: Sandeep@perceptivelife.com		“ADMINISTRATIVE AGENT” Perceptive Credit Holdings II, LP By: Perceptive Credit Opportunities GP, LLC, its general partner By:__________________________________ Name: Sandeep Dixit Title: Chief Credit Officer By:__________________________________ Name: Sam Chawla Title: Portfolio Manager

Acknowledged and agreed:

Icagen, Inc.

By:

Name: 

Title:

Exhibit G-4

Exhibit H

to Credit Agreement

FORM OF SECURITY AGREEMENT

[see attached]

Exhibit H-1

Execution Version

Security Agreement

Dated as of

August 31, 2018

among

Icagen, Inc.

as Grantor,

The Other Grantors from Time to Time Party hereto

and

Perceptive Credit Holdings II, LP,
as Administrative Agent

Exhibit H-2

Table of Contents

Section		Heading		Page
SECTION 1. Definitions, Etc.				5
Section 1.01.		Certain Uniform Commercial Code Terms		5
Section 1.02.		Additional Definitions		5
Section 1.03.		Other Defined Terms		7
SECTION 2. Representations and Warranties				8
Section 2.01.		Title.		8
Section 2.02.		Names, Etc.		8
Section 2.03.		Changes in Circumstances		8
Section 2.04.		Pledged Shares.		9
Section 2.05.		Promissory Notes		9
Section 2.06.		Intellectual Property.		9
Section 2.07.		Deposit Accounts, Securities Accounts and Commodity Accounts		10
Section 2.08.		Commercial Tort Claims		10
Section 2.09.		Update of Schedules		10
SECTION 3. Collateral				10
Section 3.01.		Granting Clause		10
SECTION 4. Further Assurances; Remedies				12
Section 4.01.		Delivery and Other Perfection		12
Section 4.02.		Other Financing Statements or Control		13
Section 4.03.		Preservation of Rights		13
Section 4.04.		Special Provisions Relating to Certain Collateral.		13
Section 4.05.		Remedies.		15
Section 4.06.		Deficiency		17
Section 4.07.		Locations, Names, Etc		17
Section 4.08.		Private Sale		17
Section 4.09.		Application of Proceeds		17
Section 4.10.		Attorney in Fact and Proxy		17
Section 4.11.		Perfection and Recordation		18
Section 4.12.		Termination		18
Section 4.13.		Further Assurances		18

Exhibit H-3

SECTION 5. Miscellaneous				19
Section 5.01.		Notices		19
Section 5.02.		No Waiver		19
Section 5.03.		Amendments, Etc.		19
Section 5.04.		Expenses.		19
Section 5.05.		Successors and Assigns		19
Section 5.06.		Counterparts		19
Section 5.07.		Governing Law; Submission to Jurisdiction; Etc.		19
Section 5.08.		Waiver of Jury Trial		20
Section 5.09.		Captions		20
Section 5.10.		Agents and Attorneys in Fact		20
Section 5.11.		Severability		20
Section 5.12.		Additional Grantors		20

Exhibits:
Exhibit A	—	Form of Joinder Agreement
Schedules:
Schedule 1	—	Certain Grantor Information
Schedule 2	—	Pledged Shares
Schedule 3	—	Promissory Notes
Schedule 4	—	Copyrights, Copyright Registrations and Applications for Copyright Registrations
Schedule 5	—	Patents and Patent Applications
Schedule 6	—	Trade Names, Trademarks, Services Marks, Trademark and Service Mark Registrations and Applications for Trademark and Service Mark Registrations
Schedule 7	—	Deposit Accounts, Securities Accounts and Commodity Accounts
Schedule 8	—	Commercial Tort Claims

Exhibit H-4

Security Agreement

This Security Agreement (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, this “Agreement”), dated as of August 31, 2018 is made by and among Icagen, Inc., a Delaware corporation (“Borrower”), each Subsidiary of Borrower that is a party hereto or may become a party hereto pursuant Section 5.12 of this Agreement (together with Borrower, collectively, the “Grantors” and each a “Grantor”), and Perceptive Credit Holdings II, LP as collateral agent (in such capacity, the “Administrative Agent”) for the Secured Parties.

The Secured Parties have agreed to provide term loans to Borrower, as provided in the Credit Agreement (as defined below).

Each Grantor (other than Borrower) has guaranteed the obligations of Borrower to Secured Parties under the Credit Agreement.

To induce the Secured Parties to extend credit under the Credit Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each Grantor has agreed to grant a security interest in the Collateral (as defined below) of such Grantor as security for the Secured Obligations (as defined below).

Accordingly, the parties hereto agree as follows:

SECTION 1. Definitions, Etc.

Section 1.01. Certain Uniform Commercial Code Terms. As used herein, the terms “Accession”, “Account”, “Account Debtor”, “Cash Proceeds”, “Certificate of Title”, “Certificated Security”, “Chattel Paper”, “Check”, “Commercial Tort Claim”, “Commodity Account”, “Commodity Contract”, “Deposit Account”, “Document”, “Electronic Chattel Paper”, “Encumbrance”, “Entitlement Holder”, “Equipment”, “Financial Asset”, “Fixture”, “General Intangible”, “Goods”, “Instrument”, “Inventory”, “Investment Property”, “Letter of Credit Rights”, “Noncash Proceeds”, “Payment Intangibles”, “Proceeds”, “Promissory Note”, “Record”, “Securities Account”, “Security”, “Security Entitlement”, “Software”, “Supporting Obligation” and “Uncertificated Security” have the respective meanings set forth in the UCC.

Section 1.02. Additional Definitions. In addition, as used herein:

“Administrative Agent” has the meaning assigned to such term in the preamble.

“Collateral” has the meaning assigned to such term in Section 3.01.

“Copyrights” has the meaning set forth in the Credit Agreement.

“Credit Agreement” means that certain Credit Agreement and Guaranty, dated as of the date hereof, among Borrower, the other Grantors from time to time party thereto, the Lenders from time to time party thereto and the Administrative Agent, as such agreement is amended, supplemented, or otherwise modified, restated, extended, renewed, or replaced from time to time.

Exhibit H-5

“Excluded Account” has the meaning set forth in the Credit Agreement.

“Excluded Asset” means:

(a) any Trademark that would be rendered invalid, abandoned, void or unenforceable by reason of it being included as part of the Collateral; provided, however, that the Proceeds, substitutions or replacements of the foregoing shall not constitute an Excluded Asset;

(b) Excluded Accounts;

(c) any assets (including intangibles) to the extent a grant of security interest therein is restricted or prohibited by, or illegal under or by, applicable law or any Governmental Authority (after giving effect to applicable anti-assignment provisions of the UCC or other applicable law);

(d) any lease, license, permit, contract or agreement to which any Grantor is a party, in each case, if and only if, and solely to the extent that, (i) the grant of a security interest therein shall constitute or result in a breach, termination or default or invalidity thereunder or thereof or give rise to or permit any other Person to terminate or exercise remedies thereunder (other than to the extent that any such term would be rendered ineffective pursuant to Sections 9-406, 9-407, 9-408 or 9-409 of the UCC of any relevant jurisdiction or any other applicable law or principles of equity) or (ii) such lease, license, contract or agreement is an “off the shelf” license of intellectual property that is not material to the operation of the business of the applicable Grantor or which can be replaced without a material expenditure; provided that immediately upon the time at which the consequences described in the foregoing clause (i) shall no longer exist, the Collateral shall include, and the applicable Grantor shall be deemed to have granted a security interest in, all of such Grantor’s right, title and interest in such lease, license, contract or agreement; provided, however, that the Proceeds of the foregoing shall not constitute an Excluded Asset;

(e) any application for registration of a trademark filed on an intent-to-use basis solely to the extent that the grant of a security interest in any such trademark application would adversely affect the validity or enforceability of the resulting trademark registration or result in cancellation of such trademark application;

(f) any asset that is subject to a Lien securing a purchase money obligation or capital lease obligation permitted to be incurred pursuant to the provisions of the Credit Agreement if the contract or other agreement in which such Lien is granted (or the documentation providing for such purchase money obligation or capital lease obligation) prohibits the creation of any other Lien on such asset;

(g) motor vehicles and other assets subject to certificates of title; and

(h) Excluded Shares.

Exhibit H-6

“Excluded Shares” means (i) any Shares of Icagen-T owned by Borrower, and (ii) any Shares of a Subsidiary of Icagen-T owned by Icagen-T; provided that in each case, such shares shall only be Excluded Shares until the pledge of such shares by Borrower or Icagen-T is no longer prohibited under the Icagen-T MSA.

“Initial Pledged Shares” means the Pledged Shares of each Issuer beneficially owned by any Grantor on the date hereof and identified in Schedule 2.

“Issuers” means, collectively, (i) the respective Persons identified on Schedule 2 under the caption “Issuer”, (ii) any other Person that shall at any time be a Subsidiary of Borrower or any other Grantor, and (iii) the issuer of any equity securities hereafter owned by any Grantor.

“Joinder” has the meaning specified in Section 5.12.

“Patents” has the meaning set forth in the Credit Agreement.

“Pledged Shares” means, collectively, (i) the Initial Pledged Shares, and (ii) all other Shares of any Issuer (other than Excluded Shares) now or hereafter owned by any Grantor, together in each case with (a) all certificates representing the same, (b) all shares, securities, moneys or other property representing a dividend on or a distribution or return of capital on or in respect of the Pledged Shares, or resulting from a split-up, revision, reclassification or other like change of the Pledged Shares or otherwise received in exchange therefor, and any warrants, rights or options issued to the holders of, or otherwise in respect of, the Pledged Shares, and (c) without prejudice to any provision of any of the Loan Documents prohibiting any merger or consolidation by an Issuer, all Shares of any successor entity of any such merger or consolidation.

“Secured Obligations” means, with respect to each Grantor, the Obligations of such Grantor.

“Shares” means shares of capital stock of a corporation, limited liability company interests, partnership interests and other ownership or equity interests of any class in any Person.

“Trademarks” has the meaning set forth in the Credit Agreement.

“UCC” shall mean the Uniform Commercial Code as in effect in the State of New York; provided, however, that if by reason of mandatory provisions of law, any or all of the attachment, perfection or priority of the Administrative Agent’s security interest in any item or portion of the Collateral is governed by the Uniform Commercial Code as in effect in a jurisdiction other than the State of New York, the term “UCC” shall mean the Uniform Commercial Code as in effect in such other jurisdiction for purposes of the provisions hereof relating to such attachment, perfection or priority and for purposes of definitions relating to such provisions.

Section 1.03. Other Defined Terms. All other capitalized terms used and not defined herein have the meanings ascribed to them in the Credit Agreement.

Exhibit H-7

SECTION 2. Representations and Warranties

Each Grantor represents and warrants to Administrative Agent, for the benefit of the Secured Parties, that:

Section 2.01. Title.

(a) Such Grantor is the sole beneficial owner of the Collateral in which it purports to grant a Lien hereunder, and no Lien exists upon such Collateral (and no right or option to acquire the same exists in favor of any other Person) other than Permitted Liens.

(b) The security interest created or provided for herein constitutes a valid first-priority (subject to Permitted Priority Liens) perfected lien on such Collateral, subject, for the following Collateral, to the occurrence of the following: (i) in the case of Collateral in which a security interest may be perfected by filing a financing statement under the UCC, the filing of a UCC financing statement naming such Grantor as debtor, Administrative Agent as secured party, and listing all personal property as collateral, (ii) with respect to any Deposit Account, Securities Account or Commodity Account, the execution of agreements among such Grantor, the applicable financial institution and Administrative Agent, effective to grant “control” (as defined in the UCC) over such Deposit Account, Securities Account or Commodity Account to Administrative Agent, (iii) with respect to any Intellectual Property not described in the foregoing clause (i), the filing of this Security Agreement or a short-form security agreement properly evidencing this Security Agreement with the applicable Intellectual Property office of the applicable government for such Intellectual Property, (iv) in the case of all certificated Shares, the delivery thereof to Administrative Agent, properly endorsed for transfer to Administrative Agent or in blank, (v) in the case of assets evidenced by certificates of title, delivery thereof to the Administrative Agent with the Lien granted hereby indicated thereon, (vi) in the case of other Collateral which requires or permits possession by the Administrative Agent to perfect its security interest therein, delivery, and endorsement if necessary, thereof to the Administrative Agent, and (vii) in the case of any other type of Collateral, such actions as set forth in Section 4.01 with respect thereto.

Section 2.02. Names, Etc. The full and correct legal name, type of organization, jurisdiction of organization, organizational ID number (if applicable) and mailing address of such Grantor as of the date hereof are correctly set forth in Schedule 1. Schedule 1 correctly specifies the place of business of such Grantor or, if such Grantor has more than one place of business, the location of the chief executive office of such Grantor.

Section 2.03. Changes in Circumstances. Such Grantor has not (a) within the period of four months prior to the date hereof, changed its location (as defined in Section 9-307 of the UCC), or (b) except as specified in Schedule 1, heretofore changed its name within the period of five years prior to the date hereof.

Exhibit H-8

Section 2.04. Pledged Shares.

(a) The Initial Pledged Shares constitute 100% of the issued and outstanding Shares of each Issuer beneficially owned by such Grantor on the date hereof (other than any Shares held in a Securities Account referred to in Schedule 7 or any Excluded Shares), whether or not registered in the name of such Grantor. Schedule 2 correctly identifies, as at the date hereof, the respective Issuers of the Initial Pledged Shares and (in the case of any corporate Issuer) the respective class and par value of such Shares and the respective number of such Shares (and registered owner thereof) represented by each such certificate.

(b) The Initial Pledged Shares are, and all other Pledged Shares that in the future will constitute Collateral will be, (i) duly authorized, validly existing, fully paid and non-assessable (in the case of any Shares issued by a corporation) and (ii) duly issued and outstanding (in the case of any equity interest in any other entity). None of such Pledged Shares are or will be subject to any contractual restriction, or any restriction under the charter, bylaws, partnership agreement or other organizational instrument of the respective Issuer thereof, upon the transfer of such Pledged Shares (except for any such restriction (i) contained in any Loan Document, (ii) contained in any Restrictive Agreement permitted under Section 9.11 of the Credit Agreement, or (iii) affecting the offering and sale of securities generally).

Section 2.05. Promissory Notes. Schedule 3 sets forth a complete and correct list of all Promissory Notes (other than any held in a Securities Account referred to in Schedule 7) held by such Grantor on the date hereof.

Section 2.06. Intellectual Property.

(a) Schedules 4, 5 and 6, respectively, set forth a complete and correct list of all of the following owned by such Grantor on the date hereof (or, in the case of any supplement to said Schedules 4, 5 and 6, effecting a pledge thereof, as of the date of such supplement): (i) applied for or registered Copyrights, (ii) applied for, issued, or registered active Patents, including the jurisdiction and patent number, (iii) applied for or registered active Trademarks, including the jurisdiction, trademark application or registration number and the application or registration date and (iv) trade names.

(b) Except as permitted by Section 9.13 of the Credit Agreement or pursuant to (i) licenses and other user agreements entered into by such Grantor in the ordinary course of business that are listed in said Schedules 4, 5 and 6 (including as supplemented by any supplement effecting a pledge thereof) and (ii) non-exclusive licenses such Grantor has done nothing to authorize or enable any other Person to use any Copyright, Patent or Trademark listed in said Schedules 4, 5 and 6 (as so supplemented), and all registrations listed in said Schedules 4, 5 and 6 (as so supplemented) are, except as noted therein, in full force and effect.

(c) Such Grantor owns and possesses the right to use all Copyrights, Patents and Trademarks listed on Schedules 4, 5 and 6, respectively. To such Grantor’s knowledge, (i) except as set forth on Schedule 4, 5 or 6 (as supplemented by any supplement effecting a pledge thereof), there is no violation by others of any right of such Grantor with respect to any Copyright, Patent or Trademark listed on Schedule 4, 5 or 6 (as so supplemented), respectively, and (ii) such Grantor is not infringing in any respect upon any Copyright, Patent or Trademark of any other Person. No proceedings alleging such infringement have been instituted in the past twelve (12) months or are pending against such Grantor and no written claim against such Grantor has been received by such Grantor in the past twelve (12) months, alleging any such violation, except as may be set forth on Schedule 4, 5 or 6 (as so supplemented).

Exhibit H-9

Section 2.07. Deposit Accounts, Securities Accounts and Commodity Accounts. Schedule 7 sets forth a complete and correct list of all Deposit Accounts, Securities Accounts and Commodity Accounts, in each case indicating any Excluded Accounts, of such Grantor on the date hereof.

Section 2.08. Commercial Tort Claims. Schedule 8 sets forth a complete and correct list of all Commercial Tort Claims of such Grantor having a value reasonably believed by such Grantor to be in excess of $250,000 on the date hereof.

Section 2.09. Update of Schedules. Each of Schedules 1 through 8 may be updated by Grantors from time to time to insure the continued accuracy of the representations set forth in this Section 2 to be made on any upcoming date on which representations and warranties are made incorporating the information in such Schedule, by Borrower providing notice (attaching an amended and restated version of such Schedule) in accordance with Section 14.02 of the Credit Agreement, or at such other times and in such manner and as set forth in the Credit Agreement.

SECTION 3. Collateral

Section 3.01. Granting Clause. As collateral security for the payment in full when due (whether at stated maturity, by acceleration or otherwise) of the Secured Obligations, each Grantor hereby pledges and grants to Administrative Agent, for the benefit of the Secured Parties, a Lien in all of such Grantor’s right, title and interest in, to and under all of its property, in each case whether tangible or intangible, wherever located, and whether now owned by such Grantor or hereafter acquired and whether now existing or hereafter coming into existence, including without limitation all of the following, but excluding all Excluded Assets (collectively, and subject to the proviso at the end of this Section 3.01, “Collateral”):

(a) all Accounts (including all trade receivables);

(b) all Chattel Paper and other Records;

(c) all Checks;

(d) all Commercial Tort Claims;

(e) all Deposit Accounts, all cash, and all other property from time to time deposited therein or otherwise credited thereto and the monies and property in the possession or under the control of Administrative Agent or any Grantor or any of its Affiliates, representative, agent or correspondent of Administrative Agent or any Grantor;

(f) all Documents;

(g) all Encumbrances;

Exhibit H-10

(h) all Equipment;

(i) all Fixtures;

(j) all General Intangibles (including in respect of any intercompany Indebtedness);

(k) all Goods not otherwise described in this Section 3;

(l) all Instruments, including all Promissory Notes and any Instrument evidencing any intercompany Indebtedness;

(m) all Intellectual Property;

(n) all Inventory;

(o) all Letter of Credit Rights and all Supporting Obligations;

(p) all Investment Property not otherwise described in this Section 3, including all Securities, all Securities Accounts and all Security Entitlements with respect thereto and Financial Assets carried therein, and all Commodity Accounts and Commodity Contracts;

(q) all Pledged Shares;

(r) all other tangible and intangible personal property of such Grantor (whether or not subject to the UCC), including, without limitation, all bank and other accounts and all cash and all investments therein, all proceeds, products, offspring, accessions, rents, profits, income, benefits, substitutions and replacements of and to any of the property of such Grantor described in the preceding clauses of this Section 3.01 (including, without limitation, any proceeds of insurance thereon and all causes of action, claims and warranties now or hereafter held by such Grantor in respect of any of the items listed above), and all books, correspondence, files, invoices and other Records, including, without limitation, all tapes, disks, cards, Software, data and computer programs in the possession or under the control of such Grantor or any other Person from time to time acting for such Grantor that at any time evidence or contain information relating to any of the property described in the preceding clauses of this Section 3.01 or are otherwise necessary or helpful in the collection or realization thereof; and

(s) all Proceeds, including all Cash Proceeds and Noncash Proceeds, of any and all of the foregoing Collateral;

in each case howsoever such Grantor’s interest therein may arise or appear (whether by ownership, security interest, claim or otherwise); provided, however, that, nothing set forth in this Section 3.01 or any other provision of this Agreement or any other Loan Document shall at any time constitute the grant of a security interest in, or a Lien on, any Excluded Asset, none of which shall constitute Collateral. For the avoidance of doubt, Administrative Agent agrees that with respect to the Intellectual Property, the rights of the licensees under the licenses permitted by the Credit Agreement will not be terminated, limited or otherwise adversely affected by (i) the execution of or (ii) the exercise of Administrative Agent’s rights under this Agreement or any other Loan Document.

Exhibit H-11

SECTION 4. Further Assurances; Remedies

In furtherance of the grant of the security interest pursuant to Section 3, Grantors hereby jointly and severally agree with Administrative Agent as follows:

Section 4.01. Delivery and Other Perfection. Each Grantor shall promptly from time to time give, execute, deliver, file, record, authorize or obtain all such financing statements, continuation statements, notices, instruments, documents, agreements or consents or other papers as may be necessary or desirable in the judgment of the Administrative Agent to create, preserve, perfect, maintain the perfection of or validate the security interest granted pursuant hereto or to enable Administrative Agent to exercise and enforce their rights hereunder with respect to such security interest, and without limiting the foregoing, shall:

(a) if any of the Pledged Shares, Investment Property or Financial Assets constituting part of the Collateral are received by Grantor, forthwith (x) deliver to Administrative Agent the certificates or instruments representing or evidencing the same, duly endorsed in blank or accompanied by such instruments of assignment and transfer in such form and substance as Administrative Agent may reasonably request, all of which thereafter shall be held by Administrative Agent, pursuant to the terms of this Agreement, as part of the Collateral and (y) take such other action as Administrative Agent may deem necessary or appropriate to duly record or otherwise perfect the security interest created hereunder in such Collateral;

(b) deliver to Administrative Agent any and all Instruments constituting part of the Collateral, endorsed and/or accompanied by such instruments of assignment and transfer in such form and substance as Administrative Agent may reasonably request; provided, that (other than in the case of the Promissory Notes described in Schedule 3) until the occurrence and during the continuation of an Event of Default, such Grantor may retain for collection in the ordinary course any Instruments received by such Grantor and Administrative Agent shall, promptly upon request of such Grantor, make appropriate arrangements for making any Instrument delivered by such Grantor available to such Grantor for purposes of presentation, collection or renewal (any such arrangement to be effected, to the extent reasonably requested by Administrative Agent, against trust receipt or like document);

(c) subject to the terms and conditions of Section 8.16 of the Credit Agreement, promptly from time to time enter into such control agreements, each in form and substance acceptable to the Administrative Agent, as may be required to perfect the security interest created hereby in any and all (i) Deposit Accounts, Securities Accounts and Commodity Accounts owned by the Obligors in the United States (other than Excluded Accounts), and (ii) Investment Property, Electronic Chattel Paper and Letter of Credit Rights (except with respect to Pledged Shares, other than any such property described in this subclause (ii) that does not exceed $100,000 in value at any time, unless the aggregate value of such property exceeds $500,000), and will promptly furnish to Administrative Agent true copies thereof; and

Exhibit H-12

(d) promptly from time to time upon the written request of Administrative Agent, take such other action as the Administrative Agent may reasonably deem necessary or appropriate duly to record or otherwise perfect the security interest created hereunder in that portion of the Collateral consisting of Intellectual Property.

Section 4.02. Other Financing Statements or Control. Except as otherwise permitted under the Loan Documents, no Grantor shall (a) file or suffer to be on file, or authorize or permit to be filed or to be on file, in any jurisdiction, any financing statement or like instrument with respect to any of the Collateral in which the Administrative Agent is not named as the sole secured party (except to the extent that such financing statement or instrument relates to a Permitted Lien), or (b) cause or permit any Person other than Administrative Agent or any holder of a Permitted Priority Lien to have “control” (as defined in Section 9-104, 9-105, 9-106 or 9-107 of the UCC) of any Deposit Account, Securities Account or Commodity Account (in each case other than Excluded Accounts), Electronic Chattel Paper, Investment Property or Letter of Credit Right constituting part of the Collateral.

Section 4.03. Preservation of Rights. Administrative Agent shall not be required to take steps necessary to preserve any rights against prior parties to any of the Collateral.

Section 4.04. Special Provisions Relating to Certain Collateral.

(a) Pledged Shares. (i) Grantors will cause the Pledged Shares to constitute at all times 100% of the total number of Shares that are not Excluded Shares of each Issuer then outstanding owned by Grantors.

(ii) Until the occurrence and during the continuation of an Event of Default, and upon receipt of written notice from Administrative Agent to Grantors with respect to the discontinuance of such voting and other rights, Grantors shall have the right to exercise all voting, consensual and other powers of ownership pertaining to the Pledged Shares for all purposes not inconsistent with the terms of this Agreement or the other Loan Documents, provided that Grantors jointly and severally agree that they will not vote the Pledged Shares in any manner that is inconsistent with the terms of this Agreement or the other Loan Documents; and Administrative Agent shall execute and deliver to Grantors or cause to be executed and delivered to Grantors all such proxies, powers of attorney, dividend and other orders, and all such instruments, without recourse, as Grantors may reasonably request for the purpose of enabling Grantors to exercise the rights and powers that they are entitled to exercise pursuant to this Section 4.04(a)(ii).

(iii) Until the occurrence and during the continuation of an Event of Default, and upon receipt of written notice from Administrative Agent to Grantors with respect to the discontinuance of such Grantors retaining such dividends and other amounts; Grantors shall be entitled to receive and retain any dividends, distributions or proceeds on the Pledged Shares.

Exhibit H-13

(iv) After the occurrence and during the continuation of an Event of Default, and upon receipt of written notice from Administrative Agent to Grantors with respect to the discontinuance of such Grantors retaining such dividends and other amounts, whether or not Administrative Agent exercises any available right to declare any Secured Obligations due and payable or seeks or pursues any other relief or remedy available to it under applicable law or under this Agreement, the other Loan Documents or any other agreement relating to such Secured Obligation, all dividends and other distributions on the Pledged Shares shall be paid directly to Administrative Agent for distribution to Secured Parties and retained by them as part of the Collateral, subject to the terms of this Agreement, and, if Administrative Agent shall so request in writing, Grantors jointly and severally agree to execute and deliver to Administrative Agent appropriate additional dividend, distribution and other orders and documents to that end, provided, that if such Event of Default is no longer continuing, any such dividend or distribution theretofore paid to Administrative Agent shall, upon request of Grantors (except to the extent theretofore applied to the Secured Obligations), be returned by Administrative Agent to Grantors.

(b) Intellectual Property. (i)  Each Grantor hereby grants to Administrative Agent, with effect from the occurrence of an Event of Default that is continuing, solely to the extent assignable, not otherwise prohibited by the documentation governing such Intellectual Property, a non-exclusive license (exercisable without payment of royalty or other compensation to such Grantor) to use, and the right to assign, license or sublicense, any of the Intellectual Property now owned or hereafter acquired by such Grantor, wherever the same may be located, solely for the purpose of enabling the Administrative Agent to exercise rights and remedies under Section 4.05 at such time as the Administrative Agent shall be lawfully entitled to exercise such rights and remedies after the occurrence and during the continuation of an Event of Default, and for no other purpose. Such license includes reasonable access to all media in which any of the licensed items may be recorded or stored and to all computer programs used for the compilation or printout thereof.

(ii) Notwithstanding anything contained herein to the contrary, but subject to any provision of the Loan Documents that limits the rights of any Grantor to dispose of its property, until the occurrence and during the continuation of an Event of Default, Grantors will be permitted to exploit, use, enjoy, protect, defend, enforce, license, sublicense, assign, sell, dispose of or take other actions with respect to the Intellectual Property in the ordinary course of the business of Grantors. In furtherance of the foregoing, unless an Event of Default has occurred and is continuing, Administrative Agent shall from time to time, upon the request of the respective Grantor, execute and deliver any instruments, certificates or other documents, in the form so requested, that such Grantor shall have certified are appropriate in its judgment to allow it to take any action permitted above (including relinquishment of the license provided pursuant to Section 4.04(b)(i) as to any specific Intellectual Property). Further, upon the payment in full of all of the Secured Obligations (other than contingent indemnification obligations for which no claim has been made or other obligations which, by their terms, survive termination of the Credit Agreement and the Warrant Obligations) or earlier expiration of this Agreement or release of the Collateral, Administrative Agent shall grant back to Grantors and otherwise terminate the license granted pursuant to Section 4.04(b)(i). The exercise of rights and remedies under Section 4.05 by the Administrative Agent shall not terminate the rights of the holders of any licenses, covenants not to xxx or sublicenses theretofore granted by Grantors in accordance with the first sentence of this Section 4.04(b)(ii).

Exhibit H-14

(c) Chattel Paper. Grantors will deliver to Administrative Agent each original of each item of Chattel Paper at any time constituting part of the Collateral.

Section 4.05. Remedies.

(a) Rights and Remedies Generally upon Event of Default. Upon the occurrence and during the continuation of an Event of Default, the Administrative Agent on behalf of the Secured Parties shall have all of the rights and remedies with respect to the Collateral of a secured party under the UCC (whether or not the Uniform Commercial Code is in effect in the jurisdiction where the rights and remedies are asserted) and such additional rights and remedies to which a secured party is entitled under the Law in effect in any jurisdiction where any rights and remedies hereunder may be asserted, including the right, to the fullest extent permitted by Law, to exercise all voting, consensual and other powers of ownership pertaining to the Collateral as if the Administrative Agent was the sole and absolute owner thereof (and each Grantor agrees to take all such action as may be appropriate to give effect to such right). Upon the occurrence of and during the continuation of an Event of Default, the Administrative Agent may exercise, on behalf of all Secured Parties, such rights and remedies described above; and without limiting the foregoing:

(i) Administrative Agent may, in its name or in the name of any Grantor or otherwise, demand, xxx for, collect or receive any money or other property at any time payable or receivable on account of or in exchange for any of the Collateral, but shall be under no obligation to do so;

(ii) Administrative Agent may make any reasonable compromise or settlement deemed desirable with respect to any of the Collateral and may extend the time of payment, arrange for payment in installments, or otherwise modify the terms of, any of the Collateral;

(iii) Administrative Agent may require Grantors to notify (and each Grantor hereby authorizes Administrative Agent to so notify) each account debtor in respect of any Account, Chattel Paper or General Intangible, and each obligor on any Instrument, constituting part of the Collateral that such Collateral has been assigned to Administrative Agent hereunder, and to instruct that any payments due or to become due in respect of such Collateral shall be made directly to Administrative Agent or as it may direct (and if any such payments, or any other Proceeds of Collateral, are received by any Grantor they shall be held in trust by such Grantor for the benefit of Administrative Agent and as promptly as possible remitted or delivered to Administrative Agent for application as provided herein);

(iv) Administrative Agent may require Grantors to assemble the Collateral at such place or places, convenient to Administrative Agent and Grantors, as Administrative Agent may direct;

Exhibit H-15

(v) Administrative Agent may require Grantors to cause the Pledged Shares to be transferred of record into the name of Administrative Agent or its nominee (and Administrative Agent agrees that if any of such Pledged Shares is transferred into its name or the name of its nominee, Administrative Agent will thereafter promptly give to the respective Grantor copies of any notices and communications received by it with respect to such Pledged Shares);

(vi) Administrative Agent may sell, lease, assign or otherwise dispose of all or any part of the Collateral, at such place or places as Administrative Agent deems best, and for cash or for credit or for future delivery (without thereby assuming any credit risk), at public or private sale, without demand of performance or notice of intention to effect any such disposition or of the time or place thereof (except such notice as is required by applicable statute and cannot be waived), and the Secured Parties, Administrative Agent or anyone else may be the purchaser, lessee, assignee or recipient of any or all of the Collateral so disposed of at any public sale (or, to the extent permitted by law, at any private sale) and thereafter hold the same absolutely, free from any claim or right of whatsoever kind, including any right or equity of redemption (statutory or otherwise), of Grantors, any such demand, notice and right or equity being hereby expressly waived and released. In the event of any sale, assignment, or other disposition of any of the Collateral consisting of Trademarks, the goodwill connected with and symbolized by the Trademarks subject to such disposition shall be included. Administrative Agent may, without notice or publication, adjourn any public or private sale or cause the same to be adjourned from time to time by announcement at the time and place fixed for the sale, and such sale may be made at any time or place to which the sale may be so adjourned; and

(vii) the Proceeds of each collection, sale or other disposition under this Section 4.05, including by virtue of the exercise of any license granted to Administrative Agent in Section 4.04(b), shall be applied in accordance with Section 4.09.

(b) Certain Securities Act Limitations. Grantors recognize that, by reason of certain prohibitions contained in the Securities Act of 1933, as amended, and applicable state securities laws, Administrative Agent may be compelled, with respect to any sale of all or any part of the Collateral, to limit purchasers to those who will agree, among other things, to acquire the Collateral for their own account, for investment and not with a view to the distribution or resale thereof. Grantors acknowledge that any such private sales may be at prices and on terms less favorable to Administrative Agent than those obtainable through a public sale without such restrictions, and, notwithstanding such circumstances, agree that any such private sale shall be deemed to have been made in a commercially reasonable manner and that Administrative Agent shall have no obligation to engage in public sales and no obligation to delay the sale of any Collateral for the period of time necessary to permit the issuer thereof to register it for public sale.

(c) Notice. Grantors agree that to the extent Administrative Agent is required by applicable law to give reasonable prior notice of any sale or other disposition of any Collateral, ten business days’ notice shall be deemed to constitute reasonable prior notice.

Exhibit H-16

(d) No Assumption of Obligations. Notwithstanding any provision in this Agreement or any other Loan Document to the contrary, Administrative Agent is not assuming any liability or obligation of any Grantor or any of its Affiliates of whatever nature, whether presently in existence or arising or asserted hereafter. All such liabilities and obligations shall be retained by and remain obligations and liabilities of the applicable Grantor and/or its Affiliates, as the case may be. Without limiting the foregoing, Administrative Agent is not assuming and shall not be responsible for any liabilities or Claims of any Grantor or its Affiliates, whether present or future, absolute or contingent and whether or not relating to a Grantor, the Obligor Intellectual Property and/or the Material Agreements, and each Grantor shall indemnify and save harmless Administrative Agent from and against all such liabilities, Claims and Liens.

Section 4.06. Deficiency. If the proceeds of sale, collection or other realization of or upon the Collateral pursuant to Section 4.05 are insufficient to cover the costs and expenses of such realization and the indefeasible payment in full in cash of the Secured Obligations (other than contingent indemnification obligations for which no claim has been made or other obligations which, by their terms, survive termination of the Credit Agreement and the Warrant Obligations), Grantors shall remain liable for any deficiency.

Section 4.07. Locations, Names, Etc . No Grantor shall (i) change its location (as defined in Section 9-307 of the UCC), or (ii) change its name from the name shown as its current legal name on Schedule 1 unless in each case 10 days’ prior written notice shall have been given to the Administrative Agent (or such shorter period as may be acceptable to Administrative Agent in its sole discretion).

Section 4.08. Private Sale. The Administrative Agent shall incur no liability as a result of the sale of the Collateral, or any part thereof, at any private sale pursuant to Section 4.05 conducted in a commercially reasonable manner. Each Grantor hereby waives any claims against Administrative Agent, the Secured Parties or any of them arising by reason of the fact that the price at which the Collateral may have been sold at such a private sale was less than the price that might have been obtained at a public sale or was less than the aggregate amount of the Secured Obligations, even if Administrative Agent accepts the first offer received and does not offer the Collateral to more than one offeree.

Section 4.09. Application of Proceeds. The Proceeds of any collection, sale or other realization of all or any part of the Collateral pursuant hereto, and any other cash at the time held by Administrative Agent under this Section 4, shall be applied by Administrative Agent, in Administrative Agent’s sole discretion, in accordance with (x) Section 4.01(b) of the Credit Agreement and/or (y) Section 4.01(b) of the Icagen-T Credit Agreement.

Section 4.10. Attorney in Fact and Proxy. Without limiting any rights or powers granted by this Agreement to the Administrative Agent on behalf of the Secured Parties, upon the occurrence and during the continuation of an Event of Default, Administrative Agent (and any of its officers, employees or agents) hereby is appointed the attorney in fact and proxy of each Grantor for the purpose of carrying out the provisions of this Section 4 and taking any action and executing any instruments that Administrative Agent may deem necessary or advisable to accomplish the purposes hereof. THIS POWER AND PROXY IS COUPLED WITH AN INTEREST AND IS IRREVOCABLE UNTIL THE PAYMENT IN FULL OF THE SECURED OBLIGATIONS. THIS POWER AND PROXY SHALL BE EFFECTIVE AUTOMATICALLY AND WITHOUT THE NECESSITY OF ANY ACTION BY ANY PERSON. Each Grantor ratifies all actions taken by the Administrative Agent pursuant to this power and proxy granted.  All prior proxies granted by any Grantor with respect to the subject matter hereof are hereby revoked. Without limiting the generality of the foregoing, so long as Administrative Agent shall be entitled under this Section 4 to make collections in respect of the Collateral, Administrative Agent shall have the right and power to receive, endorse and collect all checks made payable to the order of any Grantor representing any dividend, payment or other distribution in respect of the Collateral or any part thereof and to give full discharge for the same.

Exhibit H-17

Section 4.11. Perfection and Recordation. Each Grantor authorizes the Administrative Agent to file Uniform Commercial Code financing statements describing the Collateral as “all assets” or “all personal property and fixtures” of such Grantor (provided that no such description shall be deemed to modify the description of Collateral set forth in Section 3).

Section 4.12. Termination. When all Secured Obligations (other than contingent indemnification obligations for which no claim has been made or other obligations which, by their terms, survive termination of the Credit Agreement and the Warrant Obligations) shall have been indefeasibly paid in full, this Agreement automatically shall terminate, and the Administrative Agent shall, upon request of Grantors, promptly cause to be assigned, transferred and delivered any remaining Collateral and money received in respect thereof, to or on the order of the respective Grantor and to be released and canceled all licenses and rights referred to in Section 4.04(b), in each case, at Grantors’ sole expense. The Administrative Agent shall also, at the expense of such Grantor, promptly execute and deliver to such Grantor upon such termination such Uniform Commercial Code termination statements, certificates for terminating the liens on the intellectual property filings and such other documentation as shall be reasonably requested by the respective Grantor to effect the termination and release of the liens on the Collateral as required by this Section 4.12, in each case, at Grantors’ sole expense. If any of the Collateral shall be sold, transferred or otherwise disposed of by Grantor in a transaction permitted by the Credit Agreement or if such Collateral otherwise becomes Excluded Assets, then Administrative Agent, at Grantors’ sole expense, shall execute and deliver to such Grantor all releases or other documents reasonably necessary or desirable for the release of the Liens created hereby on such Collateral.

Section 4.13. Further Assurances. Each Grantor agrees that, from time to time upon the written request of the Administrative Agent, such Grantor will execute and deliver such further documents and do such other acts and things as the Administrative Agent may reasonably request in order fully to effectuate the purposes and objectives of this Agreement, in all cases subject to the terms of the Credit Agreement and excluding such documents, acts and things where the cost of obtaining or perfecting a security interest exceeds the practical benefit to the Lenders afforded thereby as reasonably determined by the Administrative Agent (in its sole discretion after consultation with Borrower or the applicable Grantor). The Administrative Agent shall release any Lien covering any asset that has been disposed of in accordance with the provisions of the Loan Documents.

Exhibit H-18

SECTION 5. Miscellaneous

Section 5.01. Notices. All notices, requests, consents and demands hereunder shall be delivered in accordance with Section 14.02 of the Credit Agreement.

Section 5.02. No Waiver. No failure on the part of the Administrative Agent to exercise, and no course of dealing with respect to, and no delay in exercising, any right, power or remedy hereunder shall operate as a waiver thereof; nor shall any single or partial exercise by the Administrative Agent of any right, power or remedy hereunder preclude any other or further exercise thereof or the exercise of any other right, power or remedy. The remedies herein are cumulative and are not exclusive of any remedies provided by law.

Section 5.03. Amendments, Etc. The terms of this Agreement may be waived, altered or amended only by an instrument in writing duly executed by each Grantor and the Majority Lenders (unless the consent of each Lender is required in accordance with Section 14.04 of the Credit Agreement).

Section 5.04. Expenses.

(a) Grantors shall pay or reimburse Administrative Agent for costs and expenses in accordance with Section 14.03 of the Credit Agreement.

(b) Grantors shall hereby indemnify the Administrative Agent, the Secured Parties, their Affiliates, and their respective directors, officers, employees, attorneys, agents, advisors and controlling parties in accordance with Section 14.03(c) of the Credit Agreement.

Section 5.05. Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the respective successors and assigns of each Grantor, Administrative Agent and the Secured Parties (provided, that no Grantor shall assign or transfer its rights or obligations hereunder unless consented to in writing by the Lenders in accordance with the Credit Agreement).

Section 5.06. Counterparts. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument and any of the parties hereto may execute this Agreement by signing any such counterpart.

Section 5.07. Governing Law; Submission to Jurisdiction; Etc.

(a) Governing Law. This Agreement and the rights and obligations of the parties hereunder shall be governed by, and construed in accordance with, the law of the State of New York, without regard to principles of conflicts of laws that would result in the application of the laws of any other jurisdiction; provided, that Section 5-1401 of the New York General Obligations Law shall apply.

Exhibit H-19

(b) Submission to Jurisdiction. Each Grantor agrees that any suit, action or proceeding with respect to this Agreement or any other Loan Document to which it is a party or any judgment entered by any court in respect thereof may be brought in the Supreme Court of the State of New York sitting in New York County or in the United States District Court for the Southern District of New York and irrevocably submits to the exclusive jurisdiction of each such court for the purpose of any such suit, action, proceeding or judgment. This Section 5.07(b) is for the benefit of the Administrative Agent only and, as a result, Administrative Agent shall not be prevented from taking proceedings in any other courts located in the United States with jurisdiction, or to the extent assets of a Grantor are or may be located in a foreign jurisdiction, in such foreign jurisdiction. To the extent allowed by applicable Laws, the Administrative Agent may take concurrent proceedings in any number of jurisdictions located in the United States and any foreign jurisdictions where the assets of any Grantor are or may be located.

(c) Waiver of Venue. Each Grantor irrevocably waives to the fullest extent permitted by law any objection that it may now or hereafter have to the laying of the venue of any suit, action or proceeding arising out of or relating to this Agreement and hereby further irrevocably waives to the fullest extent permitted by law any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum. A final judgment (in respect of which time for all appeals has elapsed) in any such suit, action or proceeding shall be conclusive and may be enforced in any court to the jurisdiction of which such Grantor is or may be subject, by suit upon judgment.

(d) Service of Process. Each party to this Agreement irrevocably consents to service of process in the manner provided for notices in Section 5.01. Nothing in this Agreement will affect the right of any party to this Agreement to serve process in any other manner permitted by applicable law.

Section 5.08. Waiver of Jury Trial. Each Party hereto hereby waives, to the fullest extent permitted by applicable law, any right it may have to a trial by jury in any legal proceeding directly or indirectly arising out of or relating to this agreement or the transactions contemplated hereby.

Section 5.09. Captions. The table of contents, captions and section headings appearing herein are included solely for convenience of reference and are not intended to affect the interpretation of any provision of this Agreement.

Section 5.10. Agents and Attorneys in Fact. The Administrative Agent may employ agents and attorneys in fact in connection herewith and except for gross negligence or willful misconduct shall not be responsible for the negligence or misconduct of any such agents or attorneys in fact selected by it in good faith.

Section 5.11. Severability. If any provision hereof is found by a court to be invalid or unenforceable, to the fullest extent permitted by applicable law the parties agree that such invalidity or unenforceability shall not impair the validity or enforceability of any other provision hereof.

Section 5.12. Additional Grantors. Additional Persons may from time to time after the date of this Agreement become Grantors under this Agreement by executing and delivering to Administrative Agent a supplemental agreement (together with all schedules thereto, a “Joinder”) to this Agreement, in substantially the form attached hereto as Exhibit A. Accordingly, upon the execution and delivery of any such Joinder by any such Person, such Person shall automatically and immediately, and without any further action on the part of any Person, become a “Grantor” under and for all purposes of this Agreement, and each of the Schedules hereto shall be supplemented in the manner specified in such Joinder. In addition, upon the execution and delivery of any such Joinder, the new Grantor makes the representations and warranties set forth in Section 2 subject to the Schedules set forth in the Joinder.

[Signature Pages Follow]

Exhibit H-20

IN WITNESS WHEREOF, the parties hereto have caused this Security Agreement to be duly executed and delivered as of the day and year first above written.

	GRANTORS:
	Icagen, Inc.
	By:	/s/ Xxxxxxx Xxxxxxxxxx
		Name: Xxxxxxx Xxxxxxxxxx
		Title: Chief Executive Officer
	Icagen Corp.
	By:	/s/ Xxxxxxx Xxxxxxxxxx
		Name: Xxxxxxx Xxxxxxxxxx
		Title: Chief Executive Officer
	Caldera Discovery, Inc.
	By:	/s/ Xxxxxxx Xxxxxxxxxx
		Name: Xxxxxxx Xxxxxxxxxx
		Title: Chief Executive Officer
	XRPro Sciences, Inc.
	By:	/s/ Xxxxxxx Xxxxxxxxxx
		Name: Xxxxxxx Xxxxxxxxxx
		Title: Chief Executive Officer

signature page
security agreement

Exhibit H-21

	Accepted and agreed to as of the date first above written.
	Perceptive Credit Holdings II, LP, as Administrative Agent
	By: Perceptive Credit Opportunities GP, LLC, its general partner
	By:	/s/ Xxxxxxx Xxxxx
		Name: Xxxxxxx Xxxxx
		Title: Chief Credit Officer
	By:	/s/ Xxx Xxxxxx
		Name: Xxx Xxxxxx
		Title: Portfolio Manager

signature page
security agreement

Exhibit H-22

EXHIBIT A

to Security Agreement

FORM OF JOINDER AGREEMENT

This Joinder Agreement (this “Joinder”), dated as of [_______, ___] is by [Name of Additional Grantor], a [__________] [corporation] (the “Additional Grantor”), in favor of Perceptive Credit Holdings II, LP, as collateral agent (in such capacity, the “Administrative Agent”) for the Secured Parties.

A. Reference is made to (i) that certain Credit Agreement and Guaranty (as amended, supplemented, restated, extended, renewed or replaced from time to time, the “Credit Agreement”), dated as of August 31, 2018 among Icagen, Inc., a Delaware corporation (“Borrower”), certain Grantors party thereto, certain Lenders party thereto and the Administrative Agent, and (ii) that certain Security Agreement (as amended, supplemented, restated, extended, renewed or replaced from time to time, the “Security Agreement”; capitalized terms used herein but not defined shall have the meaning ascribed to such terms therein), dated as of August 31, 2018, among certain Grantors party thereto and the Administrative Agent.

B. Section 5.12 of the Security Agreement provides that additional Persons may from time to time after the date of the Security Agreement become Grantors under the Security Agreement by executing and delivering to the Administrative Agent a supplemental agreement to the Security Agreement in the form of this Joinder.

C. To induce the Secured Parties to maintain the term loans pursuant to the Credit Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Additional Grantor has agreed to execute and deliver (i) a Guarantee Assumption Agreement under the Credit Agreement, and (ii) this Joinder to the Administrative Agent.

The Additional Grantor hereby agrees to become a “Grantor” for all purposes of the Security Agreement (and hereby supplements each of the Schedules to the Security Agreement in the manner specified in Appendix A hereto). Without limitation, as collateral security for the payment in full when due (whether at stated maturity, by acceleration or otherwise) of the Secured Obligations, the Additional Grantor hereby pledges and grants to the Administrative Agent, for the benefit of the Secured Parties, as provided in Section 3 of the Security Agreement a security interest in all of the Additional Grantor’s right, title and interest in, to and under the Collateral of the Additional Grantor, in each case whether tangible or intangible, wherever located, and whether now owned by the Additional Grantor or hereafter acquired and whether now existing or hereafter coming into existence. In addition, subject to the Schedules attached hereto, the Additional Grantor hereby makes the representations and warranties set forth in Section 2 of the Security Agreement, with respect to itself and its obligations under this Joinder, as if each reference in such Sections to the Loan Documents included reference to this Joinder.

[SIGNATURE PAGES FOLLOW]

Exhibit H-23

In Witness Whereof, the Additional Grantor has caused this Joinder Agreement to be duly executed and delivered as of the day and year first above written.

[Insert Name of Additional Grantor],

as Grantor

By:

Name:

Title:

Perceptive Credit Holdings II, LP,

as Administrative Agent

By: Perceptive Credit Opportunities GP, LLC,

its general partner

By:

Name:

Title:

By:

Name:

Title:

Exhibit H-24

SCHEDULE 1

Certain Grantor Information

Name of Entity		Jurisdiction of Incorporation		Federal Employer ID Number		Organizational ID		Address
Icagen, Inc. (formerly known as Caldera Pharmaceuticals, Inc. and XRpro Sciences, Inc.)		Delaware		00-0000000		3723366		0000 Xxxxxxx Xxxx, Xxxxx 000 Xxxxxx, XX 00000
Icagen Corp. (formerly XRpro Corp.)		Nevada		00-0000000		NV20101523783		0000 Xxxxxxx Xxxx, Xxxxx 000 Xxxxxx, XX 00000
Caldera Discovery, Inc.		Delaware		00-0000000		5717856		0000 Xxxxxxx Xxxx, Xxxxx 000 Xxxxxx, XX 00000
XRpro Sciences, Inc.		Delaware		Not applied for		5904530		0000 Xxxxxxx Xxxx, Xxxxx 000 Xxxxxx, XX 00000

***

Exhibit H-25

SCHEDULE 2

Pledged Shares

Grantor		Issuer		Number of Shares		Class		Certificate No.(s)
Icagen, Inc.		Icagen Corp.		100,000		Common		C-02
Icagen, Inc.		Caldera Discovery, Inc.		1,000		Common		C-02
Icagen, Inc.		XRpro Sciences, Inc.		100		Common		C-01

***

Exhibit H-26

SCHEDULE 3

Promissory Notes

None

***

Exhibit H-27

SCHEDULE 4

Copyrights, Copyright Registrations and Applications for Copyright Registrations

None

***
 

Exhibit H-28

SCHEDULE 5

Patents and Patent Applications

Owner

Title

Country

Application No.

Pub. No.

Patent No.

Status

Icagen, Inc.

METHOD FOR DETECTING BINDING EVENTS USING MICRO-X-RAY FLUORESCENCE SPECTROMETRY

United States

09/859,701

2003-0027129

7,858,385

Patented

Icagen, Inc.

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

Europe

3748920

1525458

1525458

Patented

Icagen, Inc.

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

Belgium

3748920

1525458

1525458

Patented

Icagen, Inc.

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

Switzerland/ Liechtenstein

3748920

1525458

1525458

Patented

Icagen, Inc.

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

Germany

3748920

1525458

1525458

Patented

Exhibit H-29

Owner

Title

Country

Application No.

Pub. No.

Patent No.

Status

Icagen, Inc.

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

Denmark

3748920

1525458

1525458

Patented

Icagen, Inc.

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

Spain

3748920

1525458

1525458

Patented

Icagen, Inc.

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

Finland

3748920

1525458

1525458

Patented

Icagen, Inc.

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

France

3748920

1525458

1525458

Patented

Icagen, Inc.

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

United Kingdom

3748920

1525458

1525458

Patented

Exhibit H-30

Owner

Title

Country

Application No.

Pub. No.

Patent No.

Status

Icagen, Inc.

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

Italy

3748920

1525458

1525458

Patented

Icagen, Inc.

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

Sweden

3748920

1525458

1525458

Patented

Icagen, Inc.

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

Netherlands

3748920

1525458

1525458

Patented

Icagen, Inc.

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

Japan

2004-524531

2006-503268

4560403

Patented

Icagen, Inc.

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

Singapore

200500360-3

109345

109345

Patented

Exhibit H-31

Owner

Title

Country

Application No.

Pub. No.

Patent No.

Status

Icagen, Inc.

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

United States

11/444,660

2007-0003008

7,519,145

Patented

Icagen, Inc.

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

United States

12/396,592

2009-0175410

7,929,662

Patented

Icagen, Inc.

METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING

Europe

4755687.3

1644095

1644095

Patented

Icagen, Inc.

METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING

Switzerland/ Liechtenstein

4755687.3

1644095

1644095

Patented

Icagen, Inc.

METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING

Germany

4755687.3

1644095

1644095

Patented

Icagen, Inc.

METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING

France

4755687.3

1644095

1644095

Patented

Exhibit H-32

Owner

Title

Country

Application No.

Pub. No.

Patent No.

Status

Icagen, Inc.

METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING

United Kingdom

4755687.3

1644095

1644095

Patented

Icagen, Inc.

METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING

Ireland

4755687.3

1644095

1644095

Patented

Icagen, Inc.

METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING

Netherlands

4755687.3

1644095

1644095

Patented

Icagen, Inc.

METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING

Japan

2006-520181

2007527524

4782676

Patented

Icagen, Inc.

METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING

Singapore

2005085584

118682

Patented

Icagen, Inc.

METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING

United States

10/621,825

2005-0011818

6,858,148

Patented

Icagen, Inc.

METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING

United States

10/986,519

2005-0095636

7,241,381

Patented

Exhibit H-33

Owner

Title

Country

Application No.

Pub. No.

Patent No.

Status

Icagen, Inc.

DRUG DEVELOPMENT AND MANUFACTURING

United States

10/880,388

2004-0235059

9,157,875

Patented

Icagen, Inc.

X-RAY FLUORESCENCE ANALYSIS METHOD

Europe

7874491.9

2084519

2084519

Patented

Icagen, Inc.

X-RAY FLUORESCENCE ANALYSIS METHOD

Switzerland/ Liechtenstein

07 874 491.9

2084519

2084519

Patented

Icagen, Inc.

X-RAY FLUORESCENCE ANALYSIS METHOD

Germany

60 2007 024 468.4

2084519

608007024468.4

Patented

Icagen, Inc.

X-RAY FLUORESCENCE ANALYSIS METHOD

Denmark

07 874 491.9

2084519

2084519

Patented

Icagen, Inc.

X-RAY FLUORESCENCE ANALYSIS METHOD

France

07 874 491.9

2084519

2084519

Patented

Icagen, Inc.

X-RAY FLUORESCENCE ANALYSIS METHOD

United Kingdom

7874491.9

2084519

2084519

Patented

Icagen, Inc.

ADVANCED DRUG DEVELOPMENT AND MANUFACTURING

Hong Kong (via EP -005EPDV)

13104259.3

1177280

1177280

Patented

Icagen, Inc.

X-RAY FLUORESCENCE ANALYSIS METHOD

Ireland

7874491.9

1177280

2084519

Patented

Exhibit H-34

Owner

Title

Country

Application No.

Pub. No.

Patent No.

Status

Icagen, Inc.

X-RAY FLUORESCENCE ANALYSIS METHOD

Italy

7874491.9

1177280

2084519

Patented

Icagen, Inc.

X-RAY FLUORESCENCE ANALYSIS METHOD

Netherlands

7874491.9

1177280

2084519

Patented

Icagen, Inc.

X-RAY FLUORESCENCE ANALYSIS METHOD

Sweden

7874491.9

1177280

2084519

Patented

Icagen, Inc.

X-RAY MICROSCOPE

Europe

12164870.3

2511844

2511844

Patented

Icagen, Inc.

X-RAY MICROSCOPE

Switzerland and Lichtenstein

12164870.3

2511844

2511844

Patented

Icagen, Inc.

X-RAY MICROSCOPE

Germany

12164870.3

2511844

602007042616.2

Patented

Icagen, Inc.

X-RAY MICROSCOPE

France

12164870.3

2511844

2511844

Patented

Icagen, Inc.

X-RAY MICROSCOPE

United Kingdom

12164870.3

2511844

2511844

Patented

Icagen, Inc.

ADVANCED DRUG DEVELOPMENT AND MANUFACTURING

Hong Kong (via EP -005EPDV)

2013104259.3

1177280

1177280

Patented

Icagen, Inc.

X-RAY MICROSCOPE

Ireland

12164870.3

2511844

2511844

Patented

Icagen, Inc.

ADVANCED DRUG DEVELOPMENT AND MANUFACTURING

Japan

2009-532446

2010509566

5143841

Patented

Exhibit H-35

Owner

Title

Country

Application No.

Pub. No.

Patent No.

Status

Icagen, Inc.

ADVANCED DRUG DEVELOPMENT AND MANUFACTURING

Japan

2014-123249

2014-123249

5913441

Patented

Icagen, Inc.

ADVANCED DRUG DEVELOPMENT AND MANUFACTURING

United States

14/693,094

2015-0309021

N/A

Pending

Icagen, Inc.

ADVANCED DRUG DEVELOPMENT AND MANUFACTURING

United States

15/876,931

N/A

N/A

Pending

Icagen, Inc.

WELL PLATE

Europe

8798006.6

2183644

2183644

Patented

Icagen, Inc.

WELL PLATE

Belgium

8798007.6

2183644

2183644

Patented

Icagen, Inc.

WELL PLATE

Switzerland/ Liechtenstein

8798008.6

2183644

2183644

Patented

Icagen, Inc.

WELL PLATE

Germany

8798009.6

2183644

602008044640.9

Patented

Icagen, Inc.

WELL PLATE

Denmark

8798010.6

2183644

2183644

Patented

Icagen, Inc.

WELL PLATE

Spain

8798011.6

2183644

2183644

Patented

Icagen, Inc.

WELL PLATE

Finland

8798012.6

2183644

2183644

Patented

Icagen, Inc.

WELL PLATE

France

8798013.6

2183644

2183644

Patented

Icagen, Inc.

WELL PLATE

United Kingdom

8798014.6

2183644

2183644

Patented

Icagen, Inc.

WELL PLATE

Ireland

8798015.6

2183644

2183644

Patented

Icagen, Inc.

WELL PLATE

Italy

8798016.6

2183644

2183644

Patented

Icagen, Inc.

WELL PLATE

Netherlands

8798017.6

2183644

2183644

Patented

Exhibit H-36

Owner

Title

Country

Application No.

Pub. No.

Patent No.

Status

Icagen, Inc.

WELL PLATE

Norway

8798018.6

2183644

2183644

Patented

Icagen, Inc.

WELL PLATE

Sweden

8798019.6

2183644

2183644

Patented

Icagen, Inc.

WELL PLATE

Japan

2010-521206

2010537171

5628035

Patented

Icagen, Inc.

WELL PLATE

Japan

2013-117600

0000000000

5755682

Patented

Icagen, Inc.

WELL PLATE

Japan

2014-202871

0000000000

6076308

Patented

Icagen, Inc.

WELL PLATE

United States

12/192,762

2009-0046832

8,238,515

Patented

Icagen, Inc.

WELL PLATE

United States

13/567,613

2013-0034205

8,873,707

Patented

Icagen, Inc.

WELL PLATE

United States

14/508,322

2015-0023467

9,476,846

Patented

Icagen, Inc.

WELL PLATE

United States

15/273,767

2017-0010228

N/A

Pending

Icagen, Inc.

METHOD AND APPARATUS FOR MEASURING PROTEIN POST-TRANSLATIONAL MODIFICATION

Japan

2010-5272

2010539944

5743135

Patented

Icagen, Inc.

METHOD AND APPARATUS FOR MEASURING PROTEIN POST-TRANSLATIONAL MODIFICATION

Japan

2014-221166

0000000000

N/A

Pending

Icagen, Inc.

METHOD AND APPARATUS FOR MEASURING PROTEIN POST-TRANSLATIONAL MODIFICATION

United States

15/052,914

2016-0201111

9976172

Patented

Exhibit H-37

Owner

Title

Country

Application No.

Pub. No.

Patent No.

Status

Icagen, Inc.

METHOD AND APPARATUS FOR MEASURING PROTEIN POST-TRANSLATIONAL MODIFICATION

United States

15/961,480

N/A

N/A

Pending

Icagen, Inc.

METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS

China

200980125952.3

102083365

ZL 200980125952.3

Patented

Icagen, Inc.

METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS

China

201310298029.8

103411988

2077368

Patented

Icagen, Inc.

METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS

China

201510083796.6

N/A

N/A

Pending

Icagen, Inc.

METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS

Europe

09774467.6

2306897

2306897

Patented

Exhibit H-38

Owner

Title

Country

Application No.

Pub. No.

Patent No.

Status

Icagen, Inc.

METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS

Switzerland/ Liechtenstein

09774467.6

2306897

2306897

Patented

Icagen, Inc.

METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS

Germany

09774467.6

2306897

2306897

Patented

Icagen, Inc.

METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS

France

09774467.6

2306897

2306897

Patented

Icagen, Inc.

METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS

United Kingdom

09774467.6

2306897

2306897

Patented

Icagen, Inc.

METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS

Hong Kong

11112984.0

1158478

1158478

Patented

Icagen, Inc.

METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE

United States

12/496,532

2010-0003697

8,431,357

Patented

Exhibit H-39

Owner

Title

Country

Application No.

Pub. No.

Patent No.

Status

Icagen, Inc.

METHOD FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE USING X-RAY FLUORESCENCE

United States

13/871,697

2013-0236887

9,063,154

Patented

Icagen, Inc.

METHOD FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE

United States

14/669,923

2015-0198615

9,506,931

Patented

Icagen, Inc.

METHOD FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE

United States

15/334,854

2017-0045530

N/A

Pending

Icagen, Inc.

METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE

United States

13/317,341

2012-0093286

9,063,066

Patented

Icagen, Inc.

METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE

United States

14/715,206

2015-0276631

9,435,756

Patented

Icagen, Inc.

METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE

United States

14/715,218

2015-0276632

9,442,085

Patented

Exhibit H-40

Owner

Title

Country

Application No.

Pub. No.

Patent No.

Status

Icagen, Inc.

METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE

United States

14/715,233

2015-0260664

9,335,284

Patented

Icagen, Inc.

METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE

United States

15/227,292

2016-0341678

N/A

Pending

Icagen, Inc.

METHODS AND APPARATUS FOR MEASURING METALS AND METALLOIDS

International

PCT/US17/28064

N/A

N/A

Pending

Icagen, Inc.

METHODS OF DETECTION USING X-RAY FLUORESCENCE

United States

62/558,528

N/A

N/A

Pending

Exhibit H-41

SCHEDULE 6

Trade Names, Trademarks, Services Marks, Trademark and Service Xxxx Registrations and Applications for Trademark and Service Xxxx Registrations

Owner		Xxxx		Country		Application No.		Registration No.		Status
Icagen, Inc.		ICAGEN		USA		87008899		5243971		Live
Icagen, Inc.		MXRF		USA		85291101		4390286		Live
Icagen, Inc.		XRPRO		USA		77377389		3507712		Live

***

Exhibit H-42

SCHEDULE 7

Deposit Accounts, Securities Accounts and Commodity Accounts

Obligor		Type of Account		Name & Address of Financial Institutions
Icagen, Inc.		Commercial Checking		XX Xxxxxx Chase Bank XX Xxx 000000 Xxx Xxxxxxx, Xxxxx 00000-0000 0000 Xxxxxx Xxxx, Xxxx Xxxxx, XX 00000
Icagen Corp		Commercial Checking		XX Xxxxxx Xxxxx Bank XX Xxx 000000 Xxx Xxxxxxx, Xxxxx 00000-0000 0000 Xxxxxx Xxxx, Xxxx Xxxxx, XX 00000
Icagen, Inc.		Business Advantage Checking		Bank of America XX Xxx 00000 Xxxxxxxxxx, XX 00000

***

Exhibit H-43

SCHEDULE 8

Commercial Tort Claims

None

***

Exhibit H-44

Exhibit I

to Credit Agreement

FORM OF COLLATERAL QUESTIONNAIRE

[see attached]

Exhibit I-1

Execution Version

Collateral Questionnaire

This Collateral Questionnaire, dated as of August 31, 2018, is delivered pursuant to (i) that certain Credit Agreement and Guaranty, dated as the date hereof (the “Parent Credit Agreement”), by and among Icagen, Inc., a Delaware corporation (“Parent”), certain of the Parent’s Subsidiaries from time to time parties thereto, the lenders from time to time party thereto and Perceptive Credit Holdings II, LP (the “Administrative Agent”), and (ii) that certain Credit Agreement and Guaranty, dated as the date hereof (the “Icagen-T Credit Agreement” and collectively with the Parent Credit Agreement, the “Credit Agreements”), by and among Icagen-T, Inc., a Delaware corporation (“Icagen-T”), Parent, certain of the Parent’s Subsidiaries from time to time parties thereto, the lenders from time to time party thereto, and the Administrative Agent. Capitalized terms used but not defined herein shall have the meanings as assigned to them in the respective Credit Agreements. As used herein, the term “Obligor” means Parent and each of Parent’s Subsidiaries.

I. Current Information

A. Legal Names, Organizations, Jurisdictions of Organization and Organizational Identification Numbers. The full and exact legal name (as it appears in each respective certificate or articles of incorporation, limited liability membership agreement or similar organizational documents, in each case as amended to date), the type of organization, the jurisdiction of organization (or formation, as applicable), and the organizational identification number (not tax id. number) of each Obligor are as follows:

Name of Obligor		Type of organization (e.g. corporation, limited liability company, limited partnership)		Jurisdiction of Organization/ Formation		Organizational Identification Number
Icagen, Inc.		C Corporation		Delaware		3723366
Icagen-T, Inc.		C Corporation		Delaware		6070175
Icagen Corp.		C Corporation		Nevada		NV 20101523783
Caldera Discovery, Inc.		C Corporation		Delaware		5717856
XRpro Sciences, Inc.		C Corporation		Delaware		5904530

B. Chief Executive Offices and Mailing Addresses. The chief executive office address and the preferred mailing address (if different than chief executive office or residence) of each Obligor are as follows:

Name of Obligor		Address of Chief Executive Office		Mailing Address (if different than CEO or residence)
Icagen, Inc.		0000 Xxxxxxx Xxxx. 000 Xxxxxxxx Xxxxxxxx Xxxx Xxxxxx, XX 00000
Icagen Corp.		0000 Xxxxxxx Xxxx. 000 Xxxxxxxx Xxxxxxxx Xxxx Xxxxxx, XX 00000
Icagen-T, Inc.		0000 X. Xxxxxxxxxx Xxxx Xxxxx Xxx Xxxxxx, XX 00000
Caldera Discovery, Inc.		0000 Xxxxxxx Xxxx. 000 Xxxxxxxx Xxxxxxxx Xxxx Xxxxxx, XX 00000
XRpro Sciences, Inc.		0000 Xxxxxxx Xxxx. 000 Xxxxxxxx Xxxxxxxx Xxxx Xxxxxx, XX 00000

Exhibit I-2

C. Changes in Names, Jurisdiction of Organization or Corporate Structure.

Except as set forth below, no Obligor has changed its name, jurisdiction of organization or its corporate structure in any way (e.g. by merger, consolidation, change in corporate form, change in jurisdiction of organization or otherwise) within the past five (5) years:

Obligor		Date of Change		Description of Change
Icagen, Inc.		8/28/15 12/02/14		XRpro Sciences, Inc., Caldera Pharmaceuticals, Inc.
Icagen Corp.		12/15/15		XRpro Corp. d/b/a Icagen, XRpro Corp.

D. Prior Addresses.

Except as set forth below, no Obligor has changed its chief executive office within the past five (5) years:

Obligor		Prior Address/City/State/Zip Code
Icagen, Inc.		Xxx Xxxxxxx Xxxxxx, Xxxxx X0000, Xxxxxxxxx, XX 00000
Icagen Corp.		Xxx Xxxxxxx Xxxxxx, Xxxxx X0000, Xxxxxxxxx, XX 00000
Caldera Discovery, Inc.		Xxx Xxxxxxx Xxxxxx, Xxxxx X0000, Xxxxxxxxx, XX 00000
XRpro Sciences, Inc.		Xxx Xxxxxxx Xxxxxx, Xxxxx X0000, Xxxxxxxxx, XX 00000

E. Acquisitions of Equity Interests or Assets.

Except as set forth below, no Obligor has acquired the equity interests of another entity or substantially all the assets of another entity within the past five (5) years:

Obligor		Date of Acquisition		Description of Acquisition
Icagen-T, Inc.		6/27/16		Acquired substantially all the assets of Sanofi US Services Inc.

Exhibit I-3

II. Additional Information.

Tangible Personal Property. Set forth below are all the locations where any Obligor currently maintains any material amount (fair market value of $25,000 or more per location) of its tangible personal property (including goods, inventory and equipment) of such Obligor (whether or not in the possession of such Obligor):

Obligor		Address/City/State/Zip Code		County
Icagen, Inc.		0000 Xxxxxxx Xxxx. 000 Xxxxxxxx Xxxxxxxx Xxxx Xxxxxx, XX 00000		Durham
Icagen Corp.		0000 Xxxxxxx Xxxx. 000 Xxxxxxxx Xxxxxxxx Xxxx Xxxxxx, XX 00000		Durham
Icagen-T, Inc.		0000 X. Xxxxxxxxxx Xxxx Xxxxx Xxx Xxxxxx, XX 00000		Pima
Caldera Discovery, Inc.		0000 Xxxxxxx Xxxx. 000 Xxxxxxxx Xxxxxxxx Xxxx Xxxxxx, XX 00000		Durham

III. Miscellaneous

A. Authority to File Financing Statements. Each of the undersigned, hereby authorizes the Administrative Agent to file financing or continuation statements, and amendments thereto, in all jurisdictions and with all filing offices as the Administrative Agent may reasonably determine are necessary or advisable to perfect the security interest granted or to be granted to the Administrative Agent under the applicable Security Agreement or any other Loan Document. Such financing statements may describe the collateral in the same manner as described in any of the Loan Documents or may contain an indication or description of collateral that describes such property in any other manner as the Administrative Agent may determine, in its sole discretion, is necessary, advisable or prudent to ensure the perfection of the security interest in the collateral granted to the Administrative Agent, including, without limitation, describing such property as “all assets” or “all personal property.”

Exhibit I-4

In Witness Whereof, the undersigned hereto have caused this Collateral Questionnaire to be executed as of the date first above written.

	Obligors:
	Icagen, Inc.
	By:
	Name:	Xxxxxxx Xxxxxxxxxx
	Title:	Chief Executive Officer
	Icagen-T, Inc.
	By:
	Name:	Xxxxxxx Xxxxxxxxxx
	Title:	Chief Executive Officer
	Icagen Corp.
	By:
	Name:	Xxxxxxx Xxxxxxxxxx
	Title:	Chief Executive Officer
	Caldera Discovery, Inc.
	By:
	Name:	Xxxxxxx Xxxxxxxxxx
	Title:	Chief Executive Officer
	XRPro Sciences, Inc.
	By:
	Name:	Xxxxxxx Xxxxxxxxxx
	Title:	Chief Executive Officer

[Signature Page to Collateral Questionnaire]

Exhibit I-5

Appendix A
to Collateral Questionnaire

Investment Related Property

Securities. Set forth below is a list of all equity interests owned by an Obligor together with the type of organization which issued such equity interests (e.g. corporation, limited liability company, partnership or trust):

Obligor		Issuer		Type of Organization		# of Shares Owned		Total Shares Outstanding		% of Interest Pledged		Certificate No. (if uncertificated, please indicate so)		Par Value
Icagen, Inc.		Caldera Discovery, Inc.		corporation		1,000		1,000		100		C-02		$.001
Icagen, Inc.		XRpro Sciences, Inc.		corporation		100		100		100		C-01		$.001
Icagen, Inc.		Icagen Corp.		corporation		100,000		100,000		100		C-02		$.01
Icagen, Inc.		Icagen-T, Inc.		corporation		100		100		100		C-01		$.001

Securities Accounts. Set forth below is a list of all securities accounts of any Obligor in which any Obligor customarily maintains securities or other assets having an aggregate value in excess of $10,000:

Obligor		Type of Account		Name & Address of Financial Institutions
None

Exhibit I-6

Deposit Accounts. Set forth below is a list of all bank accounts of any Obligor (checking, savings, money market or the like) in which any Obligor customarily maintains in excess of $10,000.

Obligor		Type of Account		Name & Address of Financial Institutions
Icagen, Inc.		Commercial Checking		XX Xxxxxx Xxxxx Bank XX Xxx 000000 Xxx Xxxxxxx, Xxxxx 00000-0000 0000 Xxxxxx Xxxx, Xxxx Xxxxx, XX 00000
Icagen Corp.		Commercial Checking		XX Xxxxxx Chase Bank XX Xxx 000000 Xxx Xxxxxxx, Xxxxx 00000-0000 0000 Xxxxxx Xxxx, Xxxx Xxxxx, XX 00000
Icagen-T, Inc.		Commercial Checking		XX Xxxxxx Xxxxx Bank XX Xxx 000000 Xxx Xxxxxxx, Xxxxx 00000-0000 0000 Xxxxxx Xxxx, Xxxx Xxxxx, XX 00000

Instruments. Set forth below is a list of all instruments (other than checks to be deposited in the ordinary course of business) owed to any Obligor in the principal amount of greater than $25,000:

Obligor		Issuer of Instrument		Principal Amount of Instrument		Maturity Date
None

Exhibit I-7

Appendix B
to Collateral Questionnaire

Intellectual Property

Set forth below is a list for each Obligor of all of such Obligor’s (a) copyrights registered with, and copyright applications pending in, the United States Copyright Office or any non-United States copyright-granting governmental authority, (b) patents issued from, and patent applications pending in, the United States Patent and Trademark Office (the “USPTO”) or any non-United States patent-granting governmental authority, and (c) trademarks registered with, and trademark applications pending in, the USPTO or any non-United States trademark-granting governmental authority:

Patents

Reference

Title

Country

Application No.

Pub. No.

Patent No.

Status

ICA-001

METHOD FOR DETECTING BINDING EVENTS USING MICRO-X-RAY FLUORESCENCE SPECTROMETRY

United States

09/859,701

2003-0027129

7,858,385

Patented

ICA-002EP

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

Europe

3748920

1525458

1525458

Patented

ICA-002BE

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

Belgium

3748920

1525458

1525458

Patented

ICA-002CH

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

Switzerland/ Liechtenstein

3748920

1525458

1525458

Patented

ICA-002DE

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

Germany

3748920

1525458

1525458

Patented

Exhibit I-8

Reference

Title

Country

Application No.

Pub. No.

Patent No.

Status

ICA-002DK

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

Denmark

3748920

1525458

1525458

Patented

ICA-002ES

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

Spain

3748920

1525458

1525458

Patented

ICA-002FI

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

Finland

3748920

1525458

1525458

Patented

ICA-002FR

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

France

3748920

1525458

1525458

Patented

ICA-002GB

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

United Kingdom

3748920

1525458

1525458

Patented

ICA-002IT

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

Italy

3748920

1525458

1525458

Patented

ICA-002SE

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

Sweden

3748920

1525458

1525458

Patented

ICA-002NL

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

Netherlands

3748920

1525458

1525458

Patented

Exhibit I-9

Reference

Title

Country

Application No.

Pub. No.

Patent No.

Status

ICA-002JP

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

Japan

2004-524531

2006-503268

4560403

Patented

ICA-002SG

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

Singapore

200500360-3

109345

109345

Patented

ICA-002C2

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

United States

11/444,660

2007-0003008

7,519,145

Patented

ICA-002C3

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

United States

12/396,592

2009-0175410

7,929,662

Patented

ICA-003EP

METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING

Europe

4755687.3

1644095

1644095

Patented

ICA-003CH

METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING

Switzerland/ Liechtenstein

4755687.3

1644095

1644095

Patented

ICA-003DE

METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING

Germany

4755687.3

1644095

1644095

Patented

ICA-003FR

METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING

France

4755687.3

1644095

1644095

Patented

Exhibit I-10

Reference

Title

Country

Application No.

Pub. No.

Patent No.

Status

ICA-003GB

METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING

United Kingdom

4755687.3

1644095

1644095

Patented

ICA-003IE

METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING

Ireland

4755687.3

1644095

1644095

Patented

ICA-003NL

METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING

Netherlands

4755687.3

1644095

1644095

Patented

ICA-003JP

METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING

Japan

2006-520181

2007527524

4782676

Patented

ICA-003SG

METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING

Singapore

2005085584

118682

Patented

ICA-003

METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING

United States

10/621,825

2005-0011818

6,858,148

Patented

ICA-003C1

METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING

United States

10/986,519

2005-0095636

7,241,381

Patented

ICA-004

DRUG DEVELOPMENT AND MANUFACTURING

United States

10/880,388

2004-0235059

9,157,875

Patented

ICA-005EP

X-RAY FLUORESCENCE ANALYSIS METHOD

Europe

7874491.9

2084519

2084519

Patented

ICA-005CH

X-RAY FLUORESCENCE ANALYSIS METHOD

Switzerland/ Liechtenstein

07 874 491.9

2084519

2084519

Patented

Exhibit I-11

Reference

Title

Country

Application No.

Pub. No.

Patent No.

Status

ICA-005DE

X-RAY FLUORESCENCE ANALYSIS METHOD

Germany

60 2007 024 468.4

2084519

608007024468.4

Patented

ICA-005DK

X-RAY FLUORESCENCE ANALYSIS METHOD

Denmark

07 874 491.9

2084519

2084519

Patented

ICA-005FR1

X-RAY FLUORESCENCE ANALYSIS METHOD

France

07 874 491.9

2084519

2084519

Patented

ICA-005GB

X-RAY FLUORESCENCE ANALYSIS METHOD

United Kingdom

7874491.9

2084519

2084519

Patented

ICA-005HK

ADVANCED DRUG DEVELOPMENT AND MANUFACTURING

Hong Kong (via EP -005EPDV)

13104259.3

1177280

1177280

Patented

ICA-005IE

X-RAY FLUORESCENCE ANALYSIS METHOD

Ireland

7874491.9

1177280

2084519

Patented

ICA-005IT

X-RAY FLUORESCENCE ANALYSIS METHOD

Italy

7874491.9

1177280

2084519

Patented

ICA-005NL

X-RAY FLUORESCENCE ANALYSIS METHOD

Netherlands

7874491.9

1177280

2084519

Patented

ICA-005SE

X-RAY FLUORESCENCE ANALYSIS METHOD

Sweden

7874491.9

1177280

2084519

Patented

ICA-005EPDV

X-RAY MICROSCOPE

Europe

12164870.3

2511844

2511844

Patented

ICA-005CHDV

X-RAY MICROSCOPE

Switzerland and Lichtenstein

12164870.3

2511844

2511844

Patented

ICA-005DEDV

X-RAY MICROSCOPE

Germany

12164870.3

2511844

602007042616.2

Patented

Exhibit I-12

Reference

Title

Country

Application No.

Pub. No.

Patent No.

Status

ICA-005FRDV

X-RAY MICROSCOPE

France

12164870.3

2511844

2511844

Patented

ICA-005GBDV

X-RAY MICROSCOPE

United Kingdom

12164870.3

2511844

2511844

Patented

ICA-005HK

ADVANCED DRUG DEVELOPMENT AND MANUFACTURING

Hong Kong (via EP -005EPDV)

2013104259.3

1177280

1177280

Patented

ICA-005IEDV

X-RAY MICROSCOPE

Ireland

12164870.3

2511844

2511844

Patented

ICA-005JP

ADVANCED DRUG DEVELOPMENT AND MANUFACTURING

Japan

2009-532446

2010509566

5143841

Patented

ICA-005JPDV2

ADVANCED DRUG DEVELOPMENT AND MANUFACTURING

Japan

2014-123249

2014-123249

5913441

Patented

ICA-005C1

ADVANCED DRUG DEVELOPMENT AND MANUFACTURING

United States

14/693,094

2015-0309021

N/A

Pending

ICA-005C2

ADVANCED DRUG DEVELOPMENT AND MANUFACTURING

United States

15/876,931

N/A

N/A

Pending

ICA-006EP

WELL PLATE

Europe

8798006.6

2183644

2183644

Patented

ICA-006BE

WELL PLATE

Belgium

8798007.6

2183644

2183644

Patented

ICA-006CH

WELL PLATE

Switzerland/ Liechtenstein

8798008.6

2183644

2183644

Patented

ICA-006DE

WELL PLATE

Germany

8798009.6

2183644

602008044640.9

Patented

ICA-006DK

WELL PLATE

Denmark

8798010.6

2183644

2183644

Patented

ICA-006ES

WELL PLATE

Spain

8798011.6

2183644

2183644

Patented

ICA-006FI

WELL PLATE

Finland

8798012.6

2183644

2183644

Patented

ICA-006FR

WELL PLATE

France

8798013.6

2183644

2183644

Patented

ICA-006GB

WELL PLATE

United Kingdom

8798014.6

2183644

2183644

Patented

ICA-006IE

WELL PLATE

Ireland

8798015.6

2183644

2183644

Patented

Exhibit I-13

Reference

Title

Country

Application No.

Pub. No.

Patent No.

Status

ICA-006IT

WELL PLATE

Italy

8798016.6

2183644

2183644

Patented

ICA-006 NL

WELL PLATE

Netherlands

8798017.6

2183644

2183644

Patented

ICA-006NO

WELL PLATE

Norway

8798018.6

2183644

2183644

Patented

ICA-006SE

WELL PLATE

Sweden

8798019.6

2183644

2183644

Patented

XXX-000XX

XXXX XXXXX

Xxxxx

0000-000000

2010537171

5628035

Patented

XXX-000XXXX

XXXX XXXXX

Xxxxx

0000-000000

0000000000

5755682

Patented

XXX-000XXXX0

XXXX XXXXX

Xxxxx

0000-000000

0000000000

6076308

Patented

XXX-000

XXXX XXXXX

Xxxxxx Xxxxxx

12/192,762

2009-0046832

8,238,515

Patented

ICA-006C1

WELL PLATE

United States

13/567,613

2013-0034205

8,873,707

Patented

ICA-006C2

WELL PLATE

United States

14/508,322

2015-0023467

9,476,846

Patented

ICA-006C3

WELL PLATE

United States

15/273,767

2017-0010228

N/A

Pending

ICA-007JP

METHOD AND APPARATUS FOR MEASURING PROTEIN POST-TRANSLATIONAL MODIFICATION

Japan

2010-5272

2010539944

5743135

Patented

ICA-007JPDV1

METHOD AND APPARATUS FOR MEASURING PROTEIN POST-TRANSLATIONAL MODIFICATION

Japan

2014-221166

0000000000

N/A

Pending

ICA-007C1/XR7-US2

METHOD AND APPARATUS FOR MEASURING PROTEIN POST-TRANSLATIONAL MODIFICATION

United States

15/052,914

2016-0201111

N/A

Pending

Exhibit I-14

Reference

Title

Country

Application No.

Pub. No.

Patent No.

Status

ICA-007C2

METHOD AND APPARATUS FOR MEASURING PROTEIN POST-TRANSLATIONAL MODIFICATION

United States

15/961,480

N/A

N/A

Pending

ICA-008CN

METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS

China

200980125952.3

102083365

ZL 200980125952.3

Patented

ICA-008CNDV

METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS

China

201310298029.8

103411988

2077368

Patented

ICA-008CNDV2

METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS

China

201510083796.6

N/A

N/A

Pending

ICA-008EP

METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS

Europe

09774467.6

2306897

2306897

Patented

ICA-008CH

METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS

Switzerland/ Liechtenstein

09774467.6

2306897

2306897

Patented

ICA-008DE

METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS

Germany

09774467.6

2306897

2306897

Patented

Exhibit I-15

Reference

Title

Country

Application No.

Pub. No.

Patent No.

Status

ICA-008FR

METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS

France

09774467.6

2306897

2306897

Patented

ICA-008GB

METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS

United Kingdom

09774467.6

2306897

2306897

Patented

ICA-008HK

METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS

Hong Kong

11112984.0

1158478

1158478

Patented

ICA-008

METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE

United States

12/496,532

2010-0003697

8,431,357

Patented

ICA-008C1

METHOD FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE USING X-RAY FLUORESCENCE

United States

13/871,697

2013-0236887

9,063,154

Patented

ICA-008C2

METHOD FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE

United States

14/669,923

2015-0198615

9,506,931

Patented

ICA-008C3

METHOD FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE

United States

15/334,854

2017-0045530

N/A

Pending

ICA-009

METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE

United States

13/317,341

2012-0093286

9,063,066

Patented

ICA-009C1

METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE

United States

14/715,206

2015-0276631

9,435,756

Patented

ICA-009C2

METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE

United States

14/715,218

2015-0276632

9,442,085

Patented

ICA-009C3

METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE

United States

14/715,233

2015-0260664

9,335,284

Patented

ICA-009C4

METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE

United States

15/227,292

2016-0341678

N/A

Pending

ICA-010PC

METHODS AND APPARATUS FOR MEASURING METALS AND METALLOIDS

International

PCT/US17/28064

N/A

N/A

Pending

ICA-013PR

METHODS OF DETECTION USING X-RAY FLUORESCENCE

United States

62/558,528

N/A

N/A

Pending

Trademarks

Xxxx		Country		Application No.		Registration No.		Status
ICAGEN		USA		87008899		5243971		Live
MXRF		USA		85291101		4390286		Live
XRPRO		USA		77377389		3507712		Live

Exhibit I-16

Schedule 3(w)(iii)

Agreements Relating to Intellectual Property

None

Exhibit I-17

Appendix C
to Collateral Questionnaire

Inventory and Equipment

1. Inventory and Equipment. Set forth below are all the locations where any Obligor currently maintains any material amount (aggregate fair market value of $25,000 or more per location) of inventory and equipment of such Obligor (whether or not in the possession of such Obligor):

Obligor		Address/City/State/Zip Code		County		Description of Assets and Value
Icagen, Inc.		0000 Xxxxxxx Xxxx. 000 Xxxxxxxx Xxxxxxxx Xxxx Xxxxxx, XX 00000		Durham		See chart below
Icagen Corp.		0000 Xxxxxxx Xxxx. 000 Xxxxxxxx Xxxxxxxx Xxxx Xxxxxx, XX 00000		Durham		See chart below
Icagen-T, Inc.		0000 X. Xxxxxxxxxx Xxxx Xxxxx Xxx Xxxxxx, XX 00000		Pima		See chart below

ICAGEN CORP.

FIXED ASSETS

Description		Original Purchase Price				Net Book Value
Laboratory Equipment
Syncopatch 384 - Rerurbished - Nanion Technologies		$	533,290.26			$	368,224.22
384 Well Acoustic Dispenser			253,739.78				144,994.16
Orbis Edax XRF Machine			203,440.66				-
Xrpro Machine - Bruker Nano			201,143.27				29,462.96
***Quotation 20120093*** Nanion Npc-16			170,380.38				97,360.22
Ionworks Quattro Also Fa1			68,564.39				39,179.65
BlueCatBio - Bluewasher 2017			59,320.00				52,258.10
Patchexpress 7000A Patch			44,950.16				25,685.80

Exhibit I-18

Description		Original Purchase Price				Net Book Value
Nikon Te-2000 Microscope Components For			34,618.96				19,782.26
Caliper Ls Lab Ship 3000 Instruments			33,789.05				19,308.03
Patchstar Micromanipulator With Control			31,836.96				18,192.55
Applied Biosystem Procise 494			31,687.80				-
Cap** -Microscope Accessories And Software  Quote			30,220.00				17,268.57
Excitation source Mo, u-focus, Polycapil  (upgrade equipment)			30,033.84				15,290.22
SDD - Package VH30-L150-130kcps			29,696.88				13,080.77
Xxxxxxxx Purchase of equipment for CFF deal			28,456.33
Multiclamp Patch Clamp Sy			26,817.51				15,324.29
Molecular Devices Spectromax M5 Plate Reader.			19,989.83				11,422.76
Advanced Chemtech Apex 396 Peptide Synthezizer with PC and Software			19,247.00				5,408.75
Discover Sp Microwave System			19,022.65				10,870.08
Thermo Multidrop Combo Dispenser			18,637.36				10,649.92
Thermo Multidrop Combo Dispenser			18,637.36				10,649.92
Hera A1502 CO2 CU TC 120V			17,761.16				16,703.95
Cap** -Velocity 11 Vprep And Benchcell And			17,726.99				10,129.71
5-125ul 384 channel pipeting head			17,581.25				5,845.51
Cap** -Revised Quote Per Meeting 9/15/10: Nikon			16,480.86				9,417.63
Nikon Inverted Microscopes With Xxxxxxxx			15,928.56				9,102.03
Nikon Inverted Microscopes With Xxxxxxxx			15,928.56				9,102.03
Nikon Inverted Microscopes With Xxxxxxxx			15,928.56				9,102.03
M5E Spectramax M5E Htrf Certified			15,643.13				8,938.93
Autopatch System 50% Patchxpress 14/122			15,065.75				8,609.00

Exhibit I-19

Description		Original Purchase Price				Net Book Value
Autopatch System 50% Patchxpress 14/122			14,281.07				8,160.61
Cap** -Ti-S/L100 Inverted Microscope With Flourescence			14,032.78				8,018.73
Viaflo 384 Baseunti and two plate holders			14,000.00				4,654.79
Viaflo 384 Base Unit with two plate holders			13,042.19				6,210.57
Xxxxxx- Incubator, Dual Chamber Co2/Co2;			12,722.22				7,269.84
Viaflo96			10,801.00				3,599.63
-80C Freezer			10,320.00				5,897.14
Syncorpatch dedicated workdesk and shipping costs			10,302.50				7,849.52
C6 Flow Cytometer, Cflow Plus Software And			10,030.87				5,731.92
Freezone Plus 4.5 Liter Cascade Benchtop Freeze Dr			9,933.00				5,676.00
Platemate Plus/2X2 Air Displacement Pipetting Head			9,124.00				5,213.71
Cap** -M5 Reader Capital			8,579.25				4,902.43
Sorvall Centrifuge Package			8,485.62				4,848.93
Moecular Devices Spectramax Gemini XS with Laptop			8,048.13				2,325.45
Sterilgard? 603A E? Quote Number: 10764.A			7,540.94				4,309.11
Vnxe 3100 Equipment And S			7,498.53				4,284.87
Cap** -Sterigard Iii Biosafety Cabinets Model			7,402.50				4,230.00
00 Xxxxxxx Xxxxxxx Xxxxxxxx 00000 UL			7,394.76				2,905.08
Double Stack Cell Culture Incubators			6,361.11				3,634.92
Double Stack Cell Culture Incubators			6,361.11				3,634.92
Double Stack Cell Culture Incubators			6,361.11				3,634.92
Double Stack Cell Culture Incubators			6,361.10				3,634.91
Csampler - 96 Well Plate And 24 Tube Rack			6,219.14				3,553.79
Savant Speedvac			5,600.00				5,066.67
Ipipette Pro, 96 Channel, 0.5-100Ul, Motorized			5,595.50				3,197.43

Exhibit I-20

Description		Original Purchase Price				Net Book Value
Warner Perfusion Stepper			5,565.18				3,180.10
96 Channel Pipetting			5,516.99				2,167.39
Cap** -Innova Co-170 Direct Heat Co2 Incubator With High			5,447.81				3,113.04
SP Industries CO2 Incubator			5,376.25				1,510.82
300 ul 96 Channel pipetting head - Vioflo 96			5,242.19				2,496.28
Cap** -Platecranes Include Softlinx Software For Control			5,062.00				2,892.57
Cap** -Flat Top Stage For Nikon Ti - Linear Enc			4,806.80				2,746.74
VersaLaser VL-200 25W			4,750.00				1,272.32
Applied BioSystems Procise 494 Protein Sequencer			4,682.70				1,303.09
Micromanipulator			4,528.67				2,587.81
Cap** -Multi-Format Cell Dispenser For Select.			4,275.00				2,442.86
Refridgerated Microcentrifuge_Eppendorf			4,266.09				2,437.77
Molecular Devisces - Spectramax Plus 384 Microplate reader			4,000.00				1,565.17
Peak analysis - Alignment nest			4,000.00				2,285.71
Upgrade Of Cybio Unit 384			3,960.00				2,262.86
Air Science - Fume Hood			3,769.87				2,145.36
Sterilgard? E3 Cabinet 98850 (Sl#)			3,740.00				2,137.14
Cap** -Electroporator Ecm 830 & 630 Combo Systems			3,615.39				2,065.93
Cap** -Nikon Ts100 Inverted Tissue Culture Microscopes			3,392.50				1,938.57
Labworld Laboratory Equipment			3,205.74				2,824.10
SpectraMax Plus Plate Reader			3,176.40				1,418.04
Ludl Piezo Z Instert (200 Micron)			3,150.00				1,800.00
ThermoScientific Forma-86 Ultralow Freezer Model 906			3,054.69				858.42
Xxxxxx Xxxx Xxxx Xxx-0000 Xxxxxxx			2,864.06				1,636.61

Exhibit I-21

Description		Original Purchase Price				Net Book Value
Sherline Lathe 441oA CNC System			2,691.54				1,037.38
Thermo Scientific Heracell 150i, Copper Interior			2,627.03				738.24
Neon Transfection System Starter Kit			2,610.28				1,491.59
Cap** -Plateloc, 120V Including Plateloc Utility			2,550.00				1,457.14
Nikon Eclipse TS100 Microscope			2,550.00				765.75
Cap** -Multidrop 384 With Stackers			2,517.29				1,438.45
Xxxxx VWR Cryopro BR-1			2,260.31				646.02
Cap** -Dmso Dry Compound Plate Storage Box For			2,250.00				1,285.71
ABI 492 Peptide Sequencer and HPLC			2,250.00				591.78
Xxxxxxxxxx? X0 Biological Safety Cabinet			2,224.88				1,271.36
Retiga 2000R Cooled Ccd Camera Microscpe Camera			2,218.65				1,267.80
00 Xxxxxxx Xxxxxxxx 00-00Xx			2,155.35				846.74
Cap** -Cellometer Auto T4 Plus Cell Counting System			1,985.00				1,134.29
Cap** -Innova Co-170 Direct Hear Co2 Incubator			1,796.25				1,026.43
12 Channel Voyager Pippette 50Ul			1,720.44				672.52
12 Cnhannel Vision Pipette - 3 of including charging stations			1,704.00				567.89
Cap** -Revised Quote Per Meeting 9/15/10: Nikon			1,685.60				963.20
Cap** -Platecranes Include Softlinx Software For Control			1,657.80				947.31
Volocity Visualization (First License)			1,557.50				890.00
Volocity Quantitation (First License)			1,557.50				890.00
Viaflo 8 Channel Voyager Pippette 5-125Ul			1,539.93				516.22
Upgrade Of Existing Ts100 Inverted Tissue Culture			1,528.54				873.45
Viaflo Voyager Pipette 50 - 1250ul			1,525.50				512.58
Burleigh Manipulator			1,518.56				867.75
Mve 616 Ln2 Freezer			1,351.23				772.13

Exhibit I-22

Description		Original Purchase Price				Net Book Value
Lightcycler? 480 Block Kit 96-Well Block			1,250.00				714.29
Thermo Savant Discovery Speedvac high throughput evaporator with Rotor			1,227.57				402.38
Cap** -Platecranes Include Softlinx Software For Control			1,105.20				631.54
Zymark Twister 63808 Universal Microplate Handler			1,065.33				87.46
RDP Electrosense LVDT Transducer			1,046.75				691.60
Neon 100Ul Tips Capital			963.80				550.74
Alpha Unit For Ptc-200/225 96V #Als-1296			952.62				544.35
“Xxxxxx Xxxxxx, Inc Mes Ma”			941.98				538.27
Volocity Restoration (First License)			857.50				490.00
Fusion Instrument 0000-00-000000000 Co 185			846.91				483.95
Ludl 10-Position 25/32Mm Filter Wheel			815.00				465.71
Cap** -Ludl Motor Control Driver For Xy Axis			788.00				450.29
Gemini Twin Shaking Water			715.40				408.80
Mac6000 Dc Controller For Filterwheels			689.25				393.86
Centrifuge			676.59				386.62
Xxxxx Gel Drying Vacuum Pump FBGDPX10			672.03				188.85
Quad Filter Set For Dapi, Cy2, Cy3, Cy5, Wi			656.25				375.00
Filter Wheel 25Mm 6Pos, Emission Dc Motor			620.25				354.43
Tc Inverted Microscope			545.38				311.64
96-Well Fast Reaction Module			499.16				285.23
Neon 10Ul Tips Capital			481.90				275.37
Alpha Unit 48/48  #Ald-1244 Capital			476.55				272.31
Improvision License Server			475.00				271.43
Misc-Equip Centra-Cl2 120V 50/60Hz			446.06				254.89
Misc-Equip Centra-Cl2 120V 50/60Hz			446.06				254.89
Cap** -Belly Dancer Xxxxxxx Capital			368.24				210.42

Exhibit I-23

Description		Original Purchase Price				Net Book Value
Mac 6000 Piezo Controller			337.50				192.86
Hood Retrofit And Install			299.85				171.34
Cap** -96 Well Pipetting Head Capital			253.82				145.04
Misc-Equip 236 W/2092S/2091S			252.97				144.56
Misc-Equip 236 W/2092S/2091S			252.97				144.56
Lightcycler Gene Scanning Sw System Ii (1 Copy)			250.00				142.86
000 Xxxx Xxxxx Xxxx #Xxx-0000 Capital			238.27				136.16
Dual Alpha Xxxx 00/00  # Xxx-0000			238.27				136.16
“Ez Load” Pipetting Head, Dispo Tips, 96-Channel,			232.50				132.86
“Ez Load” Pipetting Head, Dispo Tips, 96-Channel,			232.50				132.86
Cap** -Joystick Control - Mac 6000			212.80				121.60
C6 Flow Cytometer, Cflow Plus Software And			206.25				117.86
Alpha Xxxx 00  #Als-1260 Capital			190.52				108.87
Cap** -Velocity Bench Cell Rack Standard 660Mm			165.00				94.29
43100-010 Base Stand For Purifier 4Ft 37304003726			150.61				86.06
Fume Hood Installation &			149.17				85.24
Base Stand For Purifier 4Ft 37304003726			144.72				82.69
Misc-Supplies 4’ Adjustable Height Base Xxxx			138.97				79.41
Lightcycler? 480 Lims Interface Module For System			125.00				71.43
Filter Wheel Flange Set Capital			110.00				62.86
Laser Head For Genetic An			105.19				60.11
Piezo Stage Insert Adapter, Nikon Ti			98.50				56.29
Installed Fumes Hoods & C			81.88				46.79
Emission Flange Capital			71.50				40.86
Cap** -Sterigard Iii Biosafety Cabinets Model			50.00				28.57
Total Laboratory Equipment			2,457,662.63				1,221,286.89
Demising costs - Pfizer premises			34,711.04				15,427.13
Office signage			3,263.38				502.06
Floor tiling			1,000.00				157.89
Total Leasehold Improvements		$	38,974.42			$	16,087.08

Exhibit I-24

Description		Original Purchase Price				Net Book Value
Computer Equipment
Alphanumeric HP Network improvements		$	15,357.13			$	10,238.09
Access System - First Security			5,383.75				448.65
Access System - First Security			5,187.25				432.27
Lenovo Thinkpad T460s 20F9 14” Core I5 6300U 8 gb Ram 256 GB Serial No 20F9003GUSPC0FAKPN; 20F9003GUSPc0FAKUN			3,705.06				1,955.45
Hp 6040			3,000.00				-
Vnxe 3100			2,500.00				-
Apple Macbook pro transferred - Xxxxxx Xxxxxxxxxx			1,841.69				-
Lenovo Thinkpad T460, LED monitor USB Dock			1,839.02				919.51
Lenovi Think pad T460S 20F9 14” Core I5 6300U 8gb Ram 256 GB = Serial No 20F9003GUSPC0FAHZ7			1,754.06				925.75
Lenovo Thinkpad X1 Carbon 20FB - 14” Core I5 8 Gb Ram 256GB SD Serial No 20FB002RUSR90MD78Y			1,607.23				892.91
Lenovo Thinkpad X1 carbon 20FB - 14” Serial 20F8002RUSR90LJL7V			1,578.97				921.07
Lenovo Thinkpad Carbon 20FB 14” Core I5 8gb			1,565.04				565.15
Thinkpad			1,525.55				1,228.92
Lenovo Thinkpad T460s20F9 14” Core I5 Serial 20F9003GUSPCOFD8RH			1,505.01				919.73

Exhibit I-25

Description		Original Purchase Price				Net Book Value
Poweredge R710			1,000.00				-
Poweredge R710			1,000.00				-
Poweredge R710			1,000.00				-
Poweredge R710			1,000.00				-
Lenoco Laptop - Credit card purchase			864.02				120.00
Thinkpad X1 Carbon (34608W6)			507.50				-
Thinkpad X1 Carbon (34608W6)			507.50				-
Thinkpad T440 (20B7S01V00)			225.00				-
Thinkpad T440 (20B7S01V00)			225.00				-
Thinkpad T440 (20B7S01V00)			225.00				-
Thinkpad T440 (20B7S01V00)			225.00				-
Thinkpad T440 (20B7S01V00)			225.00				-
Thinkpad T440 (20B7S01V00)			225.00				-
Thinkpad T440 (20B7S01V00)			225.00				-
Thinkpad T440 (20B7S01V00)			225.00				-
Thinkpad T440 (20B7S01V00)			225.00				-
Thinkpad T440 (20B7S01V00)			225.00				-
Thinkpad T440 (20B7S01V00)			225.00				-
Thinkpad T440 (20B7S01V00)			225.00				-
Thinkpad T440 (20B7S01V00)			225.00				-
Thinkpad T440 (20B7S01V00)			225.00				-
Thinkpad T440 (20B7S01V00)			225.00				-
Thinkpad T440 (20B7S01V00)			225.00				-
Poweredge 2950			225.00				-
Poweredge 2950			225.00				-
Thinkpad W520 (4284A96)			200.00				-
Hp 4300			115.00				-
Hp 4300			115.00				-
Hp 2035			85.00				-
Hp 4345			75.00				-
Hp 3005			70.00				-
Hp 3005			70.00				-
Total Computer Equipment		$	59,008.78			$	19,567.49

Exhibit I-26

Description		Original Purchase Price				Net Book Value
Computer software
Adobe Software		$	713.32			$	39.63
Oracle Software			3,277.75				91.04
MS Server			739.40				41.08
SnagIT			174.95				9.72
MS Apps			12,158.03				675.44
Abase XE Platform			102,716.25				5,706.45
DNAstar			9,000.00				500.00
Spotfire			5,334.00				296.34
Lenovo			2,022.73				449.50
Windows			1,741.50				725.60
DNSstar - Biology Suite Service plan			3,600.00				-
Graphpad			3,750.00				312.50
Arxspan software			21,675.00				1,806.25
Xxxxxx Xxxxx - Spotfire - annual support			1,708.00				142.33
Oracle TOAD DBA Suite - Insight			1,700.38				141.70
Mccaffee - Insight			1,301.34				108.45
IDBS Abase software			28,132.76				2,344.40
Procurify			3,431.75				-
Biovia			68,668.59				11,444.77
IDBS Data Management Software			7,385.25				1,846.31
Docusign			2,898.00				724.50
DNAstar			2,688.00				224.00
DNAStar			2,560.00				1,280.00
Procurify			3,169.92				2,113.28
Total Computer Software			290,546.92				31,023.29
Total Fixed Assets Corp		$	2,846,192.75			$	1,287,964.74

Exhibit I-27

ICAGEN T

FIXED ASSETS

		BALANCE				NBV
LABORATORY EQUIPMENT
Bio-Rad  BioLogic LP System with BioFrac Fraction Collector and LP DataView Software; Price is per Quote #17-Q26868V5		$	11,885.75			$	10,470.78
Specialty Coating systems - G3P-8 Spin Coater, 115V/60Hz			6,261.13				4,770.39
Biodipy TMR FP D555/fp595 dual mirror, optical mudule d555fp/B850_482			5,864.02				4,398.01
Lab -20 Degree Freezer - VWR			3,663.09				3,401.44
Formlabs Inc.   Form2 Complete Package with Grey Resin, includes:  Form2 3D Printer, Grey Resin Cartridge #GPGR03, Build Platform for Form 2, Finish Kit for Form 2, Resin Tank for Form 2; Price is per Quote #00016343			3,499.00				3,040.80
Integra Biosciences Corp. 16 Channel ViaFlo II Pipette, .5-12.5uL and charging station			3,038.33				2,640.45
VWR General purpose refrigerator 26CF			2,499.85				1,993.93
Integra Biosciences Corp.   Voyager II, 8 Channel, 50-1250uL with charging stand			1,590.12				1,381.89
Sanofi Purchase price paid			1.00				0.00
Total Laboratory Equipment		$	38,302.29			$	32,097.69
COMPUTER EQUIPMENT
Oracle Database Appliance X6-2M Model Family		$	23,160.41			$	10,936.87
Reliant Technology - Net App equipment			12,105.45				11,432.93
Total Computer Equipment		$	35,265.86			$	22,369.79

Exhibit I-28

		BALANCE				NBV
COMPUTER SOFTWARE
Chemical Computing Group Molecular Operating Enviro		$	109,400.00			$	54,700.00
Dotmatics [13] Annual named user licenses for Studies ELN			104,787.00				52,393.50
Water Software Licenses			93,163.50				60,348.19
Schrodinger			87,500.00				0.00
Schroedinger			87,500.00				0.00
Shrodibnger			87,500.00				0.00
Schrodinger			87,500.00				0.00
Schrodinger			87,500.00				0.00
Schrodinger			87,500.00				87,500.00
Dassualt Systemes			73,703.55				24,567.85
Titan Software			63,648.27				42,432.18
Xxxxxx Mosaic Software support and Maint April to March			60,617.40				0.00
IDBS Activity Base XE - 12 months			57,600.00				0.00
Elsevier - Reaxys			50,400.00				16,800.00
Tititan Software -			47,127.00				0.00
Xxxxxx Xxxxx Chemdraw			23,390.40				7,796.80
Insught Direct			23,311.64				9,713.18
ArxLab Notebook			20,400.00				(0.00	)
SciQuest Inc			20,000.00				5,000.00
Virscidian - Analytical Studio			15,600.00				7,583.33
PerkinElmer Informatics, Inc. Bronze Support for Columbus Server Software.  Price is per five user package.  Server hardware and operating system 10/2/17 to 10/1/18			11,637.12				1,939.52
Univa			11,520.00				4,800.00
Kelaroo			9,000.00				0.00
Insight Direct			8,308.80				0.00

Exhibit X-00

		XXXXXXX				XXX
XXX/XXX Xxxxxxxxx Xxxxx 0000, Stand-Alone User Subscription(s), Subscription-to-Perpetual			7,838.00				3,265.83
Procurify			7,637.76				1,909.44
Microsoft Windows Server			7,233.40				2,612.06
brac32 - BCM-ADV-COM-32-63-1YR-R Bright Cluster Manager - Advanced Edition, commercial customer, 32-63 nodes, 1 year support			5,405.00				2,252.08
Information Professionals			4,450.00				0.00
The Edge Software license and maintenance			4,218.00				1,757.50
Webroot SecureAnywhere Business - Endpoint Protection - Subscription license renewal (1 year)			4,194.28				873.81
Meraki Mx 84 Adv Sec Lic And Sup 3Yr			4,126.82				1,490.24
Insight Microsoft Windows Server software			3,467.89				2,022.94
2018 Prowatch System annual software support and licenses for Icagen-T security.			3,459.20				1,441.33
Total Computer Software		$	1,380,645.03			$	393,199.79
Totals		$	1,454,213.18			$	447,667.27

Exhibit I-30

Icagen Corp. Inventory as of June 30, 2018

INVENTORY

		End of Month # of Chips				End of Month Inventory Value
Syncropatch Inventory			98			$	28,616.00
PatchXpress Chip Inventory			202			$	35,522.00
Qpatch Chaip Inventory			98			$	18,032.00
Total						$	79,17.00

2. Warehousemen and Bailees. Except as set forth below, no persons (including warehousemen and bailees) other than an Obligor have possession of any material amount (fair market value of $25,000 or more per location) of assets of any Obligor:

Obligor		Address/City/State/Zip Code		County		Description of Assets and Value
None

Exhibit I-31

Appendix D
to Collateral Questionnaire

Real Estate Related UCC Collateral

1. Fixtures. Set forth below are all the locations where any Obligor owns or leases any real property:

Obligor		Address/City/ State/Zip Code		County		Owned or Leased
Icagen Inc.		0000 Xxxxxxx Xxxx 000 Xxxxxxxx Xxxxxxxx Xxxx Xxxxxx, XX 00000		Durham		Sublease
Icagen Corp.		0000 Xxxxxxx Xxxx 000 Xxxxxxxx Xxxxxxxx Xxxx Xxxxxx, XX 00000		Durham		Sublease
Icagen-T, Inc.		0000 X. Xxxxxxxxxx Xxxx Xxxxx Xxx Xxxxxx, XX 00000		Pima		Owned premises with the right of reverter to Sanofi in the event of default.
Caldera Discovery, Inc.		0000 Xxxxxxx Xxxx 000 Xxxxxxxx Xxxxxxxx Xxxx Xxxxxx, XX 00000		Durham		Sublease

2. “As Extracted” Collateral. Set forth below are all the locations where any Obligor owns, leases or has an interest in any wellhead or minehead:

Obligor		Address/City/State/Zip Code		County
None

3. Timber to be Cut. Set forth below are all locations where any Obligor owns goods that are timber to be cut:

Obligor		Address/City/State/Zip Code		County
None

Exhibit I-32

Appendix E
to Collateral Questionnaire

Names

1. Trade Names.

Current Names. Set forth below is each trade name or assumed name currently used by any Obligor or by which any Obligor is known or is transacting any business:

Obligor		Trade/Assumed Name
None

Past Names. Set forth below is each trade name or assumed name used by any Obligor during the past five (5) years or by which any Obligor has been known or has transacted any business during the past five (5) years other than the names identified in Section I.A. of this Collateral Questionnaire:

Obligor		Trade/Assumed Name
None

Exhibit I-33

Exhibit J

to Credit Agreement

FORM OF PATENT SECURITY AGREEMENT

[see attached]

Exhibit J-1

Execution Version

PATENT SECURITY AGREEMENT

August 31, 2018

WHEREAS, Icagen, Inc., a Delaware corporation (“Borrower”) and each entity that becomes a “Grantor” under the Security Agreement (together with Borrower, the “Grantors” and each, a “Grantor”) are parties to that certain Security Agreement, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Security Agreement”; capitalized terms used herein without definition shall have the meanings set forth in the Security Agreement), among certain Grantors party thereto from time to time and Perceptive Credit Holdings II, LP, as administrative agent for the Secured Parties (in such capacity, the “Administrative Agent”), pursuant to which Grantors have granted in favor of the Administrative Agent a lien on all of their personal property constituting Collateral, including without limitation the patents and patent applications listed on Schedule A hereto; and

WHEREAS, it is a condition to the advance of the loans and other obligations secured by the Security Agreement, that each Grantor execute and deliver, and cause to be filed in the U.S. Patent and Trademark Office, this Patent Security Agreement;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged:

As collateral security for the prompt and complete payment in full and performance when due (whether at stated maturity, by acceleration or otherwise) of the Secured Obligations, each Grantor hereby pledges and grants to the Administrative Agent for the benefit of the Secured Parties a security interest in all patents and patent applications owned by such Grantor and constituting Collateral, in each case whether now owned by Grantor or hereafter acquired and whether now existing or hereafter coming into existence, including without limitation those listed on Schedule A hereto.

This Patent Security Agreement and the rights and obligations of the parties hereunder shall be governed by, and construed in accordance with, the law of the State of New York, without regard to principles of conflicts of laws that would result in the application of the laws of any other jurisdiction; provided, that Section 5-1401 of the New York General Obligations Law shall apply.

[signature to follow]

Exhibit J-2

IN WITNESS WHEREOF, the Grantors have caused this Patent Security Agreement to be duly executed and delivered as of the day and year first above written.

Icagen, Inc.,

as Grantor

By:

Name:

Title:

Icagen Corp.,

as Grantor

By:

Name:  

Title:  

Caldera Discovery, Inc.,

as Grantor

By:

Name:  

Title:  

XRPro Sciences, Inc.,

as Grantor

By:

Name:  

Title:  

signature page
patent security agreement

Exhibit J-3

Schedule A

to Patent Security Agreement

PATENTS AND PATENT APPLICATIONS

Owner

Title

Country

Application No.

Pub. No.

Patent No.

Status

Icagen, Inc.

METHOD FOR DETECTING BINDING EVENTS USING MICRO-X-RAY FLUORESCENCE SPECTROMETRY

United States

09/859,701

2003-0027129

7,858,385

Patented

Icagen, Inc.

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

United States

11/444,660

2007-0003008

7,519,145

Patented

Icagen, Inc.

FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE

United States

12/396,592

2009-0175410

7,929,662

Patented

Icagen, Inc.

METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING

United States

10/621,825

2005-0011818

6,858,148

Patented

Icagen, Inc.

METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING

United States

10/986,519

2005-0095636

7,241,381

Patented

Icagen, Inc.

DRUG DEVELOPMENT AND MANUFACTURING

United States

10/880,388

2004-0235059

9,157,875

Patented

Icagen, Inc.

ADVANCED DRUG DEVELOPMENT AND MANUFACTURING

United States

14/693,094

2015-0309021

N/A

Pending

Icagen, Inc.

ADVANCED DRUG DEVELOPMENT AND MANUFACTURING

United States

15/876,931

N/A

N/A

Pending

Icagen, Inc.

WELL PLATE

United States

12/192,762

2009-0046832

8,238,515

Patented

SCHEDULE A TO PATENT SECURITY AGREEMENT

Exhibit J-4

Owner

Title

Country

Application No.

Pub. No.

Patent No.

Status

Icagen, Inc.

WELL PLATE

United States

13/567,613

2013-0034205

8,873,707

Patented

Icagen, Inc.

WELL PLATE

United States

14/508,322

2015-0023467

9,476,846

Patented

Icagen, Inc.

WELL PLATE

United States

15/273,767

2017-0010228

N/A

Pending

Icagen, Inc.

METHOD AND APPARATUS FOR MEASURING PROTEIN POST-TRANSLATIONAL MODIFICATION

United States

15/052,914

2016-0201111

9976172

Patented

Icagen, Inc.

METHOD AND APPARATUS FOR MEASURING PROTEIN POST-TRANSLATIONAL MODIFICATION

United States

15/961,480

N/A

N/A

Pending

Icagen, Inc.

METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE

United States

12/496,532

2010-0003697

8,431,357

Patented

Icagen, Inc.

METHOD FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE USING X-RAY FLUORESCENCE

United States

13/871,697

2013-0236887

9,063,154

Patented

Icagen, Inc.

METHOD FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE

United States

14/669,923

2015-0198615

9,506,931

Patented

Icagen, Inc.

METHOD FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE

United States

15/334,854

2017-0045530

N/A

Pending

Icagen, Inc.

METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE

United States

13/317,341

2012-0093286

9,063,066

Patented

Icagen, Inc.

METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE

United States

14/715,206

2015-0276631

9,435,756

Patented

Icagen, Inc.

METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE

United States

14/715,218

2015-0276632

9,442,085

Patented

Icagen, Inc.

METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE

United States

14/715,233

2015-0260664

9,335,284

Patented

Icagen, Inc.

METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE

United States

15/227,292

2016-0341678

N/A

Pending

Icagen, Inc.

METHODS OF DETECTION USING X-RAY FLUORESCENCE

United States

62/558,528

N/A

N/A

Pending

SCHEDULE A TO PATENT SECURITY AGREEMENT

Exhibit J-5

Exhibit K

to Credit Agreement

FORM OF TRADEMARK SECURITY AGREEMENT

[see attached]

Exhibit K-1

Execution Version

TRADEMARK SECURITY AGREEMENT

August 31, 2018

WHEREAS, Icagen, Inc., a Delaware corporation (“Borrower”) and each entity that becomes a “Grantor” under the Security Agreement (together with Borrower, the “Grantors” and each, a “Grantor”) are parties to that certain Security Agreement, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Security Agreement”; capitalized terms used herein without definition shall have the meanings set forth in the Security Agreement), among certain Grantors party thereto from time to time and Perceptive Credit Holdings II, LP, as administrative agent for the Secured Parties (in such capacity, the “Administrative Agent”), pursuant to which Grantors have granted in favor of the Administrative Agent a lien on all of their personal property constituting Collateral, including without limitation the trademarks and trademark applications listed on Schedule A hereto; and

WHEREAS, it is a condition to the advance of the loans and other obligations secured by the Security Agreement, that each Grantor execute and deliver, and cause to be filed in the U.S. Patent and Trademark Office, this Trademark Security Agreement;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged:

As collateral security for the prompt and complete payment in full and performance when due (whether at stated maturity, by acceleration or otherwise) of the Secured Obligations, each Grantor hereby pledges and grants to the Administrative Agent for the benefit of the Secured Parties a security interest in all of the trademarks, whether now owned or at any time hereafter acquired, owned by such Grantor and constituting Collateral that are registered with, or for which applications for registration have been filed with, the United States Patent and Trademark Office, including the trademarks listed on Schedule A hereto (excluding any application for registration of a trademark filed on an intent-to-use basis solely to the extent that the grant of a security interest in any such trademark application would materially adversely affect the validity or enforceability of the resulting trademark registration or result in cancellation of such trademark application).

This Trademark Security Agreement and the rights and obligations of the parties hereunder shall be governed by, and construed in accordance with, the law of the State of New York, without regard to principles of conflicts of laws that would result in the application of the laws of any other jurisdiction; provided, that Section 5-1401 of the New York General Obligations Law shall apply.

[signature to follow]

Exhibit K-2

IN WITNESS WHEREOF, the Grantors have caused this Trademark Security Agreement to be duly executed and delivered as of the day and year first above written.

Icagen, Inc.,

as Grantor

By:

Name:

Title:

Icagen Corp.,

as Grantor

By:

Name:

Title:

Caldera Discovery, Inc.,

as Grantor

By:

Name:

Title:

XRPro Sciences, Inc.,

as Grantor

By:

Name:

Title:

signature page

trademark security agreement

Exhibit K-3

Schedule A

to Trademark Security Agreement

REGISTERED TRADEMARKS AND TRADEMARK APPLICATIONS

Owner

Xxxx

Country

Application No.

Registration No.

Status

Icagen, Inc.

ICAGEN

USA

87008899

5243971

Live

Icagen, Inc.

MXRF

USA

85291101

4390286

Live

Icagen, Inc.

XRPRO

USA

77377389

3507712

Live

SCHEDULE A TO TRADEMARK SECURITY AGREEMENT

Exhibit K-4

Exhibit L

to Credit Agreement

FORM OF COPYRIGHT SECURITY AGREEMENT

[see attached]

Exhibit L-1

Execution Version

COPYRIGHT SECURITY AGREEMENT

August 31, 2018

WHEREAS, Icagen, Inc., a Delaware corporation (“Borrower”) and each entity that becomes a “Grantor” under the Security Agreement (together with Borrower, the “Grantors” and each, a “Grantor”) are parties to that certain Security Agreement, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Security Agreement”; capitalized terms used herein without definition shall have the meanings set forth in the Security Agreement), among certain Grantors party thereto from time to time and Perceptive Credit Holdings II, LP, as administrative agent for the Secured Parties (in such capacity, the “Administrative Agent”), pursuant to which Grantors have granted in favor of the Administrative Agent a lien on all of their personal property constituting Collateral, including without limitation the copyrights listed on Schedule A hereto; and

WHEREAS, it is a condition to the advance of the loans and other obligations secured by the Security Agreement, that each Grantor execute and deliver, and cause to be filed in the U.S. Copyright Office, this Copyright Security Agreement;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged:

As collateral security for the prompt and complete payment in full and performance when due (whether at stated maturity, by acceleration or otherwise) of the Secured Obligations, each Grantor hereby pledges and grants to the Administrative Agent for the benefit of the Secured Parties a security interest in all copyrights, whether now owned or at any time hereafter acquired, owned by such Grantor and constituting Collateral that are registered with the United States Copyright Office, including the copyrights listed on Schedule A hereto.

This Copyright Security Agreement and the rights and obligations of the parties hereunder shall be governed by, and construed in accordance with, the law of the State of New York, without regard to principles of conflicts of laws that would result in the application of the laws of any other jurisdiction; provided, that Section 5-1401 of the New York General Obligations Law shall apply.

[signature to follow]

Exhibit L-2

IN WITNESS WHEREOF, the Grantors have caused this Copyright Security Agreement to be duly executed and delivered as of the day and year first above written.

Icagen, Inc.,

as Grantor

By:

Name:

Title:

Icagen Corp.,

as Grantor

By:

Name:

Title:

Caldera Discovery, Inc.,

as Grantor

By:

Name:

Title:

XRPro Sciences, Inc.,

as Grantor

By:

Name:

Title:

signature page
copyright security agreement

Exhibit L-3

Schedule A

to Copyright Security Agreement

REGISTERED COPYRIGHTS

**NONE AS OF THE CLOSING DATE**

SCHEDULE A TO COPYRIGHT SECURITY AGREEMENT

Exhibit L-4

Exhibit M

to Credit Agreement

FORM OF CLOSING DATE CERTIFICATE

Date: August 31, 2018, being the Closing Date

Reference is made to the Credit Agreement and Guaranty, dated as of August 31, 2018 (as from time to time amended, restated, supplemented or otherwise modified, the “Credit Agreement”), among Icagen, Inc., a Delaware corporation (“Borrower”), the Subsidiary Guarantors from time to time party thereto, the Lenders from time to time party thereto, and Perceptive Credit Holdings II, LP, as administrative agent for the Lenders (in such capacity, the “Administrative Agent”). The terms defined in the Credit Agreement are herein used as therein defined.

The undersigned, being a Responsible Officer of the Borrower, hereby certifies on behalf of the Borrower and not individually, that:

1. Both immediately before and after giving effect to the Term Loan to be made on the date hereof,

a. the representations and warranties set forth in each Loan Document (including in Section 7 of the Credit Agreement) are, in each case, true and correct in all material respects (or, in the case of any such representation or warranty already qualified by materiality, in all respects), and

b. no Default has occurred and is continuing, or will result from the making of the Term Loan being advanced on the Closing Date.

2. all of the conditions set forth in Section 6.01 have been satisfied or waived by the Administrative Agent on or prior to the date hereof.

[SIGNATURE PAGE FOLLOWS]

Exhibit M-1

IN WITNESS WHEREOF, the undersigned has executed this certificate on the date first written above.

Icagen, Inc.

By:

Name:  

Title:  

Exhibit M-2

COMPLIANCE CERTIFICATE

August 31, 2018

This certificate is delivered pursuant to Section 6.01(e) of, and in connection with the consummation of the transactions contemplated in, the Credit Agreement and Guaranty, dated as of August 31, 2018 (as from time to time amended, restated, supplemented or otherwise modified, the “Credit Agreement”), among Icagen, Inc., a Delaware corporation (“Borrower”), the Subsidiary Guarantors from time to time party thereto, the Lenders from time to time party thereto, and Perceptive Credit Holdings II, LP, as administrative agent for the Lenders (in such capacity, the “Administrative Agent”). Capitalized terms used herein and not otherwise defined herein are used herein as defined in the Credit Agreement.

The undersigned, a duly authorized Responsible Officer of Borrower having the name and title set forth below under his signature, hereby certifies solely in his capacity as an officer of Borrower and not in any individual capacity, on behalf of Borrower for the benefit of the Administrative Agent and the Lenders and pursuant to Section 6.01(e) of the Credit Agreement that such Responsible Officer of Borrower is familiar with the Credit Agreement and that, in accordance with each of the following sections of the Credit Agreement, each of the following is true on the date hereof, both before and after giving effect to the Term Loan, if any, to be made on or before the date hereof:

Attached hereto as Annex A are the calculations used to determine compliance with each financial covenant contained in Section 10 of the Credit Agreement (as required on the Closing Date).

[Signature follows]

Exhibit M-3

IN WITNESS WHEREOF, the undersigned has executed this certificate on the date first written above.

Icagen, Inc.

By: 

Name:  Xxxxxxx Xxxxxxxxxx

Title:  Chief Executive Officer

Exhibit M-4

Annex A

to Compliance Certificate

CALCULATIONS OF FINANCIAL COVENANT COMPLIANCE

I.		Section 10.01:  Minimum Liquidity
A.		Minimum aggregate balance of cash at any time in one or more accounts (which accounts shall, on and after the Closing Date (or such later date as agreed to by the Administrative Agent in its reasonable discretion), be Controlled Accounts), free and clear of all Liens, other than Liens granted under the Loan Documents in favor of the Administrative Agent and other Permitted Liens, during the fiscal period for which the financial statements attached hereto as Annex A are being delivered:		$___________
B.		Is Line IA greater than (x) from the Closing Date until March 31, 2019, $1,000,000, or (y) thereafter, $1,500,000?:		Yes: In compliance; No: Not in compliance

Exhibit M-5